U.S. patent application number 16/858509 was filed with the patent office on 2020-12-31 for amatoxin antibody-drug conjugates and uses thereof.
The applicant listed for this patent is Magenta Therapeutics, Inc.. Invention is credited to Francesca Gallo, Torsten Hechler, Michael Kulke, Christian Lutz, Charlotte Fenton McDonagh, Christoph Mueller, Andreas Pahl, Rajiv Panwar, Ganapathy N. Sarma, Werner Simon.
Application Number | 20200407440 16/858509 |
Document ID | / |
Family ID | 1000005101961 |
Filed Date | 2020-12-31 |
United States Patent
Application |
20200407440 |
Kind Code |
A1 |
McDonagh; Charlotte Fenton ;
et al. |
December 31, 2020 |
AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF
Abstract
Amatoxins, as well as antibody-drug conjugates (ADCs) comprising
an amatoxin are provided, as well as compositions and methods of
using the same. The compositions and methods provided herein can
also be used to prepare a patient for hematopoietic stem cell
transplant therapy and to improve the engraftment of hematopoietic
stem cell transplants by selectively depleting endogenous
hematopoietic stem cells prior to the transplant procedure. Methods
and compositions for the treatment of various hematopoietic
diseases, metabolic disorders, cancers, and autoimmune diseases, as
well as prevention of graft-versus-host-disease (GVHD), are
provided.
Inventors: |
McDonagh; Charlotte Fenton;
(Winchester, MA) ; Panwar; Rajiv; (Acton, MA)
; Sarma; Ganapathy N.; (Belmont, MA) ; Hechler;
Torsten; (Ladenburg, DE) ; Kulke; Michael;
(Ladenburg, DE) ; Pahl; Andreas; (Ladenburg,
DE) ; Mueller; Christoph; (Ladenburg, DE) ;
Simon; Werner; (Ladenburg, DE) ; Lutz; Christian;
(Ladenburg, DE) ; Gallo; Francesca; (Ladenburg,
DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Magenta Therapeutics, Inc. |
Cambridge |
MA |
US |
|
|
Family ID: |
1000005101961 |
Appl. No.: |
16/858509 |
Filed: |
April 24, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62838290 |
Apr 24, 2019 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/6803 20170801;
C07K 2319/55 20130101; C07K 2317/565 20130101; A61K 45/06 20130101;
C07K 16/2803 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; A61K 45/06 20060101 A61K045/06; A61K 47/68 20170101
A61K047/68 |
Claims
1. An anti-CD1117 antibody-drug conjugate (ADC) comprising an
antibody, or an antigen-binding fragment thereof, conjugated to an
amatoxin via a linker, wherein the ADC has the structure of formula
(I): ##STR00082## or a stereoisomer thereof; wherein: Q is S; L is
a non-cleavable linker; Z is a chemical moiety formed by a coupling
reaction between a reactive substituent present on L and a reactive
substituent present within the antibody, or antigen-binding
fragment thereof; and Ab is the antibody, or the antigen binding
fragment thereof, wherein the antibody, or the antigen binding
fragment thereof, is selected from the group consisting of a) an
anti-CD117 antibody, or antigen binding fragment thereof,
comprising a heavy chain comprising an HC-CDR1, an HC-CDR2, and an
HC-CDR3 or a variable region from the heavy chain variable region
amino acid sequence of Ab55, Ab54, Ab56, Ab57, Ab58, Ab61, Ab66,
Ab67, Ab68, Ab69, Ab85, Ab86, Ab87, Ab88, Ab89, Ab77, Ab79, Ab81,
Ab85, or Ab249; and a light chain comprising an HC-CDR1, an
HC-CDR2, and an HC-CDR3 or a variable region from the light chain
variable region amino acid sequence of Ab55, Ab54, Ab56, Ab57,
Ab58, Ab61, Ab66, Ab67, Ab68, Ab69, Ab85, Ab86, Ab87, Ab88, Ab89,
Ab77, Ab79, Ab81, Ab85, or Ab249; b) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 or a variable
region from the heavy chain variable region amino acid sequence of
SEQ ID NO: 147, 164, 166, 168, 170, 172, 174, 176, 178, 180, 183,
185, 187, 189, 191, 193, 195, 197, 199, 201, 202, 204, 206, 208,
210, 212, 214, 216, 218, 220, 222, 224, 226, 238, or 243; and a
light chain comprising an LC-CDR1, an LC-CDR2, and an LC-CDR3 or a
variable region from the light chain variable region amino acid
sequence of SEQ ID NO: 148, 149, 150, 151, 152, 153, 154, 155, 156,
157, 158, 159, 160, 161, 162, 163, 165, 167, 169, 171, 173, 175,
177, 179, 181, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200,
203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227,
228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240, 241,
242, or 244; c) an anti-CD117 antibody, or antigen binding fragment
thereof, comprising a heavy chain comprising a heavy chain
(HC)-CDR1, HC-CDR2, and HC-CDR3 comprising an amino acid sequence
as set forth in SEQ ID No: 11, 12, and 13, respectively, and a
light chain comprising a light chain (LC)-CDR1, LC-CDR2, and
LC-CDR3 comprising an amino acid sequence as set forth in SEQ ID
Nos: 14, 15, and 16, respectively; d) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising a heavy chain (HC)-CDR1, HC-CDR2, and HC-CDR3 comprising
an amino acid sequence as set forth in SEQ ID Nos: 245, 246, and
247, respectively, and a light chain comprising alight chain
(LC)-CDR1, LC-CDR2, and LC-CDR3 comprising an amino acid sequence
as set forth in SEQ ID Nos: 248, 249, and 250, respectively; e) an
anti-CD117 antibody, or antigen binding fragment thereof,
comprising a heavy chain comprising a variable region comprising an
amino acid sequence as set forth in SEQ ID NO: 9 and a light chain
comprising a variable region comprising an amino acid sequence as
set forth in SEQ ID NO: 10; and f) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising a variable region comprising an amino acid sequence as
set forth in SEQ ID NO: 243, and alight chain comprising a variable
region comprising an amino acid sequence as set forth in SEQ ID NO:
244.
2. The ADC of claim 1, having the structure of formula (Ia):
##STR00083##
3. The ADC of claim 1, having the structure of formula (Ib):
##STR00084##
4. The ADC of claim 1 wherein L comprises one or more of a bond,
--(C.dbd.O)--, a --C(O)NH-- group, an --OC(O)NH-- group,
C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 heteroalkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 heteroalkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6 heteroalkynylene,
C.sub.3-C.sub.6 cycloalkylene, heterocycloalkylene, arylene,
heteroarylene, a --(CH.sub.2CH.sub.2O).sub.p-- group where p is an
integer from 1-6, or a solubility enhancing group; wherein each
C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 heteroalkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 heteroalkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6 heteroalkynylene,
C.sub.3-C.sub.6 cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene may optionally be substituted with from 1 to 5
substituents independently selected for each occasion from the
group consisting of alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, alkaryl, alkyl heteroaryl, amino, ammonium, acyl,
acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido,
carbamate, aryl, heteroaryl, sulfinyl, sulfonyl, hydroxyl, alkoxy,
sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy,
mercapto, and nitro; or each C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 heteroalkenylene, C.sub.2-C.sub.6 alkynylene,
C.sub.2-C.sub.6 heteroalkynylene, C.sub.3-C.sub.6 cycloalkylene,
heterocycloalkylene, arylene, or heteroarylene may optionally be
interrupted by one or more heteroatoms selected from O, S and
N.
5. The ADC of claim 4, wherein the solubility enhancing group has
the formula --O.sub.a--C(O)NH--SO.sub.2--NR.sup.1--, wherein: a is
0 or 1; and R.sup.1 is selected from the group consisting of
hydrogen, C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24
cycloalkyl groups, C.sub.2-C.sub.24 (hetero)aryl groups,
C.sub.3-C.sub.24 alkyl(hetero)aryl groups and C.sub.3-C.sub.24
(hetero)arylalkyl groups, each of which may be optionally
substituted or optionally interrupted by one or more heteroatoms
selected from O, S and NR.sup.3, wherein R.sup.3 is independently
selected from the group consisting of hydrogen and C.sub.1-C.sub.4
alkyl.
6. The ADC of claim 1, wherein L comprises a --(CH.sub.2).sub.n--
unit, where n is an integer from 2-6.
7. The ADC of claim 6, wherein L is --(CH.sub.2).sub.n--, where n
is 6.
8. The ADC of claim 7, wherein Ab, Z, and L, taken together as
Ab-Z-L, is represented by the formula: ##STR00085## wherein S is
the sulfur atom of a cysteine residue present in the antibody, or
the antigen-binding fragment thereof.
9. An antibody-drug conjugate (ADC) comprising an antibody, or an
antigen-binding fragment thereof, conjugated to an amatoxin via a
linker, the ADC having the structure of formula (I): ##STR00086##
or a stereoisomer thereof; wherein: Q is S; L is a cleavable
linker; Z is a chemical moiety formed by a coupling reaction
between a reactive substituent present on L and a reactive
substituent present within the antibody, or antigen-binding
fragment thereof; and Ab is the antibody, or the antigen binding
fragment thereof, wherein the antibody, or the antigen binding
fragment thereof, is selected from the group consisting of a) an
anti-CD117 antibody, or antigen binding fragment thereof,
comprising a heavy chain comprising an HC-CDR1, an HC-CDR2, and an
HC-CDR3 or a variable region from the heavy chain variable region
amino acid sequence of Ab55, Ab54, Ab56, Ab57, Ab58, Ab61, Ab66,
Ab67, Ab68, Ab69, Ab85, Ab86, Ab87, Ab88, Ab89, Ab77, Ab79, Ab81,
Ab85, or Ab249; and a light chain comprising an HC-CDR1, an
HC-CDR2, and an HC-CDR3 or a variable region from the light chain
variable region amino acid sequence of Ab55, Ab54, Ab56, Ab57,
Ab58, Ab61, Ab66, Ab67, Ab68, Ab69, Ab85, Ab86, Ab87, Ab88, Ab89,
Ab77, Ab79, Ab81, Ab85, or Ab249; b) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 or a variable
region from the heavy chain variable region amino acid sequence of
SEQ ID NO: 147, 164, 166, 168, 170, 172, 174, 176, 178, 180, 183,
185, 187, 189, 191, 193, 195, 197, 199, 201, 202, 204, 206, 208,
210, 212, 214, 216, 218, 220, 222, 224, 226, 238, or 243; and a
light chain comprising an LC-CDR1, an LC-CDR2, and an LC-CDR3 or a
variable region from the light chain variable region amino acid
sequence of SEQ ID NO: 148, 149, 150, 151, 152, 153, 154, 155, 156,
157, 158, 159, 160, 161, 162, 163, 165, 167, 169, 171, 173, 175,
177, 179, 181, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200,
203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227,
228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240, 241,
242, or 244; c) an anti-CD117 antibody, or antigen binding fragment
thereof, comprising a heavy chain comprising a heavy chain
(HC)-CDR1, HC-CDR2, and HC-CDR3 comprising an amino acid sequence
as set forth in SEQ ID No: 11, 12, and 13, respectively, and a
light chain comprising a light chain (LC)-CDR1, LC-CDR2, and
LC-CDR3 comprising an amino acid sequence as set forth in SEQ ID
Nos: 14, 15, and 16, respectively; d) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising a heavy chain (HC)-CDR1, HC-CDR2, and HC-CDR3 comprising
an amino acid sequence as set forth in SEQ ID Nos: 245, 246, and
247, respectively, and a light chain comprising alight chain
(LC)-CDR1, LC-CDR2, and LC-CDR3 comprising an amino acid sequence
as set forth in SEQ ID Nos: 248, 249, and 250, respectively; e) an
anti-CD117 antibody, or antigen binding fragment thereof,
comprising a heavy chain comprising a variable region comprising an
amino acid sequence as set forth in SEQ ID NO: 9 and a light chain
comprising a variable region comprising an amino acid sequence as
set forth in SEQ ID NO: 10; and f) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising a variable region comprising an amino acid sequence as
set forth in SEQ ID NO: 243, and alight chain comprising a variable
region comprising an amino acid sequence as set forth in SEQ ID NO:
244.
10. The ADC of claim 9, having the structure of formula (Ia):
##STR00087##
11. The ADC of claim 9, having the structure of formula (Ib):
##STR00088##
12. The ADC of claim 9, wherein L comprises one or more of a
hydrazine, a disulfide, a thioether, an amino acid, a peptide
consisting of up to 10 amino acids, a p-aminobenzyl (PAB) group, a
heterocyclic self-immolative group, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 heteroalkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 heteroalkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.2-C.sub.6 heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl,
heterocycloalkyl, aryl, heteroaryl, a --(C.dbd.O)-- group, a
--C(O)NH-- group, an --OC(O)NH-- group, a
--(CH.sub.2CH.sub.2O).sub.p-- group where p is an integer from 1-6,
or a solubility enhancing group; wherein each C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 heteroalkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.2-C.sub.6 heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl group may be optionally
substituted with from 1 to 5 substituents independently selected
for each occasion from the group consisting of alkyl, alkenyl,
alkynyl, cycloalkyl, heterocycloalkyl, alkaryl, alkyl heteroaryl,
amino, ammonium, acyl, acyloxy, acylamino, aminocarbonyl,
alkoxycarbonyl, ureido, carbamate, aryl, heteroaryl, sulfinyl,
sulfonyl, hydroxyl, alkoxy, sulfanyl, halogen, carboxy,
trihalomethyl, cyano, hydroxy, mercapto, and nitro; or each
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 heteroalkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.2-C.sub.6 heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl group may optionally be
interrupted by one or more heteroatoms selected from O, S and
N.
13. The ADC of claim 12, wherein the solubility enhancing group has
the formula --O.sub.a--C(O)NH--SO.sub.2--NR.sup.1--, wherein: a is
0 or 1; and R.sup.1 is selected from the group consisting of
hydrogen, C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24
cycloalkyl groups, C.sub.2-C.sub.24 (hetero)aryl groups,
C.sub.3-C.sub.24 alkyl(hetero)aryl groups and C.sub.3-C.sub.24
(hetero)arylalkyl groups, each of which may be optionally
substituted or optionally interrupted by one or more heteroatoms
selected from O, S and NR.sup.3, wherein R.sup.3 is independently
selected from the group consisting of hydrogen and C.sub.1-C.sub.4
alkyl.
14. The ADC of claim 9, wherein L comprises a peptide selected from
the group consisting of Phe-Lys, Val-Lys, Phe-Ala, Phe-Cit,
Val-Ala, Val-Cit, and Val-Arg.
15. The ADC of claim 14, further comprising a PAB group.
16. The ADC of claim 15, wherein L is represented by the formula:
##STR00089##
17. An ADC comprising an antibody conjugated to an amatoxin, the
ADC having a structure according to formula (II): ##STR00090## or a
stereoisomer thereof, wherein Ab is an antibody, or an antigen
binding fragment thereof, selected from the group consisting of a)
an anti-CD117 antibody, or an antigen binding fragment thereof,
comprising a heavy chain comprising an HC-CDR1, an HC-CDR2, and an
HC-CDR3 or a variable region from the heavy chain variable region
amino acid sequence of Ab55, Ab54, Ab56, Ab57, Ab58, Ab61, Ab66,
Ab67, Ab68, Ab69, Ab85, Ab86, Ab87, Ab88, Ab89, Ab77, Ab79, Ab81,
Ab85, or Ab249; and a light chain comprising an HC-CDR1, an
HC-CDR2, and an HC-CDR3 or a variable region from the light chain
variable region amino acid sequence of Ab55, Ab54, Ab56, Ab57,
Ab58, Ab61, Ab66, Ab67, Ab68, Ab69, Ab85, Ab86, Ab87, Ab88, Ab89,
Ab77, Ab79, Ab81, Ab85, or Ab249; b) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 or a variable
region from the heavy chain variable region amino acid sequence of
SEQ ID NO: 147, 164, 166, 168, 170, 172, 174, 176, 178, 180, 183,
185, 187, 189, 191, 193, 195, 197, 199, 201, 202, 204, 206, 208,
210, 212, 214, 216, 218, 220, 222, 224, 226, 238, or 243; and a
light chain comprising an LC-CDR1, an LC-CDR2, and an LC-CDR3 or a
variable region from the light chain variable region amino acid
sequence of SEQ ID NO: 148, 149, 150, 151, 152, 153, 154, 155, 156,
157, 158, 159, 160, 161, 162, 163, 165, 167, 169, 171, 173, 175,
177, 179, 181, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200,
203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227,
228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240, 241,
242, or 244; c) an anti-CD117 antibody, or antigen binding fragment
thereof, comprising a heavy chain comprising a heavy chain
(HC)-CDR1, HC-CDR2, and HC-CDR3 comprising an amino acid sequence
as set forth in SEQ ID No: 11, 12, and 13, respectively, and a
light chain comprising a light chain (LC)-CDR1, LC-CDR2, and
LC-CDR3 comprising an amino acid sequence as set forth in SEQ ID
Nos: 14, 15, and 16, respectively; d) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising a heavy chain (HC)-CDR1, HC-CDR2, and HC-CDR3 comprising
an amino acid sequence as set forth in SEQ ID Nos: 245, 246, and
247, respectively, and a light chain comprising alight chain
(LC)-CDR1, LC-CDR2, and LC-CDR3 comprising an amino acid sequence
as set forth in SEQ ID Nos: 248, 249, and 250, respectively; e) an
anti-CD117 antibody, or antigen binding fragment thereof,
comprising a heavy chain comprising a variable region comprising an
amino acid sequence as set forth in SEQ ID NO: 9 and a light chain
comprising a variable region comprising an amino acid sequence as
set forth in SEQ ID NO: 10; and f) an anti-CD117 antibody, or
antigen binding fragment thereof, comprising a heavy chain
comprising a variable region comprising an amino acid sequence as
set forth in SEQ ID NO: 243, and alight chain comprising a variable
region comprising an amino acid sequence as set forth in SEQ ID NO:
244.
18. The ADC of claim 17, having the structure of formula (IIa):
##STR00091##
19. The ADC of claim 17, having the structure of formula (IIb):
##STR00092##
20. The ADC of any one of claims 1, 9, or 17, wherein the antibody,
or the antigen binding fragment thereof, comprises either an Fc
region comprising at least one mutation selected from the group
consisting of D265C, H435A, L234A, or L235A (according to EU
index); or an Fc region comprising D265C, H435A, L234A, or L235A
(according to EU index) mutations.
21. A method of depleting a population of cells in a human subject,
said method comprising administering the ADC of any one of claims
1, 9, or 17, to the subject, wherein the ADC comprises an antibody,
or an antigen-binding fragment thereof, that specifically binds to
an extracellular antigen expressed by cells in the population of
cells.
22. A method of conditioning a human subject for cell
transplantation, said method comprising administering the ADC of
any one of claims 1, 9, or 17, to the human subject such that the
endogenous stem or endogenous immune cells in the human subject are
depleted, wherein the ADC specifically binds to an extracellular
antigen expressed by the endogenous stem or endogenous immune
cells.
23. The method of claim 21, further comprising administering to the
human subject allogenic stem cells or allogeneic immune cells.
24. A pharmaceutical composition comprising the ADC of any one of
claims 1, 9, or 17, and a pharmaceutically acceptable carrier.
Description
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application No. 62/838,290, filed on Apr. 24, 2019. The contents of
the priority application are hereby incorporated by reference
herein.
FIELD
[0002] The present invention relates to amatoxins, Antibody-Drug
Conjugates (ADCs) comprising an amatoxin, compositions comprising
such ADCs, and methods for using the same.
BACKGROUND
[0003] Monoclonal antibodies (mAb) can be conjugated to a
therapeutic agent to form an antibody drug conjugate (ADC). ADCs
can exhibit increased efficacy, as compared to an unconjugated
antibody. The linkage of the antibody to the drug can be direct, or
indirect via a linker. An important aspect of successful
therapeutic ADCs is that the ADC be not only effective but
well-tolerated. Often the cytotoxin impacts both efficacy and
tolerability.
[0004] ADCs have been proposed as a therapeutic regimen for
preparing patients for transplant and stem cell therapy. By
conditioning a patient with a cell-specific ADC, stem cells or
immune cells can be selectively depleted while leaving the
patient's remaining immune system largely intact. For example,
Palchaudhuri et al. (2016) Nat. Biotechnol. 34, 738-745 describes
the use of a single dose of an anti-CD45 ADC where an anti-CD45
antibody was conjugated to saporin, and its ability to enable
engraftment of donor cells and for treatment in a sickle-cell
anemia model. Unlike irradiation, the CD45-SAP ADC was reported to
have avoided neutropenia and anemia, and provided for rapid
recovery of T and B cells with minimal overall toxicity. There
remains a need for toxins that can be used for non-genotoxic
targeted ADC-conditioning where the toxin is potent to the target
cells while minimizing patient side effects.
SUMMARY
[0005] The present invention provides an amatoxin that can be used
in an antibody drug conjugate (ADC), e.g., for delivery of the
amatoxin to a target cell.
[0006] Presented herein is an antibody-drug conjugate (ADC)
comprising an antibody, or an antigen-binding fragment thereof,
conjugated to an amatoxin via a linker, wherein the ADC has the
structure of formula (I):
##STR00001##
[0007] or a stereoisomer thereof;
[0008] wherein: [0009] Q is S; [0010] L is a non-cleavable linker;
[0011] Z is a chemical moiety formed by a coupling reaction between
a reactive substituent present on L and a reactive substituent
present within the antibody, or antigen-binding fragment thereof;
and [0012] Ab is the antibody, or the antigen binding fragment
thereof.
[0013] In certain embodiments, an ADC disclosed herein has the
structure of formula (Ia):
##STR00002##
[0014] In other embodiments, an ADC disclosed herein has the
structure of formula (b):
##STR00003##
[0015] In certain embodiments, L comprises one or more of a bond,
--(C.dbd.O)--, a --C(O)NH-- group, an --OC(O)NH-- group,
C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 heteroalkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 heteroalkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6 heteroalkynylene,
C.sub.3-C.sub.6 cycloalkylene, heterocycloalkylene, arylene,
heteroarylene, a --(CH.sub.2CH.sub.2O).sub.p-- group where p is an
integer from 1-6, or a solubility enhancing group; wherein each
C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 heteroalkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 heteroalkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6 heteroalkynylene,
C.sub.3-C.sub.6 cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene may optionally be substituted with from 1 to 5
substituents independently selected for each occasion from the
group consisting of alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, alkaryl, alkyl heteroaryl, amino, ammonium, acyl,
acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido,
carbamate, aryl, heteroaryl, sulfinyl, sulfonyl, hydroxyl, alkoxy,
sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy,
mercapto, and nitro; or each C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 heteroalkenylene, C.sub.2-C.sub.6 alkynylene,
C.sub.2-C.sub.6 heteroalkynylene, C.sub.3-C.sub.6 cycloalkylene,
heterocycloalkylene, arylene, or heteroarylene may optionally be
interrupted by one or more heteroatoms selected from O, S and
N.
[0016] In some embodiments, the solubility enhancing group has the
formula --O.sub.a--C(O)NH--SO.sub.2--NR.sup.1--, wherein: [0017] a
is 0 or 1; and [0018] R.sup.1 is selected from the group consisting
of hydrogen, C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24
cycloalkyl groups, C.sub.2-C.sub.24 (hetero)aryl groups,
C.sub.3-C.sub.24 alkyl(hetero)aryl groups and C.sub.3-C.sub.24
(hetero)arylalkyl groups, each of which may be optionally
substituted or optionally interrupted by one or more heteroatoms
selected from O, S and NR.sup.3, wherein R.sup.3 is independently
selected from the group consisting of hydrogen and C.sub.1-C.sub.4
alkyl.
[0019] In some embodiments, L comprises a --(CH.sub.2).sub.n--
unit, where n is an integer from 2-6, e.g., n is 6.
[0020] In some embodiments, wherein Ab, Z, and L, taken together as
Ab-Z-L, is represented by the formula:
##STR00004##
wherein S is the sulfur atom of a cysteine residue present in the
antibody, or the antigen-binding fragment thereof.
[0021] Also disclosed herein is an antibody-drug conjugate (ADC)
comprising an antibody, or an antigen-binding fragment thereof,
conjugated to an amatoxin via a linker, the ADC having the
structure of formula (I):
##STR00005##
[0022] or a stereoisomer thereof;
[0023] wherein: [0024] Q is S; [0025] L is a cleavable linker;
[0026] Z is a chemical moiety formed by a coupling reaction between
a reactive substituent present on L and a reactive substituent
present within the antibody, or antigen-binding fragment thereof;
and [0027] Ab is the antibody, or the antigen binding fragment
thereof.
[0028] In one embodiment, the ADC has a structure of formula
(Ia):
##STR00006##
[0029] In another embodiment, the ADC has the structure of formula
(b):
##STR00007##
[0030] In one embodiment, L comprises one or more of a hydrazine, a
disulfide, a thioether, an amino acid, a peptide consisting of up
to 10 amino acids, a p-aminobenzyl (PAB) group, a heterocyclic
self-immolative group, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
heteroalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
heteroalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6
heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl, heterocycloalkyl, aryl,
heteroaryl, a --(C.dbd.O)-- group, a --C(O)NH-- group, an
--OC(O)NH-- group, a --(CH.sub.2CH.sub.2O).sub.p-- group where p is
an integer from 1-6, or a solubility enhancing group; wherein each
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 heteroalkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.2-C.sub.6 heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl group may be optionally
substituted with from 1 to substituents independently selected for
each occasion from the group consisting of alkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, alkaryl, alkyl heteroaryl, amino,
ammonium, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl,
ureido, carbamate, aryl, heteroaryl, sulfinyl, sulfonyl, hydroxyl,
alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy,
mercapto, and nitro; or each C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
heteroalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
heteroalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6
heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl, heterocycloalkyl, aryl,
or heteroaryl group may optionally be interrupted by one or more
heteroatoms selected from O, S and N.
[0031] In one embodiment, the solubility enhancing group has the
formula --O.sub.a--C(O)NH--SO.sub.2--NR.sup.1--, wherein: [0032] a
is 0 or 1; and [0033] R.sup.1 is selected from the group consisting
of hydrogen, C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24
cycloalkyl groups, C.sub.2-C.sub.24 (hetero)aryl groups,
C.sub.3-C.sub.24 alkyl(hetero)aryl groups and C.sub.3-C.sub.24
(hetero)arylalkyl groups, each of which may be optionally
substituted or optionally interrupted by one or more heteroatoms
selected from O, S and NR.sup.3, wherein R.sup.3 is independently
selected from the group consisting of hydrogen and C.sub.1-C.sub.4
alkyl.
[0034] In certain embodiments, L comprises a peptide selected from
the group consisting of Phe-Lys, Val-Lys, Phe-Ala, Phe-Cit,
Val-Ala, Val-Cit, and Val-Arg.
[0035] In certain embodiments, an ADC described herein further
comprises a PAB group.
[0036] In one embodiment, L is represented by the formula:
##STR00008##
[0037] Also disclosed herein is an ADC comprising an antibody
conjugated to an amatoxin, the ADC having a structure according to
formula (II):
##STR00009## [0038] or a stereoisomer thereof, wherein Ab is an
antibody, or an antigen binding fragment thereof.
[0039] In one embodiment, the ADC has the structure of formula
(IIa):
##STR00010##
[0040] In another embodiment, the ADC has the structure of formula
(Ib):
##STR00011##
[0041] In certain embodiments, an antibody, or antigen-binding
fragment of an antibody, used in the ADCs described herein, has
binding regions disclosed in the Sequence Table,
[0042] In one embodiment, the antibody, or the antigen binding
fragment thereof, comprises either an Fc region comprising at least
one mutation selected from the group consisting of D265C, H435A,
L234A, or L235A (according to EU index); or an Fc region comprising
D265C, H435A, L234A, or L235A (according to EU index)
mutations.
[0043] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD117.
[0044] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD45.
[0045] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD137.
[0046] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD5.
[0047] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD2.
[0048] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD117 and comprises a
heavy chain comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 or a
variable region from the heavy chain variable region amino acid
sequence of Ab55, Ab54, Ab56, Ab57, Ab58, Ab61, Ab66, Ab67, Ab68,
Ab69, Ab85, Ab86, Ab87, Ab88, Ab89, Ab77, Ab79, Ab81, Ab85, or
Ab249; and a light chain comprising an HC-CDR1, an HC-CDR2, and an
HC-CDR3 or a variable region from the light chain variable region
amino acid sequence of Ab55, Ab54, Ab56, Ab57, Ab58, Ab61, Ab66,
Ab67, Ab68, Ab69, Ab85, Ab86, Ab87, Ab88, Ab89, Ab77, Ab79, Ab81,
Ab85, or Ab249;
[0049] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD117 and comprises a
heavy chain comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 or a
variable region from the heavy chain variable region amino acid
sequence of SEQ ID NO: 147, 164, 166, 168, 170, 172, 174, 176, 178,
180, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 202, 204,
206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 238, or 243;
and a light chain comprising an LC-CDR1, an LC-CDR2, and an LC-CDR3
or a variable region from the light chain variable region amino
acid sequence of SEQ ID NO: 148, 149, 150, 151, 152, 153, 154, 155,
156, 157, 158, 159, 160, 161, 162, 163, 165, 167, 169, 171, 173,
175, 177, 179, 181, 182, 184, 186, 188, 190, 192, 194, 196, 198,
200, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225,
227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240,
241, 242, or 244.
[0050] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD117 and comprises a
heavy chain comprising a heavy chain (HC)-CDR1, HC-CDR2, and
HC-CDR3 comprising an amino acid sequence as set forth in SEQ ID
No: 11, 12, and 13, respectively, and a light chain comprising a
light chain (LC)-CDR1, LC-CDR2, and LC-CDR3 comprising an amino
acid sequence as set forth in SEQ ID Nos: 14, 15, and 16,
respectively.
[0051] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD117 and comprises a
heavy chain comprising a heavy chain (HC)-CDR1, HC-CDR2, and
HC-CDR3 comprising an amino acid sequence as set forth in SEQ ID
Nos: 245, 246, and 247, respectively, and a light chain comprising
a light chain (LC)-CDR1, LC-CDR2, and LC-CDR3 comprising an amino
acid sequence as set forth in SEQ ID Nos: 248, 249, and 250,
respectively.
[0052] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD117 and comprises a
heavy chain comprising a variable region comprising an amino acid
sequence as set forth in SEQ ID NO: 9 and a light chain comprising
a variable region comprising an amino acid sequence as set forth in
SEQ ID NO: 10.
[0053] In one embodiment, the antibody, or the antigen binding
fragment thereof, specifically binds to human CD117 and comprises a
heavy chain comprising a variable region comprising an amino acid
sequence as set forth in SEQ ID NO: 243, and a light chain
comprising a variable region comprising an amino acid sequence as
set forth in SEQ ID NO: 244.
[0054] Also disclosed herein is a method of depleting a population
of cells in a human subject, said method comprising administering
an ADC disclosed herein to the subject, wherein the ADC comprises
an antibody, or an antigen-binding fragment thereof, that
specifically binds to an extracellular antigen expressed by cells
in the population of cells.
[0055] Also provided is a method of conditioning a human subject
for cell transplantation, said method comprising administering an
ADC disclosed herein, to the human subject such that the endogenous
stem or endogenous immune cells in the human subject are depleted,
wherein the ADC specifically binds to an extracellular antigen
expressed by the endogenous stem or endogenous immune cells.
[0056] In one embodiment, the method further comprises
administering to the human subject allogenic stem cells or
allogeneic immune cells.
[0057] Also provided is a pharmaceutical composition comprising an
ADC disclosed herein, and a pharmaceutically acceptable
carrier.
BRIEF DESCRIPTION OF FIGURES
[0058] FIG. 1 depicts the structures of formulae IV (FIG. 1A), VI
(FIG. 1B), and IIa (FIG. 1C). "Ab" in FIGS. 1A to 1C represents an
antibody. FIGS. 1A, 1B, and 1C represent Conjugates A, B, and C,
respectively, referred to in the examples. Conjugates A, B, and C
are also referred to as ADC A, ADC B, and ADC C.
[0059] FIG. 2 graphically depicts results from in vitro cytoxicity
assays using Kasumi-1 cells in the presence of ADC with
pre-incubation of ADC in media (A) or 50% human serum (B) to
evaluate serum stability of conjugates.
[0060] FIG. 3 graphically depicts results from in vitro cytoxicity
assays using Kasumi-1 cells in the presence of ADC with iteration
on the time of incubation with titrated ADC samples to evaluate
differences in the kinetics of cytotoxicity between cleavable and
non-cleavable conjugates.
[0061] FIG. 4 graphically depicts results from two in vitro cell
killing assays using Kasumi-1 cells (4A) and CD34+ cells (4B). The
ADC tested was anti-CD117 ADC C.
[0062] FIG. 5 graphically depicts the ability of anti-CD117 ADC C
to potently deplete human CD34+ in the bone marrow of humanized NSG
mice.
[0063] FIG. 6 are Kaplan Meier plots reflecting the survival of
Kasumi-1 implanted humanized NSG mice treated with the indicated
doses of conjugates or controls.
[0064] FIG. 7 graphically depicts the efficacy of Conjugate C as
evaluated in male cynomolgus monkeys. 2.0 mg/kg dose (LALA) 30.2867
batch issues may have resulted in a decrease in HSC sensitivity
[0065] FIG. 8 graphically depicts tolerability of ADCs containing
either Conjugate A or Conjugate C in male cynomolgus monkeys.
[0066] FIG. 9 graphically depicts pharmacokinetic analysis of
conjugate A and conjugate C administered to male cynomolgus
monkeys.
[0067] FIG. 10 graphically depicts that anti-CD2 and CD5 ADC C are
able to deplete T cells.
[0068] FIG. 11 graphically depicts that while anti-CD2 ADCs A and C
are saturated by Day 5, some cells still express CD5.
[0069] FIGS. 12A and 12B graphically depict results showing
anti-CD45 ADCs A or C (FIG. 14A) or anti-CD45 ADCs A or B (FIG.
14B) in in vitro cell killing assays.
[0070] FIG. 13 graphically depicts results showing anti-CD45 ADCs A
or C in in vitro cell killing assays.
[0071] FIG. 14 graphically depicts results of anti-CD45 ADCs A or C
in in vivo cell depletion experiments.
[0072] FIG. 15 graphically depicts results from administration of
anti-CD45 ADCs A or C to mice at a number of dose amounts. Levels
of peripheral lymphocytes, HSCs, and lymphocytes are shown. All
ADCs were administered at 1 mg/kg.
[0073] FIG. 16 graphically depicts results showing anti-CD137 ADCs
A and C in a T cell killing assay.
[0074] FIG. 17 graphically depicts cell line serum stability of
anti-CD137 ADCs A and C over 48 hours.
DETAILED DESCRIPTION
[0075] For clarity of disclosure, and not by way of limitation, the
detailed description of the invention is divided into the
subsections which follow.
Definitions
[0076] Unless stated otherwise, the following terms and phrases as
used herein are intended to have the following meanings.
[0077] The term "acyl" as used herein refers to --C(.dbd.O)R,
wherein R is hydrogen ("aldehyde"), C.sub.1-C.sub.12 alkyl,
C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, C.sub.3-C.sub.7
carbocyclyl, C.sub.6-C.sub.20 aryl, 5-10 membered heteroaryl, or
5-10 membered heterocyclyl, as defined herein. Non-limiting
examples include formyl, acetyl, propanoyl, benzoyl, and
acryloyl.
[0078] The term "C.sub.1-C.sub.12 alkyl" as used herein refers to a
straight chain or branched, saturated hydrocarbon having from 1 to
12 carbon atoms. Representative C.sub.1-C.sub.12 alkyl groups
include, but are not limited to, -methyl, -ethyl, -n-propyl,
-n-butyl, -n-pentyl, and -n-hexyl; while branched C.sub.1-C.sub.12
alkyls include, but are not limited to, -isopropyl, -sec-butyl,
-isobutyl, -tert-butyl, -isopentyl, and 2-methylbutyl. A
C.sub.1-C.sub.12 alkyl group can be unsubstituted or
substituted.
[0079] The term "alkenyl" as used herein refers to C.sub.2-C.sub.12
hydrocarbon containing normal, secondary, or tertiary carbon atoms
with at least one site of unsaturation, i.e., a carbon-carbon,
sp.sup.2 double bond. Examples include, but are not limited to:
ethylene or vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl,
-1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl,
-2,3-dimethyl-2-butenyl, and the like. An alkenyl group can be
unsubstituted or substituted.
[0080] "Alkynyl" as used herein refers to a C.sub.2-C.sub.12
hydrocarbon containing normal, secondary, or tertiary carbon atoms
with at least one site of unsaturation, i.e., a carbon-carbon, sp
triple bond. Examples include, but are not limited to acetylenic
and propargyl. An alkynyl group can be unsubstituted or
substituted.
[0081] "Aryl" as used herein refers to a C.sub.6-C.sub.20
carbocyclic aromatic group. Examples of aryl groups include, but
are not limited to, phenyl, naphthyl and anthracenyl. An aryl group
can be unsubstituted or substituted.
[0082] "Arylalkyl" as used herein refers to an acyclic alkyl
radical in which one of the hydrogen atoms bonded to a carbon atom,
typically a terminal or sp.sup.3 carbon atom, is replaced with an
aryl radical. Typical arylalkyl groups include, but are not limited
to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl,
2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl,
2-naphthophenylethan-1-yl and the like. The arylalkyl group
comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including
alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to
6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms. An
alkaryl group can be unsubstituted or substituted.
[0083] "Cycloalkyl" as used herein refers to a saturated
carbocyclic radical, which may be mono- or bicyclic. Cycloalkyl
groups include a ring having 3 to 7 carbon atoms as a monocycle or
7 to 12 carbon atoms as a bicycle. Examples of monocyclic
cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, and cyclooctyl. A cycloalkyl group can be
unsubstituted or substituted.
[0084] "Cycloalkenyl" as used herein refers to an unsaturated
carbocyclic radical, which may be mono- or bicyclic. Cycloalkenyl
groups include a ring having 3 to 6 carbon atoms as a monocycle or
7 to 12 carbon atoms as a bicycle. Examples of monocyclic
cycloalkenyl groups include 1-cyclopent-1-enyl, 1-cyclopent-2-enyl,
1-cyclopent-3-enyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, and
1-cyclohex-3-enyl. A cycloalkenyl group can be unsubstituted or
substituted.
[0085] "Heteroaralkyl" as used herein refers to an acyclic alkyl
radical in which one of the hydrogen atoms bonded to a carbon atom,
typically a terminal or sp.sup.3 carbon atom, is replaced with a
heteroaryl radical. Typical heteroarylalkyl groups include, but are
not limited to, 2-benzimidazolylmethyl, 2-furylethyl, and the like.
The heteroarylalkyl group comprises 6 to 20 carbon atoms, e.g. the
alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the
heteroarylalkyl group is 1 to 6 carbon atoms and the heteroaryl
moiety is 5 to 14 carbon atoms and 1 to 3 heteroatoms selected from
N, O, P, and S. The heteroaryl moiety of the heteroarylalkyl group
may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms
or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1
to 3 heteroatoms selected from N, O, P, and S), for example: a
bicyclo[4,5], [5,5], [5,6], or [6,6] system.
[0086] "Heteroaryl" and "heterocycloalkyl" as used herein refer to
an aromatic or non-aromatic ring system, respectively, in which one
or more ring atoms is a heteroatom, e.g. nitrogen, oxygen, and
sulfur. The heteroaryl or heterocycloalkyl radical comprises 2 to
20 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and
S. A heteroaryl or heterocycloalkyl may be a monocycle having 3 to
7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected
from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to
9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and
S), for example: a bicyclo[4,5], [5,5], [5,6], or [6,6] system.
Heteroaryl and heterocycloalkyl can be unsubstituted or
substituted.
[0087] Heteroaryl and heterocycloalkyl groups are described in
Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (W.
A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7,
and 9; "The Chemistry of Heterocyclic Compounds, A series of
Monographs" (John Wiley & Sons, New York, 1950 to present), in
particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc.
(1960) 82:5566.
[0088] Examples of heteroaryl groups include by way of example and
not limitation pyridyl, thiazolyl, tetrahydrothiophenyl,
pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,
tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl,
quinolinyl, isoquinolinyl, benzimidazolyl, isoxazolyl, pyrazinyl,
pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazolyl,
purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl,
quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl,
carbazolyl, phenanthridinyl, acridinyl, pyrimidinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl,
phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl,
imidazolinyl, pyrazolidinyl, pyrazolinyl, benzotriazolyl,
benzisoxazolyl, and isatinoyl.
[0089] Examples of heterocycloalkyls include by way of example and
not limitation dihydroypyridyl, tetrahydropyridyl (piperidyl),
tetrahydrothiophenyl, piperidinyl, 4-piperidonyl, pyrrolidinyl,
2-pyrrolidonyl, tetrahydrofuranyl, tetrahydropyranyl,
bis-tetrahydropyranyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, decahydroquinolinyl,
octahydroisoquinolinyl, piperazinyl, quinuclidinyl, and
morpholinyl.
[0090] By way of example and not limitation, carbon bonded
heteroaryls and heterocycloalkyls are bonded at position 2, 3, 4,
5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine,
position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a
pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran,
thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4,
or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of
an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an
aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4,
5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of
an isoquinoline. Still more typically, carbon bonded heterocycles
include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl,
3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl,
2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl,
4-thiazolyl, or 5-thiazolyl.
[0091] By way of example and not limitation, nitrogen bonded
heteroaryls and heterocycloalkyls are bonded at position 1 of an
aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline,
3-pyrroline, imidazole, imidazolidine, 2-imidazoline,
3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline,
piperidine, piperazine, indole, indoline, 1H-indazole, position 2
of a isoindole, or isoindoline, position 4 of a morpholine, and
position 9 of a carbazole, or beta-carboline. Still more typically,
nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl,
1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
[0092] "Substituted" as used herein and as applied to any of the
above alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl,
heteroaryl, heterocyclyl, and the like, means that one or more
hydrogen atoms are each independently replaced with a substituent.
Unless otherwise constrained by the definition of the individual
substituent, the foregoing chemical moieties, such as "alkyl",
"alkylene", "heteroalkyl", "heteroalkylene", "alkenyl",
"alkenylene", "heteroalkenyl", "heteroalkenylene", "alkynyl",
"alkynylene", "heteroalkynyl", "heteroalkynylene", "cycloalkyl",
"cycloalkylene", "heterocycloalkyl", heterocycloalkylene", "aryl,"
"arylene", "heteroaryl", and "heteroarylene" groups can optionally
be substituted. Typical substituents include, but are not limited
to, --X, --R, --OH, --OR, --SH, --SR, NH.sub.2, --NHR,
--N(R).sub.2, --N.sup.+(R).sub.3, --CX.sub.3, --CN, --OCN, --SCN,
--NCO, --NCS, --NO, --NO.sub.2, --N.sub.3, --NC(.dbd.O)H,
--NC(.dbd.O)R, --C(.dbd.O)H, --C(.dbd.O)R, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)N(R).sub.2, --SO.sub.3--, --SO.sub.3H,
--S(.dbd.O).sub.2R, --OS(.dbd.O).sub.2OR,
--S(.dbd.O).sub.2NH.sub.2, --S(.dbd.O).sub.2N(R).sub.2,
--S(.dbd.O)R, --OP(.dbd.O)(OH).sub.2, --OP(.dbd.O)(OR).sub.2,
--P(.dbd.O)(OR).sub.2, --PO.sub.3, --PO.sub.3H.sub.2, --C(.dbd.O)X,
--C(.dbd.S)R, --CO.sub.2H, --CO.sub.2R, --CO.sub.2--,
--C(.dbd.S)OR, --C(.dbd.O)SR, --C(.dbd.S)SR, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)N(R).sub.2, --C(.dbd.S)NH.sub.2, --C(.dbd.S)N(R).sub.2,
--C(.dbd.NH)NH.sub.2, and --C(.dbd.NR)N(R).sub.2; wherein each X is
independently selected for each occasion from F, C, Br, and I; and
each R is independently selected for each occasion from
C.sub.1-C.sub.12 alkyl, C.sub.6-C.sub.20 aryl, C.sub.3-C.sub.14
heterocycloalkyl or heteroaryl, protecting group and prodrug
moiety. Wherever a group is described as "optionally substituted,"
that group can be substituted with one or more of the above
substituents, independently for each occasion.
[0093] It is to be understood that certain radical naming
conventions can include either a mono-radical or a di-radical,
depending on the context. For example, where a substituent requires
two points of attachment to the rest of the molecule, it is
understood that the substituent is a di-radical. For example, a
substituent identified as alkyl that requires two points of
attachment includes di-radicals such as --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH(CH.sub.3)CH.sub.2--, and the
like. Other radical naming conventions clearly indicate that the
radical is a di-radical such as "alkylene," "alkenylene,"
"arylene," "heterocycloalkylene," and the like.
[0094] Wherever a substituent is depicted as a di-radical (i.e.,
has two points of attachment to the rest of the molecule), it is to
be understood that the substituent can be attached in any
directional configuration unless otherwise indicated.
[0095] "Isomerism" means compounds that have identical molecular
formulae but differ in the sequence of bonding of their atoms or in
the arrangement of their atoms in space. Isomers that differ in the
arrangement of their atoms in space are termed "stereoisomers."
Stereoisomers that are not mirror images of one another are termed
"diastereoisomers," and stereoisomers that are non-superimposable
mirror images of each other are termed "enantiomers," or sometimes
"optical isomers."
[0096] A carbon atom bonded to four non-identical substituents is
termed a "chiral center." "Chiral isomer" means a compound with at
least one chiral center. Compounds with more than one chiral center
may exist either as an individual diastereomer or as a mixture of
diastereomers, termed "diastereomeric mixture." When one chiral
center is present, a stereoisomer may be characterized by the
absolute configuration (R or S) of that chiral center. Absolute
configuration refers to the arrangement in space of the
substituents attached to the chiral center. The substituents
attached to the chiral center under consideration are ranked in
accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn
et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et
al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc.
1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J.
Chem. Educ. 1964, 41, 116). A mixture containing equal amounts of
individual enantiomeric forms of opposite chirality is termed a
"racemic mixture."
[0097] The compounds disclosed in this description and in the
claims may comprise one or more asymmetric centers, and different
diastereomers and/or enantiomers of each of the compounds may
exist. The description of any compound in this description and in
the claims is meant to include all enantiomers, diastereomers, and
mixtures thereof, unless stated otherwise. In addition, the
description of any compound in this description and in the claims
is meant to include both the individual enantiomers, as well as any
mixture, racemic or otherwise, of the enantiomers, unless stated
otherwise. When the structure of a compound is depicted as a
specific enantiomer, it is to be understood that the invention of
the present application is not limited to that specific enantiomer.
Accordingly, enantiomers, optical isomers, and diastereomers of
each of the structural formulae of the present disclosure are
contemplated herein. In the present specification, the structural
formula of the compound represents a certain isomer for convenience
in some cases, but the present disclosure includes all isomers,
such as geometrical isomers, optical isomers based on an
asymmetrical carbon, stereoisomers, tautomers, and the like, it
being understood that not all isomers may have the same level of
activity. The compounds may occur in different tautomeric forms.
The compounds according to the disclosure are meant to include all
tautomeric forms, unless stated otherwise. When the structure of a
compound is depicted as a specific tautomer, it is to be understood
that the invention of the present application is not limited to
that specific tautomer.
[0098] The compounds of any formula described herein include the
compounds themselves, as well as their salts, and their solvates,
if applicable. A salt, for example, can be formed between an anion
and a positively charged group (e.g., amino) on a compound of the
disclosure. Suitable anions include chloride, bromide, iodide,
sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate,
methanesulfonate, trifluoroacetate, glutamate, glucuronate,
glutarate, malate, maleate, succinate, fumarate, tartrate,
tosylate, salicylate, lactate, naphthalenesulfonate, and acetate
(e.g., trifluoroacetate). The term "pharmaceutically acceptable
anion" refers to an anion suitable for forming a pharmaceutically
acceptable salt. Likewise, a salt can also be formed between a
cation and a negatively charged group (e.g., carboxylate) on a
compound of the disclosure. Suitable cations include sodium ion,
potassium ion, magnesium ion, calcium ion, and an ammonium cation
such as tetramethylammonium ion. Examples of some suitable
substituted ammonium ions are those derived from: ethylamine,
diethylamine, dicyclohexylamine, triethylamine, butylamine,
ethylenediamine, ethanolamine, diethanolamine, piperazine,
benzylamine, phenylbenzylamine, choline, meglumine, and
tromethamine, as well as amino acids, such as lysine and arginine.
The compounds of the disclosure also include those salts containing
quaternary nitrogen atoms.
[0099] Examples of suitable inorganic anions include, but are not
limited to, those derived from the following inorganic acids:
hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric,
nitrous, phosphoric, and phosphorous. Examples of suitable organic
anions include, but are not limited to, those derived from the
following organic acids: 2-acetyoxybenzoic, acetic, ascorbic,
aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic,
ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic,
glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic,
isethionic, lactic, lactobionic, lauric, maleic, malic,
methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic,
pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic,
salicylic, stearic, succinic, sulfanilic, tartaric,
toluenesulfonic, and valeric. Examples of suitable polymeric
organic anions include, but are not limited to, those derived from
the following polymeric acids: tannic acid, carboxymethyl
cellulose.
[0100] Additionally, the compounds of the present disclosure, for
example, the salts of the compounds, can exist in either hydrated
or unhydrated (the anhydrous) form or as solvates with other
solvent molecules. Non-limiting examples of hydrates include
monohydrates, dihydrates, etc. Non-limiting examples of solvates
include ethanol solvates, acetone solvates, etc. "Solvate" means
solvent addition forms that contain either stoichiometric or
non-stoichiometric amounts of solvent. Some compounds have a
tendency to trap a fixed molar ratio of solvent molecules in the
crystalline solid state, thus forming a solvate. If the solvent is
water the solvate formed is a hydrate; and if the solvent is
alcohol, the solvate formed is an alcoholate. Hydrates are formed
by the combination of one or more molecules of water with one
molecule of the substance in which the water retains its molecular
state as H.sub.2O. A hydrate refers to, for example, a
mono-hydrate, a di-hydrate, a tri-hydrate, etc.
[0101] In addition, a crystal polymorphism may be present for the
compounds or salts thereof represented by the formulae disclosed
herein. It is noted that any crystal form, crystal form mixture, or
anhydride or hydrate thereof, is included in the scope of the
present disclosure.
[0102] As used herein, the term "about" refers to a value that is
within 10% above or below the value being described. For example,
the term "about 5 nM" indicates a range of from 4.5 nM to 5.5
nM.
[0103] As used herein, the term "amatoxin" refers to a member of
the amatoxin family of peptides produced by Amanita phalloides
mushrooms, or a variant or derivative thereof, such as a variant or
derivative thereof capable of inhibiting RNA polymerase II
activity. Suitable amatoxins and derivatives thereof are further
described herein below. As described herein, amatoxins may be
conjugated to an antibody, or antigen-binding fragment thereof, for
instance, by way of a linker moiety (L) (thus forming a conjugate
(i.e., ADC)). Exemplary methods of amatoxin conjugation and linkers
useful for such processes are described below.
[0104] As used herein, the term "antibody" refers to an
immunoglobulin molecule that specifically binds to, or is
immunologically reactive with, a particular antigen, and includes
monoclonal, genetically engineered, and otherwise modified forms of
antibodies, including but not limited to chimeric antibodies,
humanized antibodies, heteroconjugate antibodies (e.g., bi- tri-
and quad-specific antibodies, diabodies, triabodies, and
tetrabodies), and antigen binding fragments of antibodies,
including, for example, Fab', F(ab').sub.2, Fab, Fv, rIgG, and scFv
fragments. Unless otherwise indicated, the term "monoclonal
antibody" (mAb) is meant to include both intact molecules, as well
as antibody fragments (including, for example, Fab and F(ab').sub.2
fragments) that are capable of specifically binding to a target
protein. As used herein, the Fab and F(ab').sub.2 fragments refer
to antibody fragments that lack the Fc fragment of an intact
antibody. Examples of these antibody fragments are described
herein.
[0105] As used herein, the term "monoclonal antibody" refers to an
antibody that is derived from a single clone, including any
eukaryotic, prokaryotic, or phage clone, and not the method by
which it is produced.
[0106] The antibodies of the present invention are generally
isolated or recombinant. "Isolated," when used herein refers to a
polypeptide, e.g., an antibody, that has been separated and/or
recovered from a cell or cell culture from which it was expressed.
Thus, an "isolated antibody," refers to an antibody which is
substantially free of other antibodies having different antigenic
specificities. For instance, an isolated antibody that specifically
binds to CD117 is substantially free of antibodies that
specifically bind antigens other than CD117.
[0107] The term "antigen-binding fragment," as used herein, refers
a fragment of an antibody that retains the ability to specifically
bind to a target antigen. The antigen-binding function of an
antibody can be performed by fragments of a full-length antibody.
The antibody fragment can be, for example, a Fab, F(ab').sub.2,
scFv, diabody, a triabody, an affibody, a nanobody, an aptamer, or
a domain antibody. Examples of binding fragments encompassed of the
term "antigen-binding fragment" of an antibody include, but are not
limited to: (i) a Fab fragment, a monovalent fragment consisting of
the V.sub.L, V.sub.H, C.sub.L, and C.sub.H1 domains; (ii) a
F(ab').sub.2 fragment, a bivalent fragment containing two Fab
fragments linked by a disulfide bridge at the hinge region; (iii) a
Fd fragment consisting of the V.sub.H and C.sub.H1 domains; (iv) a
Fv fragment consisting of the V.sub.L and V.sub.H domains of a
single arm of an antibody, (v) a dAb including V.sub.H and V.sub.L
domains; (vi) a dAb fragment that consists of a V.sub.H domain
(see, e.g., Ward et al., Nature 341:544-546, 1989); (vii) a dAb
which consists of a V.sub.H or a V.sub.L domain; (viii) an isolated
complementarity determining region (CDR); and (ix) a combination of
two or more (e.g., two, three, four, five, or six) isolated CDRs
which may optionally be joined by a synthetic linker. Furthermore,
although the two domains of the Fv fragment, V.sub.L and V.sub.H,
are coded for by separate genes, they can be joined, using
recombinant methods, by a linker that enables them to be made as a
single protein chain in which the V.sub.L and V.sub.H regions pair
to form monovalent molecules (known as single chain Fv (scFv); see,
for example, Bird et al., Science 242:423-426, 1988 and Huston et
al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988). Antibody
fragments can be obtained using conventional techniques known to
those of skill in the art, and the fragments can be screened for
utility in the same manner as intact antibodies. Antigen-binding
fragments can be produced by recombinant DNA techniques, enzymatic
or chemical cleavage of intact immunoglobulins, or, in certain
cases, by chemical peptide synthesis procedures known in the
art.
[0108] As used herein, the term "anti-CD117 antibody" or "an
antibody that binds to CD117" refers to an antibody that is capable
of binding CD117, e.g., human CD117, with sufficient affinity such
that the antibody is useful as a diagnostic and/or therapeutic
agent in targeting CD117. The amino acid sequences of the two main
isoforms of human CD117 are provided in SEQ ID NO: 145 (isoform 1)
and SEQ ID NO: 146 (isoform 2). An "anti-CD117 ADC" refers to an
ADC wherein the antibody is an anti-CD117 antibody.
[0109] As used herein, the term "anti-CD45 antibody" or "an
antibody that binds to CD45" refers to an antibody that is capable
of binding CD45, e.g., human CD117, with sufficient affinity such
that the antibody is useful as a diagnostic and/or therapeutic
agent in targeting CD45. An "anti-CD45 ADC" refers to an ADC
wherein the antibody is an anti-CD45 antibody.
[0110] As used herein, the term "anti-CD137 antibody" or "an
antibody that binds to CD137" refers to an antibody that is capable
of binding CD137, e.g., human CD137, with sufficient affinity such
that the antibody is useful as a diagnostic and/or therapeutic
agent in targeting CD137. An "anti-CD137 ADC" refers to an ADC
wherein the antibody is an anti-CD137 antibody.
[0111] As used herein, the term "anti-CD2 antibody" or "an antibody
that binds to CD2" refers to an antibody that is capable of binding
CD2, e.g., human CD2, with sufficient affinity such that the
antibody is useful as a diagnostic and/or therapeutic agent in
targeting CD2. An "anti-CD2 ADC" refers to an ADC wherein the
antibody is an anti-CD2 antibody.
[0112] As used herein, the term "anti-CD5 antibody" or "an antibody
that binds to CD5" refers to an antibody that is capable of binding
CD5, e.g., human CD5, with sufficient affinity such that the
antibody is useful as a diagnostic and/or therapeutic agent in
targeting CD5. An "anti-CD5 ADC" refers to an ADC wherein the
antibody is an anti-CD5 antibody.
[0113] As used herein, the term "bispecific antibody" refers to,
for example, a monoclonal, often a human or humanized antibody that
is capable of binding at least two different antigens or at; least
two different epitopes that may be on the same antigen or different
antigens. For instance, one of the binding specificities can be
directed towards a hematopoietic stem cell surface antigen, CD117
(e.g., GNNK+ CD117), and the other can specifically bind a
different hematopoietic stem cell surface antigen or another cell
surface protein, such as a receptor or receptor subunit involved in
a signal transduction pathway that potentiates cell growth, among
others.
[0114] As used herein, the term "complementarity determining
region" (CDR) refers to a hypervariable region found both in the
light chain and the heavy chain variable domains of an antibody.
The more highly conserved portions of variable domains are referred
to as framework regions (FRs). The amino acid positions that
delineate a hypervariable region of an antibody can vary, depending
on the context and the various definitions known in the art. Some
positions within a variable domain may be viewed as hybrid
hypervariable positions in that these positions can be deemed to be
within a hypervariable region under one set of criteria while being
deemed to be outside a hypervariable region under a different set
of criteria. One or more of these positions can also be found in
extended hypervariable regions. The antibodies described herein may
contain modifications in these hybrid hypervariable positions. The
variable domains of native heavy and light chains each contain four
framework regions that primarily adopt a .beta.-sheet
configuration, connected by three CDRs, which form loops that
connect, and in some cases form part of, the .beta.-sheet
structure. The CDRs in each chain are held together in close
proximity by the framework regions in the order
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and, with the CDRs from the other
antibody chains, contribute to the formation of the target binding
site of antibodies (see Kabat et al., Sequences of Proteins of
Immunological Interest, National Institute of Health, Bethesda,
Md., 1987). In certain embodiments, numbering of immunoglobulin
amino acid residues is performed according to the immunoglobulin
amino acid residue numbering system of Kabat et al., unless
otherwise indicated (although any antibody numbering scheme,
including, but not limited to IMGT and Chothia, can be
utilized).
[0115] As used herein, the terms "condition" and "conditioning"
refer to processes by which a patient is prepared for receipt of a
transplant, e.g., a transplant containing hematopoietic stem cells.
Such procedures promote the engraftment of a hematopoietic stem
cell transplant (for instance, as inferred from a sustained
increase in the quantity of viable hematopoietic stem cells within
a blood sample isolated from a patient following a conditioning
procedure and subsequent hematopoietic stem cell transplantation.
According to the methods described herein, a patient may be
conditioned for hematopoietic stem cell transplant therapy by
administration to the patient of an ADC capable of binding an
antigen expressed by hematopoietic stem cells, such as CD117 (e.g.,
GNNK+ CD117). Administration of an ADC capable of binding an HSC
antigen to a patient in need of hematopoietic stem cell transplant
therapy can promote the engraftment of a hematopoietic stem cell
graft, for example, by selectively depleting endogenous
hematopoietic stem cells, thereby creating a vacancy filled by an
exogenous hematopoietic stem cell transplant.
[0116] As used herein, the term "conjugate" refers to a compound
formed by the chemical bonding of a reactive functional group of
one molecule, such as an antibody or antigen-binding fragment
thereof, with an appropriately reactive functional group of another
molecule, such as a cytotoxin described herein. Conjugates may
include a linker between the two molecules bound to one another.
Examples of linkers that can be used for the formation of a
conjugate include peptide-containing linkers, such as those that
contain naturally occurring or non-naturally occurring amino acids,
such as D-amino acids. Linkers can be prepared using a variety of
strategies described herein and known in the art. Depending on the
reactive components therein, a linker may be cleaved, for example,
by enzymatic hydrolysis, photolysis, hydrolysis under acidic
conditions, hydrolysis under basic conditions, oxidation, disulfide
reduction, nucleophilic cleavage, or organometallic cleavage (see,
for example, Leriche et al., Bioorg. Med. Chem., 20:571-582, 2012).
Notably, the term "conjugate" (when referring to a compound) is
also referred to interchangeably herein as a "drug conjugate",
"antibody drug conjugate" or "ADC".
[0117] As used herein, the term "coupling reaction" refers to a
chemical reaction in which two or more substituents suitable for
reaction with one another react so as to form a chemical moiety
that joins (e.g., covalently) the molecular fragments bound to each
substituent. Coupling reactions include those in which a reactive
substituent bound to a fragment that is a cytotoxin, such as a
cytotoxin known in the art or described herein, reacts with a
suitably reactive substituent bound to a fragment that is an
antibody, or antigen-binding fragment thereof, such as an antibody,
antigen-binding fragment thereof, or specific anti-CD117 antibody
that binds CD117 (such as GNNK+ CD117) known in the art or
described herein. Examples of suitably reactive substituents
include a nucleophile/electrophile pair (e.g., a thiol/haloalkyl
pair, an amine/carbonyl pair, or a thio/.alpha.,.beta.-unsaturated
carbonyl pair, among others), a diene/dienophile pair (e.g., an
azide/alkyne pair, among others), and the like. Coupling reactions
include, without limitation, thiol alkylation, hydroxyl alkylation,
amine alkylation, amine condensation, amidation, esterification,
disulfide formation, cycloaddition (e.g., [4+2] Diels-Alder
cycloaddition, [3+2] Huisgen cycloaddition, among others),
nucleophilic aromatic substitution, electrophilic aromatic
substitution, and other reactive modalities known in the art or
described herein.
[0118] As used herein, "CRU (competitive repopulating unit)" refers
to a unit of measure of long-term engrafting stem cells, which can
be detected after in-vivo transplantation.
[0119] As used herein, the term "donor" refers to a human or animal
from which one or more cells are isolated prior to administration
of the cells, or progeny thereof, into a recipient. The one or more
cells may be, for example, a population of hematopoietic stem
cells.
[0120] As used herein, the term "diabody" refers to a bivalent
antibody containing two polypeptide chains, in which each
polypeptide chain includes V.sub.H and V.sub.L domains joined by a
linker that is too short (e.g., a linker composed of five amino
acids) to allow for intramolecular association of V.sub.H and
V.sub.L domains on the same peptide chain. This configuration
forces each domain to pair with a complementary domain on another
polypeptide chain so as to form a homodimeric structure.
Accordingly, the term "triabody" refers to trivalent antibodies
containing three peptide chains, each of which contains one V.sub.H
domain and one V.sub.L domain joined by a linker that is
exceedingly short (e.g., a linker composed of 1-2 amino acids) to
permit intramolecular association of V.sub.H and V.sub.L domains
within the same peptide chain. In order to fold into their native
structures, peptides configured in this way typically trimerize so
as to position the V.sub.H and V.sub.L domains of neighboring
peptide chains spatially proximal to one another (see, for example,
Holliger et al., Proc. Natl. Acad. Sci. USA 90:6444-48, 1993).
[0121] As used herein, "drug-to-antibody ratio" or "DAR" refers to
the number of drugs, e.g., amatoxin, attached to the antibody of a
conjugate. The DAR of an ADC can range from 1 to 8, although higher
loads are also possible depending on the number of linkage sites on
an antibody. In certain embodiments, the conjugate has a DAR of 1,
2, 3, 4, 5, 6, 7, or 8.
[0122] As used herein, the term "endogenous" describes a substance,
such as a molecule, cell, tissue, or organ (e.g., a hematopoietic
stem cell or a cell of hematopoietic lineage, such as a
megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell,
myeloblast, basophil, neutrophil, eosinophil, microglial cell,
granulocyte, monocyte, osteoclast, antigen-presenting cell,
macrophage, dendritic cell, natural killer cell, T-lymphocyte, or
B-lymphocyte) that is found naturally in a particular organism,
such as a human patient.
[0123] As used herein, the term "engraftment potential" is used to
refer to the ability of hematopoietic stem and progenitor cells to
repopulate a tissue, whether such cells are naturally circulating
or are provided by transplantation. The term encompasses all events
surrounding or leading up to engraftment, such as tissue homing of
cells and colonization of cells within the tissue of interest. The
engraftment efficiency or rate of engraftment can be evaluated or
quantified using any clinically acceptable parameter as known to
those of skill in the art and can include, for example, assessment
of competitive repopulating units (CRU); incorporation or
expression of a marker in tissue(s) into which stem cells have
homed, colonized, or become engrafted; or by evaluation of the
progress of a subject through disease progression, survival of
hematopoietic stem and progenitor cells, or survival of a
recipient. Engraftment can also be determined by measuring white
blood cell counts in peripheral blood during a post-transplant
period. Engraftment can also be assessed by measuring recovery of
marrow cells by donor cells in a bone marrow aspirate sample.
[0124] As used herein, the term "exogenous" describes a substance,
such as a molecule, cell, tissue, or organ (e.g., a hematopoietic
stem cell or a cell of hematopoietic lineage, such as a
megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell,
myeloblast, basophil, neutrophil, eosinophil, microglial cell,
granulocyte, monocyte, osteoclast, antigen-presenting cell,
macrophage, dendritic cell, natural killer cell, T-lymphocyte, or
B-lymphocyte) that is not found naturally in a particular organism,
such as a human patient. Exogenous substances include those that
are provided from an external source to an organism or to cultured
matter extracted therefrom.
[0125] The terms "Fc", "Fc region," and "Fc domain," as used herein
refer to the portion of an IgG antibody that correlates to a
crystallizable fragment obtained by papain digestion of an IgG
molecule. The Fc region comprises the C-terminal half of two heavy
chains of an IgG molecule that are linked by disulfide bonds. It
has no antigen binding activity but contains the carbohydrate
moiety and binding sites for complement and Fc receptors, including
the FcRn receptor. An Fc region contains the second constant domain
CH2 (e.g., residues at EU positions 231-340 of IgG1) and the third
constant domain CH3 (e.g., residues at EU positions 341-447 of
human IgG1). As used herein, the Fc region includes the "lower
hinge region" (e.g., residues at EU positions 233-239 of IgG1). Fc
can refer to this region in isolation, or this region in the
context of an antibody, antibody fragment, or Fc fusion protein.
Polymorphisms have been observed at a number of positions in Fc
domains, including but not limited to EU positions 270, 272, 312,
315, 356, and 358, and thus slight differences between the
sequences presented in the instant application and sequences known
in the art can exist. Thus, a "wild type IgG Fc domain" or "WT IgG
Fc domain" refers to any naturally occurring IgG Fc region (i.e.,
any allele). The sequences of the heavy chains of human IgG1, IgG2,
IgG3 and IgG4 can be found in a number of sequence databases, for
example, at the Uniprot database (www.uniprot.org) under accession
numbers P01857 (IGHG1_HUMAN), P01859 (IGHG2_HUMAN), P01860
(IGHG3_HUMAN), and P01861 (IGHG1_HUMAN), respectively. An example
of a "WT" Fc region is provided in SEQ ID NO: 122 (which provides a
heavy chain constant region containing an Fc region).
[0126] The terms "modified Fc region" or "variant Fc region" as
used herein refers to an IgG Fc domain comprising one or more amino
acid substitutions, deletions, insertions or modifications
introduced at any position within the Fc region.
[0127] The terms "full length antibody" and "intact antibody" are
used herein interchangeably to refer to an antibody in its
substantially intact form, and not an antibody fragment as defined
herein. In one embodiment, an ADC described herein comprises an
intact antibody. Thus, for an IgG antibody, an intact antibody
comprises two heavy chains each comprising a variable region, a
constant region and an Fc region, and two light chains each
comprising a variable region and a constant region. More
specifically, an intact IgG comprises two light chains each
comprising a light chain variable region (VL) and alight chain
constant region (CL), and comprises two heavy chains each
comprising a heavy chain variable region (VH) and three heavy chain
constant regions (CH1, CH2, and CH3). CH2 and CH3 represent the Fc
region of the heavy chain.
[0128] As used herein, the term "framework region" or "FW region"
includes amino acid residues that are adjacent to the CDRs of an
antibody or antigen-binding fragment thereof. FW region residues
may be present in, for example, human antibodies, humanized
antibodies, monoclonal antibodies, antibody fragments, Fab
fragments, single chain antibody fragments, scFv fragments,
antibody domains, and bispecific antibodies, among others.
[0129] As used herein, the term "hematopoietic stem cells" ("HSCs")
refers to immature blood cells having the capacity to self-renew
and to differentiate into mature blood cells containing diverse
lineages including but not limited to granulocytes (e.g.,
promyelocytes, neutrophils, eosinophils, basophils), erythrocytes
(e.g., reticulocytes, erythrocytes), thrombocytes (e.g.,
megakaryoblasts, platelet producing megakaryocytes, platelets),
monocytes (e.g., monocytes, macrophages), dendritic cells,
microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells
and T-cells). Such cells may include CD34.sup.+ cells. CD34.sup.+
cells are immature cells that express the CD34 cell surface marker.
In humans, CD34+ cells are believed to include a subpopulation of
cells with the stem cell properties defined above, whereas in mice,
HSCs are CD34-. In addition, HSCs also refer to long term
repopulating HSCs (LT-HSC) and short term repopulating HSCs
(ST-HSC). LT-HSCs and ST-HSCs are differentiated, based on
functional potential and on cell surface marker expression. For
example, human HSCs are CD34+, CD38-, CD45RA-, CD90+, CD49F+, and
lin- (negative for mature lineage markers including CD2, CD3, CD4,
CD7, CD8, CD10, CD11B, CD19, CD20, CD56, CD235A). In mice, bone
marrow LT-HSCs are CD34-, SCA-1+, C-kit+, CD135-, Slamfl/CD150+,
CD48-, and lin- (negative for mature lineage markers including
Ter119, CD11b, Gr, CD3, CD4, CD8, B220, IL7ra), whereas ST-HSCs are
CD34+, SCA-1+, C-kit+, CD135-, Slamfl/CD150+, and lin- (negative
for mature lineage markers including Ter119, CD11b, Gr, CD3, CD4,
CD8, B220, IL7ra). In addition, ST-HSCs are less quiescent and more
proliferative than LT-HSCs under homeostatic conditions. However,
LT-HSC have greater self-renewal potential (i.e., they survive
throughout adulthood, and can be serially transplanted through
successive recipients), whereas ST-HSCs have limited self-renewal
(i.e., they survive for only a limited period of time, and do not
possess serial transplantation potential). Any of these HSCs can be
used in the methods described herein. ST-HSCs are particularly
useful because they are highly proliferative and thus, can more
quickly give rise to differentiated progeny.
[0130] As used herein, the term "hematopoietic stem cell functional
potential" refers to the functional properties of hematopoietic
stem cells which include 1) multi-potency (which refers to the
ability to differentiate into multiple different blood lineages
including, but not limited to, granulocytes (e.g., promyelocytes,
neutrophils, eosinophils, basophils), erythrocytes (e.g.,
reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts,
platelet producing megakaryocytes, platelets), monocytes (e.g.,
monocytes, macrophages), dendritic cells, microglia, osteoclasts,
and lymphocytes (e.g., NK cells, B-cells and T-cells), 2)
self-renewal (which refers to the ability of hematopoietic stem
cells to give rise to daughter cells that have equivalent potential
as the mother cell, and further that this ability can repeatedly
occur throughout the lifetime of an individual without exhaustion),
and 3) the ability of hematopoietic stem cells or progeny thereof
to be reintroduced into a transplant recipient whereupon they home
to the hematopoietic stem cell niche and re-establish productive
and sustained hematopoiesis.
[0131] As used herein, the term "human antibody" is intended to
include antibodies having variable and constant regions derived
from human germline immunoglobulin sequences. A human antibody may
include amino acid residues not encoded by human germline
immunoglobulin sequences (e.g., mutations introduced by random or
site-specific mutagenesis in vitro or during gene rearrangement or
by somatic mutation in vivo). However, the term "human antibody",
as used herein, is not intended to include antibodies in which CDR
sequences derived from the germline of another mammalian species,
such as a mouse, have been grafted onto human framework sequences.
A human antibody can be produced in a human cell (for example, by
recombinant expression) or by a non-human animal or a prokaryotic
or eukaryotic cell that is capable of expressing functionally
rearranged human immunoglobulin (such as heavy chain and/or light
chain) genes. When a human antibody is a single chain antibody, it
can include a linker peptide that is not found in native human
antibodies. For example, an Fv can contain a linker peptide, such
as two to about eight glycine or other amino acid residues, which
connects the variable region of the heavy chain and the variable
region of the light chain. Such linker peptides are considered to
be of human origin. Human antibodies can be made by a variety of
methods known in the art including phage display methods using
antibody libraries derived from human immunoglobulin sequences.
Human antibodies can also be produced using transgenic mice that
are incapable of expressing functional endogenous immunoglobulins,
but which can express human immunoglobulin genes (see, for example,
PCT Publication Nos. WO 1998/24893; WO 1992/01047; WO 1996/34096;
WO 1996/33735; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425;
5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771;
and 5,939,598).
[0132] A "humanized" antibody refers to an antibody that contains
minimal sequences derived from non-human immunoglobulin. Thus,
"humanized" forms of non-human (e.g., murine) antibodies are
chimeric antibodies that contain minimal sequence derived from the
non-human antibody. All or substantially all of the FW regions may
also be those of a human immunoglobulin sequence. The humanized
antibody can also contain at least a portion of an immunoglobulin
constant region (Fc), typically that of a human immunoglobulin
consensus sequence. Methods of antibody humanization are known in
the art and have been described, for example, in Riechmann et al.,
Nature 332:323-7, 1988; U.S. Pat. Nos. 5,530,101; 5,585,089;
5,693,761; 5,693,762; and 6,180,370.
[0133] As used herein, patients that are "in need of" a
hematopoietic stem cell transplant include patients that exhibit a
defect or deficiency in one or more blood cell types, as well as
patients having a stem cell disorder, autoimmune disease, cancer,
or other pathology described herein. Hematopoietic stem cells
generally exhibit 1) multi-potency, and can thus differentiate into
multiple different blood lineages including, but not limited to,
granulocytes (e.g., promyelocytes, neutrophils, eosinophils,
basophils), erythrocytes (e.g., reticulocytes, erythrocytes),
thrombocytes (e.g., megakaryoblasts, platelet producing
megakaryocytes, platelets), monocytes (e.g., monocytes,
macrophages), dendritic cells, microglia, osteoclasts, and
lymphocytes (e.g., NK cells, B-cells and T-cells), 2) self-renewal,
and can thus give rise to daughter cells that have equivalent
potential as the mother cell, and 3) the ability to be reintroduced
into a transplant recipient whereupon they home to the
hematopoietic stem cell niche and re-establish productive and
sustained hematopoiesis. Hematopoietic stem cells can thus be
administered to a patient defective or deficient in one or more
cell types of the hematopoietic lineage in order to re-constitute
the defective or deficient population of cells in vivo. For
example, the patient may be suffering from cancer, and the
deficiency may be caused by administration of a chemotherapeutic
agent or other medicament that depletes, either selectively or
non-specifically, the cancerous cell population. Additionally or
alternatively, the patient may be suffering from a hemoglobinopathy
(e.g., a non-malignant hemoglobinopathy), such as sickle cell
anemia, thalassemia, Fanconi anemia, aplastic anemia, and
Wiskott-Aldrich syndrome. The subject may be one that is suffering
from adenosine deaminase severe combined immunodeficiency (ADA
SCID), HIV/AIDS, metachromatic leukodystrophy, Diamond-Blackfan
anemia, and Schwachman-Diamond syndrome. The subject may have or be
affected by an inherited blood disorder (e.g., sickle cell anemia)
or an autoimmune disorder. Additionally or alternatively, the
subject may have or be affected by a malignancy, such as
neuroblastoma or a hematologic cancer. For instance, the subject
may have a leukemia, lymphoma, or myeloma. In some embodiments, the
subject has acute myeloid leukemia, acute lymphoid leukemia,
chronic myeloid leukemia, chronic lymphoid leukemia, multiple
myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma.
In some embodiments, the subject has myelodysplastic syndrome. In
some embodiments, the subject has an autoimmune disease, such as
scleroderma, multiple sclerosis, ulcerative colitis, Crohn's
disease, Type 1 diabetes, or another autoimmune pathology described
herein. In some embodiments, the subject is in need of chimeric
antigen receptor T-cell (CART) therapy. In some embodiments, the
subject has or is otherwise affected by a metabolic storage
disorder. The subject may suffer or otherwise be affected by a
metabolic disorder selected from the group consisting of glycogen
storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers
Disease, sphingolipidoses, metachromatic leukodystrophy, or any
other diseases or disorders which may benefit from the treatments
and therapies disclosed herein and including, without limitation,
severe combined immunodeficiency, Wiscott-Aldrich syndrome, hyper
immunoglobulin M (IgM) syndrome, Chediak-Higashi disease,
hereditary lymphohistiocytosis, osteopetrosis, osteogenesis
imperfecta, storage diseases, thalassemia major, sickle cell
disease, systemic sclerosis, systemic lupus erythematosus, multiple
sclerosis, juvenile rheumatoid arthritis and those diseases, or
disorders described in "Bone Marrow Transplantation for
Non-Malignant Disease," ASH Education Book, 1:319-338 (2000), the
disclosure of which is incorporated herein by reference in its
entirety as it pertains to pathologies that may be treated by
administration of hematopoietic stem cell transplant therapy.
Additionally or alternatively, a patient "in need of" a
hematopoietic stem cell transplant may one that is or is not
suffering from one of the foregoing pathologies, but nonetheless
exhibits a reduced level (e.g., as compared to that of an otherwise
healthy subject) of one or more endogenous cell types within the
hematopoietic lineage, such as megakaryocytes, thrombocytes,
platelets, erythrocytes, mast cells, myeloblasts, basophils,
neutrophils, eosinophils, microglia, granulocytes, monocytes,
osteoclasts, antigen-presenting cells, macrophages, dendritic
cells, natural killer cells, T-lymphocytes, and B-lymphocytes. One
of skill in the art can readily determine whether one's level of
one or more of the foregoing cell types, or other blood cell type,
is reduced with respect to an otherwise healthy subject, for
instance, by way of flow cytometry and fluorescence activated cell
sorting (FACS) methods, among other procedures, known in the
art.
[0134] As used herein a "neutral antibody" refers to an antibody,
or an antigen binding fragment thereof, that is not capable of
significantly neutralizing, blocking, inhibiting, abrogating,
reducing or interfering with the activities of a particular or
specified target (e.g., CD117), including the binding of receptors
to ligands or the interactions of enzymes with substrates. In one
embodiment, a neutral anti-CD117 antibody, or fragment thereof, is
an anti-CD117 antibody that does not substantially inhibit
SCF-dependent cell proliferation and does not cross block SCF
binding to CD117. An example of a neutral antibody is Ab67 (or an
antibody having the binding regions of Ab67). In contrast, an
"antagonist" anti-CD117 antibody inhibits SCF-dependent
proliferation and is able to cross block SCF binding to CD117. An
example of an antagonist antibody is Ab55 (or an antibody having
the binding regions of Ab55).
[0135] As used herein, the term "recipient" refers to a patient
that receives a transplant, such as a transplant containing a
population of hematopoietic stem cells. The transplanted cells
administered to a recipient may be, e.g., autologous, syngeneic, or
allogeneic cells.
[0136] As used herein, the term "sample" refers to a specimen
(e.g., blood, blood component (e.g., serum or plasma), urine,
saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g.,
placental or dermal), pancreatic fluid, chorionic villus sample,
and cells) taken from a subject.
[0137] As used herein, the term "scFv" refers to a single chain Fv
antibody in which the variable domains of the heavy chain and the
light chain from an antibody have been joined to form one chain.
scFv fragments contain a single polypeptide chain that includes the
variable region of an antibody light chain (V.sub.L) (e.g., CDR-L1,
CDR-L2, and/or CDR-L3) and the variable region of an antibody heavy
chain (V.sub.H) (e.g., CDR-H1, CDR-H2, and/or CDR-H3) separated by
a linker. The linker that joins the V.sub.L and V.sub.H regions of
a scFv fragment can be a peptide linker composed of proteinogenic
amino acids. Alternative linkers can be used to so as to increase
the resistance of the scFv fragment to proteolytic degradation (for
example, linkers containing D-amino acids), in order to enhance the
solubility of the scFv fragment (for example, hydrophilic linkers
such as polyethylene glycol-containing linkers or polypeptides
containing repeating glycine and serine residues), to improve the
biophysical stability of the molecule (for example, a linker
containing cysteine residues that form intramolecular or
intermolecular disulfide bonds), or to attenuate the immunogenicity
of the scFv fragment (for example, linkers containing glycosylation
sites). It will also be understood by one of ordinary skill in the
art that the variable regions of the scFv molecules described
herein can be modified such that they vary in amino acid sequence
from the antibody molecule from which they were derived. For
example, nucleotide or amino acid substitutions leading to
conservative substitutions or changes at amino acid residues can be
made (e.g., in CDR and/or framework residues) so as to preserve or
enhance the ability of the scFv to bind to the antigen recognized
by the corresponding antibody.
[0138] The terms "specific binding" or "specifically binding", as
used herein, refers to the ability of an antibody to recognize and
bind to a specific protein structure (epitope) rather than to
proteins generally. If an antibody is specific for epitope "A", the
presence of a molecule containing epitope A (or free, unlabeled A),
in a reaction containing labeled "A" and the antibody, will reduce
the amount of labeled A bound to the antibody. By way of example,
an antibody "binds specifically" to a target if the antibody, when
labeled, can be competed away from its target by the corresponding
non-labeled antibody. In one embodiment, an antibody specifically
binds to a target, e.g., CD117, CD45, CD2, CD5, CD137, CD134, or
CD252, if the antibody has a K.sub.D for the target of at least
about 10.sup.-4 M, 10.sup.-5 M, 10.sup.-6 M, 10.sup.-7 M, 10.sup.-8
M, 10.sup.-9 M, 10.sup.-10 M, 10.sup.-11 M, 10.sup.-12 M, or less
(less meaning a number that is less than 10.sup.-12, e.g.
10.sup.-13). In one embodiment, the term "specific binding to
CD117" or "specifically binds to CD117," as used herein, refers to
an antibody or that binds to CD117 and has a dissociation constant
(K.sub.D) of 1.0.times.10.sup.-7 M or less, as determined by
surface plasmon resonance. In one embodiment, K.sub.D (M) is
determined according to standard bio-layer interferometery (BLI).
In one embodiment, K.sub.off (1/s) is determined according to
standard bio-layer interferometery (BLI). It shall be understood,
however, that the antibody may be capable of specifically binding
to two or more antigens which are related in sequence. For example,
in one embodiment, an antibody can specifically bind to both human
and a non-human (e.g., mouse or non-human primate) orthologs of
CD117, CD45, CD2, CD5, CD137, CD134, or CD252.
[0139] As used herein, the terms "subject" and "patient" refer to
an organism, such as a human, that receives treatment for a
particular disease or condition as described herein. For instance,
a patient, such as a human patient, may receive treatment prior to
hematopoietic stem cell transplant therapy in order to promote the
engraftment of exogenous hematopoietic stem cells.
[0140] As used herein, the phrase "substantially cleared from the
blood" refers to a point in time following administration of a
therapeutic agent, e.g., an ADC comprising an amatoxin, to a
patient when the concentration of the therapeutic agent in a blood
sample isolated from the patient is such that the therapeutic agent
is not detectable by conventional means (for instance, such that
the therapeutic agent is not detectable above the noise threshold
of the device or assay used to detect the therapeutic agent). A
variety of techniques known in the art can be used to detect
antibodies, or antibody fragments, such as ELISA-based detection
assays known in the art or described herein. Additional assays that
can be used to detect antibodies, or antibody fragments, include
immunoprecipitation techniques and immunoblot assays, among others
known in the art.
[0141] As used herein, the phrase "stem cell disorder" broadly
refers to any disease, disorder, or condition that may be treated
or cured by conditioning a subject's target tissues, and/or by
ablating an endogenous stem cell population in a target tissue
(e.g., ablating an endogenous hematopoietic stem or progenitor cell
population from a subject's bone marrow tissue) and/or by
engrafting or transplanting stem cells in a subject's target
tissues. For example, Type I diabetes has been shown to be cured by
hematopoietic stem cell transplant and may benefit from
conditioning in accordance with the compositions and methods
described herein. Additional disorders that can be treated using
the compositions and methods described herein include, without
limitation, sickle cell anemia, thalassemias, Fanconi anemia,
aplastic anemia, Wiskott-Aldrich syndrome, ADA SCID, HIV/AIDS,
metachromatic leukodystrophy, Diamond-Blackfan anemia, and
Schwachman-Diamond syndrome. Additional diseases that may be
treated using the patient conditioning and/or hematopoietic stem
cell transplant methods described herein include inherited blood
disorders (e.g., sickle cell anemia) and autoimmune disorders, such
as scleroderma, multiple sclerosis, ulcerative colitis, and Crohn's
disease. Additional diseases that may be treated using the
conditioning and/or transplantation methods described herein
include a malignancy, such as a neuroblastoma or a hematologic
cancer, such as leukemia, lymphoma, and myeloma. For instance, the
cancer may be acute myeloid leukemia, acute lymphoid leukemia,
chronic myeloid leukemia, chronic lymphoid leukemia, multiple
myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma.
Additional diseases treatable using the conditioning and/or
transplantation methods described herein include myelodysplastic
syndrome. In some embodiments, the subject has or is otherwise
affected by a metabolic storage disorder. For example, the subject
may suffer or otherwise be affected by a metabolic disorder
selected from the group consisting of glycogen storage diseases,
mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease,
sphingolipidoses, metachromatic leukodystrophy, or any other
diseases or disorders which may benefit from the treatments and
therapies disclosed herein and including, without limitation,
severe combined immunodeficiency, Wiscott-Aldrich syndrome, hyper
immunoglobulin M (IgM) syndrome, Chediak-Higashi disease,
hereditary lymphohistiocytosis, osteopetrosis, osteogenesis
imperfecta, storage diseases, thalassemia major, sickle cell
disease, systemic sclerosis, systemic lupus erythematosus, multiple
sclerosis, juvenile rheumatoid arthritis and those diseases, or
disorders described in "Bone Marrow Transplantation for
Non-Malignant Disease," ASH Education Book, 1:319-338 (2000), the
disclosure of which is incorporated herein by reference in its
entirety as it pertains to pathologies that may be treated by
administration of hematopoietic stem cell transplant therapy.
[0142] As used herein, the term "transfection" refers to any of a
wide variety of techniques commonly used for the introduction of
exogenous DNA into a prokaryotic or eukaryotic host cell, such as
electroporation, lipofection, calcium-phosphate precipitation,
DEAE-dextran transfection and the like.
[0143] As used herein, the terms "treat" or "treatment" refers to
reducing the severity and/or frequency of disease symptoms,
eliminating disease symptoms and/or the underlying cause of said
symptoms, reducing the frequency or likelihood of disease symptoms
and/or their underlying cause, and improving or remediating damage
caused, directly or indirectly, by disease. Beneficial or desired
clinical results include, but are not limited to, promoting the
engraftment of exogenous hematopoietic cells in a patient following
antibody conditioning therapy as described herein and subsequent
hematopoietic stem cell transplant therapy. Additional beneficial
results include an increase in the cell count or relative
concentration of hematopoietic stem cells in a patient in need of a
hematopoietic stem cell transplant following conditioning therapy
and subsequent administration of an exogenous hematopoietic stem
cell graft to the patient. Beneficial results of therapy described
herein may also include an increase in the cell count or relative
concentration of one or more cells of hematopoietic lineage, such
as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell,
myeloblast, basophil, neutrophil, eosinophil, microglial cell,
granulocyte, monocyte, osteoclast, antigen-presenting cell,
macrophage, dendritic cell, natural killer cell, T-lymphocyte, or
B-lymphocyte, following conditioning therapy and subsequent
hematopoietic stem cell transplant therapy. Additional beneficial
results may include the reduction in quantity of a disease-causing
cell population, such as a population of cancer cells (e.g., CD117+
leukemic cells) or autoimmune cells (e.g., CD117+ autoimmune
lymphocytes, such as a CD117+ T-cell that expresses a T-cell
receptor that cross-reacts with a self-antigen). Insofar as the
methods of the present invention are directed to preventing
disorders, it is understood that the term "prevent" does not
require that the disease state be completely thwarted. Rather, as
used herein, the term preventing refers to the ability of the
skilled artisan to identify a population that is susceptible to
disorders, such that administration of the compounds of the present
invention may occur prior to onset of a disease. The term does not
imply that the disease state is completely avoided.
[0144] As used herein, the terms "variant" and "derivative" are
used interchangeably and refer to naturally-occurring, synthetic,
and semi-synthetic analogues of a compound, peptide, protein, or
other substance described herein. A variant or derivative of a
compound, peptide, protein, or other substance described herein may
retain or improve upon the biological activity of the original
material.
[0145] As used herein, the term "vector" includes a nucleic acid
vector, such as a plasmid, a DNA vector, a plasmid, a RNA vector,
virus, or other suitable replicon. Expression vectors described
herein may contain a polynucleotide sequence as well as, for
example, additional sequence elements used for the expression of
proteins and/or the integration of these polynucleotide sequences
into the genome of a mammalian cell. Certain vectors that can be
used for the expression of antibodies and antibody fragments of the
invention include plasmids that contain regulatory sequences, such
as promoter and enhancer regions, which direct gene transcription.
Other useful vectors for expression of antibodies and antibody
fragments contain polynucleotide sequences that enhance the rate of
translation of these genes or improve the stability or nuclear
export of the mRNA that results from gene transcription. These
sequence elements may include, for example, 5' and 3' untranslated
regions and a polyadenylation signal site in order to direct
efficient transcription of the gene carried on the expression
vector. The expression vectors described herein may also contain a
polynucleotide encoding a marker for selection of cells that
contain such a vector. Examples of a suitable marker include genes
that encode resistance to antibiotics, such as ampicillin,
chloramphenicol, kanamycin, and nourseothricin.
Antibody-Drug Conjugates (ADCs)
[0146] Antibodies, and antigen-binding fragments thereof, as
described herein can be conjugated (linked) to a cytotoxic molecule
(i.e., a cytotoxin), thus forming an antibody-drug conjugate (ADC).
As used herein, the terms "cytotoxin", "cytotoxic moiety", and
"drug" are used interchangeably.
[0147] In particular, the ADCs as disclosed herein include an
antibody (including an antigen-binding fragment thereof) conjugated
to an amatoxin, e.g., amatoxin set forth in Formula (V), wherein
the cytotoxic moiety, when not conjugated to an antibody, has a
cytotoxic or cytostatic effect. In various embodiments, the
cytotoxic moiety exhibits reduced or no cytotoxicity when bound in
a conjugate, but resumes cytotoxicity after cleavage from the
linker. In various embodiments, the cytotoxic moiety maintains
cytotoxicity without cleavage from the linker. In some embodiments,
the cytotoxic molecule is conjugated to a cell internalizing
antibody, or antigen-binding fragment thereof as disclosed herein,
such that following the cellular uptake of the antibody, or
fragment thereof, the cytotoxin may access its intracellular target
and, e.g., mediate hematopoietic cell death. ADCs of the present
disclosure therefore may be of the general formula
Ab-(Z-L-Cy).sub.n,
wherein an antibody or antigen-binding fragment thereof (Ab) is
conjugated (covalently linked) to linker (L), through a chemical
moiety (Z), to a cytotoxic moiety (Cy).
[0148] Accordingly, the antibody or antigen-binding fragment
thereof may be conjugated to a number of drug moieties as indicated
by integer n, which represents the average number of cytotoxins per
antibody, which may range, e.g., from about 1 to about 20. Any
number of cytotoxins can be conjugated to the antibody, e.g., 1, 2,
3, 4, 5, 6, 7, or 8. In some embodiments, n is from 1 to 4. In some
embodiments, n is 1. In some embodiments, n is 2. The average
number of drug moieties per antibody in preparations of ADC from
conjugation reactions may be characterized by conventional means
such as mass spectroscopy, ELISA assay, and HPLC. The quantitative
distribution of ADC in terms of n may also be determined. In some
instances, separation, purification, and characterization of
homogeneous ADC where n is a certain value from ADC with other drug
loadings may be achieved by means such as reverse phase HPLC or
electrophoresis.
[0149] For some antibody-drug conjugates, n may be limited by the
number of attachment sites on the antibody. For example, where the
attachment is a cysteine thiol, an antibody may have only one or
several cysteine thiol groups, or may have only one or several
sufficiently reactive thiol groups through which a linker may be
attached. Generally, antibodies do not contain many free and
reactive cysteine thiol groups which may be linked to a drug
moiety; primarily, cysteine thiol residues in antibodies exist as
disulfide bridges. In certain embodiments, an antibody may be
reduced with a reducing agent such as dithiothreitol (DTT) or
tricarbonylethylphosphine (TCEP), under partial or total reducing
conditions, to generate reactive cysteine thiol groups.
[0150] In certain embodiments, fewer than the theoretical maximum
of drug moieties are conjugated to an antibody during a conjugation
reaction. An antibody may contain, for example, lysine residues
that do not react with the drug-linker intermediate or linker
reagent, as discussed below. Only the most reactive lysine groups
may react with an amine-reactive linker reagent. In certain
embodiments, an antibody is subjected to denaturing conditions to
reveal reactive nucleophilic groups such as lysine or cysteine.
[0151] The loading (drug/antibody ratio) of an ADC may be
controlled in different ways, e.g., by: (i) limiting the molar
excess of drug-linker intermediate or linker reagent relative to
antibody, (ii) limiting the conjugation reaction time or
temperature, (iii) partial or limiting reductive conditions for
cysteine thiol modification, (iv) engineering by recombinant
techniques the amino acid sequence of the antibody such that the
number and position of cysteine residues is modified for control of
the number and/or position of linker-drug attachments.
Cytotoxins
[0152] The cytotoxin of the antibody-drug conjugates described
herein is an amatoxin or derivative thereof. Amatoxins are potent
and selective inhibitors of RNA polymerase II and thereby also
inhibit the transcription and protein biosynthesis of the affected
cells. As used herein, the term "amatoxin" refers to a member of
the amatoxin family of peptides produced by Amanita phalloides
mushrooms, or a variant or derivative thereof, such as a variant or
derivative thereof capable of inhibiting RNA polymerase II
activity. Amatoxins are rigid bicyclic octapeptides having the
basic sequence Ile-Trp-Gly-Ile-Gly-Cys-Asn(or Asp)-Pro, crosslinked
by an attachment between the Cys sulfur and position 2 of the Trp
indole ring, forming a tryptathionine. Depending on the particular
amatoxin, certain amino acid substituents are varied by
post-translational modification (i.e. Pro to Hyp; Ile to DHIle; and
Trp to 5-OH Trp).
[0153] Amatoxins may be isolated from a variety of mushroom species
(e.g., Amanita phalloides, Galerina marginata, Lepiota
brunneo-incarnata) or may be prepared semi-synthetically or
synthetically. Different mushroom species contain varying amounts
of different amatoxin family members. A member of this family,
.alpha.-amanitin, is known to be an extremely potent inhibitor of
eukaryotic RNA polymerase II and to a lesser degree, RNA polymerase
Ill, thereby inhibiting transcription and protein biosynthesis.
Wieland, Int. J. Pept. Protein Res. 1983, 22(3):257-276.
[0154] Structures of the various naturally occurring amatoxins are
represented by formula (III) and accompanying Table 1, and are
disclosed in, e.g., Zanotti et al., Int. J. Peptide Protein Res.
30, 1987, 450-459, which is incorporated by reference herein in its
entirety.
##STR00012##
TABLE-US-00001 TABLE 1 Amatoxin structures Name R.sub.1 R.sub.2
R.sub.3, R.sub.4 R.sub.5 R.sub.6, R.sub.7 R.sub.8 R.sub.9
.alpha.-amanitin OH OH H OH H NH.sub.2 OH .beta.-amanitin OH OH H
OH H OH OH .gamma.-amanitin OH H H OH H NH.sub.2 OH
.epsilon.-amanitin OH H H OH H OH OH Amanin OH OH H H H OH OH
Amaninamide OH OH H H H NH.sub.2 OH Amanullin H H H OH H NH.sub.2
OH Amanullinic acid H H H OH H OH OH Proamanullin H H H OH H
NH.sub.2 H
[0155] Antibodies, or antigen-binding fragments thereof, that
recognize and bind to an antigen expressed on the cell surface of a
human stem cell or a T cell can be conjugated to an amatoxin, such
as an .alpha.-amanitin or a derivative thereof, as described in,
for example, U.S. Pat. Nos. 9,233,173 and 9,399,681 and US Patent
Application Publication Nos. 2016/0089450, 2016/0002298,
2015/0218220, 2014/0294865, the disclosure of each of which is
incorporated herein by reference as it pertains, for example, to
amatoxins, such as .alpha.-amanitin, as well as covalent linkers
that can be used for covalent conjugation. Exemplary methods of
amatoxin conjugation and linkers useful for such processes are
described herein. Exemplary linker-containing amatoxins useful for
conjugation to an antibody, or antigen-binding fragment, in
accordance with the compositions and methods are also described
herein.
[0156] As used herein, the term "amatoxin derivative" or "amanitin
derivative" refers to an amatoxin that has been chemically modified
at one or more positions relative to a naturally occurring
amatoxin, such as .alpha.-amanitin, .beta.-amanitin,
.gamma.-amanitin, .epsilon.-amanitin, amanin, amaninamide,
amanullin, amanullinic acid, or proamanullin. In each instance, the
derivative may be obtained by chemical modification of a naturally
occurring compound ("semi-synthetic"), or may be obtained from an
entirely synthetic source. Synthetic routes to various amatoxin
derivatives are disclosed in, for example, U.S. Pat. No. 9,676,702
and in Perrin et al., J. Am. Chem. Soc. 2018, 140, p. 6513-6517,
each of which is incorporated by reference herein in their entirety
with respect to synthetic methods for preparing and derivatizing
amatoxins.
[0157] In some embodiments, the amatoxin or derivative thereof is
represented by formula (V):
##STR00013##
or an enantiomer or diastereomer thereof.
[0158] In some embodiments, Q is S.
[0159] In one embodiment, the amatoxin or derivative thereof is
represented by formula (Va):
##STR00014##
[0160] In some embodiments, Q is S.
[0161] In this particular embodiment, the amatoxin or derivative
thereof is represented by formula (Vb):
##STR00015##
[0162] In some embodiments, Q is S.
[0163] Additional amatoxins that may be used for conjugation to an
antibody, or antigen-binding fragment thereof, in accordance with
the compositions and methods described herein are described, for
example, in WO 2016/142049; WO 2016/071856; WO 2017/149077; WO
2018/115466; and WO 2017/046658, the disclosures of which are
incorporated herein by reference in their entirety.
Linkers
[0164] The term "Linker" as used herein means a divalent chemical
moiety comprising a covalent bond or a chain of atoms that
covalently attaches an antibody or fragment thereof (Ab) to an
amatoxin as described herein, e.g., an amatoxin of formulae (IV),
(IVa), (IVb), (V), (Va), or (Vb), to form an antibody-drug
conjugate (ADC).
[0165] Covalent attachment of the antibody and the amatoxin
requires the linker to have two reactive functional groups, i.e.
bivalency in a reactive sense. Bivalent linker reagents which are
useful to attach two or more functional or biologically active
moieties, such as peptides, nucleic acids, drugs, toxins,
antibodies, haptens, and reporter groups are known, and methods
have been described their resulting conjugates (Hermanson, G. T.
(1996) Bioconjugate Techniques; Academic Press: New York, p.
234-242).
[0166] Accordingly, present linkers have two reactive termini, one
for conjugation to an antibody and the other for conjugation to an
amatoxin. The antibody conjugation reactive terminus of the linker
(reactive moiety, defined herein as Z') is typically a chemical
moiety that is capable of conjugation to the antibody through,
e.g., a cysteine thiol or lysine amine group on the antibody, and
so is typically a thiol-reactive group such as a Michael acceptor
(as in maleimide), a leaving group, such as a chloro, bromo, iodo,
or an R-sulfanyl group, or an amine-reactive group such as a
carboxyl group. Conjugation of the linker to the antibody is
described more fully herein below.
[0167] The amatoxin conjugation reactive terminus of the linker is
typically a chemical moiety that is capable of conjugation to the
amatoxin through formation of a bond with a reactive substituent
within the amatoxin molecule. Non-limiting examples include, for
example, formation of an amide bond with a basic amine or carboxyl
group on the amatoxin, via a carboxyl or basic amine group on the
linker, respectively, or formation of an ether or the like, via
alkylation of an OH group on the amatoxin via e.g., a leaving group
on the linker.
[0168] When the term "linker" is used in describing the linker in
conjugated form, one or both of the reactive termini will be absent
(such as reactive moiety Z', having been converted to chemical
moiety Z, as described herein below) or incomplete (such as being
only the carbonyl of the carboxylic acid) because of the formation
of the bonds between the linker and/or the amatoxin, and between
the linker and/or the antibody or antigen-binding fragment thereof.
Such conjugation reactions are described further herein below.
[0169] A variety of linkers can be used to conjugate the
antibodies, antigen-binding fragments, and ligands described to a
cytotoxic molecule. Generally, linkers suitable for the present
disclosure may be substantially stable in circulation, but allow
for release of the amatoxin within or in close proximity to the
target cells. In some embodiments, certain linkers suitable for the
present disclosure may be categorized as "cleavable" or
"non-cleavable". Generally, cleavable linkers contain one or more
functional groups that is cleaved in response to a physiological
environment. For example, a cleavable linker may contain an
enzymatic substrate (e.g., valine-alanine) that degrades in the
presence of an intracellular enzyme (e.g., cathepsin B), an
acid-cleavable group (e.g., a hydrozone) that degrades in the
acidic environment of a cellular compartment, or a reducible group
(e.g., a disulfide) that degrades in an intracellular reducing
environment. By contrast, generally, non-cleavable linkers are
released from the ADC during degradation (e.g., lysosomal
degradation) of the antibody moiety of the ADC inside the target
cell.
Non-Cleavable Linkers
[0170] Non-cleavable linkers suitable for use herein further may
include one or more groups selected from a bond, --(C.dbd.O)--,
C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 heteroalkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 heteroalkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6 heteroalkynylene,
C.sub.3-C.sub.6 cycloalkylene, heterocycloalkylene, arylene,
heteroarylene, and combinations thereof, each of which may be
optionally substituted, and/or may include one or more heteroatoms
(e.g., S, N, or O) in place of one or more carbon atoms.
Non-limiting examples of such groups include (CH.sub.2).sub.p,
(C.dbd.O)(CH.sub.2).sub.p, and polyethyleneglycol (PEG;
(CH.sub.2CH.sub.2O).sub.p), units, wherein p is an integer from
1-6, independently selected for each occasion.
[0171] In some embodiments, the linker L comprises one or more of a
bond, --(C.dbd.O)--, a --C(O)NH-- group, an --OC(O)NH-- group,
C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 heteroalkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 heteroalkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6 heteroalkynylene,
C.sub.3-C.sub.6 cycloalkylene, heterocycloalkylene, arylene,
heteroarylene, a --(CH.sub.2CH.sub.2O).sub.p-- group where p is an
integer from 1-6, or a solubility enhancing group;
[0172] wherein each C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6
heteroalkylene, C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6
heteroalkenylene, C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6
heteroalkynylene, C.sub.3-C.sub.6 cycloalkylene,
heterocycloalkylene, arylene, or heteroarylene may optionally be
substituted with from 1 to 5 substituents independently selected
for each occasion from the group consisting of alkyl, alkenyl,
alkynyl, cycloalkyl, heterocycloalkyl, alkaryl, alkyl heteroaryl,
amino, ammonium, acyl, acyloxy, acylamino, aminocarbonyl,
alkoxycarbonyl, ureido, carbamate, aryl, heteroaryl, sulfinyl,
sulfonyl, hydroxyl, alkoxy, sulfanyl, halogen, carboxy,
trihalomethyl, cyano, hydroxy, mercapto, and nitro;
[0173] In some embodiments, each C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 heteroalkenylene, C.sub.2-C.sub.6 alkynylene,
C.sub.2-C.sub.6 heteroalkynylene, C.sub.3-C.sub.6 cycloalkylene,
heterocycloalkylene, arylene, or heteroarylene may optionally be
interrupted by one or more heteroatoms selected from O, S and
N.
[0174] In some embodiments, each C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 heteroalkenylene, C.sub.2-C.sub.6 alkynylene,
C.sub.2-C.sub.6 heteroalkynylene, C.sub.3-C.sub.6 cycloalkylene,
heterocycloalkylene, arylene, or heteroarylene may optionally be
interrupted by one or more heteroatoms selected from O, S and N and
may be optionally substituted with from 1 to 5 substituents
independently selected for each occasion from the group consisting
of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkaryl,
alkyl heteroaryl, amino, ammonium, acyl, acyloxy, acylamino,
aminocarbonyl, alkoxycarbonyl, ureido, carbamate, aryl, heteroaryl,
sulfinyl, sulfonyl, hydroxyl, alkoxy, sulfanyl, halogen, carboxy,
trihalomethyl, cyano, hydroxy, mercapto, and nitro.
[0175] In some embodiments, the linker L comprises a solubility
enhancing group of the formula
--O.sub.a--C(O)NH--SO.sub.2--N(R.sup.1)--, wherein:
[0176] a is 0 or 1;
[0177] R.sup.1 is selected from the group consisting of hydrogen,
C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24 cycloalkyl groups,
C.sub.2-C.sub.24 (hetero)aryl groups, C.sub.3-C.sub.24
alkyl(hetero)aryl groups and C.sub.3-C.sub.24 (hetero)arylalkyl
groups, each of which may be optionally substituted or optionally
interrupted by one or more heteroatoms selected from O, S and
NR.sup.3, wherein R.sup.3 is independently selected from the group
consisting of hydrogen and C.sub.1-C.sub.4 alkyl. Such solubility
enhancing groups are described in, for example, U.S. Pat. No.
9,636,421 and U.S. Patent Application Publication No. 2017/0298145,
the disclosures of each of which are incorporated herein by
reference in their entirety.
[0178] In some embodiments, the solubility enhancing group of the
formula --O.sub.a--C(O)NH--SO.sub.2--N(R')-- further comprises a
C.sub.1-C.sub.6 alkylene or a --(CH.sub.2CH.sub.2O).sub.p-- group,
where p is an integer from 1-6. Non-limiting examples of such
solubility enhancing groups include those depicted in Table 2,
above.
TABLE-US-00002 TABLE 2 Exemplary solubility enhancing groups
##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020## m
= 1-6 ##STR00021## ##STR00022##
[0179] In some embodiments, the non-cleavable linker comprises a
--(CH.sub.2).sub.n-- unit, where n is an integer from, 2-12, e.g.,
2-6. In some embodiments, the non-cleavable linker comprises a
--(CH.sub.2).sub.n-- where n is 1, 2, 3, 4, 5, or 6. In some
embodiments, the non-cleavable linker is --(CH.sub.2).sub.n-- where
n is 6, represented by the formula:
##STR00023##
Cleavable Linkers
[0180] In some embodiments, the linker conjugating the antibody or
antigen binding fragment thereof and the amatoxin is cleavable
under intracellular conditions, such that cleavage of the linker
releases the drug unit from the antibody in the intracellular
environment. Cleavable linkers are designed to exploit the
differences in local environments, e.g., extracellular and
intracellular environments, including, for example, pH, reduction
potential or enzyme concentration, to trigger the release of the
amatoxin in the target cell. Generally, cleavable linkers are
relatively stable in circulation, but are particularly susceptible
to cleavage in the intracellular environment through one or more
mechanisms (e.g., including, but not limited to, activity of
proteases, peptidases, and glucuronidases). Cleavable linkers used
herein are substantially stable in circulating plasma and/or
outside the target cell and may be cleaved at some efficacious rate
inside the target cell or in close proximity to the target
cell.
[0181] Suitable cleavable linkers include those that may be
cleaved, for instance, by enzymatic hydrolysis, photolysis,
hydrolysis under acidic conditions, hydrolysis under basic
conditions, oxidation, disulfide reduction, nucleophilic cleavage,
or organometallic cleavage (see, for example, Leriche et al.,
Bioorg. Med. Chem., 20:571-582, 2012, the disclosure of which is
incorporated herein by reference as it pertains to linkers suitable
for covalent conjugation). Suitable cleavable linkers may include,
for example, chemical moieties such as a hydrazine, a disulfide, a
thioether or a dipeptide.
[0182] Linkers hydrolyzable under acidic conditions include, for
example, hydrazones, semicarbazones, thiosemicarbazones,
cis-aconitic amides, orthoesters, acetals, ketals, or the like.
(See, e.g., U.S. Pat. Nos. 5,122,368; 5,824,805; 5,622,929;
Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville
et al., 1989, Biol. Chem. 264:14653-14661, the disclosure of each
of which is incorporated herein by reference in its entirety as it
pertains to linkers suitable for covalent conjugation. Such linkers
are relatively stable under neutral pH conditions, such as those in
the blood, but are unstable at below pH 5.5 or 5.0, the approximate
pH of the lysosome.
[0183] Linkers cleavable under reducing conditions include, for
example, a disulfide. A variety of disulfide linkers are known in
the art, including, for example, those that can be formed using
SATA (N-succinimidyl-S-acetylthioacetate), SPDP
(N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB
(N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT
(N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene)-
, SPDB and SMPT (See, e.g., Thorpe et al., 1987, Cancer Res.
47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody
Conjugates in Radioimagery and Therapy of Cancer (C. W. Vogel ed.,
Oxford U. Press, 1987. See also U.S. Pat. No. 4,880,935, the
disclosure of each of which is incorporated herein by reference in
its entirety as it pertains to linkers suitable for covalent
conjugation.
[0184] Linkers susceptible to enzymatic hydrolysis can be, e.g., a
peptide-containing linker that is cleaved by an intracellular
peptidase or protease enzyme, including, but not limited to, a
lysosomal or endosomal protease. One advantage of using
intracellular proteolytic release of the therapeutic agent is that
the agent is typically attenuated when conjugated and the serum
stabilities of the conjugates are typically high. In some
embodiments, the peptidyl linker is at least two amino acids long
or at least three amino acids long. Exemplary amino acid linkers
include a dipeptide, a tripeptide, a tetrapeptide or a
pentapeptide. Examples of suitable peptides include those
containing amino acids such as Valine, Alanine, Citrulline (Cit),
Phenylalanine, Lysine, Leucine, and Glycine. Amino acid residues
which comprise an amino acid linker component include those
occurring naturally, as well as minor amino acids and non-naturally
occurring amino acid analogs, such as citrulline. Exemplary
dipeptides include valine-citrulline (vc or val-cit) and
alanine-phenylalanine (af or ala-phe). Exemplary tripeptides
include glycine-valine-citrulline (gly-val-cit) and
glycine-glycine-glycine (gly-gly-gly). In some embodiments, the
linker includes a dipeptide such as Val-Cit, Ala-Val, or Phe-Lys,
Val-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp-Cit.
Linkers containing dipeptides such as Val-Cit or Phe-Lys are
disclosed in, for example, U.S. Pat. No. 6,214,345, the disclosure
of which is incorporated herein by reference in its entirety as it
pertains to linkers suitable for covalent conjugation. In some
embodiments, the linker comprises a dipeptide selected from Val-Ala
and Val-Cit.
[0185] Linkers suitable for conjugating the antibodies,
antigen-binding fragments, described herein to a cytotoxic molecule
include those capable of releasing an amatoxin by a 1,6-elimination
process. Chemical moieties capable of this elimination process
include the p-aminobenzyl (PAB) group, 6-maleimidohexanoic acid,
pH-sensitive carbonates, and other reagents as described in Jain et
al., Pharm. Res. 32:3526-3540, 2015, the disclosure of which is
incorporated herein by reference in its entirety as it pertains to
linkers suitable for covalent conjugation.
[0186] In some embodiments, the linker includes a "self-immolative"
group such as the afore-mentioned PAB or PABC
(para-aminobenzyloxycarbonyl), which are disclosed in, for example,
Carl et al., J. Med. Chem. (1981) 24:479-480; Chakravarty et al
(1983) J. Med. Chem. 26:638-644; U.S. Pat. No. 6,214,345;
US20030130189; US20030096743; U.S. Pat. No. 6,759,509;
US20040052793; U.S. Pat. Nos. 6,218,519; 6,835,807; 6,268,488;
US20040018194; WO98/13059; US20040052793; U.S. Pat. Nos. 6,677,435;
5,621,002; US20040121940; WO2004/032828). Other such chemical
moieties capable of this process ("self-immolative linkers")
include methylene carbamates and heteroaryl groups such as
aminothiazoles, aminoimidazoles, aminopyrimidines, and the like.
Linkers containing such heterocyclic self-immolative groups are
disclosed in, for example, U.S. Patent Publication Nos. 20160303254
and 20150079114, and U.S. Pat. No. 7,754,681; Hay et al. (1999)
Bioorg. Med. Chem. Lett. 9:2237; US 2005/0256030; de Groot et al
(2001) J. Org. Chem. 66:8815-8830; and U.S. Pat. No. 7,223,837. In
some embodiments, a dipeptide is used in combination with a
self-immolative linker.
[0187] In some embodiments, the linker L comprises one or more of a
hydrazine, a disulfide, a thioether, an amino acid, a peptide
consisting of up to 10 amino acids, a p-aminobenzyl (PAB) group, a
heterocyclic self-immolative group, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 heteroalkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 heteroalkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.2-C.sub.6 heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl,
heterocycloalkyl, aryl, heteroaryl, a --(C.dbd.O)-- group, a
--C(O)NH-- group, an --OC(O)NH-- group, a
--(CH.sub.2CH.sub.2O).sub.p-- group where p is an integer from 1-6,
or a solubility enhancing group;
[0188] wherein each C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
heteroalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
heteroalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6
heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl, heterocycloalkyl, aryl,
or heteroaryl group may be optionally substituted with from 1 to 5
substituents independently selected for each occasion from the
group consisting of alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, alkaryl, alkyl heteroaryl, amino, ammonium, acyl,
acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido,
carbamate, aryl, heteroaryl, sulfinyl, sulfonyl, hydroxyl, alkoxy,
sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy,
mercapto, and nitro.
[0189] In some embodiments, each C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 heteroalkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 heteroalkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.2-C.sub.6 heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl group may optionally be
interrupted by one or more heteroatoms selected from O, S and
N.
[0190] In some embodiments, each C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 heteroalkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 heteroalkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.2-C.sub.6 heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl group may optionally be
interrupted by one or more heteroatoms selected from O, S and N and
may be optionally substituted with from 1 to 5 substituents
independently selected for each occasion from the group consisting
of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkaryl,
alkyl heteroaryl, amino, ammonium, acyl, acyloxy, acylamino,
aminocarbonyl, alkoxycarbonyl, ureido, carbamate, aryl, heteroaryl,
sulfinyl, sulfonyl, hydroxyl, alkoxy, sulfanyl, halogen, carboxy,
trihalomethyl, cyano, hydroxy, mercapto, and nitro.
[0191] One of skill in the art will recognize that one or more of
the groups listed may be present in the form of a bivalent
(diradical) species, e.g., C.sub.1-C.sub.6 alkylene and the
like.
[0192] In some embodiments, the linker L comprises a solubility
enhancing group of the formula
--O.sub.a--C(O)NH--SO.sub.2--N(R.sup.1)--, wherein:
[0193] a is 0 or 1;
[0194] R.sup.1 is selected from the group consisting of hydrogen,
C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24 cycloalkyl groups,
C.sub.2-C.sub.24 (hetero)aryl groups, C.sub.3-C.sub.24
alkyl(hetero)aryl groups and C.sub.3-C.sub.24 (hetero)arylalkyl
groups, each of which may be optionally substituted or optionally
interrupted by one or more heteroatoms selected from O, S and
NR.sup.3, wherein R.sup.3 is independently selected from the group
consisting of hydrogen and C.sub.1-C.sub.4 alkyl. Such solubility
enhancing groups are described in, for example, U.S. Pat. No.
9,636,421 and U.S. Patent Application Publication No. 2017/0298145,
the disclosures of each of which are incorporated herein by
reference in their entirety.
[0195] In some embodiments, the solubility enhancing group of the
formula --O.sub.a--C(O)NH--SO.sub.2--N(R.sup.1)-- further comprises
a C.sub.1-C.sub.6 alkylene or a --(CH.sub.2CH.sub.2O).sub.p--
group, where p is an integer from 1-6. Non-limiting examples of
such solubility enhancing groups include those depicted in Table 2,
above.
[0196] In some embodiments, the linker includes a p-aminobenzyl
group (PAB). In one embodiment, the p-aminobenzyl group is disposed
between the cytotoxic drug and a protease cleavage site in the
linker. In one embodiment, the p-aminobenzyl group is part of a
p-aminobenzyloxycarbonyl unit. In one embodiment, the p-aminobenzyl
group is part of a p-aminobenzylamido unit.
[0197] In some embodiments, the linker comprises a dipeptide
selected from the group consisting of Phe-Lys, Val-Lys, Phe-Ala,
Phe-Cit, Val-Ala, Val-Cit, and Val-Arg. In some embodiments, the
linker comprises one or more of PAB, Val-Cit-PAB, Val-Ala-PAB,
Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys,
Gly-Gly-Arg, Ala-Ala-Asn-PAB, or Ala-PAB.
[0198] In some embodiments, the linker comprises a combination of
one or more of a peptide, oligosaccharide, --(CH.sub.2).sub.p--,
--(CH.sub.2CH.sub.2O).sub.p--, PAB, Val-Cit-PAB, Val-Ala-PAB,
Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys,
Gly-Gly-Arg, Ala-Ala-Asn-PAB, or Ala-PAB.
[0199] In some embodiments, the linker comprises a
--(C.dbd.O)(CH.sub.2).sub.p-- unit, wherein p is an integer from
1-6.
[0200] In some embodiments, the linker comprises
PAB-Ala-Val-propionyl, represented by the formula:
##STR00024##
[0201] In some embodiments, the linker comprises
PAB-Cit-Val-propionyl, represented by the formula:
##STR00025##
[0202] Such PAB-dipeptide-propionyl linkers are disclosed in, e.g.,
International Patent Application Publication No. WO2017/149077,
which is incorporated by reference herein in its entirety. Further,
the cytotoxins disclosed in WO2017/149077 are incorporated by
reference herein.
[0203] It will be recognized by one of skill in the art that any
one or more of the chemical groups, moieties and features disclosed
herein may be combined in multiple ways to form linkers useful for
conjugation of the antibodies and amatoxins as disclosed herein.
Further linkers useful in conjunction with the compositions and
methods described herein, are described, for example, in U.S.
Patent Application Publication No. 2015/0218220, the disclosure of
which is incorporated herein by reference in its entirety.
Linker-Amatoxin and Linker-Antibody Conjugation
[0204] In certain embodiments, the linker is reacted with an
amatoxin or derivative thereof according to any of formulae (V),
(Va), or (Vb) under appropriate conditions to form a
linker-amatoxin conjugate. In certain embodiments, reactive groups
are used on the amatoxin or linker to form a covalent
attachment.
[0205] The amatoxin-linker conjugate is subsequently reacted with
the antibody, derivatized antibody, or antigen-binding fragment
thereof, under appropriate conditions to form the ADC.
Alternatively, the linker may first be reacted with the antibody,
derivatized antibody or antigen-binding fragment thereof, to form a
linker-antibody conjugate, and then reacted with the amatoxin to
form the ADC. Such conjugation reactions will now be described more
fully.
[0206] A number of different reactions are available for covalent
attachment of linkers or amatoxin-linker conjugates to the antibody
or antigen-binding fragment thereof. Suitable attachment points on
the antibody molecule include, but are not limited to, the amine
groups of lysine, the free carboxylic acid groups of glutamic acid
and aspartic acid, the sulfhydryl groups of cysteine, and the
various moieties of aromatic amino acids. For instance,
non-specific covalent attachment may be undertaken using a
carbodiimide reaction to link a carboxy (or amino) group on a
linker to an amino (or carboxy) group on an antibody moiety.
Additionally, bifunctional agents such as dialdehydes or
imidoesters may also be used to link the amino group on a linker to
an amino group on an antibody moiety. Also available for attachment
of amatoxins to antibody moieties is the Schiff base reaction. This
method involves the periodate oxidation of a glycol or hydroxy
group on either the antibody or linker, thus forming an aldehyde
which is then reacted with the linker or antibody, respectively.
Covalent bond formation occurs via formation of a Schiff base
between the aldehyde and an amino group. Isothiocyanates may also
be used as coupling agents for covalently attaching amatoxins or
antibody moieties to linkers. Other techniques are known to the
skilled artisan and within the scope of the present disclosure.
[0207] Linkers useful in for conjugation to the antibodies or
antigen-binding fragments as described herein include, without
limitation, linkers containing a chemical moiety Z, formed by a
coupling reaction between the antibody and a reactive chemical
moiety (referred to herein as a reactive substituent, Z') on the
linker as depicted in Table 3, below. Wavy lines designate points
of attachment to the antibody or antigen-binding fragment, and the
cytotoxic molecule, respectively.
TABLE-US-00003 TABLE 3 Exemplary chemical moieties Z formed by
coupling reactions in the formation of antibody-drug conjugates.
Exemplary Coupling Reactions Chemical Moiety Z Formed by Coupling
Reactions [3 + 2] Cycloaddition ##STR00026## [3 + 2] Cycloaddition
##STR00027## [3 + 2] Cycloaddition, Esterification ##STR00028## [3
+ 2] Cycloaddition, Esterification ##STR00029## [3 + 2]
Cycloaddition, Esterification ##STR00030## [3 + 2] Cycloaddition,
Esterification ##STR00031## [3 + 2] Cycloaddition, Esterification
##STR00032## [3 + 2] Cycloaddition, Esterification ##STR00033## [3
+ 2] Cycloaddition, Esterification ##STR00034## [3 + 2]
Cycloaddition, Esterification ##STR00035## [3 + 2] Cycloaddition,
Esterification ##STR00036## [3 + 2] Cycloaddition, Esterification
##STR00037## [3 + 2] Cycloaddition, Esterification ##STR00038## [3
+ 2] Cycloaddition, Etherification ##STR00039## [3 + 2]
Cycloaddition ##STR00040## Michael addition ##STR00041## Michael
addition ##STR00042## Imine condensation, Amidation ##STR00043##
Imine condensation ##STR00044## Disulfide formation ##STR00045##
Thiol alkylation ##STR00046## Condensation, Michael addition
##STR00047##
[0208] One of skill in the art will recognize that a reactive
substituent Z' attached to the linker and a reactive substituent on
the antibody or antigen-binding fragment thereof, are engaged in
the covalent coupling reaction to produce the chemical moiety Z,
and will recognize the reactive substituent Z'. Therefore,
antibody-drug conjugates useful in conjunction with the methods
described herein may be formed by the reaction of an antibody, or
antigen-binding fragment thereof, with a linker or amatoxin-linker
conjugate, as described herein, the linker or amatoxin-linker
conjugate including a reactive substituent Z', suitable for
reaction with a reactive substituent on the antibody, or
antigen-binding fragment thereof, to form the chemical moiety
Z.
[0209] As depicted in Table 3, examples of suitably reactive
substituents Z' on the linker and reactive substituents on the
antibody or antigen-binding fragment thereof include a
nucleophile/electrophile pair (e.g., a thiol/haloalkyl pair, an
amine/carbonyl pair, or a thiol/.alpha.,.beta.-unsaturated carbonyl
pair, and the like), a diene/dienophile pair (e.g., an azide/alkyne
pair, or a diene/.alpha.,.beta.-unsaturated carbonyl pair, among
others), and the like. Coupling reactions between the reactive
substitutents to form the chemical moiety Z include, without
limitation, thiol alkylation, hydroxyl alkylation, amine
alkylation, amine or hydroxylamine condensation, hydrazine
formation, amidation, esterification, disulfide formation,
cycloaddition (e.g., [4+2] Diels-Alder cycloaddition, [3+2] Huisgen
cycloaddition, among others), nucleophilic aromatic substitution,
electrophilic aromatic substitution, and other reactive modalities
known in the art or described herein. In some embodiments, the
reactive substituent Z' is an electrophilic functional group
suitable for reaction with a nucleophilic functional group on the
antibody, or antigen-binding fragment thereof.
[0210] Reactive substituents that may be present within an
antibody, or antigen-binding fragment thereof, as disclosed herein
include, without limitation, nucleophilic groups such as
(i)N-terminal amine groups, (ii) side chain amine groups, e.g.
lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv)
sugar hydroxyl or amino groups where the antibody is glycosylated.
Reactive substituents that may be present within an antibody, or
antigen-binding fragment thereof, as disclosed herein include,
without limitation, hydroxyl moieties of serine, threonine, and
tyrosine residues; amino moieties of lysine residues; carboxyl
moieties of aspartic acid and glutamic acid residues; and thiol
moieties of cysteine residues, as well as propargyl, azido,
haloaryl (e.g., fluoroaryl), haloheteroaryl (e.g.,
fluoroheteroaryl), haloalkyl, and haloheteroalkyl moieties of
non-naturally occurring amino acids. In some embodiments, the
reactive substituents present within an antibody, or
antigen-binding fragment thereof as disclosed herein include, are
amine or thiol moieties. Certain antibodies have reducible
interchain disulfides, i.e. cysteine bridges. Antibodies may be
made reactive for conjugation with linker reagents by treatment
with a reducing agent such as DTT (dithiothreitol). Each cysteine
bridge will thus form, theoretically, two reactive thiol
nucleophiles. Additional nucleophilic groups can be introduced into
antibodies through the reaction of lysines with 2-iminothiolane
(Traut's reagent) resulting in conversion of an amine into a thiol.
Reactive thiol groups may be introduced into the antibody (or
fragment thereof) by introducing one, two, three, four, or more
cysteine residues (e.g., preparing mutant antibodies comprising one
or more non-native cysteine amino acid residues). U.S. Pat. No.
7,521,541 teaches engineering antibodies by introduction of
reactive cysteine amino acids.
[0211] In some embodiments, the reactive substituent Z' attached to
the linker is a nucleophilic group which is reactive with an
electrophilic group present on an antibody. Useful electrophilic
groups on an antibody include, but are not limited to, aldehyde and
ketone carbonyl groups. A nucleophilic group (e.g., a) heteroatom
of can react with an electrophilic group on an antibody and form a
covalent bond to the antibody. Useful nucleophilic groups include,
but are not limited to, hydrazide, oxime, amino, hydroxyl,
hydrazine, thiosemicarbazone, hydrazine carboxylate, and
arylhydrazide.
[0212] In some embodiments, chemical moiety Z is the product of a
reaction between reactive nucleophilic substituents present within
the antibodies, or antigen-binding fragments thereof, such as amine
and thiol moieties, and a reactive electrophilic substituent Z'
attached to the linker. For instance, Z' may be a Michael acceptor
(e.g., maleimide), activated ester, electron-deficient carbonyl
compound, or an aldehyde, among others.
[0213] Several representative and non-limiting examples of reactive
substituents Z' and the resulting chemical moieties Z are provided
in Table 4.
TABLE-US-00004 TABLE 4 Complementary reactive substituents and
chemical moieties Functional Group on Antibody Z' group Z group
Naturally Occurring ##STR00048## ##STR00049## ##STR00050##
##STR00051## ##STR00052## ##STR00053## Synthetically Introduced
##STR00054## ##STR00055## ##STR00056## ##STR00057## ##STR00058##
##STR00059## ##STR00060## ##STR00061## ##STR00062## R = H or alkyl
(Y = O or NH)
[0214] For instance, linkers suitable for the synthesis of
linker-antibody conjugates and ADCs include, without limitation,
reactive substituents Z' attached to the linker, such as a
maleimide or haloalkyl group. These may be attached to the linker
by, for example, reagents such as succinimidyl
4-(N-maleimidomethyl)-cyclohexane-L-carboxylate (SMCC),
N-succinimidyl iodoacetate (SIA), sulfo-SMCC,
m-maleimidobenzoyl-N-hydroxysuccinimidyl ester (MBS), sulfo-MBS,
and succinimidyl iodoacetate, among others described, in for
instance, Liu et al., 18:690-697, 1979, the disclosure of which is
incorporated herein by reference as it pertains to linkers for
chemical conjugation.
[0215] In some embodiments, the reactive substituent Z' attached to
linker L is a maleimide, azide, or alkyne. An example of a
maleimide-containing linker is the non-cleavable
maleimidocaproyl-based linker, which is particularly useful for the
conjugation of microtubule-disrupting agents such as auristatins.
Such linkers are described by Doronina et al., Bioconjugate Chem.
17:14-24, 2006, the disclosure of which is incorporated herein by
reference as it pertains to linkers for chemical conjugation.
[0216] In some embodiments, the reactive substituent Z' is
--(C.dbd.O)-- or --NH(C.dbd.O)--, such that the linker may be
joined to the antibody, or antigen-binding fragment thereof, by an
amide or urea moiety, respectively, resulting from reaction of the
--(C.dbd.O)-- or --NH(C.dbd.O)-- group with an amino group of the
antibody or antigen-binding fragment thereof.
[0217] In some embodiments, the reactive substituent Z' is an
N-maleimidyl group, halogenated N-alkylamido group, sulfonyloxy
N-alkylamido group, carbonate group, sulfonyl halide group, thiol
group or derivative thereof, alkynyl group comprising an internal
carbon-carbon triple bond, (hetero)cycloalkynyl group,
bicyclo[6.1.0]non-4-yn-9-yl group, alkenyl group comprising an
internal carbon-carbon double bond, cycloalkenyl group, tetrazinyl
group, azido group, phosphine group, nitrile oxide group, nitrone
group, nitrile imine group, diazo group, ketone group,
(O-alkyl)hydroxylamino group, hydrazine group, halogenated
N-maleimidyl group, 1,1-bis (sulfonylmethyl)methylcarbonyl group or
elimination derivatives thereof, carbonyl halide group, or an
allenamide group, each of which may be optionally substituted. In
some embodiments, the reactive substituent comprises a cycloalkene
group, a cycloalkyne group, or an optionally substituted
(hetero)cycloalkynyl group.
[0218] In some embodiments, the chemical moiety Z is selected from
Table 3 or Table 4. In some embodiments, the chemical moiety Z
is:
##STR00063##
where S is a sulfur atom which represents the reactive substituent
present within an antibody, or antigen-binding fragment thereof,
that specifically binds to an antigen expressed on the cell surface
of a human stem cell or a T cell (e.g., from the --SH group of a
cysteine residue).
[0219] In some embodiments, the linker-reactive substituent group,
taken together as L-Z', prior to conjugation with the antibody or
antigen binding fragment thereof, has the structure:
##STR00064##
where the wavy line indicates the point of attachment to a
substituent on the amatoxin. This linker-reactive substituent group
L-Z' may alternatively be referred to as
N-beta-maleimidopropyl-Val-Ala-para-aminobenzyl (BMP-Val-Ala-PAB).
The wavy line at the linker terminus indicates the point of
attachment to the amatoxin. In some embodiments, the linker L and
the chemical moiety Z, after conjugation to the antibody, taken
together as L-Z-Ab, has the structure:
##STR00065##
where S is a sulfur atom which represents the reactive substituent
present within an antibody, or antigen-binding fragment thereof,
that specifically binds to an antigen expressed on the cell surface
of a human stem cell or a T cell (e.g., from the --SH group of a
cysteine residue. The wavy line at the linker terminus indicates
the point of attachment to the amatoxin.
[0220] In some embodiments, the linker-reactive substituent group,
taken together as L-Z', prior to conjugation with the antibody or
antigen binding fragment thereof, has the structure:
##STR00066##
This linker-reactive substituent group may alternatively be
referred to as 1-n-hexyl-maleimide, which is a non-cleavable
linker. The wavy line at the linker terminus indicates the point of
attachment to the amatoxin. In some embodiments, the linker L and
the chemical moiety Z, after conjugation to the antibody, taken
together as L-Z-Ab, has the structure:
##STR00067##
where S is a sulfur atom which represents the reactive substituent
present within an antibody, or antigen-binding fragment thereof,
that specifically binds to an antigen expressed on the cell surface
of a human stem cell or a T cell (e.g., from the --SH group of a
cysteine residue). The wavy line at the linker terminus indicates
the point of attachment to the amatoxin. One of skill in the art
will recognize that in this embodiment, the linker-reactive
substituent group structure L-Z', prior to conjugation with the
antibody or antigen binding fragment thereof, includes a maleimide
as the group Z'. The foregoing linker moieties and amatoxin-linker
conjugates, among others useful in conjunction with the
compositions and methods described herein, are described, for
example, in U.S. Patent Application Publication No. 2015/0218220
and Patent Application Publication No. WO2017/149077, the
disclosure of each of which is incorporated herein by reference in
its entirety.
[0221] In one aspect, the cytotoxin of the ADC as disclosed herein
is an amatoxin or derivative thereof as represented by any of
formulae (V), (Va), or (Vb). One of skill in the art will recognize
that such amatoxins present multiple possibilities for attachment
points to the linker.
[0222] In some embodiments, the amatoxin has the structure of
formula (V), and the linker is attached by an ether bond to the OH
group of the hydroxyl tryptophan residue. In such embodiments, the
ADC may be represented by formula (I):
##STR00068##
or a stereoisomer thereof; wherein:
[0223] Q is S;
[0224] L is a linker;
[0225] Z is a chemical moiety formed by a coupling reaction between
a reactive substituent present on L and a reactive substituent
present within an antibody, or antigen-binding fragment thereof;
and
[0226] Ab is an antibody,
[0227] each as disclosed herein.
[0228] In some embodiments, the amatoxin has the structure of
formula (Va), and the linker is attached by an ether bond to the OH
group of the hydroxyl tryptophan residue. In such embodiments, the
ADC may be represented by formula (Ia):
##STR00069##
[0229] In some embodiments, the amatoxin has the structure of
formula (Vb), and the linker is attached by an ether bond to the OH
group of the hydroxyl tryptophan residue. In such embodiments, the
ADC may be represented by formula (Ib):
##STR00070##
[0230] In some embodiments, the linker L of the ADC of formula (I),
(Ia), or (Ib) is a non-cleavable linker. In some embodiments, the
non-cleavable linker L comprises one or more of a bond,
--(C.dbd.O)--, a --C(O)NH-- group, an --OC(O)NH-- group,
C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 heteroalkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 heteroalkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6 heteroalkynylene,
C.sub.3-C.sub.6 cycloalkylene, heterocycloalkylene, arylene,
heteroarylene, a --(CH.sub.2CH.sub.2O).sub.p-- group where p is an
integer from 1-6, or a solubility enhancing group;
[0231] wherein each C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6
heteroalkylene, C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6
heteroalkenylene, C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6
heteroalkynylene, C.sub.3-C.sub.6 cycloalkylene,
heterocycloalkylene, arylene, or heteroarylene may optionally be
substituted with from 1 to 5 substituents independently selected
for each occasion from the group consisting of alkyl, alkenyl,
alkynyl, cycloalkyl, heterocycloalkyl, alkaryl, alkyl heteroaryl,
amino, ammonium, acyl, acyloxy, acylamino, aminocarbonyl,
alkoxycarbonyl, ureido, carbamate, aryl, heteroaryl, sulfinyl,
sulfonyl, hydroxyl, alkoxy, sulfanyl, halogen, carboxy,
trihalomethyl, cyano, hydroxy, mercapto, and nitro; or
[0232] each C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6
heteroalkylene, C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6
heteroalkenylene, C.sub.2-C.sub.6 alkynylene, C.sub.2-C.sub.6
heteroalkynylene, C.sub.3-C.sub.6 cycloalkylene,
heterocycloalkylene, arylene, or heteroarylene may optionally be
interrupted by one or more heteroatoms selected from O, S and
N.
[0233] In some embodiments, the non-cleavable linker L comprises a
solubility enhancing group of the formula
--O.sub.a--C(O)NH--SO.sub.2--NR.sup.1--, wherein:
[0234] a is 0 or 1; and
[0235] R.sup.1 is selected from the group consisting of hydrogen,
C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24 cycloalkyl groups,
C.sub.2-C.sub.24 (hetero)aryl groups, C.sub.3-C.sub.24
alkyl(hetero)aryl groups and C.sub.3-C.sub.24 (hetero)arylalkyl
groups, each of which may be optionally substituted, optionally
interrupted, or both, by one or more heteroatoms selected from O, S
and NR.sup.3, wherein R.sup.3 is independently selected from the
group consisting of hydrogen and C.sub.1-C.sub.4 alkyl.
[0236] In some embodiments, the non-cleavable linker L comprises a
--(CH.sub.2).sub.n-- unit, where n is an integer from 2-6. In some
embodiments, the non-cleavable linker L is --(CH.sub.2).sub.n--,
where n is 6.
[0237] In some embodiments, Ab, Z, and the non-cleavable linker L,
taken together as Ab-Z-L, is represented by the formula:
##STR00071##
where S is a sulfur atom which represents the reactive substituent
present within the antibody, or antigen-binding fragment thereof,
that specifically binds to an antigen expressed on a cell, e.g.,
surface of a human stem cell or a T cell (e.g., from the --SH group
of a cysteine residue). The wavy line at the linker terminus
indicates the point of attachment to the amatoxin.
[0238] In some embodiments, the ADC according to formula (I) is
represented by formula (II):
##STR00072##
a stereoisomer thereof, or a pharmaceutically acceptable salt
thereof.
[0239] In some embodiments, the ADC according to formula (II) is
represented by formula (IIa):
##STR00073##
a stereoisomer thereof, or a pharmaceutically acceptable salt
thereof.
[0240] In some embodiments, the ADC according to formula (II) is
represented by formula (Ib):
##STR00074##
a stereoisomer thereof, or a pharmaceutically acceptable salt
thereof.
[0241] Surprisingly, according to the present disclosure, it has
been found that ADCs comprising an amatoxin and a non-cleavable
linker conjugating the amatoxin to the antibody moiety of the ADC
have improved tolerability as compared to an ADC comprising an
amatoxin and a cleavable linker. For example, in some embodiments,
the improved tolerability may be increased therapeutic index. In
some embodiments, the improved tolerability may be a smaller
elevation, or absence of elevation, of one or more blood liver
enzyme levels (e.g., AST, ALT, ADH, or total bilirubin) at a
particular dose of the ADC comprising a non-cleavable linker as
compared to an ADC comprising a cleavable linker.
[0242] In some embodiments, the linker L of the ADC of formula (I),
(Ia), or (Ib) is a cleavable linker. In some embodiments, the
cleavable linker L comprises one or more of a hydrazine, a
disulfide, a thioether, an amino acid, a peptide consisting of up
to 10 amino acids, a p-aminobenzyl (PAB) group, a heterocyclic
self-immolative group, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
heteroalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
heteroalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6
heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl, heterocycloalkyl, aryl,
heteroaryl, a --(C.dbd.O)-- group, a --C(O)NH-- group, an
--OC(O)NH-- group, a --(CH.sub.2CH.sub.2O).sub.p-- group where p is
an integer from 1-6, or a solubility enhancing group;
[0243] wherein each C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
heteroalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
heteroalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6
heteroalkynyl, C.sub.3-C.sub.6 cycloalkyl, heterocycloalkyl, aryl,
or heteroaryl group may be optionally substituted with from 1 to 5
substituents independently selected for each occasion from the
group consisting of alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, alkaryl, alkyl heteroaryl, amino, ammonium, acyl,
acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido,
carbamate, aryl, heteroaryl, sulfinyl, sulfonyl, hydroxyl, alkoxy,
sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy,
mercapto, and nitro;
[0244] or each C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 heteroalkenyl,
C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 heteroalkynyl,
C.sub.3-C.sub.6 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
group may optionally be interrupted by one or more heteroatoms
selected from O, S and N.
[0245] In some embodiments, the cleavable linker L comprises a
solubility enhancing group of the formula
--O.sub.a--C(O)NH--SO.sub.2--NR.sup.1--, wherein:
[0246] a is 0 or 1; and
[0247] R.sup.1 is selected from the group consisting of hydrogen,
C.sub.1-C.sub.24 alkyl groups, C.sub.3-C.sub.24 cycloalkyl groups,
C.sub.2-C.sub.24 (hetero)aryl groups, C.sub.3-C.sub.24
alkyl(hetero)aryl groups and C.sub.3-C.sub.24 (hetero)arylalkyl
groups, each of which may be optionally substituted or optionally
interrupted by one or more heteroatoms selected from O, S and
NR.sup.3, wherein R.sup.3 is independently selected from the group
consisting of hydrogen and C.sub.1-C.sub.4 alkyl.
[0248] In some embodiments, the cleavable linker L comprises a
peptide selected from the group consisting of Phe-Lys, Val-Lys,
Phe-Ala, Phe-Cit, Val-Ala, Val-Cit, and Val-Arg.
[0249] In some embodiments, the cleavable linker L further
comprises a PAB group.
[0250] In some embodiments, the cleavable linker L is represented
by the formula:
##STR00075##
Preparation of Antibody-Drug Conjugates
[0251] In the ADCs of formula Ab-(Z-L-Cy), as disclosed herein,
such as an ADC of any of formulae (I), (Ia), or (Ib), (II), (IIa),
or (IIb), an antibody or antigen binding fragment thereof (Ab) is
conjugated to one or more cytotoxic drug moieties (Cy; e.g., an
amatoxin), for example, from about 1 to about 20 cytotoxic moieties
per antibody, through a linker L and a chemical moiety Z, each as
disclosed herein. In some embodiments, n is 1. In some embodiments,
n is about 1 to about 5, about 1 to about 4, about 1 to about 3, or
about 3 to about 5. In some embodiments, n is about 1, about 2,
about 3, or about 4.
[0252] The ADCs of the present disclosure may be prepared by
several routes, employing organic chemistry reactions, conditions,
and reagents known to those skilled in the art, including: (1)
reaction of a reactive substituent of an antibody or antigen
binding fragment thereof with a bivalent linker reagent to form
Ab-Z-L as described herein above, followed by reaction with a
cytotoxic moiety Cy; or (2) reaction of a reactive substituent of a
cytotoxic moiety with a bivalent linker reagent to form Cy-L-Z',
followed by reaction with a reactive substituent of an antibody or
antigen binding fragment thereof as described herein above, to form
an ADC of formula Ab-(Z-L-Cy).sub.n. Additional methods for
preparing ADC are described herein.
[0253] In one embodiment, the antibody or antigen binding fragment
thereof can have one or more carbohydrate groups that can be
chemically modified to have one or more sulfhydryl groups. The ADC
is then formed by conjugation through the sulfhydryl group's sulfur
atom as described herein above.
[0254] In another embodiment, the antibody can have one or more
carbohydrate groups that can be oxidized to provide an aldehyde
(--CHO) group (see, for e.g., Laguzza, et al., J. Med. Chem. 1989,
32(3), 548-55). The ADC is then formed by conjugation through the
corresponding aldehyde as described herein above. Other protocols
for the modification of proteins for the attachment or association
of cytotoxins are described in Coligan et al., Current Protocols in
Protein Science, vol. 2, John Wiley & Sons (2002), incorporated
herein by reference.
[0255] Methods for the conjugation of linker-drug moieties to
cell-targeted proteins such as antibodies, immunoglobulins or
fragments thereof are found, for example, in U.S. Pat. Nos.
5,208,020; 6,441,163; WO2005037992; WO2005081711; and
WO2006/034488, all of which are hereby expressly incorporated by
reference in their entirety.
[0256] Alternatively, a fusion protein comprising the antibody and
cytotoxic agent may be made, e.g., by recombinant techniques or
peptide synthesis. The length of DNA may comprise respective
regions encoding the two portions of the conjugate either adjacent
one another or separated by a region encoding a linker peptide
which does not destroy the desired properties of the conjugate.
[0257] In some embodiments, the ADC of formula (IIa) may be
prepared by conjugation of a thiol group on the antibody to the
amatoxin-linker conjugate Cy-L-Z', represented by the
structure:
##STR00076##
This amatoxin-linker conjugate may be prepared according to Schemes
1 to 3, starting from commercially available 6-hydroxytryptophan
(1). Compound 1 may be protected with tert-butyloxycarbonyl
anhydride ((BOC).sub.2O). Hexahydropyrroloindole 3 may be produced
as a mixture of cis and trans isomers upon irradiation of protected
hydroxytryptophan 2 in the presence of oxygen and a sensitizer
(Rose Bengal). Preparation of compound 3 (as well as procedure for
preparation of compounds 2 to Va) are provided in International
Patent Application Publication No. WO2019/030173, the disclosure of
which is incorporated by reference herein in its entirety.
Commercial 9-fluorenylmethoxycarbonyl (FMOC) protected
4-hydroxyproline (4) may be alkylated with allyl bromide and
subsequently attached to tetrahydropyranyl (THP) polystyrene resin
under mild acidic conditions (pyridinium para-toluenesulfonate;
PPTS) to give the resin bound allyl ester 5, which may be
deprotected with palladium tetrakistriphenylphosphine palladium and
dimethyl barbituric acid to give intermediate 6. Protected amino
acid 7 may be prepared according to the method reported in
International Patent Application Publication No. WO2014/009025, the
disclosure of which is incorporated herein in its entirety.
Protected amine 7 may then be coupled to resin bound hydroxyproline
6 to afford peptide 8.
##STR00077## ##STR00078##
[0258] Peptide 8 may then be subjected to multiple coupling and
deprotection reactions to provide monocyclic intermediate 9 (Scheme
2). Amino acids FmocAsn(Trt)OH, FmocCys(OTrt)OH, FmocGlyOH,
FmocIleOH, FmocGlyOH, and hexahydropyrroloindole 3 may be utilized
in sequential solid phase coupling reactions to yield intermediate
9. Each amino acid may be coupled using PyBOP/HOBT in
dichloromethane and dimethylformamide (DMF) in the presence of
diisopropylethylamine (DIEA). Deprotection may be performed with
20% piperidine in DMF.
##STR00079## ##STR00080##
[0259] Following the final coupling reaction, intermediate 9 may be
cleaved from the solid phase support resin with trifluoroacetic
acid in the presence of triisopropylsilane to give peptide 10.
Treatment of 10 with diphenylphosphorylazide (DPPA) and DIEA
induced macrocyclization, and deprotection with ammoniacal methanol
provided the amatoxin derivative 11 (i.e., formula Va, where
Q=S).
[0260] The maleimidohexyl amatoxin conjugate 14 may be prepared
from compound 11 according to Scheme 3. Diels-Alder adduct 12 may
be prepared from maleimide and 2,5-dimethylfuran and then alkylated
with 1,6-dibromohexane to give protected linker 13. Compound 11 may
be alkylated with compound 13 in dimethyl sulfoxide (DMSO) in the
presence of sodium hydroxide, followed by heating to 100.degree. C.
in DMSO to afford the amatoxin-linker conjugate 14. Procedures for
preparing compounds 12 and 13, as well as O-alkylation of a related
amatoxin (.alpha.-amanitin) have been previously reported in U.S.
Patent Application Publication No. 2018/0043033, the disclosure of
which is incorporated by reference herein in its entirety.
##STR00081##
Antibodies
[0261] The ADC compositions and methods disclosed herein comprise
an agent to facilitate the selective delivery of such ADCs to a
population of cells in the target tissues (e.g., hematopoietic stem
cells of the bone marrow stem cell niche). The cell target
specificity of the ADC is determined by an antigen binding protein
such as an antibody, or antigen binding portion thereof.
[0262] In one embodiment, the invention includes ADCs comprising
antibodies, and antigen-binding fragments thereof, that
specifically bind to human CD45, CD49d (VLA-4), CD49f(VLA-6), CD51,
CD84, CD90, CD117, CD133, CD134, CD184 (CXCR4), HLA-DR, CD11a,
CD18, CD34, CD41/61, CD43, CD58, CD71, CD97, CD162, CD166, CD205
and CD361, CD13, CD33, CD34, CD44, CD4, CD59, CD84/CD150,
CD90/Thy1, CD93, CD105/Endoglin, CD123/IL-3R, CD126/IL-6R, CD133,
CD135/Flt3 receptor, CD166/ALCAM, Prominin 2, Erythropoietin R,
Endothelial Cell-Selective Adhesion Molecule, CD244, Tie1, Tie2,
MPL, G-CSFR, CSF3R, IL-1R, gp130, Leukemia inhibitory factor
Receptor, oncostatin M receptor, Embigin and IL-18R. Other examples
of antigens that can be bound by the ADCs disclosed herein include,
but are not limited to, CD7, CDw12, CD13, CD15, CD19, CD21, CD22,
CD29, CD30, CD33, CD34, CD36, CD38, CD40, CD41, CD42a, CD42b,
CD42c, CD42d, CD43, CD45RA, CD45RB, CD45RC, CD45RO, CD48, CD49b,
CD49d, CD49e, CD49f, CD50, CD53, CD55, CD64a, CD68, CD71, CD72,
CD73, CD81, CD82, CD85A, CD85K, CD90, CD99, CD104, CD105, CD109,
CD110, CD111, CD112, CD114, CD115, CD123, CD124, CD126, CD127,
CD130, CD131, CD133, CD135, CD138, CD151, CD157, CD162, CD164,
CD168, CD172a, CD173, CD174, CD175, CD175s, CD176, CD183, CD191,
CD200, CD201, CD205, CD217, CD220, CD221, CD222, CD223, CD224,
CD225, CD226, CD227, CD228, CD229, CD230, CD235a, CD235b, CD236,
CD236R, CD238, CD240, CD242, CD243, CD277, CD292, CDw293, CD295,
CD298, CD309, CD318, CD324, CD325, CD338, CD344, CD349 or CD350.
Other examples of antigens that can be bound by the ADCs disclosed
herein include, but are not limited to, CD11a, CD18, CD37, CD47,
CD52, CD58, CD62L, CD69, CD74, CD97, CD103, CD132, CD156a, CD179a,
CD79b, CD184, CD232, CD244, CD252, CD302, CD305, CD317 and
CD361.
[0263] In certain embodiments, an antibody, or antigen binding
fragment thereof, in an ADC described herein has a certain
dissociation rate which is particularly advantageous when used as a
part of a conjugate. For example, an anti-CD117 antibody has, in
certain embodiments, an off rate constant (Koff) for human CD117
and/or rhesus CD117 of 1.times.10.sup.-2 to 1.times.10.sup.-3,
1.times.10.sup.-3 to 1.times.10.sup.-4, 1.times.10.sup.-5 to
1.times.10.sup.-6, 1.times.10.sup.-6 to 1.times.10.sup.-7 or
1.times.10.sup.-7 to 1.times.10.sup.-8, as measured by bio-layer
interferometry (BLI). In some embodiments, the antibody or
antigen-binding fragment thereof binds a cell surface antigen
(e.g., human CD117 and/or rhesus CD117) with a K.sub.D of about 100
nM or less, about 90 nM or less, about 80 nM or less, about 70 nM
or less, about 60 nM or less, about 50 nM or less, about 40 nM or
less, about 30 nM or less, about 20 nM or less, about 10 nM or
less, about 8 nM or less, about 6 nM or less, about 4 nM or less,
about 2 nM or less, about 1 nM or less as determined by a Bio-Layer
Interferometry (BLI) assay.
Anti-CD117 Antibodies
[0264] In one embodiment, the present invention includes ADCs
comprising antibodies, and antigen-binding fragments thereof, that
specifically bind to CD117, such as GNNK+ CD117. Such ADCs may be
used as therapeutic agents to, for example, (i) treat cancers and
autoimmune diseases characterized by CD117+ cells and (ii) promote
the engraftment of transplanted hematopoietic stem cells in a
patient in need of transplant therapy. These therapeutic activities
can be caused, for instance, by the binding of isolated anti-CD117
antibodies, antigen-binding fragments thereof, that bind to CD117
(e.g., GNNK+ CD117) expressed on the surface of a cell, such as a
cancer cell, autoimmune cell, or hematopoietic stem cell and
subsequently inducing cell death. The depletion of endogenous
hematopoietic stem cells can provide a niche toward which
transplanted hematopoietic stem cells can home, and subsequently
establish productive hematopoiesis. In this way, transplanted
hematopoietic stem cells may successfully engraft in a patient,
such as human patient suffering from a stem cell disorder described
herein.
[0265] Antibodies and antigen-binding fragments capable of binding
human CD117 (also referred to as c-Kit, mRNA NCBI Reference
Sequence: NM_000222.2, Protein NCBI Reference Sequence:
NP_000213.1), including those capable of binding GNNK+ CD117, can
be used in conjunction with the compositions and methods described
herein in order to condition a patient for hematopoietic stem cell
transplant therapy. Polymorphisms affecting the coding region or
extracellular domain of CD117 in a significant percentage of the
population are not currently well-known in non-oncology
indications. There are at least four isoforms of CD117 that have
been identified, with the potential of additional isoforms
expressed in tumor cells. Two of the CD117 isoforms are located on
the intracellular domain of the protein, and two are present in the
external juxtamembrane region. The two extracellular isoforms,
GNNK+ and GNNK-, differ in the presence (GNNK+) or absence (GNNK-)
of a 4 amino acid sequence. These isoforms are reported to have the
same affinity for the ligand (SCF), but ligand binding to the GNNK-
isoform was reported to increase internalization and degradation.
The GNNK+ isoform can be used as an immunogen in order to generate
antibodies capable of binding CD117, as antibodies generated
against this isoform will be inclusive of the GNNK+ and GNNK-
proteins. The amino acid sequences of human CD117 isoforms 1 and 2
are described in SEQ ID Nos: 145 and 146, respectively. In certain
embodiments, anti-human CD117 (hCD117) antibodies disclosed herein
are able to bind to both isoform 1 and isoform 2 of human
CD117.
[0266] As described below, a yeast library screen of human
antibodies was performed to identify novel anti-CD117 antibodies,
and fragments thereof, having diagnostic and therapeutic use.
Antibody 54 (Ab54), Antibody 55 (Ab55), Antibody 56 (Ab56),
Antibody 57 (Ab57), Antibody 58 (Ab58), Antibody 61 (Ab61),
Antibody 66 (Ab66), Antibody 67 (Ab67), Antibody 68 (Ab68), and
Antibody 69 (Ab69) were human antibodies that were identified in
this screen. These antibodies cross react with human CD117 and
rhesus CD117. Further, these antibodies disclosed herein are able
to bind to both isoforms of human CD117, i.e., isoform 1 (SEQ ID
NO: 145) and isoform 2 (SEQ ID NO: 146).
[0267] The amino acid sequences for the various binding regions of
anti-CD117 antibodies, including Ab54, Ab55, Ab56, Ab57, Ab58,
Ab61, Ab66, Ab67, Ab68, and Ab69 are described in the Sequence
Table below. Included in the invention are ADCs comprising human
anti-CD117 antibodies comprising the CDRs as set forth in the
Sequence Table below, as well as human anti-CD117 antibodies
comprising the variable regions set forth in the Sequence Table
below.
[0268] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 55. The heavy chain variable
region (VH) amino acid sequence of Antibody 55 (i.e., Ab55) is set
forth in SEQ ID NO: 19 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 55 are set forth in SEQ ID NO: 21
(VH CDR1); SEQ ID NO: 22 (VH CDR2), and SEQ ID NO: 23 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 55 is described in SEQ ID NO: 20 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 55 are set forth in
SEQ ID NO: 24 (VL CDR1); SEQ ID NO: 25 (VL CDR2), and SEQ ID NO: 26
(VL CDR3). The heavy chain constant region of Antibody 55 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 55 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 21, 22, and 23, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 24, 25, and 26.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 20, and a heavy chain
variable region as set forth in SEQ ID NO: 19.
[0269] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 54. The heavy chain variable
region (VH) amino acid sequence of Antibody 54 (i.e., Ab54) is set
forth in SEQ ID NO: 29 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 54 are set forth in SEQ ID NO: 31
(VH CDR1); SEQ ID NO: 32 (VH CDR2), and SEQ ID NO: 33 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 54 is described in SEQ ID NO: 30 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 54 are set forth in
SEQ ID NO: 34 (VL CDR1); SEQ ID NO: 35 (VL CDR2), and SEQ ID NO: 36
(VL CDR3). The heavy chain constant region of Antibody 54 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 54 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 31, 32, and 33, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 34, 35, and 36.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 30, and a heavy chain
variable region as set forth in SEQ ID NO: 29.
[0270] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 56. The heavy chain variable
region (VH) amino acid sequence of Antibody 56 (i.e., Ab56) is set
forth in SEQ ID NO: 39 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 56 are set forth in SEQ ID NO: 41
(VH CDR1); SEQ ID NO: 42 (VH CDR2), and SEQ ID NO: 43 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 56 is described in SEQ ID NO: 40 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 56 are set forth in
SEQ ID NO: 44 (VL CDR1); SEQ ID NO: 45 (VL CDR2), and SEQ ID NO: 46
(VL CDR3). The heavy chain constant region of Antibody 56 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 56 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 41, 42, and 43, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 44, 45, and 46.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 40, and a heavy chain
variable region as set forth in SEQ ID NO: 39.
[0271] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 57. The heavy chain variable
region (VH) amino acid sequence of Antibody 57 (i.e., Ab57) is set
forth in SEQ ID NO: 49 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 57 are set forth in SEQ ID NO: 51
(VH CDR1); SEQ ID NO: 52 (VH CDR2), and SEQ ID NO: 53 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 57 is described in SEQ ID NO: 50 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 57 are set forth in
SEQ ID NO: 54 (VL CDR1); SEQ ID NO: 55 (VL CDR2), and SEQ ID NO: 56
(VL CDR3). The heavy chain constant region of Antibody 57 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 57 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 51, 52, and 53, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 54, 55, and 56.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 50, and a heavy chain
variable region as set forth in SEQ ID NO: 49.
[0272] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 58. The heavy chain variable
region (VH) amino acid sequence of Antibody 58 (i.e., Ab58) is set
forth in SEQ ID NO: 59 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 58 are set forth in SEQ ID NO: 61
(VH CDR1); SEQ ID NO: 62 (VH CDR2), and SEQ ID NO: 63 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 58 is described in SEQ ID NO: 60 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 58 are set forth in
SEQ ID NO: 64 (VL CDR1); SEQ ID NO: 65 (VL CDR2), and SEQ ID NO: 66
(VL CDR3). The heavy chain constant region of Antibody 58 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 58 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 61, 62, and 63, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 64, 65, and 66.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 60, and a heavy chain
variable region as set forth in SEQ ID NO: 59.
[0273] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 61. The heavy chain variable
region (VH) amino acid sequence of Antibody 61 (i.e., Ab61) is set
forth in SEQ ID NO: 69 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 61 are set forth in SEQ ID NO: 71
(VH CDR1); SEQ ID NO: 72 (VH CDR2), and SEQ ID NO: 73 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 61 is described in SEQ ID NO: 70 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 61 are set forth in
SEQ ID NO: 74 (VL CDR1); SEQ ID NO: 75 (VL CDR2), and SEQ ID NO: 76
(VL CDR3). The heavy chain constant region of Antibody 61 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 61 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 71, 72, and 73, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 74, 75, and 76.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 70, and a heavy chain
variable region as set forth in SEQ ID NO: 69.
[0274] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 66. The heavy chain variable
region (VH) amino acid sequence of Antibody 66 (i.e., Ab66) is set
forth in SEQ ID NO: 79 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 66 are set forth in SEQ ID NO: 81
(VH CDR1); SEQ ID NO: 82 (VH CDR2), and SEQ ID NO: 83 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 66 is described in SEQ ID NO: 80 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 66 are set forth in
SEQ ID NO: 84 (VL CDR1); SEQ ID NO: 85 (VL CDR2), and SEQ ID NO: 86
(VL CDR3). The heavy chain constant region of Antibody 66 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 66 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 81, 82, and 83, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 84, 85, and 86.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 80, and a heavy chain
variable region as set forth in SEQ ID NO: 79.
[0275] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 67. The heavy chain variable
region (VH) amino acid sequence of Antibody 67 is set forth in SEQ
ID NO: 9 (see Sequence Table). The VH CDR domain amino acid
sequences of Antibody 67 are set forth in SEQ ID NO 11 (VH CDR1);
SEQ ID NO: 12 (VH CDR2), and SEQ ID NO: 13 (VH CDR3). The light
chain variable region (VL) amino acid sequence of Antibody 67 is
described in SEQ ID NO: 10 (see Table 2). The VL CDR domain amino
acid sequences of Antibody 67 are set forth in SEQ ID NO 14 (VL
CDR1); SEQ ID NO: 15 (VL CDR2), and SEQ ID NO: 16 (VL CDR3). The
full length heavy chain (HC) of Antibody 67 is set forth in SEQ ID
NO: 110, and the full length heavy chain constant region of
Antibody 67 is set forth in SEQ ID NO: 122. The light chain (LC) of
Antibody 67 is set forth in SEQ ID NO: 109. The light chain
constant region of Antibody 67 is set forth in SEQ ID NO: 121.
Thus, in certain embodiments, an anti-CD117 antibody, or
antigen-binding portion thereof, comprises a variable heavy chain
CDR set (CDR1, CDR2, and CDR3) as set forth in SEQ ID Nos: 11, 12,
and 13, and alight chain variable region CDR set as set forth in
SEQ ID Nos: 14, 15, and 16. In other embodiments, an anti-CD117
antibody, or antigen-binding portion thereof, comprises a variable
heavy chain comprising the amino acid residues set forth in SEQ ID
NO: 9, and a heavy chain variable region as set forth in SEQ ID NO:
10. In further embodiments, an anti-CD117 antibody comprises a
heavy chain comprising SEQ ID NO: 110 and a light chain comprising
SEQ ID NO: 109.
[0276] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 68. The heavy chain variable
region (VH) amino acid sequence of Antibody 68 (i.e., Ab68) is set
forth in SEQ ID NO: 89 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 68 are set forth in SEQ ID NO: 91
(VH CDR1); SEQ ID NO: 92 (VH CDR2), and SEQ ID NO: 93 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 68 is described in SEQ ID NO: 90 (see Sequence Table). The
VL CDR domain amino acid sequences of Antibody 68 are set forth in
SEQ ID NO: 94 (VL CDR1); SEQ ID NO: 95 (VL CDR2), and SEQ ID NO: 96
(VL CDR3). The heavy chain constant region of Antibody 68 is set
forth in SEQ ID NO: 122. The light chain constant region of
Antibody 68 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 91, 92, and 93, and a light chain
variable region CDR set as set forth in SEQ ID Nos: 94, 95, and 96.
In other embodiments, an anti-CD117 antibody, or antigen-binding
portion thereof, comprises a variable light chain comprising the
amino acid residues set forth in SEQ ID NO: 90, and a heavy chain
variable region as set forth in SEQ ID NO: 89.
[0277] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 69. The heavy chain variable
region (VH) amino acid sequence of Antibody 69 (i.e., Ab69) is set
forth in SEQ ID NO: 99 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 69 are set forth in SEQ ID NO: 101
(VH CDR1); SEQ ID NO: 102 (VH CDR2), and SEQ ID NO: 103 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 69 is described in SEQ ID NO: 100 (see Sequence Table).
The VL CDR domain amino acid sequences of Antibody 69 are set forth
in SEQ ID NO: 104 (VL CDR1); SEQ ID NO: 105 (VL CDR2), and SEQ ID
NO: 106 (VL CDR3). The heavy chain constant region of Antibody 69
is set forth in SEQ ID NO: 122. The light chain constant region of
Antibody 69 is set forth in SEQ ID NO: 121. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 101, 102, and 103, and a light
chain variable region CDR set as set forth in SEQ ID Nos: 104, 105,
and 106. In other embodiments, an anti-CD117 antibody, or
antigen-binding portion thereof, comprises a variable light chain
comprising the amino acid residues set forth in SEQ ID NO: 100, and
a heavy chain variable region as set forth in SEQ ID NO: 99.
[0278] Further, the amino acid sequences for the various binding
regions of the anti-CD117 antibodies Ab77, Ab79, Ab81, Ab85, Ab86,
Ab87, Ab88, and Ab89 are described in the Sequence Table provided
below. Anti-CD117 antibodies having these sequences can also be
used in the ADCs described herein.
[0279] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 77. The heavy chain variable
region (VH) amino acid sequence of Antibody 77 (i.e., Ab77) is set
forth in SEQ ID NO: 147 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 77 are set forth in SEQ ID NO: 263
(VH CDR1); SEQ ID NO: 2 (VH CDR2), and SEQ ID NO: 3 (VH CDR3). The
light chain variable region (VL) amino acid sequence of Antibody 77
is described in SEQ ID NO: 231 (see Sequence Table). The VL CDR
domain amino acid sequences of Antibody 77 are set forth in SEQ ID
NO: 264 (VL CDR1); SEQ ID NO: 265 (VL CDR2), and SEQ ID NO: 266 (VL
CDR3). The heavy chain constant region of Antibody 77 is set forth
in SEQ ID NO: 269. The light chain constant region of Antibody 77
is set forth in SEQ ID NO: 283. Thus, in certain embodiments, an
anti-CD117 antibody, or antigen-binding portion thereof, comprises
a variable heavy chain CDR set (CDR1, CDR2, and CDR3) as set forth
in SEQ ID Nos: 263, 2, and 3, and a light chain variable region CDR
set as set forth in SEQ ID Nos: 264, 265, and 266. In other
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable light chain comprising the amino acid
residues set forth in SEQ ID NO: 231, and a heavy chain variable
region as set forth in SEQ ID NO: 147.
[0280] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 79. The heavy chain variable
region (VH) amino acid sequence of Antibody 79 (i.e., Ab79) is set
forth in SEQ ID NO: 147 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 79 are set forth in SEQ ID NO: 263
(VH CDR1); SEQ ID NO: 2 (VH CDR2), and SEQ ID NO: 3 (VH CDR3). The
light chain variable region (VL) amino acid sequence of Antibody 79
is described in SEQ ID NO: 233 (see Sequence Table). The VL CDR
domain amino acid sequences of Antibody 79 are set forth in SEQ ID
NO: 267 (VL CDR1); SEQ ID NO: 265 (VL CDR2), and SEQ ID NO: 266 (VL
CDR3). The heavy chain constant region of Antibody 79 is set forth
in SEQ ID NO: 269. The light chain constant region of Antibody 79
is set forth in SEQ ID NO: 283. Thus, in certain embodiments, an
anti-CD117 antibody, or antigen-binding portion thereof, comprises
a variable heavy chain CDR set (CDR1, CDR2, and CDR3) as set forth
in SEQ ID Nos: 263, 2, and 3, and a light chain variable region CDR
set as set forth in SEQ ID Nos: 267, 265, and 266. In other
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable light chain comprising the amino acid
residues set forth in SEQ ID NO: 233, and a heavy chain variable
region as set forth in SEQ ID NO: 147.
[0281] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 81. The heavy chain variable
region (VH) amino acid sequence of Antibody 81 (i.e., Ab81) is set
forth in SEQ ID NO: 147 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 81 are set forth in SEQ ID NO: 263
(VH CDR1); SEQ ID NO: 2 (VH CDR2), and SEQ ID NO: 3 (VH CDR3). The
light chain variable region (VL) amino acid sequence of Antibody 81
is described in SEQ ID NO: 235 (see Sequence Table). The VL CDR
domain amino acid sequences of Antibody 81 are set forth in SEQ ID
NO: 264 (VL CDR1); SEQ ID NO: 268 (VL CDR2), and SEQ ID NO: 266 (VL
CDR3). The heavy chain constant region of Antibody 81 is set forth
in SEQ ID NO: 269. The light chain constant region of Antibody 81
is set forth in SEQ ID NO: 283. Thus, in certain embodiments, an
anti-CD117 antibody, or antigen-binding portion thereof, comprises
a variable heavy chain CDR set (CDR1, CDR2, and CDR3) as set forth
in SEQ ID Nos: 263, 2, and 3, and a light chain variable region CDR
set as set forth in SEQ ID Nos: 264, 268, and 266. In other
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable light chain comprising the amino acid
residues set forth in SEQ ID NO: 235, and a heavy chain variable
region as set forth in SEQ ID NO: 147.
[0282] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 85. The heavy chain variable
region (VH) amino acid sequence of Antibody 85 (i.e., Ab86) is set
forth in SEQ ID NO: 243 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 85 are set forth in SEQ ID NO: 245
(VH CDR1); SEQ ID NO: 246 (VH CDR2), and SEQ ID NO: 247 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 85 is described in SEQ ID NO: 242 (see Sequence Table).
The VL CDR domain amino acid sequences of Antibody 85 are set forth
in SEQ ID NO: 248 (VL CDR1); SEQ ID NO: 249 (VL CDR2), and SEQ ID
NO: 250 (VL CDR3). The heavy chain constant region of Antibody 85
is set forth in SEQ ID NO: 269. The light chain constant region of
Antibody 85 is set forth in SEQ ID NO: 283. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 245, 246, and 247, and a light
chain variable region CDR set as set forth in SEQ ID Nos: 248, 249,
and 250. In other embodiments, an anti-CD117 antibody, or
antigen-binding portion thereof, comprises a variable light chain
comprising the amino acid residues set forth in SEQ ID NO: 244, and
a heavy chain variable region as set forth in SEQ ID NO: 243.
[0283] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 86. The heavy chain variable
region (VH) amino acid sequence of Antibody 86 (i.e., Ab86) is set
forth in SEQ ID NO: 251 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 86 are set forth in SEQ ID NO: 245
(VH CDR1); SEQ ID NO: 253 (VH CDR2), and SEQ ID NO: 3 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 86 is described in SEQ ID NO: 252 (see Sequence Table).
The VL CDR domain amino acid sequences of Antibody 86 are set forth
in SEQ ID NO: 254 (VL CDR1); SEQ ID NO: 249 (VL CDR2), and SEQ ID
NO: 255 (VL CDR3). The heavy chain constant region of Antibody 86
is set forth in SEQ ID NO: 269. The light chain constant region of
Antibody 86 is set forth in SEQ ID NO: 283. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 245, 253, and 3, and a light
chain variable region CDR set as set forth in SEQ ID Nos: 254, 249,
and 255. In other embodiments, an anti-CD117 antibody, or
antigen-binding portion thereof, comprises a variable light chain
comprising the amino acid residues set forth in SEQ ID NO: 252, and
a heavy chain variable region as set forth in SEQ ID NO: 251.
[0284] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 87. The heavy chain variable
region (VH) amino acid sequence of Antibody 87 (i.e., Ab87) is set
forth in SEQ ID NO: 243 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 87 are set forth in SEQ ID NO: 245
(VH CDR1); SEQ ID NO: 246 (VH CDR2), and SEQ ID NO: 247 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 87 is described in SEQ ID NO: 256 (see Sequence Table).
The VL CDR domain amino acid sequences of Antibody 87 are set forth
in SEQ ID NO: 257 (VL CDR1); SEQ ID NO: 5 (VL CDR2), and SEQ ID NO:
255 (VL CDR3). The heavy chain constant region of Antibody 87 is
set forth in SEQ ID NO: 269. The light chain constant region of
Antibody 87 is set forth in SEQ ID NO: 283. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 245, 246, and 247, and alight
chain variable region CDR set as set forth in SEQ ID Nos: 257, 5,
and 255. In other embodiments, an anti-CD117 antibody, or
antigen-binding portion thereof, comprises a variable light chain
comprising the amino acid residues set forth in SEQ ID NO: 256, and
a heavy chain variable region as set forth in SEQ ID NO: 243.
[0285] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 88. The heavy chain variable
region (VH) amino acid sequence of Antibody 88 (i.e., Ab88) is set
forth in SEQ ID NO: 258 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 88 are set forth in SEQ ID NO: 245
(VH CDR1); SEQ ID NO: 259 (VH CDR2), and SEQ ID NO: 3 (VH CDR3).
The light chain variable region (VL) amino acid sequence of
Antibody 88 is described in SEQ ID NO: 256 (see Sequence Table).
The VL CDR domain amino acid sequences of Antibody 88 are set forth
in SEQ ID NO: 257 (VL CDR1); SEQ ID NO: 5 (VL CDR2), and SEQ ID NO:
255 (VL CDR3). The heavy chain constant region of Antibody 88 is
set forth in SEQ ID NO: 269. The light chain constant region of
Antibody 88 is set forth in SEQ ID NO: 283. Thus, in certain
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable heavy chain CDR set (CDR1, CDR2, and
CDR3) as set forth in SEQ ID Nos: 245, 259, and 3, and a light
chain variable region CDR set as set forth in SEQ ID Nos: 257, 5,
and 255. In other embodiments, an anti-CD117 antibody, or
antigen-binding portion thereof, comprises a variable light chain
comprising the amino acid residues set forth in SEQ ID NO: 256, and
a heavy chain variable region as set forth in SEQ ID NO: 258.
[0286] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 89. The heavy chain variable
region (VH) amino acid sequence of Antibody 89 (i.e., Ab89) is set
forth in SEQ ID NO: 260 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 89 are set forth in SEQ ID NO: 245
(VH CDR1); SEQ ID NO: 2 (VH CDR2), and SEQ ID NO: 3 (VH CDR3). The
light chain variable region (VL) amino acid sequence of Antibody 89
is described in SEQ ID NO: 252 (see Sequence Table). The VL CDR
domain amino acid sequences of Antibody 89 are set forth in SEQ ID
NO: 254 (VL CDR1); SEQ ID NO: 249 (VL CDR2), and SEQ ID NO: 255 (VL
CDR3). The heavy chain constant region of Antibody 89 is set forth
in SEQ ID NO: 269. The light chain constant region of Antibody 89
is set forth in SEQ ID NO: 283. Thus, in certain embodiments, an
anti-CD117 antibody, or antigen-binding portion thereof, comprises
a variable heavy chain CDR set (CDR1, CDR2, and CDR3) as set forth
in SEQ ID Nos: 245, 2, and 3, and a light chain variable region CDR
set as set forth in SEQ ID Nos: 254, 249, and 255. In other
embodiments, an anti-CD117 antibody, or antigen-binding portion
thereof, comprises a variable light chain comprising the amino acid
residues set forth in SEQ ID NO: 252, and a heavy chain variable
region as set forth in SEQ ID NO: 260.
[0287] In one embodiment, the invention provides an ADC comprising
an anti-CD117 antibody, or antigen-binding fragment thereof,
comprising binding regions, e.g., CDRs, variable regions,
corresponding to those of Antibody 249. The heavy chain variable
region (VH) amino acid sequence of Antibody 249 (i.e., Ab249) is
set forth in SEQ ID NO: 238 (see Sequence Table). The VH CDR domain
amino acid sequences of Antibody 249 are set forth in SEQ ID NO:
286 (VH CDR1); SEQ ID NO: 2 (VH CDR2), and SEQ ID NO: 287 (VH
CDR3). The light chain variable region (VL) amino acid sequence of
Antibody 249 is described in SEQ ID NO: 242 (see Sequence Table).
The VL CDR domain amino acid sequences of Antibody 249 are set
forth in SEQ ID NO: 288 (VL CDR1); SEQ ID NO: 249 (VL CDR2), and
SEQ ID NO: 289 (VL CDR3). The heavy chain constant region of
Antibody 249 is set forth in SEQ ID NO: 269. The light chain
constant region of Antibody 249 is set forth in SEQ ID NO: 283.
Thus, in certain embodiments, an anti-CD117 antibody, or
antigen-binding portion thereof, comprises a variable heavy chain
CDR set (CDR1, CDR2, and CDR3) as set forth in SEQ ID Nos: 286, 2,
and 287, and a light chain variable region CDR set as set forth in
SEQ ID Nos: 288, 249, and 289. In other embodiments, an anti-CD117
antibody, or antigen-binding portion thereof, comprises a variable
light chain comprising the amino acid residues set forth in SEQ ID
NO: 242, and a heavy chain variable region as set forth in SEQ ID
NO: 238.
Further, included in the disclosure is anti-CD117 antibody drug
conjugates (ADCs) comprising binding regions (heavy and light chain
CDRs or variable regions) as set forth in SEQ ID Nos: 147 to 168.
In one embodiment, the anti-CD117 antibody, or antigen binding
portion thereof, comprises a heavy chain variable region as set
forth in the amino acid sequence of SEQ ID NO: 147, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 148. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 147,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 149. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 147, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 150. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 147, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 151. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 147, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 152. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 147, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 153. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 147,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 154. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 147, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 155. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 147, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 156. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 147, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 157. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 147, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 158. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 147,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 159. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 147, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 160. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 147, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 161. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 147, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 162. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 147, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 163. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 164,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 165. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 166, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 167. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 168, and alight chain variable region as set
forth in the amino acid sequence of SEQ ID NO: 169. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 170, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 171. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 172, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 173. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 174,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 175. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 176, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 177. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 178, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 179. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 180, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 181. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 172, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 182. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 183,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 184. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 185, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 186. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 187, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 188. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 189, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 190. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 191, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 192. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 193,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 194. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 195, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 196. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 197, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 198. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 199, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 200. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 201, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 190. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 202,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 203. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 204, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 205. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 206, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 207. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 208, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 209. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 210, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 211. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 212,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 213. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 214, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 215. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 216, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 217. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 218, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 219. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 220, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 221. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 222,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 223. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 224, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 225. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 226, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 227. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 147, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 228. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 147, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 229. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 147,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 230. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 147, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 231. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 147, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 232. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 147, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 233. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 147, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 234. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 147,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 235. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 147, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 236.
[0289] In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, of an ADC described herein comprises a
heavy chain variable region as set forth in the amino acid sequence
of SEQ ID NO: 147, and a light chain variable region as set forth
in the amino acid sequence of SEQ ID NO: 237. In one embodiment,
the anti-CD117 antibody, or antigen binding portion thereof,
comprises a heavy chain variable region as set forth in the amino
acid sequence of SEQ ID NO: 243, and a light chain variable region
as set forth in the amino acid sequence of SEQ ID NO: 244. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 251, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 252. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 243, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 256. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 258,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 256. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 260, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 252. In one embodiment, the
anti-CD117 antibody, or antigen binding portion thereof, comprises
a heavy chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 238, and a light chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 239. In one
embodiment, the anti-CD117 antibody, or antigen binding portion
thereof, comprises a heavy chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 147, and a light chain
variable region as set forth in the amino acid sequence of SEQ ID
NO: 239. In one embodiment, the anti-CD117 antibody, or antigen
binding portion thereof, comprises a heavy chain variable region as
set forth in the amino acid sequence of SEQ ID NO: 147, and a light
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 240. In one embodiment, the anti-CD117 antibody, or
antigen binding portion thereof, comprises a heavy chain variable
region as set forth in the amino acid sequence of SEQ ID NO: 238,
and a light chain variable region as set forth in the amino acid
sequence of SEQ ID NO: 241. In one embodiment, the anti-CD117
antibody, or antigen binding portion thereof, comprises a heavy
chain variable region as set forth in the amino acid sequence of
SEQ ID NO: 238, and a light chain variable region as set forth in
the amino acid sequence of SEQ ID NO: 242.
[0290] Certain of the anti-CD117 antibodies described herein are
neutral antibodies, in that the antibodies do not substantially
inhibit CD117 activity on a CD117 expressing cell. Neutral
antibodies can be identified using, for example, an in in vitro
stem cell factor (SCF)-dependent cell proliferation assay. In an
SCF dependent cell proliferation assay, a neutral CD117 antibody
will not kill CD34+ cells that are dependent on SCF to divide, as a
neutral antibody will not block SCF from binding to CD117 such as
to inhibit CD117 activity.
[0291] Neutral antibodies can be used for diagnostic purposes,
given their ability to specifically bind to human CD117, but are
also effective for killing CD117 expressing cells when conjugated
to a cytotoxin, such as those described herein. Typically,
antibodies used in conjugates have agonistic or antagonistic
activity that is unique to the antibody. Described herein, however,
is a unique approach to conjugates, especially in the context
wherein the conjugate is being used as a conditioning agent prior
to a stem cell transplantation. While antagonistic antibodies alone
or in combination with a cytotoxin as a conjugate can be effective
given the killing ability of the antibody alone in addition to the
cytotoxin, conditioning with a conjugate comprising a neutral
anti-CD117 antibody presents an alternative strategy where the
activity of the antibody is secondary to the effect of the
cytotoxin, but the internalizing and affinity characteristics,
e.g., dissociation rate, of the antibody are important for
effective delivery of the cytotoxin.
[0292] Examples of neutral anti-CD117 antibodies include Ab58,
Ab61, Ab66, Ab67, Ab68, and Ab69. A comparison of the amino acid
sequences of the CDRs of neutral, anti-CD117 antibody CDRs reveals
consensus sequences among two groups of neutral antibodies
identified. Ab58 and Ab61 share the same light chain CDRs and HC
CDR3, with slight variations in the HC CDR1 and HC CDR2. Consensus
sequences for the HC CDR1 and CDR2 are described in SEQ ID Nos: 133
and 134. Ab66, Ab67, Ab68, and Ab69 are also neutral antibodies.
While Ab66, Ab67, Ab68, and Ab69 share the same light chain CDRs
and the same HC CDR3, these antibodies have variability within
their HC CDR1 and HC CDR2 regions. Consensus sequences for these
antibodies in the HC CDR1 and HC CDR2 regions are provided in SEQ
ID Nos: 139 and 140, respectively.
[0293] Antagonist antibodies are also provided herein, including
Ab54, Ab55, Ab56, and Ab57. While Ab54, Ab55, Ab56, and Ab57 share
the same light chain CDRs and the same HC CDR3, these antibodies
have variability within their HC CDR1 and HC CDR2 regions.
Consensus sequences for these antibodies in the HC CDR1 and HC CDR2
regions are provided in SEQ ID Nos: 127 and 128, respectively.
[0294] Anti-CD117 antibodies that may be used in the compositions
and methods disclosed herein are also described in US 2019-0153114
and US 2019-0144558, the antibody sequences of which are hereby
incorporated by reference.
[0295] In one embodiment, the anti-CD117 antibody, or antigen
binding fragment thereof, comprises variable regions having an
amino acid sequence that is at least 95%, 96%, 97% or 99% identical
to the SEQ ID Nos disclosed herein. Alternatively, the anti-CD117
antibody, or antigen binding fragment thereof, comprises CDRs
comprising the SEQ ID Nos disclosed herein with framework regions
of the variable regions described herein having an amino acid
sequence that is at least 95%, 96%, 97% or 99% identical to the SEQ
ID Nos disclosed herein.
[0296] The anti-CD117 antibodies described herein can be in the
form of full-length antibodies, bispecific antibodies, dual
variable domain antibodies, multiple chain or single chain
antibodies, and/or binding fragments that specifically bind human
CD117, including but not limited to Fab, Fab', (Fab')2, Fv), scFv
(single chain Fv), surrobodies (including surrogate light chain
construct), single domain antibodies, camelized antibodies and the
like. They also can be of, or derived from, any isotype, including,
for example, IgA (e.g., IgA1 or IgA2), IgD, IgE, IgG (e.g. IgG1,
IgG2, IgG3 or IgG4), or IgM. In some embodiments, the anti-CD117
antibody is an IgG (e.g. IgG1, IgG2, IgG3 or IgG4).
[0297] Antibodies for use in conjunction with the methods described
herein include variants of those antibodies described above, such
as antibody fragments that contain or lack an Fc domain, as well as
humanized variants of non-human antibodies described herein and
antibody-like protein scaffolds (e.g., .sup.10Fn3 domains)
containing one or more, or all, of the CDRs or equivalent regions
thereof of an antibody, or antibody fragment, described herein.
Exemplary antigen-binding fragments of the foregoing antibodies
include a dual-variable immunoglobulin domain, a single-chain Fv
molecule (scFv), a diabody, a triabody, a nanobody, an
antibody-like protein scaffold, a Fv fragment, a Fab fragment, a
F(ab').sub.2 molecule, and a tandem di-scFv, among others.
[0298] In one embodiment, anti-CD117 antibodies comprising one or
more radiolabeled amino acids are provided. A radiolabeled
anti-CD117 antibody may be used for both diagnostic and therapeutic
purposes (conjugation to radiolabeled molecules is another possible
feature). Nonlimiting examples of labels for polypeptides include,
but are not limited to 3H, 14C, 15N, 35S, 90Y, 99Tc, and 125I,
131I, and 186Re. Methods for preparing radiolabeled amino acids and
related peptide derivatives are known in the art (see for instance
Junghans et al., in Cancer Chemotherapy and Biotherapy 655-686 (2d
edition, Chafner and Longo, eds., Lippincott Raven (1996)) and U.S.
Pat. Nos. 4,681,581, 4,735,210, 5,101,827, U.S. Pat. No. 5,102,990
(U.S. RE35,500), U.S. Pat. No. 5,648,471 and U.S. Pat. No.
5,697,902. For example, a radioisotope may be conjugated by a
chloramine T method.
Anti-CD45 Antibodies
[0299] In one embodiment, the present invention includes ADCs
comprising antibodies, and antigen-binding fragments thereof, that
specifically bind to a CD45 polypeptide, e.g., a human CD45
polypeptide, and uses thereof. In an exemplary embodiment, the
antibody, or antigen-binding fragment thereof, that specifically
binds to a CD45 polypeptide comprises a heavy chain variable region
and a light chain variable region.
[0300] CD45 is a hematopoietic cell-specific transmembrane protein
tyrosine phosphatase essential for T and B cell antigen
receptor-mediated signaling. CD45 includes a large extracellular
domain, and a phosphatase containing cytosolic domain. CD45 may act
as both a positive and negative regulator depending on the nature
of the stimulus and the cell type involved. Although there are a
large number of permutations possible in the CD45 gene, only six
isoforms are traditionally identified in humans. The isoforms are
RA, RO, RB, RAB, RBC and RABC (Hermiston et al. 2003 "CD45: a
critical regulator of signaling thresholds in immune cells." Annu
Rev Immunol. 2:107-137.). CD45RA is expressed on naive T cells, and
CD45RO is expressed on activated and memory T cells, some B cell
subsets, activated monocytes/macrophages, and granulocytes. CD45RB
is expressed on peripheral B cells, naive T cells, thymocytes,
weakly on macrophages, and dendritic cells.
[0301] In certain embodiments, the anti-CD45 antibody is selected
from apamistamab (also known 90Y-BC8, lomab-B, BC8; as described
in, e.g., US20170326259, WO2017155937, and Orozco et al. Blood.
127.3 (2016): 352-359.) or BC8-B10 (as described, e.g., in Li et
al. PloS one 13.10 (2018): e0205135.), each of which is
incorporated by reference. Other anti-CD45 antibodies have been
described, for example, in WO2003048327, WO2016016442,
US20170226209, US20160152733, U.S. Pat. No. 9,701,756;
US20110076270, or U.S. Pat. No. 7,825,222, each of which is
incorporated by reference.
Anti-CD137 Antibodies
[0302] The present invention includes ADCs comprising antibodies,
and antigen-binding fragments thereof, that specifically bind to a
CD137 polypeptide, e.g., a human CD137 polypeptide, and uses
thereof. In an exemplary embodiment, the antibody, or
antigen-binding fragment thereof, that specifically binds to a
CD137 polypeptide comprises a heavy chain variable region and a
light chain variable region.
[0303] T cells have been shown to express CD137, as this antigen is
a transmembrane TNF receptor superfamily of costimulatory molecules
and is expressed on a variety of hematopoietic cells and promotes T
cell activation and regulates proliferation and survival of T cells
(see, e.g., Cannons et al., J. Immunol. 167:1313-1324, 2001, the
disclosure of which is incorporated herein by reference as it
pertains to the expression of CD137 by T cells). CD137 is
alternatively named tumor necrosis factor receptor superfamily
member 9 (TNFRSF9), 4-1BB, or induced by lymphocyte activation
(ILA).
[0304] In certain embodiments, the anti-CD137 antibody is selected
from ADG106 (as described in, e.g., US20190055314, WO2019037711,
WO2019036855); AGEN2373 (as described in, e.g., WO2018191502,
US20180344870); ATOR-1017 (as described in, e.g., WO2018091740,
US20180118841) PE0166 (as described in, e.g., Song et al. AACR
2019, Abstract 2397/21), urelumab (also known as BMS-663513; as
described in, e.g., WO2004010947, WO2005035584, US20090068192, U.S.
Pat. Nos. 7,659,384, 8,475,790, 8,137,667, US20100183621, U.S. Pat.
No. 8,716,452, US20120141494, U.S. Pat. No. 9,382,328,
US20140193422, WO2016029073, US20160368998, WO2017181034,
US20190062445, Chin et al. Nature communications. 9.1 (2018):
4679.; Segal et al. Clinical Cancer Research. 23.8 (2017):
1929-1936.); and utomilumab (also known as PF-05082566, MOR-7480.;
as described in, e.g., WO2012032433, US20120237498, US20140178368,
WO2012145183, WO2015119923, WO2015179236, US20160152722,
US20190031765, WO2017130076, Chin et al. Nature communications. 9.1
(2018): 4679.; Segal et al. Clinical Cancer Research. 24.8 (2018):
1816-1823; Fisher et al. Cancer Immunology, Immunotherapy. 61.10
(2012): 1721-1733), each of which is incorporated by reference.
[0305] Other anti-CD137 antibodies have been described, for
example, in WO2018134787, WO2019020774, WO2017077085,
US20180327504, US20190099488, US2019006045, US20190015508,
WO2019014328, US20190071510, WO2018127787, US20180258177, U.S. Ser.
No. 10/174,122, WO2016110584, WO2018017761, WO2018098370,
US20130149301, WO2019027754, WO2018156740, US20160244528,
WO2016134358, U.S. Ser. No. 10/233,251, US20170226215,
US20160083474, WO2017049452, US20180282422, WO2015188047,
WO2010132389, US20120076722, US20110177104, WO2011031063,
US20080305113, US20080008716, U.S. Pat. No. 7,829,088,
US20090041763, WO2006126835, Soderstrom et al. Circulation J. 81.12
(2017): 1945-1952; Makkouk, et al. Annals of Oncology 28.2 (2016):
415-420; Martinez-Forero et al. J. of Immunology. 190.12 (2013):
6694-6706; Dubrot et al. Cancer immunology, immunotherapy. 59.8
(2010): 1223-1233; each of which is incorporated by reference.
[0306] In another embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises an amino acid sequence having at least 95% identity to an
anti-CD137 antibody herein, e.g., at least 95%, 96%, 97%, 98%, 99%,
or 100% identity to an anti-CD137 antibody herein. In certain
embodiments, an antibody comprises a modified heavy chain (HC)
variable region comprising an HC variable domain of an anti-CD137
antibody herein, or a variant thereof, which variant (i) differs
from the anti-CD137 antibody in 1, 2, 3, 4 or 5 amino acids
substitutions, additions or deletions; (ii) differs from the
anti-CD137 antibody in at most 5, 4, 3, 2, or 1 amino acids
substitutions, additions or deletions; (iii) differs from the
anti-CD137 antibody in 1-5, 1-3, 1-2, 2-5 or 3-5 amino acids
substitutions, additions or deletions and/or (iv) comprises an
amino acid sequence that is at least about 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98% or 99% identical to the anti-CD137 antibody, wherein
in any of (i)-(iv), an amino acid substitution may be a
conservative amino acid substitution or a non-conservative amino
acid substitution; and wherein the modified heavy chain variable
region can have an enhanced biological activity relative to the
heavy chain variable region of the anti-CD137 antibody, while
retaining the CD137 binding specificity of the antibody.
[0307] In one embodiment, an anti-CD137 antibody that may be used
in the methods and compositions (including ADCs) described herein
is the murine anti-CD137 antibody BBK2 (Thermo Fisher; MS621PABX)
or an anti-CD137 antibody comprising antigen binding regions
corresponding to the BBK2 antibody. The BBK2 antibody (which may
also be referred to as a BBK-2 antibody or an anti-4-1BB antibody),
is a mouse monoclonal antibody (IgG1, kappa) that binds to the
ectodomain of human 4-1BB recombinant protein (4-1BB is also known
as CD137). In certain embodiments, the methods and compositions of
the disclosure include an anti-CD137 antibody comprising the
binding regions (e.g., the CDRs) of the BBK2 antibody. In another
embodiment, the methods and compositions of the disclosure comprise
an antibody that competitively inhibits the binding of the BBK2
antibody to its epitope on CD137. In certain embodiments, the
anti-CD137 antibody is humanized BBK2 or chimeric BBK2.
[0308] In one embodiment, the methods and compositions described
herein include a chimeric anti-CD137 (ch-BBK2) antibody comprising
the variable heavy and light chain regions of BBK2. In certain
embodiments, the chimeric BBK2 antibody is an IgG1 antibody
comprising human constant regions. The heavy chain amino acid
sequence of ch-BBK2 is described in SEQ ID NO: 290, and the light
chain amino acid sequence of ch-BBK2 is described in SEQ ID NO:
291. The CDR regions (CDR1, CDR2, and CDR3) of each of the heavy
and light chain sequences are described in bold below. The CDR
regions of BBK2 can be defined according to Kabat numbering. CDRs
as defined by Kabat numbering are described below for each of the
heavy and light chain sequences (described in bold below). The
variable regions of BBK2 are italicized.
TABLE-US-00005 (ch-BBK2 heavy chain; SEQ ID NO: 290)
QVQLQQPGAELVRPGASVKLSCKASGYTFT WVKQRPGQGLEWIG
KATLTVDKSSNTVYMQLNSPTSEDSAVYYCTR WGQGTSVTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
(ch-BBK2 light chain; SEQ ID NO: 291) DIQMTQTTSALSASLGDRVTIGC
WYQQKPDGTVKLLIY GVPSRFSGSG SGTDYSLTIRNLEQEDVATYFC
FGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVV
CLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
QGLSSPVTKSFNRGEC
[0309] Thus, in one embodiment, the VH CDR amino acid sequences of
anti-CD137 antibody BBK2 (including ch-BBK2) are as follows: SYWIN
(VH CDR1; SEQ ID NO: 292); NIYPSDSYTNYNQKFKD (VH CDR2; SEQ ID NO:
293) and NGVEGYPHYYAMEY (VH CDR3; SEQ ID NO: 294), and the VL CDR
amino acid sequences of anti-CD137 antibody BBK2 (including
ch-BBK2) are as follows: RASQDLSNHLY (VL CDR1; SEQ ID NO: 295);
YTSRLHS (VL CDR2; SEQ ID NO: 296) and QQGYTLPYT (VL CDR3; SEQ ID
NO: 297).
[0310] The heavy chain variable region of BBK2 is set forth in SEQ
ID NO: 298 as
QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFK
DKATLTVDKSSNTVYMQLNSPTSEDSAVYYCTRNGVEGYPHYYAMEYWGQGTSVTVSS. The
light chain variable region of BBK2 is set forth in SEQ ID NO: 299
as
DIQMTQTTSALSASLGDRVTIGCRASQDLSNHLYWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
SGTDYSLTIRNLEQEDVATYFCQQGYTLPYTFGGGTKLEIK. Anti-CD137 antibodies
(including anti-CD137 ADCs) can comprise the heavy and light chain
variable region amino acid sequences as set forth in SEQ ID Nos:
298 and 299, respectively.
[0311] In one embodiment, the anti-CD137 antibody, e.g., a chimeric
(ch-BBK2) antibody or a humanized BBK2 antibody, comprises a heavy
chain variable region comprising a CDR1 comprising the amino acid
sequence of SEQ ID NO: 292, a CDR2 comprising the amino acid
sequence of SEQ ID NO: 293, and a CDR3 comprising the amino acid
sequence of SEQ ID NO: 294; and comprises a light chain variable
region comprising a CDR1 comprising the amino acid sequence of SEQ
ID NO: 295, a CDR2 comprising the amino acid sequence of SEQ ID NO:
296, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
297.
[0312] In one embodiment, the anti-CD137 antibody, e.g., a chimeric
(ch-BBK2) antibody or a humanized BBK2 antibody, comprises a heavy
chain variable region comprising a CDR1 comprising the amino acid
sequence of SEQ ID NO: 292, a CDR2 comprising the amino acid
sequence of SEQ ID NO: 293, and a CDR3 comprising the amino acid
sequence of SEQ ID NO: 294; and comprises a light chain variable
region comprising a CDR1 comprising the amino acid sequence of SEQ
ID NO: 295, a CDR2 comprising the amino acid sequence of SEQ ID NO:
296, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
297.
[0313] Thus, BBK2, humanized BBK2, or chimeric BBK2 antibodies can
be used in the anti-CD137 ADCs and methods described herein. Each
of these antibodies can be conjugated to any of the cytotoxin
described below using methods known in the art and those described
herein.
Anti-CD5 Antibodies
[0314] In certain embodiments, compositions and methods described
herein include an ADC comprising an antibody, or fragment thereof,
that specifically binds to human CD5. Human CD5 is also referred to
as LEU or T1. Human CD5 is a type-I transmembrane glycoprotein
found on the surface of thymocytes, T lymphocytes and a subset of B
lymphocytes. Two isoforms of human CD5 have been identified.
Isoform 1 contains 438 amino acids and is described in Jones. et
al. (1988) Nature 323 (6086), 346-349 and below (NCBI Reference
Sequence: NP_001333385.1):
TABLE-US-00006 (SEQ ID NO: 363) MVCSQSWGRS SKQWEDPSQASKVCQRLNCG
VPLSLGPFLV TYTPQSSIICYGQL GSFSNCSHSRNDMCHS
LGLTCLEPQKTTPPTTRPPPTTTPEPTAPP RLQLVAQSGG QHCAGVVEFYSGSLGGTISY
EAQDKTQDLE NFLCNNLQCG SFLKHLPETE AGRAQDPGEP REHQPLPIQWKIQNSSCTSL
EHCFRKIKPQ KSGRVLALLC SGFQPKVQSR LVGGSSICEG TVEVRQGAQWAALCDSSSAR
SSLRWEEVCR EQQCGSVNSY RVLDAGDPTS RGLFCPHQKL
SQCHELWERNSYCKKVFVTCQDPNPAGLAAGTVASIILAL VLLVVLLVVC GPLAYKKLVK
KFRQKKQRQWIGPTGMNQNM SFHRNHTATV RSHAENPTAS HVDNEYSQPP RNSHLSAYPA
LEGALHRSSMQPDNSSDSDY DLHGAQRL
[0315] T cells have been shown to express CD5, which is a cell
adhesion molecule and has been implicated both in the proliferative
response of activated T cells and in T cell helper function. It has
also been shown to function as a receptor, delivering
co-stimulatory signals to T cells by interacting with CD72, a cell
surface protein exclusive to B cells. Antibodies, or
antigen-binding fragments thereof, that bind CD5 may suppress T
cell activation and T cell-mediated immune responses against
hematopoietic stem cell grafts, for example, by inhibiting the
interaction between CD5 and CD72. Antibodies, and antigen-binding
fragments thereof, that bind CD5 can also be used to kill CD5+ T
cells directly, for instance, by conjugating the antibody, or
antigen-binding fragment thereof, to a cytotoxin (such as a
cytotoxin described herein or known in the art) or by using an
unconjugated antibody, or antigen-binding fragment thereof, capable
of recruiting complement proteins to the T cell.
[0316] Additionally, subsets of activated B cells have been shown
to express CD5, and this expression pattern is particularly common
among autoreactive B cells (Werner-Favre et al., European Journal
of Immunology 19:1209-1231 (1989), the disclosure of which is
incorporated herein by reference in its entirety). CD5 has also
been shown to be expressed by subsets of NK cells; particularly
among patients that have multiple myeloma have been shown to harbor
populations of low density CD5+ (CD5LOW+) NK cells, and this
surface antigen has been implicated in NK cell activation (Ishiyama
et al., Anticancer Research 14:725-730 (1994), the disclosure of
which is incorporated herein by reference in its entirety).
Antibodies, or antigen-binding fragments thereof, that specifically
bind CD5 can thus be used to attenuate the activation of B cells
and NK cells. Antibodies, or antigen-binding fragments thereof,
that bind CD5 can also be used to kill CD5+ B cells and NK cells
directly, for instance, by conjugating the antibody, or
antigen-binding fragment thereof, to a cytotoxin (such as a
cytotoxin described herein or known in the art) or by using an
unconjugated antibody, or antigen-binding fragment thereof, capable
of recruiting complement proteins to the B cell or NK cell.
[0317] The present invention encompasses ADCs comprising
antibodies, and antigen-binding fragments thereof, that
specifically bind to a CD5 polypeptide, e.g., a human CD5
polypeptide, and uses thereof. In an exemplary embodiment, the
antibody, or antigen-binding fragment thereof, that specifically
binds to a CD5 polypeptide comprises a heavy chain variable region
and a light chain variable region.
[0318] In one embodiment, an ADC comprises an antibody comprising
the heavy chain variable region comprises one or more
complementarity determining regions (CDRs). In one embodiment, the
heavy chain variable region comprises a VH CDR1 comprising the
amino acid sequence of SEQ ID NO: 341. In one embodiment, the heavy
chain variable region comprises a VH CDR2 comprising the amino acid
sequence of SEQ ID NO: 342. In one embodiment, the heavy chain
variable region comprises a VH CDR3 comprising the amino acid
sequence of SEQ ID NO: 343. In one embodiment, the heavy chain
variable region comprises one or more VH CDRs selected from the
group consisting of SEQ ID NO: 341, SEQ ID NO: 342, and SEQ ID NO:
343. In one embodiment, the heavy chain variable region comprises
two or more VH CDRs selected from the group consisting of SEQ ID
NO: 341, SEQ ID NO: 342, and SEQ ID NO: 343. In one embodiment, the
heavy chain variable region comprises a VH CDR1 comprising SEQ ID
NO: 341, a VH CDR2 comprising SEQ ID NO: 342, and a VH CDR3
comprising SEQ ID NO: 343.
[0319] In one embodiment, an ADC comprises an antibody comprising
the light chain variable region comprises one or more
complementarity determining regions (CDRs). In one embodiment, the
light chain variable region comprises a VL CDR1 comprising the
amino acid sequence of SEQ ID NO: 344. In one embodiment, the light
chain variable region comprises a VL CDR2 comprising the amino acid
sequence of SEQ ID NO: 345. In one embodiment, the light chain
variable region comprises a VL CDR3 comprising the amino acid
sequence of SEQ ID NO: 346. In one embodiment, the light chain
variable region comprises one or more VL CDRs selected from the
group consisting of SEQ ID NO: 344, SEQ ID NO: 345, and SEQ ID NO:
346. In one embodiment, the light chain variable region comprises
two or more VL CDRs selected from the group consisting of SEQ ID
NO: 344, SEQ ID NO: 345, and SEQ ID NO: 346. In one embodiment, the
light chain variable region comprises a VL CDR1 comprising SEQ ID
NO: 344, a VL CDR2 comprising SEQ ID NO: 345, and a VL CDR3
comprising SEQ ID NO: 346.
[0320] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises a VH CDR1 comprising SEQ ID NO: 341, a VH CDR2 comprising
SEQ ID NO: 342, and a VH CDR3 comprising SEQ ID NO: 343, and alight
chain variable region that comprises a VL CDR1 comprising SEQ ID
NO: 344, a VL CDR2 comprising SEQ ID NO: 345, and a VL CDR3
comprising SEQ ID NO: 346.
[0321] In certain embodiments, one or more of the CDRs (i.e., one
or more heavy chain CDRs having SEQ ID NOs: 341-343, and/or one or
more light chain CDRs having SEQ ID NOs: 344-346) can comprise a
conservative amino acid substitution (or 2, 3, 4, or 5 amino acid
substitutions) while retaining the CD5 specificity of the antibody
(i.e., specificity similar to an antibody, or antigen-binding
fragment thereof, comprising heavy chain CDRs of SEQ ID NOs: 341 to
343, and light chain CDRs of SEQ ID NOs: 344 to 346).
[0322] In certain embodiments, the anti-CD5 antibody, or antigen
binding fragment thereof, is murine antibody 5D7, or a humanized
version thereof. Murine antibody 5D7 binds to human CD5 and is
described in US Patent Publication No. 20008/0245027, the contents
of which relating to the antibody sequences disclosed therein are
incorporated by reference herein. SEQ ID Nos: 353 to 358 described
in the sequence summary table correspond to the CDRs of murine
anti-CD5 antibody 5D7. A humanized version of anti-CD5 antibody 5D7
is described in SEQ ID NO: 359 (humanized heavy chain variable
region) and SEQ ID NO: 360 (humanized light chain variable region).
In one embodiment, the ADCs and uses thereof described herein
include an antibody comprising the CDRs set forth in SEQ ID Nos:
353 to 358. In one embodiment, the ADCs and uses thereof described
herein include an antibody comprising the heavy and light chain
variable regions as set forth in SEQ ID Nos: 359 and 360,
respectively.
[0323] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a heavy chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO: 359. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a heavy chain variable region that comprises an amino
acid sequence having at least 95% identity to SEQ ID NO: 359, e.g.,
at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:
359. In certain embodiments, an antibody comprises a modified heavy
chain (HC) variable region comprising an HC variable domain
comprising SEQ ID NO: 359, or a variant of SEQ ID NO: 359, which
variant (i) differs from SEQ ID NO: 359 in 1, 2, 3, 4 or 5 amino
acids substitutions, additions or deletions; (ii) differs from SEQ
ID NO: 359 in at most 5, 4, 3, 2, or 1 amino acids substitutions,
additions or deletions; (iii) differs from SEQ ID NO: 359 in 1-5,
1-3, 1-2, 2-5 or 3-5 amino acids substitutions, additions or
deletions and/or (iv) comprises an amino acid sequence that is at
least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical
to SEQ ID NO: 359, wherein in any of (i)-(iv), an amino acid
substitution may be a conservative amino acid substitution or a
non-conservative amino acid substitution; and wherein the modified
heavy chain variable region can have an enhanced biological
activity relative to the heavy chain variable region of SEQ ID NO:
359, while retaining the CD5 binding specificity of the antibody,
i.e. has a binding specificity similar to an antibody, or
antigen-binding fragment thereof, comprising SEQ ID NO: 359.
[0324] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a light chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO: 360. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a light chain variable region that comprises an amino
acid sequence having at least 95% identity to SEQ ID NO: 360, e.g.,
at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:
360. In certain embodiments, an antibody comprises a modified light
chain (LC) variable region comprising an LC variable domain
comprising SEQ ID NO: 360, or a variant of SEQ ID NO: 360, which
variant (i) differs from SEQ ID NO: 360 in 1, 2, 3, 4 or 5 amino
acids substitutions, additions or deletions; (ii) differs from SEQ
ID NO: 360 in at most 5, 4, 3, 2, or 1 amino acids substitutions,
additions or deletions; (iii) differs from SEQ ID NO: 360 in 1-5,
1-3, 1-2, 2-5 or 3-5 amino acids substitutions, additions or
deletions and/or (iv) comprises an amino acid sequence that is at
least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical
to SEQ ID NO: 360, wherein in any of (i)-(iv), an amino acid
substitution may be a conservative amino acid substitution or a
non-conservative amino acid substitution; and wherein the modified
light chain variable region can have an enhanced biological
activity relative to the light chain variable region of SEQ ID NO:
360, while retaining the CD5 binding specificity of the antibody,
i.e., has a binding specificity similar to an antibody, or
antigen-binding fragment thereof, comprising SEQ ID NO: 360.
[0325] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises an amino acid sequence having at least 95% identity to
SEQ ID NO: 359, e.g., at least 95%, 96%, 97%, 98%, 99%, or 100%
identity to SEQ ID NO: 359, and a light chain variable region that
comprises an amino acid sequence having at least 95% identity to
SEQ ID NO: 360, e.g., at least 95%, 96%, 97%, 98%, 99%, or 100%
identity to SEQ ID NO: 360. In one embodiment, the antibody, or
antigen-binding fragment thereof, comprises a heavy chain variable
region that comprises SEQ ID NO: 359, and a light chain variable
region that comprises SEQ ID NO: 360.
[0326] In another embodiment, the anti-CD5 antibody, or
antigen-binding fragment thereof, can contain a heavy chain
variable region that comprises a VH CDR1 comprising the amino acid
sequence of SEQ ID NO: 353. In one embodiment, the heavy chain
variable region comprises a VH CDR2 comprising the amino acid
sequence of SEQ ID NO: 354. In one embodiment, the heavy chain
variable region comprises a VH CDR3 comprising the amino acid
sequence of SEQ ID NO: 355. In one embodiment, the heavy chain
variable region comprises one or more VH CDRs selected from the
group consisting of SEQ ID NO: 353, SEQ ID NO: 354, and SEQ ID NO:
355. In one embodiment, the heavy chain variable region comprises
two or more VH CDRs selected from the group consisting of SEQ ID
NO: 353, SEQ ID NO: 354, and SEQ ID NO: 355. In one embodiment, the
heavy chain variable region comprises a VH CDR1 comprising SEQ ID
NO: 353, a VH CDR2 comprising SEQ ID NO: 354, and a VH CDR3
comprising SEQ ID NO: 355.
[0327] In one embodiment, the light chain variable region comprises
one or more complementarity determining regions (CDRs). In one
embodiment, the light chain variable region comprises a VL CDR1
comprising the amino acid sequence of SEQ ID NO: 356. In one
embodiment, the light chain variable region comprises a VL CDR2
comprising the amino acid sequence of SEQ ID NO: 357. In one
embodiment, the light chain variable region comprises a VL CDR3
comprising the amino acid sequence of SEQ ID NO: 358. In one
embodiment, the light chain variable region comprises one or more
VL CDRs selected from the group consisting of SEQ ID NO: 356, SEQ
ID NO: 357, and SEQ ID NO: 358. In one embodiment, the light chain
variable region comprises two or more VL CDRs selected from the
group consisting of SEQ ID NO: 356, SEQ ID NO: 357, and SEQ ID NO:
358. In one embodiment, the light chain variable region comprises a
VL CDR1 comprising SEQ ID NO: 356, a VL CDR2 comprising SEQ ID NO:
357, and a VL CDR3 comprising SEQ ID NO: 358.
[0328] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises a VH CDR1 comprising SEQ ID NO: 353, a VH CDR2 comprising
SEQ ID NO: 354, and a VH CDR3 comprising SEQ ID NO: 355, and alight
chain variable region that comprises a VL CDR1 comprising SEQ ID
NO: 356, a VL CDR2 comprising SEQ ID NO: 357, and a VL CDR3
comprising SEQ ID NO: 358.
[0329] In certain embodiments, one or more of the CDRs (i.e., one
or more heavy chain CDRs having SEQ ID NOs: 353-355, and/or one or
more light chain CDRs having SEQ ID NOs: 356-358) can comprise a
conservative amino acid substitution (or 2, 3, 4, or 5 amino acid
substitutions) while retaining the CD5 specificity of the antibody
(i.e., specificity similar to an antibody, or antigen-binding
fragment thereof, comprising heavy chain CDRs of SEQ ID NOs: 353 to
355, and light chain CDRs of SEQ ID NOs:356 to 358).
[0330] Antibodies and antigen-binding fragments thereof capable of
binding CD5 antigen can be identified using techniques known in the
art and described herein, such as by immunization, computational
modeling techniques, and in vitro selection methods, such as the
phage display and cell-based display platforms described below.
[0331] Anti-CD5 antibodies that can be used in conjunction with the
compositions and methods described herein include those that have
one or both of the following variable regions, or an amino acid
sequence having at least 85% sequence identity thereto (e.g., an
amino acid sequence having 85%, 90%, 95%, 97%, 98%, 99%, or more,
sequence identity thereto):
TABLE-US-00007 a V.sub.L having the amino acid sequence (SEQ ID NO:
325) DIQMTQSPSSMSASLGDRVTITCRASQDINSYLSWFQQKPGKSPKTLIYR
ANRLVDGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTFGG GTKLEIK; and a
V.sub.H having the amino acid sequence (SEQ ID NO: 326)
QIQLVQSGPGLKKPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLRWMGW
INTHTGEPTYADDFKGRFTFSLDTSKSTAYLQINSLRAEDTATYFCTRRG
YDWYFDVWGQGTTVTVSS.
[0332] Antibodies and antigen-binding fragments thereof containing
the foregoing V.sub.L and V.sub.H sequences are described, e.g., in
U.S. Pat. No. 5,869,619, the disclosure of which is incorporated
herein by reference as it pertains to anti-CD5 antibodies and
antigen-binding fragments thereof, such as the he1 antibody. In
some embodiments, the anti-CD5 antibody or antigen-binding fragment
thereof includes the V.sub.L and V.sub.H chains of SEQ ID NO: 325
and SEQ ID NO: 326. In some embodiments, the anti-CD5 antibody or
antigen-binding fragment thereof includes the CDRs contained in the
V.sub.L and V.sub.H chains of SEQ ID NO: 325 and SEQ ID NO: 326. In
some embodiments, the anti-CD5 antibody or antigen-binding fragment
thereof includes the CDRs contained in the V.sub.L and V.sub.H
chains of SEQ ID NO: 325 and SEQ ID NO: 326 and the remainder of
the V.sub.L and V.sub.H sequences have at least 85% sequence
identity (e.g., 85%, 90%, 95%, 97%, 98%, 99%, or greater sequence
identity) to the V.sub.L and V.sub.H sequences of SEQ ID NO: 325
and SEQ ID NO: 326.
[0333] In some embodiments, the anti-CD5 antibody or
antigen-binding fragment thereof includes the following CDRs:
[0334] a CDR-H1 having the amino acid sequence GYTFTNY (SEQ ID NO:
327); [0335] a CDR-H2 having the amino acid sequence NTHTGE (SEQ ID
NO: 328); [0336] a CDR-H3 having the amino acid sequence RGYDWYFDV
(SEQ ID NO: 329); [0337] a CDR-L1 having the amino acid sequence
RASQDINSYLS (SEQ ID NO: 330); [0338] a CDR-L2 having the amino acid
sequence RANRLVD (SEQ ID NO: 331); and [0339] a CDR-L3 having the
amino acid sequence QQYDESPWT (SEQ ID NO: 332).
[0340] Additional anti-CD5 antibodies that can be used in
conjunction with the compositions and methods described herein
include those that have one or both of the following variable
regions, or an amino acid sequence having at least 85% sequence
identity thereto (e.g., an amino acid sequence having 85%, 90%,
95%, 97%, 98%, 99%, or more, sequence identity thereto):
TABLE-US-00008 a V.sub.L having the amino acid sequence (SEQ ID NO:
333) DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIY
RANRLESGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTF GGGTKLEIK; and a
V.sub.H having the amino acid sequence (SEQ ID NO: 334)
EIQLVQSGGGLVKPGGSVRISCAASGYTFTNYGMNWVRQAPGKGLEWMGW
INTHYGEPTYADSFKGTRTFSLDDSKNTAYLQINSLRAEDTAVYFCTRRG
YDWYFDVWGQGGTTVTVSS.
[0341] Antibodies and antigen-binding fragments thereof containing
the foregoing V.sub.L and V.sub.H sequences are described, e.g., in
U.S. Pat. No. 5,869,619, the disclosure of which is incorporated
herein by reference as it pertains to anti-CD5 antibodies and
antigen-binding fragments thereof, such as the he3 antibody. In
some embodiments, the anti-CD5 antibody or antigen-binding fragment
thereof includes the CDRs contained in the V.sub.L and V.sub.H
chains of the antibody that includes the V.sub.L and V.sub.H chains
of SEQ ID NO:327 and SEQ ID NO: 328. In some embodiments, the
anti-CD5 antibody or antigen-binding fragment thereof includes the
CDRs contained in the V.sub.L and V.sub.H chains of SEQ ID NO:327
and SEQ ID NO: 328 and the remainder of the V.sub.L and V.sub.H
sequences have at least 85% sequence identity (e.g., 85%, 90%, 95%,
97%, 98%, 99%, or greater sequence identity) to the V.sub.L and
V.sub.H sequences of SEQ ID NO:327 and SEQ ID NO: 328.
[0342] In some embodiments, the anti-CD5 antibody or
antigen-binding fragment thereof includes the following CDRs:
[0343] a CDR-H1 having the amino acid sequence GYTFTNY (SEQ ID NO:
335); [0344] a CDR-H2 having the amino acid sequence NTHYGE (SEQ ID
NO: 336); [0345] a CDR-H3 having the amino acid sequence RRGYDWYFDV
(SEQ ID NO: 337); [0346] a CDR-L1 having the amino acid sequence
RASQDINSYLS (SEQ ID NO: 338); [0347] a CDR-L2 having the amino acid
sequence RANRLES (SEQ ID NO: 339); and [0348] a CDR-L3 having the
amino acid sequence QQYDESPWT (SEQ ID NO: 340).
[0349] Antibodies and antigen-binding fragments thereof containing
the foregoing CDR sequences are described, e.g., in U.S. Pat. No.
5,869,619, the disclosure of which is incorporated herein by
reference as it pertains to anti-CD5 antibodies and antigen-binding
fragments thereof.
[0350] Other anti-CD5 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, anti-CD5 antibodies that are described in U.S. Pat. Nos.
5,821,123; 5,766,886; 5,770,196; 7,153,932; 5,621,083; 6,649,742;
6,146,631; 5,756,699; 5,744,580; 6,376,217; 5,837,491; and
6,146,850, the disclosures of each of which are incorporated herein
by reference as they pertain to anti-CD5 antibodies and
antigen-binding fragments thereof.
[0351] Other anti-CD5 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, those produced by the hybridoma cell line deposited as
ATCC CRL 8000 (anti-CD5 murine antibody OKT1). Such antibodies are
described in U.S. Pat. Nos. 4,515,894; 4,657,760; and 4,363,799,
the disclosures of each of which are incorporated herein by
reference as they pertains to anti-CD5 antibodies and
antigen-binding fragments thereof.
[0352] Anti-CD5 antibodies that can be used in conjunction with the
compositions and methods described herein include those that have
one or more, or all, of the following CDRs: [0353] a CDR-H1 having
the amino acid sequence GYSITSGYY (SEQ ID NO: 341); [0354] a CDR-H2
having the amino acid sequence ISYSGFT (SEQ ID NO: 342); [0355] a
CDR-H3 having the amino acid sequence AGDRTGSWFAY (SEQ ID NO: 343);
[0356] a CDR-L1 having the amino acid sequence QDISNY (SEQ ID NO:
344); [0357] a CDR-L2 having the amino acid sequence ATS (SEQ ID
NO: 345); and [0358] a CDR-L3 having the amino acid sequence
LQYASYPFT (SEQ ID NO: 346).
[0359] Antibodies and antigen-binding fragments thereof containing
the foregoing CDR sequences are described, e.g., in U.S. Pat. No.
8,679,500, the disclosure of which is incorporated herein by
reference as it pertains to anti-CD5 antibodies and antigen-binding
fragments thereof.
[0360] Anti-CD5 antibodies that can be used in conjunction with the
compositions and methods described herein include those that have
one or more, or all, of the following CDRs: [0361] a CDR-H1 having
the amino acid sequence GYIFTNYG (SEQ ID NO: 347); [0362] a CDR-H2
having the amino acid sequence INTYNGEP (SEQ ID NO: 348); [0363] a
CDR-H3 having the amino acid sequence ARGDYYGYEDY (SEQ ID NO: 349);
[0364] a CDR-L1 having the amino acid sequence QGISNY (SEQ ID NO:
350); [0365] a CDR-L2 having the amino acid sequence YTS (SEQ ID
NO: 351); and [0366] a CDR-L3 having the amino acid sequence
QQYSKLPWT (SEQ ID NO: 352).
[0367] Antibodies and antigen-binding fragments thereof containing
the foregoing CDR sequences are described, e.g., in U.S. Pat. No.
8,679,500.
[0368] Anti-CD5 antibodies that can be used in conjunction with the
compositions and methods described herein include those that have
one or more, or all, of the following CDRs: [0369] a CDR-H1 having
the amino acid sequence FSLSTSGMG (SEQ ID NO: 353); [0370] a CDR-H2
having the amino acid sequence WWDDD (SEQ ID NO: 354); [0371] a
CDR-H3 having the amino acid sequence RRATGTGFDY (SEQ ID NO: 355);
[0372] a CDR-L1 having the amino acid sequence QDVGTA (SEQ ID NO:
356); [0373] a CDR-L2 having the amino acid sequence WTSTRHT (SEQ
ID NO: 357); and [0374] a CDR-L3 having the amino acid sequence
YNSYNT (SEQ ID NO: 358).
[0375] Antibodies and antigen-binding fragments thereof containing
the foregoing CDR sequences are described, e.g., in US Patent
Application Publication No. 2008/0254027, the disclosure of which
is incorporated herein by reference as it pertains to anti-CD5
antibodies and antigen-binding fragments thereof.
[0376] Other anti-CD5 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, anti-CD5 antibodies that are described in PCT Application
Publication No. WO1992/014491, such as the anti-CD5 antibodies
produced by hybridoma cell line deposited at the Institut Pasteur
under No. 1-1025 on Jan. 10, 1991. The disclosure of PCT
Application Publication No. WO1992/014491 is incorporated herein by
reference as it pertains to anti-CD5 antibodies and antigen-binding
fragments thereof.
[0377] Other anti-CD5 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, anti-CD5 antibodies that are described in U.S. Pat. Nos.
6,010,902 and 7,192,736, US Patent Application Publication Nos.
2011/0250203 and 2017/0129128, and PCT Application Publication Nos.
WO2016/172606; WO1994/023747; and WO1996/041608; the disclosures of
each of which are incorporated herein by reference as they pertain
to anti-CD5 antibodies and antigen binding fragments thereof.
[0378] In some embodiments, the anti-CD5 antibodies that can be
used in conjunction with the compositions and methods described
herein include those that contain a combination of CDR-H1, CDR-H2,
CDR-H3, CDR-L1, CDR-L2, and CDR-L3 regions set forth in the table
below.
TABLE-US-00009 TABLE CD5 antibody sequences Ab No. Name CDRH1 CDRH2
CDRH3 1 1D8 SGYSFTGYTM LINPYNGGTT CARDYYGSSPDFDYW 2 3I21 SGYSFTDYTM
LINPYNGGTM CARDNYGSSPDFDYW 3 4H10 SGYSFTGYTM LINPYNGGTM
CARDNYGSSPYFDYW 4 8J23 SGYSFTGYTM LINPYNGGTM CARDNYGSSPYFDYW 5 5O4
SGYSFTGYTM LINPYNGGTT CARDYYGSSPDFDYW 6 4H2 SGFTFSNYAM SISSGGNTF
CVRYYYGVTYWYFDVW 7 5G2 SGFTFSSYAM SISSGGSTY CVRYYYGIRYWYFDVW 8 8G8
SGYSFTAYNI SIDPYYGDTK CARRMITMGDWYFDVW 9 6M4 SGYSFTAYSM SIDPYYGDTK
CARRMITTGDWYFDVW 10 2E3 SGYTFTNFAI LISSNSGDVS CARHYGAHNYFDYW 11
4E24 SGYTFTNFAI LISTSSGDVS CARHYGANNYFDYW 12 4F10 SGYTFTNFAI
LISSNSGDVS CARHYGAHNYFDYW 13 7J9 SGYTFTNFAI LISSNSGDVS
CARHYGAHNYFDYW 14 7P9 SGFNIKDTYM RIDPANGNTK CAREENYYGTYYFDYW 15
8E24 SGYSFTSYWM MIHPSDSETR CARWGDHDDAMDFW 16 6L18 SGFSLTNYDV
VIWSGGNTD CARNHGDGYFNWYFDVW 17 7H7 SGFSLTNYDV VIWSGGNTD
CARNHGDGYYNWYFDVW 18 1E7 SGFTFSNYGM AINSNGDITY CARGTAWFTYW 19 8J21
SGYSFTGYTM LINPYNGGTR CARDGDDGWDIDVW 20 7I11 SGYIFANYGM WINTYTGEPT
CARRGTYWHFDVW 21 8M9 SGYNFTNYGM WINTYTGEPT CARRGSYWHFDVW 22 1P21
SGYTFTNYGM WINTYTGEPT CARRSTLVFDYW 23 2H11 SGYTFTDYYI WIYPGGGNTR
CARNGYWYFDVW 24 3M22 SGYTFTDYYI WIYPGGGNTR CARNGYWYFDVW 25 5M6
SGNTFTNFYL CIYPGNVKTK CAKEGDYDGTAYFDYW 26 5H8 SGYTFTNYGM WINTYTGEPT
CARRRDGNFDYW 27 7I19 SEFTFSNYAM TISSGGSYTY CVRHGYFDVW 28 1A20
SGYTFTSYRM RIDPYDSGTH CAFYDGAYW 29 8E15 SGFNIKDTYM RIDPANGNTK
CASYDPDYW 30 8C10 SGYSFTDYTM LINPYNGGTR CARDTTATYYFDYW 31 3P16
SGYMFTNHGM WINTYTGEPT CARRVATYFDVW 32 4F3 SGYMFTNYGM WINTYTGEPT
CTRRSHITLDYW 33 5M24 SGYIFTNYGM WINTYTGEPT CARRRTTAFDYW 34 5O24
SGFNIKDYYI WIDPENGRTE CNNGNYVRHYYFDYW 35 7B16 SGYTFINYGM WINTYTGEPT
CTRRREITFDYW 36 1E8 SGYTFTDYFI EIYPGSSNTY CARSGISPFTYW 37 2H16
SGYIFTGYNI AVYPGNGDTS CAKYDRFFASW
[0379] Antibodies and antigen-binding fragments thereof containing
the foregoing CDR sequences of the table above are described, e.g.,
in US Patent Application Publication No. 2011/0250203, the
disclosure of which is incorporated herein by reference as it
pertains to anti-CD5 antibodies and antigen binding fragments
thereof.
Anti-CD2 Antibodies
[0380] Compositions and methods described herein include, in
certain embodiments, an antibody, or fragment thereof, that
specifically binds to human CD2. Human CD2 is also referred to as
T-cell Surface Antigen T11/Leu-5, T11, CD2 antigen (p50), and Sheep
Red Blood Cell Receptor (SRBC). CD2 is expressed on T cells. Two
isoforms of human CD2 have been identified. Isoform 1 contains 351
amino acids is described in Seed, B. et al. (1987) 84: 3365-69 (see
also Sewell et al. (1986) 83: 8718-22) and below (NCBI Reference
Sequence: NP_001758.2):
TABLE-US-00010 (SEQ ID NO: 312) msfpckfvas fllifnvssk gavskeitna
letwgalgqd inldipsfqm sddiddikwe ktsdkkkiaq frkeketfke kdtyklfkng
tlkikhlktd dqdiykvsiy dtkgknvlek ifdlkiqerv skpkiswtci nttltcevmn
gtdpelnlyq dgkhlklsqr vithkwttsl sakfkctagn kvskessvep vscpekgldi
yliigicggg sllmvfvall vfyitkrkkq rsrrndeele trahrvatee rgrkphqipa
stpqnpatsq hpppppghrs qapshrpppp ghrvqhqpqk rppapsgtqv hqqkgpplpr
prvqpkpphg aaenslspss n
A second isoform of CD2 is 377 amino acids and is identified herein
as NCBI Reference Sequence: NP_001315538.1.
[0381] T cells and NK cells have been shown to express CD2, which
is a cell adhesion molecule and specific marker for such
lymphocytes. For instance, CD2 interacts with other adhesion
molecules, such as lymphocyte function-associated antigen-3
(LFA-3/CD58), to potentiate T cell activation. Antibodies and
antigen-binding fragments thereof capable of binding CD2 may
suppress T cell activation and T cell-mediated immune responses
against hematopoietic stem cell grafts, for example, by inhibiting
the interaction between CD2 and LFA-3. Antibodies and
antigen-binding fragments thereof that bind to this cell-surface
antigen can be identified using techniques known in the art and
described herein, including immunization, computational modeling
techniques, and in vitro selection methods, such as the phage
display and cell-based display platforms described below.
[0382] In certain embodiments, the present invention encompasses an
ADC comprising an antibody, or antigen-binding fragment thereof,
that specifically binds to a CD2 polypeptide, e.g., a human CD2
polypeptide, and uses thereof.
[0383] In one embodiment, an ADC comprises an anti-CD2 antibody
comprising a heavy chain variable region comprises one or more
complementarity determining regions (CDRs). In one embodiment, the
heavy chain variable region comprises a VH CDR1 comprising the
amino acid sequence of SEQ ID NO:300. In one embodiment, the heavy
chain variable region comprises a VH CDR2 comprising the amino acid
sequence of SEQ ID NO:301. In one embodiment, the heavy chain
variable region comprises a VH CDR3 comprising the amino acid
sequence of SEQ ID NO:302. In one embodiment, the heavy chain
variable region comprises one or more VH CDRs selected from the
group consisting of SEQ ID NO:300, SEQ ID NO:301, and SEQ ID
NO:302. In one embodiment, the heavy chain variable region
comprises two or more VH CDRs selected from the group consisting of
SEQ ID NO:300, SEQ ID NO:301, and SEQ ID NO:302.
[0384] In one embodiment, the heavy chain variable region comprises
a VH CDR1 comprising SEQ ID NO:300, a VH CDR2 comprising SEQ ID
NO:301, and a VH CDR3 comprising SEQ ID NO:302.
[0385] In one embodiment, an ADC comprises an anti-CD2 antibody
comprising light chain variable region comprises one or more
complementarity determining regions (CDRs). In one embodiment, the
light chain variable region comprises a VL CDR1 comprising the
amino acid sequence of SEQ ID NO:303. In one embodiment, the light
chain variable region comprises a VL CDR2 comprising the amino acid
sequence of SEQ ID NO:304. In one embodiment, the light chain
variable region comprises a VL CDR3 comprising the amino acid
sequence of SEQ ID NO:305. In one embodiment, the light chain
variable region comprises one or more VL CDRs selected from the
group consisting of SEQ ID NO:303, SEQ ID NO:304, and SEQ ID
NO:305. In one embodiment, the light chain variable region
comprises two or more VL CDRs selected from the group consisting of
SEQ ID NO:303, SEQ ID NO:304, and SEQ ID NO:305. In one embodiment,
the light chain variable region comprises a VL CDR1 comprising SEQ
ID NO:303, a VL CDR2 comprising SEQ ID NO:304, and a VL CDR3
comprising SEQ ID NO:305.
[0386] In an exemplary embodiment, the anti-CD2 antibody, or
antigen-binding fragment thereof, comprises a heavy chain variable
region that comprises a VH CDR1 comprising SEQ ID NO:300, a VH CDR2
comprising SEQ ID NO:301, and a VH CDR3 comprising SEQ ID NO:302,
and alight chain variable region that comprises a VL CDR1
comprising SEQ ID NO:303, a VL CDR2 comprising SEQ ID NO:304, and a
VL CDR3 comprising SEQ ID NO:305.
[0387] In certain embodiments, one or more of the CDRs (i.e., one
or more heavy chain CDRs having SEQ ID NOs: 300-302, and/or one or
more light chain CDRs having SEQ ID NOs: 303-305) can comprise a
conservative amino acid substitution (or 2, 3, 4, or 5 amino acid
substitutions) while retaining the CD2 specificity of the antibody
(i.e., specificity similar to an antibody, or antigen-binding
fragment thereof, comprising heavy chain CDRs of SEQ ID NOs: 300 to
302, and light chain CDRs of SEQ ID NOs:303 to 305).
[0388] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a heavy chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO: 306. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a heavy chain variable region that comprises an amino
acid sequence having at least 95% identity to SEQ ID NO: 306, e.g.,
at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:
306. In certain embodiments, an antibody comprises a modified heavy
chain (HC) variable region comprising an HC variable domain
comprising SEQ ID NO: 306, or a variant of SEQ ID NO: 306, which
variant (i) differs from SEQ ID NO: 306 in 1, 2, 3, 4 or 5 amino
acids substitutions, additions or deletions; (ii) differs from SEQ
ID NO: 306 in at most 5, 4, 3, 2, or 1 amino acids substitutions,
additions or deletions; (iii) differs from SEQ ID NO: 306 in 1-5,
1-3, 1-2, 2-5 or 3-5 amino acids substitutions, additions or
deletions and/or (iv) comprises an amino acid sequence that is at
least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical
to SEQ ID NO: 306, wherein in any of (i)-(iv), an amino acid
substitution may be a conservative amino acid substitution or a
non-conservative amino acid substitution; and wherein the modified
heavy chain variable region can have an enhanced biological
activity relative to the heavy chain variable region of SEQ ID NO:
306, while retaining the CD2 binding specificity of the antibody,
i.e. has a binding specificity similar to an antibody, or
antigen-binding fragment thereof, comprising SEQ ID NO: 306. In one
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a heavy chain variable region that differs from the amino
acid sequence set forth in SEQ ID NO: 306 at one, two, three or
four amino acids. For example, the antibody, or antigen-binding
fragment thereof, can comprise a heavy chain variable region that
differs from the amino acid sequence set forth in SEQ ID NO: 306 at
one, two, three, or four of positions 12, 13, 28, and/or 48. In one
embodiment, the heavy chain variable region differs from the amino
acid sequence set forth in SEQ ID NO:306 at positions 12, 13, 28,
and 48. In one embodiment, the heavy chain variable region
comprises one, two, three, or four of the following substitutions
with respect to the sequence set forth in SEQ ID NO:306: K12Q;
K13R; T28I; and M48V. In one embodiment, the heavy chain variable
region comprises the substitutions K12Q; K13R; T28I; and M48V with
respect to SEQ ID NO:306.
[0389] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a light chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO:307. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a light chain variable region that comprises an amino
acid sequence having at least 95% identity to SEQ ID NO:307, e.g.,
at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID
NO:307. In certain embodiments, an antibody comprises a modified
light chain (LC) variable region comprising an LC variable domain
comprising SEQ ID NO: 307, or a variant of SEQ ID NO: 307, which
variant (i) differs from SEQ ID NO: 307 in 1, 2, 3, 4 or 5 amino
acids substitutions, additions or deletions; (ii) differs from SEQ
ID NO: 307 in at most 5, 4, 3, 2, or 1 amino acids substitutions,
additions or deletions; (iii) differs from SEQ ID NO: 307 in 1-5,
1-3, 1-2, 2-5 or 3-5 amino acids substitutions, additions or
deletions and/or (iv) comprises an amino acid sequence that is at
least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical
to SEQ ID NO: 307, wherein in any of (i)-(iv), an amino acid
substitution may be a conservative amino acid substitution or a
non-conservative amino acid substitution; and wherein the modified
light chain variable region can have an enhanced biological
activity relative to the light chain variable region of SEQ ID
NO:307, while retaining the CD2 binding specificity of the
antibody, i.e., has a binding specificity similar to an antibody,
or antigen-binding fragment thereof, comprising SEQ ID NO:307.
[0390] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises an amino acid sequence having at least 95% identity to
SEQ ID NO: 306, e.g., at least about 95%, about 96%, about 97%,
about 98%, about 99%, or 100% identity to SEQ ID NO: 306, and
alight chain variable region that comprises an amino acid sequence
having at least about 95% identity to SEQ ID NO:307, e.g., at least
about 95%, about 96%, about 97%, about 98%, about 99%, or 100%
identity to SEQ ID NO:307. In one embodiment, the antibody, or
antigen-binding fragment thereof, comprises a heavy chain variable
region that comprises SEQ ID NO: 306, and a light chain variable
region that comprises SEQ ID NO:307. In one embodiment, the
antibody is an Ab1 antibody that comprises a heavy chain variable
region comprising SEQ ID NO:306, and alight chain variable region
comprising SEQ ID NO:307.
[0391] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a heavy chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO:308. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a heavy chain variable region that comprises an amino
acid sequence having at least 95% identity to SEQ ID NO:308, e.g.,
at least about 95%, about 96%, about 97%, about 98%, about 99%, or
100% identity to SEQ ID NO:308. In an exemplary embodiment, the
antibody, or antigen-binding fragment thereof, comprises a heavy
chain variable region that comprises an amino acid sequence having
at least 95% identity to SEQ ID NO:308, e.g., at least about 95%,
about 96%, about 97%, about 98%, about 99%, or 100% identity to SEQ
ID NO:308, and a light chain variable region that comprises an
amino acid sequence having at least about 95% identity to SEQ ID
NO:309, e.g., at least about 95%, about 96%, about 97%, about 98%,
about 99%, or 100% identity to SEQ ID NO:309. In one embodiment,
the antibody, or antigen-binding fragment thereof, comprises a
heavy chain variable region that comprises SEQ ID NO:308, and a
light chain variable region that comprises SEQ ID NO:309. In one
embodiment, the antibody is an Ab1a antibody that comprises a heavy
chain variable region comprising SEQ ID NO:308, and a light chain
variable region comprising SEQ ID NO:309.
[0392] In one embodiment, the heavy chain variable region comprises
one or more complementarity determining regions (CDRs). In one
embodiment, the heavy chain variable region comprises a VH CDR1
comprising the amino acid sequence of SEQ ID NO:3131. In one
embodiment, the heavy chain variable region comprises a VH CDR2
comprising the amino acid sequence of SEQ ID NO:314. In one
embodiment, the heavy chain variable region comprises a VH CDR3
comprising the amino acid sequence of SEQ ID NO:315. In one
embodiment, the heavy chain variable region comprises one or more
VH CDRs selected from the group consisting of SEQ ID NO:313, SEQ ID
NO:314, and SEQ ID NO:315. In one embodiment, the heavy chain
variable region comprises two or more VH CDRs selected from the
group consisting of SEQ ID NO:313, SEQ ID NO:314, and SEQ ID
NO:315. In one embodiment, the heavy chain variable region
comprises a VH CDR1 comprising SEQ ID NO:313, a VH CDR2 comprising
SEQ ID NO:314, and a VH CDR3 comprising SEQ ID NO:315.
[0393] In one embodiment, the heavy chain variable region comprises
one or more complementarity determining regions (CDRs). In one
embodiment, the heavy chain variable region comprises a VH CDR1
comprising the amino acid sequence of SEQ ID NO:313. In one
embodiment, the heavy chain variable region comprises a VH CDR2
comprising the amino acid sequence of SEQ ID NO:314. In one
embodiment, the heavy chain variable region comprises a VH CDR3
comprising the amino acid sequence of SEQ ID NO:316. In one
embodiment, the heavy chain variable region comprises one or more
VH CDRs selected from the group consisting of SEQ ID NO:313, SEQ ID
NO:314, and SEQ ID NO:316. In one embodiment, the heavy chain
variable region comprises two or more VH CDRs selected from the
group consisting of SEQ ID NO:313, SEQ ID NO:314, and SEQ ID
NO:316. In one embodiment, the heavy chain variable region
comprises a VH CDR1 comprising SEQ ID NO:313, a VH CDR2 comprising
SEQ ID NO:314, and a VH CDR3 comprising SEQ ID NO:316.
[0394] In one embodiment, the light chain variable region comprises
one or more complementarity determining regions (CDRs). In one
embodiment, the light chain variable region comprises a VL CDR1
comprising the amino acid sequence of SEQ ID NO:317. In one
embodiment, the light chain variable region comprises a VL CDR2
comprising the amino acid sequence of SEQ ID NO:318. In one
embodiment, the light chain variable region comprises a VL CDR3
comprising the amino acid sequence of SEQ ID NO:319. In one
embodiment, the light chain variable region comprises one or more
VL CDRs selected from the group consisting of SEQ ID NO:317, SEQ ID
NO:318, and SEQ ID NO:319. In one embodiment, the light chain
variable region comprises two or more VL CDRs selected from the
group consisting of SEQ ID NO:317, SEQ ID NO:318, and SEQ ID
NO:319. In one embodiment, the light chain variable region
comprises a VL CDR1 comprising SEQ ID NO:317, a VL CDR2 comprising
SEQ ID NO:318, and a VL CDR3 comprising SEQ ID NO:319.
[0395] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises a VH CDR1 comprising SEQ ID NO:313, a VH CDR2 comprising
SEQ ID NO:314, and a VH CDR3 comprising SEQ ID NO:315, and a light
chain variable region that comprises a VL CDR1 comprising SEQ ID
NO:317, a VL CDR2 comprising SEQ ID NO:318, and a VL CDR3
comprising SEQ ID NO:319.
[0396] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises a VH CDR1 comprising SEQ ID NO:313, a VH CDR2 comprising
SEQ ID NO:314, and a VH CDR3 comprising SEQ ID NO:316, and a light
chain variable region that comprises a VL CDR1 comprising SEQ ID
NO:317, a VL CDR2 comprising SEQ ID NO:318, and a VL CDR3
comprising SEQ ID NO:319.
[0397] In certain embodiments, one or more of the CDRs (i.e., one
or more heavy chain CDRs having SEQ ID NOs: 313-316, and/or one or
more light chain CDRs having SEQ ID NOs: 317-318) can comprise a
conservative amino acid substitution (or 2, 3, 4, or 5 amino acid
substitutions) while retaining the CD2 specificity of the antibody
(i.e., specificity similar to an antibody, or antigen-binding
fragment thereof, comprising heavy chain CDRs of SEQ ID NOs: 313 to
315, and light chain CDRs of SEQ ID NOs:18 to 20; or comprising
heavy chain CDRs of SEQ ID NOs: 313, 314, 316, and light chain CDRs
of SEQ ID NOs:317 to 319).
[0398] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a heavy chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO: 320. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a heavy chain variable region that comprises an amino
acid sequence having at least about 95% identity to SEQ ID NO: 320,
e.g., at least about 95%, about 96%, about 97%, about 98%, about
99%, or 100% identity to SEQ ID NO: 320. In certain embodiments, an
antibody comprises a modified heavy chain (HC) variable region
comprising an HC variable domain comprising SEQ ID NO: 320, or a
variant of SEQ ID NO: 320, which variant (i) differs from SEQ ID
NO: 320 in 1, 2, 3, 4 or 5 amino acids substitutions, additions or
deletions; (ii) differs from SEQ ID NO: 320 in at most 5, 4, 3, 2,
or 1 amino acids substitutions, additions or deletions; (iii)
differs from SEQ ID NO: 320 in 1-5, 1-3, 1-2, 2-5 or 3-5 amino
acids substitutions, additions or deletions and/or (iv) comprises
an amino acid sequence that is at least about 75%, about 80%, about
85%, about 90%, about 95%, about 96%, about 97%, about 98% or about
99% identical to SEQ ID NO: 320, wherein in any of (i)-(iv), an
amino acid substitution may be a conservative amino acid
substitution or a non-conservative amino acid substitution; and
wherein the modified heavy chain variable region can have an
enhanced biological activity relative to the heavy chain variable
region of SEQ ID NO: 320, while retaining the CD2 binding
specificity of the antibody, i.e. has a binding specificity similar
to an antibody, or antigen-binding fragment thereof, comprising SEQ
ID NO: 320.
[0399] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a heavy chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO: 321. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a heavy chain variable region that comprises an amino
acid sequence having at least about 95% identity to SEQ ID NO: 321,
e.g., at least about 95%, about 96%, about 97%, about 98%, about
99%, or 100% identity to SEQ ID NO: 321. In certain embodiments, an
antibody comprises a modified heavy chain (HC) variable region
comprising an HC variable domain comprising SEQ ID NO: 320, or a
variant of SEQ ID NO: 321, which variant (i) differs from SEQ ID
NO: 321 in 1, 2, 3, 4 or 5 amino acids substitutions, additions or
deletions; (ii) differs from SEQ ID NO: 321 in at most 5, 4, 3, 2,
or 1 amino acids substitutions, additions or deletions; (iii)
differs from SEQ ID NO: 321 in 1-5, 1-3, 1-2, 2-5 or 3-5 amino
acids substitutions, additions or deletions and/or (iv) comprises
an amino acid sequence that is at least about 75%, about 80%, about
85%, about 90%, about 95%, about 96%, about 97%, about 98% or about
99% identical to SEQ ID NO: 321, wherein in any of (i)-(iv), an
amino acid substitution may be a conservative amino acid
substitution or a non-conservative amino acid substitution; and
wherein the modified heavy chain variable region can have an
enhanced biological activity relative to the heavy chain variable
region of SEQ ID NO: 321, while retaining the CD2 binding
specificity of the antibody, i.e. has a binding specificity similar
to an antibody, or antigen-binding fragment thereof, comprising SEQ
ID NO: 321.
[0400] In one embodiment, the antibody, or antigen-binding fragment
thereof, comprises a light chain variable region that comprises the
amino acid sequence set forth in SEQ ID NO:322. In another
embodiment, the antibody, or antigen-binding fragment thereof,
comprises a light chain variable region that comprises an amino
acid sequence having at least about 95% identity to SEQ ID NO:322,
e.g., at least about 95%, about 96%, about 97%, about 98%, about
99%, or 100% identity to SEQ ID NO:322. In certain embodiments, an
antibody comprises a modified light chain (LC) variable region
comprising an LC variable domain comprising SEQ ID NO: 322, or a
variant of SEQ ID NO: 322, which variant (i) differs from SEQ ID
NO: 322 in 1, 2, 3, 4 or 5 amino acids substitutions, additions or
deletions; (ii) differs from SEQ ID NO: 322 in at most 5, 4, 3, 2,
or 1 amino acids substitutions, additions or deletions; (iii)
differs from SEQ ID NO: 322 in 1-5, 1-3, 1-2, 2-5 or 3-5 amino
acids substitutions, additions or deletions and/or (iv) comprises
an amino acid sequence that is at least about 75%, about 80%, about
85%, about 90%, about 95%, about 96%, about 97%, about 98% or about
99% identical to SEQ ID NO: 322, wherein in any of (i)-(iv), an
amino acid substitution may be a conservative amino acid
substitution or a non-conservative amino acid substitution; and
wherein the modified light chain variable region can have an
enhanced biological activity relative to the light chain variable
region of SEQ ID NO:322, while retaining the CD2 binding
specificity of the antibody, i.e., has a binding specificity
similar to an antibody, or antigen-binding fragment thereof,
comprising SEQ ID NO:322.
[0401] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises an amino acid sequence having at least 95% identity to
SEQ ID NO: 320, e.g., at least about 95%, about 96%, about 97%,
about 98% or about 99%, or 100% identity to SEQ ID NO: 320, and
alight chain variable region that comprises an amino acid sequence
having at least about 95% identity to SEQ ID NO:322, e.g., at least
about 95%, about 96%, about 97%, about 98% or about 99%, or 100%
identity to SEQ ID NO:322. In one embodiment, the antibody, or
antigen-binding fragment thereof, comprises a heavy chain variable
region that comprises SEQ ID NO: 320, and a light chain variable
region that comprises SEQ ID NO:322.
[0402] In an exemplary embodiment, the antibody, or antigen-binding
fragment thereof, comprises a heavy chain variable region that
comprises an amino acid sequence having at least about 95% identity
to SEQ ID NO: 321, e.g., at least about 95%, about 96%, about 97%,
about 98% or about 99%, or 100% identity to SEQ ID NO: 321, and a
light chain variable region that comprises an amino acid sequence
having at least about 95% identity to SEQ ID NO:322, e.g., at least
about 95%, about 96%, about 97%, about 98% or about 99%, or 100%
identity to SEQ ID NO:322. In one embodiment, the antibody, or
antigen-binding fragment thereof, comprises a heavy chain variable
region that comprises SEQ ID NO: 321, and a light chain variable
region that comprises SEQ ID NO:322.
[0403] Anti-CD2 antibodies that can be used in conjunction with the
compositions and methods described herein include those that have
one or more, or all, of the following CDRs: [0404] a. a CDR-H1
having the amino acid sequence EYYMY (SEQ ID NO: 300); [0405] b. a
CDR-H2 having the amino acid sequence RIDPEDGSIDYVEKFKK (SEQ ID NO:
301); [0406] c. a CDR-H3 having the amino acid sequence GKFNYRFAY
(SEQ ID NO: 302); [0407] d. a CDR-L1 having the amino acid sequence
RSSQSLLHSSGNTYLN (SEQ ID NO: 303); [0408] e. a CDR-L2 having the
amino acid sequence LVSKLES (SEQ ID NO: 304); and [0409] f. a
CDR-L3 having the amino acid sequence MQFTHYPYT (SEQ ID NO:
305).
[0410] Antibodies and antigen-binding fragments thereof containing
the foregoing CDR sequences are described, e.g., in U.S. Pat. No.
6,849,258, the disclosure of which is incorporated herein by
reference as it pertains to anti-CD2 antibodies and antigen-binding
fragments thereof.
[0411] The antibodies and fragments thereof disclosed in U.S. Pat.
Nos. 5,730,979; 5,817,311; 5,951,983; and 7,592,006; such as
LO-CD2a, BTI-322, and antibodies produced by the hybridoma cell
line deposited as ATCC Deposit No. HB 11423 (e.g., antibodies or
antigen-binding fragments thereof containing one or more, or all,
of the CDR sequences of antibody LO-CD2a isolated from the
hybridoma cell line deposited as ATCC Deposit No. HB 11423) can be
used in conjunction with the compositions and methods disclosed
herein. Exemplary antibodies that may be used in conjunction with
the compositions and methods described herein include humanized
antibodies containing one or more, or all, of the CDR sequences of
an antibody isolated from the hybridoma cell line deposited as ATCC
Deposit No. HB 11423, such as MEDI-507. MEDI-507 is a humanized
anti-CD2 monoclonal antibody that contains the CDR-H and CDR-L
sequences of (a) through (f) above, and is described in Branco et
al., Transplantation 68:1588-1596 (1999). MEDI-507 is additionally
described in WO99/03502A1 and WO1994/020619A1; U.S. Pat. Nos. U.S.
Pat. Nos. 7,592,006, 6,849,258, 5,951,983, 5,817,311, and
5,730,979; and U.S. Patent Publication Nos. US2011/0280868,
US2004/0265315 and 2011/0091453, the disclosures of each of which
are incorporated herein by reference as they pertain to anti-CD2
antibodies and antigen-binding fragments thereof, such as the
anti-CD2 antibody MEDI-507. In one embodiment, the anti-CD2
antibody is Siplizumab, or an antigen-binding fragment thereof.
[0412] Other anti-CD2 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, anti-CD2 antibodies that are described in U.S. Pat. Nos.
6,541,611 and 7,250,167, the disclosures of each of which are
incorporated herein by reference as they pertain to anti-CD2
antibodies and antigen-binding fragments thereof, such as the
anti-CD2 antibody LO-CD2b and antibodies produced by the hybridoma
cell line deposited as ATCC Deposit No. PTA-802. Exemplary
antibodies that may be used in conjunction with the compositions
and methods described herein include humanized antibodies
containing one or more, or all, of the CDR sequences of an antibody
isolated from the hybridoma cell line deposited as ATCC Deposit No.
PTA-802.
[0413] Other anti-CD2 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, anti-CD2 antibodies that are described in U.S. Pat. Nos.
5,795,572 and 5,807,734, the disclosures of each of which are
incorporated herein by reference as they pertains to anti-CD2
antibodies and antigen-binding fragments thereof, such as the
anti-CD2 antibody produced by hybridoma cell line deposited as ATCC
Deposit No. HB 69277. For instance, anti-CD2 antibodies and
antigen-binding fragments thereof that may be used in conjunction
with the compositions and methods described herein include those
that contain a hinge region having an amino acid sequence of
EPKSSDKTHTSPPSP (SEQ ID NO: 316), such as scFv fragments containing
a hinge region having the amino acid sequence of EPKSSDKTHTSPPSP
(SEQ ID NO: 316). The incorporation of a hinge region having the
amino acid sequence of SEQ ID NO: 316 can be beneficial, as this
hinge motif has been mutated relative to wild-type hinge region
sequences so as to eliminate potentially reactive cysteine residues
that may promote undesirable oxidative dimerization of a
single-chain antibody fragment, such as a scFv fragment.
[0414] Other anti-CD2 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, anti-CD2 antibodies that are described in U.S. Pat. No.
6,764,688, such as the anti-CD2 antibody TS2/18 and antibodies
produced by hybridoma cell line deposited as ATCC Deposit No.
HB-195. The disclosure of U.S. Pat. No. 6,764,688 is incorporated
herein by reference as it pertains to anti-CD2 antibodies and
antigen-binding fragments thereof.
[0415] Other anti-CD2 antibodies that can be used in conjunction
with the compositions and methods described herein include, for
instance, anti-CD2 antibodies that are described in U.S. Pat. Nos.
6,162,432, 6,558,662, 7,408,039, 7,332,157, 7,638,121, 7,939,062,
and 7,115,259, US Patent Application Publication No. 2006/0084107,
2014/0369974, 2002/0051784, and 2013/0183322, and PCT Publication
No. WO1992/016563, the disclosures of each of which are
incorporated herein by reference as they pertain to anti-CD2
antibodies and antigen binding fragments thereof.
Fc Mutations
[0416] The antibodies or binding fragments described herein may
also include modifications and/or mutations that alter the
properties of the antibodies and/or fragments, such as those that
increase half-life, increase or decrease ADCC, etc., as is known in
the art.
[0417] In one embodiment, an antibody, or binding fragment thereof,
comprises a variant Fc region, wherein said variant Fc region
comprises at least one amino acid modification relative to a
wild-type Fc region, such that said molecule has an altered
affinity for an FcgammaR. Certain amino acid positions within the
Fc region are known through crystallography studies to make a
direct contact with Fc.gamma.R. Specifically amino acids 234-239
(hinge region), amino acids 265-269 (B/C loop), amino acids 297-299
(C'/E loop), and amino acids 327-332 (F/G) loop. (see Sondermann et
al., 2000 Nature, 406: 267-273). Thus, the antibodies (e.g.,
anti-CD117, CD45, CD137, CD2, CD5, CD262, or CD134) described
herein may comprise variant Fc regions comprising modification of
at least one residue that makes a direct contact with an Fc.gamma.
R based on structural and crystallographic analysis. In one
embodiment, the Fc region of the antibody (or fragment thereof)
comprises an amino acid substitution at amino acid 265 according to
the EU index as in Kabat et al., Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, NH1, MD
(1991), expressly incorporated herein by references. The "EU index
as in Kabat" refers to the numbering of the human IgG1 EU antibody.
The EU index or EU index as in Kabat or EU numbering scheme refers
to the numbering of the EU antibody (Edelman et al., 1969, Proc
Natl Acad Sci USA 63:78-85, hereby entirely incorporated by
reference.) In one embodiment, the Fc region comprises a D265A
mutation. In one embodiment, the Fc region comprises a D265C
mutation. In some embodiments, the Fc region of the antibody (or
fragment thereof) comprises an amino acid substitution at amino
acid 234 according to the EU index as in Kabat. In one embodiment,
the Fc region comprises a L234A mutation. In some embodiments, the
Fc region of the antibody (or fragment thereof) comprises an amino
acid substitution at amino acid 235 according to the EU index as in
Kabat. In one embodiment, the Fc region comprises a L235A mutation.
In yet another embodiment, the Fc region comprises a L234A and
L235A mutation. In a further embodiment, the Fc region of the
antibody of an ADC described herein comprises a D265C, L234A, and
L235A mutation.
[0418] In certain aspects a variant IgG Fc domain comprises one or
more amino acid substitutions resulting in decreased or ablated
binding affinity for an Fc.gamma.R and/or C1q as compared to the
wild type Fc domain not comprising the one or more amino acid
substitutions. Fc binding interactions are essential for a variety
of effector functions and downstream signaling events including,
but not limited to, antibody dependent cell-mediated cytotoxicity
(ADCC) and complement dependent cytotoxicity (CDC). Accordingly, in
certain aspects, an antibody comprising a modified Fc region (e.g.,
comprising a L234A, L235A, and a D265C mutation) has substantially
reduced or abolished effector functions.
[0419] Affinity to an Fc region can be determined using a variety
of techniques known in the art, for example but not limited to,
equilibrium methods (e.g., enzyme-linked immunoabsorbent assay
(ELISA); KinExA, Rathanaswami et al. Analytical Biochemistry, Vol.
373:52-60, 2008; or radioimmunoassay (RIA)), or by a surface
plasmon resonance assay or other mechanism of kinetics-based assay
(e.g., BIACORE.TM.. analysis or Octet.TM. analysis (forteBIO)), and
other methods such as indirect binding assays, competitive binding
assays fluorescence resonance energy transfer (FRET), gel
electrophoresis and chromatography (e.g., gel filtration). These
and other methods may utilize a label on one or more of the
components being examined and/or employ a variety of detection
methods including but not limited to chromogenic, fluorescent,
luminescent, or isotopic labels. A detailed description of binding
affinities and kinetics can be found in Paul, W. E., ed.,
Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia
(1999), which focuses on antibody-immunogen interactions. One
example of a competitive binding assay is a radioimmunoassay
comprising the incubation of labeled antigen with the antibody of
interest in the presence of increasing amounts of unlabeled
antigen, and the detection of the antibody bound to the labeled
antigen. The affinity of the antibody of interest for a particular
antigen and the binding off-rates can be determined from the data
by scatchard plot analysis. Competition with a second antibody can
also be determined using radioimmunoassays. In this case, the
antigen is incubated with antibody of interest conjugated to a
labeled compound in the presence of increasing amounts of an
unlabeled second antibody.
[0420] Antibodies may be further engineered to further modulate
antibody half-life by introducing additional Fc mutations, such as
those described for example in (Dall'Acqua et al. (2006) J Biol
Chem 281: 23514-24), (Zalevsky et al. (2010) Nat Biotechnol 28:
157-9), (Hinton et al. (2004) J Biol Chem 279: 6213-6), (Hinton et
al. (2006) J Immunol 176: 346-56), (Shields et al. (2001) J Biol
Chem 276: 6591-604), (Petkova et al. (2006) Int Immunol 18:
1759-69), (Datta-Mannan et al. (2007) Drug Metab Dispos 35: 86-94),
(Vaccaro et al. (2005) Nat Biotechnol 23: 1283-8), (Yeung et al.
(2010) Cancer Res 70: 3269-77) and (Kim et al. (1999) Eur J Immunol
29: 2819-25), and include positions 250, 252, 253, 254, 256, 257,
307, 376, 380, 428, 434 and 435. Exemplary mutations that may be
made singularly or in combination are T250Q, M252Y,
1253A,S254T,T256E, P2571, T307A, D376V, E380A, M428L, H433K, N434S,
N434A, N434H, N434F, H435A and H435R mutations.
[0421] Thus, in one embodiment, the Fc region comprises a mutation
resulting in a decrease in half life. An antibody having a short
half life may be advantageous in certain instances where the
antibody is expected to function as a short-lived therapeutic,
e.g., the conditioning step described herein where the antibody is
administered followed by HSCs. Ideally, the antibody would be
substantially cleared prior to delivery of the HSCs, which also
generally express an antigen targeted by an ADC described herein,
e.g., CD117, but are not the target of the ADC, unlike the
endogenous stem cells. In one embodiment, the Fc regions comprise a
mutation at position 435 (EU index according to Kabat). In one
embodiment, the mutation is an H435A mutation.
[0422] In one embodiment, the antibody described herein has a half
life of equal to or less than 24 hours, a half life of equal to or
less than 22 hours, a half life of equal to or less than 20 hours,
a half life of equal to or less than 18 hours, a half life of equal
to or less than 16 hours, a half life of equal to or less than 14
hours, equal to or less than 13 hours, equal to or less than 12
hours, or equal to or less than 11 hours. In one embodiment, the
half life of the antibody is 11 hours to 24 hours; 12 hours to 22
hours; 10 hours to 20 hours; 8 hours to 18 hours; or 14 hours to 24
hours.
[0423] In some aspects, the Fc region comprises two or more
mutations that confer reduced half-life and greatly diminish or
completely abolish an effector function of the antibody. In some
embodiments, the Fc region comprises a mutation resulting in a
decrease in half-life and a mutation of at least one residue that
can make direct contact with an Fc.gamma.R (e.g., as based on
structural and crystallographic analysis). In one embodiment, the
Fc region comprises a H435A mutation, a L234A mutation, and a L235A
mutation. In one embodiment, the Fc region comprises a H435A
mutation and a D265C mutation. In one embodiment, the Fc region
comprises a H435A mutation, a L234A mutation, a L235A mutation, and
a D265C mutation.
[0424] In some embodiments, the antibody or antigen-binding
fragment thereof is conjugated to a cytotoxin (e.g., amatoxin) by
way of a cysteine residue in the Fc domain of the antibody or
antigen-binding fragment thereof. In some embodiments, the cysteine
residue is introduced by way of a mutation in the Fc domain of the
antibody or antigen-binding fragment thereof. For instance, the
cysteine residue may be selected from the group consisting of
Cys118, Cys239, and Cys265. In one embodiment, the Fc region of the
anti-CD117 antibody (or fragment thereof) comprises an amino acid
substitution at amino acid 265 according to the EU index as in
Kabat. In one embodiment, the Fc region comprises a D265C mutation.
In one embodiment, the Fc region comprises a D265C and H435A
mutation. In one embodiment, the Fc region comprises a D265C, a
L234A, and a L235A mutation. In one embodiment, the Fc region
comprises a D265C, a L234A, a L235A, and a H435A mutation.
[0425] In some embodiments of these aspects, the cysteine residue
is naturally occurring in the Fc domain of the antibody or
antigen-binding fragment thereof. For instance, the Fc domain may
be an IgG Fc domain, such as a human IgG1 Fc domain, and the
cysteine residue may be selected from the group consisting of
Cys261, Csy321, Cys367, and Cys425.
[0426] For example, in one embodiment, the Fc region of Antibody 67
is modified to comprise a D265C mutation (e.g., SEQ ID NO: 111). In
another embodiment, the Fc region of Antibody 67 is modified to
comprise a D265C, L234A, and L235A mutation (e.g., SEQ ID NO: 112).
In yet another embodiment, the Fc region of Antibody 67 is modified
to comprise a D265C and H435A mutation (e.g., SEQ ID NO: 113). In a
further embodiment, the Fc region of Antibody 67 is modified to
comprise a D265C, L234A, L235A, and H435A mutation (e.g., SEQ ID
NO: 114).
[0427] In regard to Antibody 55, in one embodiment, the Fc region
of Antibody 55 is modified to comprise a D265C mutation (e.g., SEQ
ID NO: 117). In another embodiment, the Fc region of Antibody 55 is
modified to comprise a D265C, L234A, and L235A mutation (e.g., SEQ
ID NO: 118). In yet another embodiment, the Fc region of Antibody
55 is modified to comprise a D265C and H435A mutation (e.g., SEQ ID
NO: 119). Ina further embodiment, the Fc region of Antibody 55 is
modified to comprise a D265C, L234A, L235A, and H435A mutation
(e.g., SEQ ID NO: 120).
[0428] The Fc regions of any one of Antibody 54, Antibody 55,
Antibody 56, Antibody 57, Antibody 58, Antibody 61, Antibody 66,
Antibody 67, Antibody 68, or Antibody 69 can be modified to
comprise a D265C mutation (e.g., as in SEQ ID NO: 123); a D265C,
L234A, and L235A mutation (e.g., as in SEQ ID NO: 124); a D265C and
H435A mutation (e.g., as in SEQ ID NO: 125); or a D265C, L234A,
L235A, and H435A mutation (e.g., as in SEQ ID NO: 126).
[0429] The variant Fc domains described herein are defined
according to the amino acid modifications that compose them. For
all amino acid substitutions discussed herein in regard to the Fc
region, numbering is always according to the EU index. Thus, for
example, D265C is an Fc variant with the aspartic acid (D) at EU
position 265 substituted with cysteine (C) relative to the parent
Fc domain. Likewise, e.g., D265C/L234A/L235A defines a variant Fc
variant with substitutions at EU positions 265 (D to C), 234 (L to
A), and 235 (L to A) relative to the parent Fc domain. A variant
can also be designated according to its final amino acid
composition in the mutated EU amino acid positions. For example,
the L234A/L235A mutant can be referred to as LALA. It is noted that
the order in which substitutions are provided is arbitrary.
[0430] In one embodiment, the antibody, or antigen binding fragment
thereof, comprises variable regions having an amino acid sequence
that is at least 95%, 96%, 97% or 99% identical to the SEQ ID Nos
disclosed herein. Alternatively, the antibody, or antigen binding
fragment thereof, comprises CDRs comprising the SEQ ID Nos
disclosed herein with framework regions of the variable regions
described herein having an amino acid sequence that is at least
95%, 96%, 97% or 99% identical to the SEQ ID Nos disclosed
herein.
[0431] In one embodiment, the antibody, or antigen binding fragment
thereof, comprises a heavy chain variable region and a heavy chain
constant region having an amino acid sequence that is disclosed
herein. In another embodiment, the antibody, or antigen binding
fragment thereof, comprises alight chain variable region and a
light chain constant region having an amino acid sequence that is
disclosed herein. In yet another embodiment, the antibody, or
antigen binding fragment thereof, comprises a heavy chain variable
region, a light chain variable region, a heavy chain constant
region and alight chain constant region having an amino acid
sequence that is disclosed herein.
Methods of Identifying Antibodies
[0432] Provided herein are novel ADCs that may be used, for
example, in conditioning methods for stem cell transplantation. In
view of the disclosure herein, other antibodies can be identified
that can be used in the ADCs and methods of the invention.
[0433] Methods for high throughput screening of antibody, or
antibody fragment libraries for molecules capable of binding a cell
surface antigen (e.g., CD117, CD45, CD2, CD5, CD134, CD252, CD137)
can be used to identify and affinity mature antibodies useful for
treating cancers, autoimmune diseases, and conditioning a patient
(e.g., a human patient) in need of hematopoietic stem cell therapy
as described herein. Such methods include in vitro display
techniques known in the art, such as phage display, bacterial
display, yeast display, mammalian cell display, ribosome display,
mRNA display, and cDNA display, among others. The use of phage
display to isolate ligands that bind biologically relevant
molecules has been reviewed, for example, in Felici et al.,
Biotechnol. Annual Rev. 1:149-183, 1995; Katz, Annual Rev. Biophys.
Biomol. Struct. 26:27-45, 1997; and Hoogenboom et al.,
Immunotechnology 4:1-20, 1998, the disclosures of each of which are
incorporated herein by reference as they pertain to in vitro
display techniques. Randomized combinatorial peptide libraries have
been constructed to select for polypeptides that bind cell surface
antigens as described in Kay, Perspect. Drug Discovery Des.
2:251-268, 1995 and Kay et al., Mol. Divers. 1:139-140, 1996, the
disclosures of each of which are incorporated herein by reference
as they pertain to the discovery of antigen-binding molecules.
Proteins, such as multimeric proteins, have been successfully
phage-displayed as functional molecules (see, for example, EP
0349578; EP 4527839; and EP 0589877, as well as Chiswell and
McCafferty, Trends Biotechnol. 10:80-84 1992, the disclosures of
each of which are incorporated herein by reference as they pertain
to the use of in vitro display techniques for the discovery of
antigen-binding molecules). In addition, functional antibody
fragments, such as Fab and scFv fragments, have been expressed in
in vitro display formats (see, for example, McCafferty et al.,
Nature 348:552-554, 1990; Barbas et al., Proc. Natl. Acad. Sci. USA
88:7978-7982, 1991; and Clackson et al., Nature 352:624-628, 1991,
the disclosures of each of which are incorporated herein by
reference as they pertain to in vitro display platforms for the
discovery of antigen-binding molecules). These techniques, among
others, can be used to identify and improve the affinity of
antibodies that bind, e.g., CD117, CD45, CD2, CD5, CD134, CD252,
CD137 (e.g., GNNK+ CD117) that can in turn be used to deplete
endogenous hematopoietic stem cells in a patient (e.g., a human
patient) in need of hematopoietic stem cell transplant therapy.
[0434] In addition to in vitro display techniques, computational
modeling techniques can be used to design and identify antibodies,
and antibody fragments, in silico that bind a cell surface antigen
(e.g., CD117, CD45, CD2, CD5, CD134, CD252, CD137). For example,
using computational modeling techniques, one of skill in the art
can screen libraries of antibodies, and antibody fragments, in
silico for molecules capable of binding specific epitopes, such as
extracellular epitopes of this antigen. The antibodies, and
antigen-binding fragments thereof, identified by these
computational techniques can be used in conjunction with the
therapeutic methods described herein, such as the cancer and
autoimmune disease treatment methods described herein and the
patient conditioning procedures described herein.
[0435] Additional techniques can be used to identify antibodies,
and antigen-binding fragments thereof, that bind a cell surface
antigen (e.g., CD117) on the surface of a cell (e.g., a cancer
cell, autoimmune cell, or hematopoietic stem cell) and that are
internalized by the cell, for instance, by receptor-mediated
endocytosis. For example, the in vitro display techniques described
above can be adapted to screen for antibodies, and antigen-binding
fragments thereof, that bind a cell surface antigen (e.g., CD117)
on the surface of a cancer cell, autoimmune cell, or hematopoietic
stem cell and that are subsequently internalized. Phage display
represents one such technique that can be used in conjunction with
this screening paradigm. To identify antibodies, and fragments
thereof, that bind a cell surface antigen (e.g., CD117) and are
subsequently internalized by cancer cells, autoimmune cells, or
hematopoietic stem cells, one of skill in the art can adapt the
phage display techniques described, for example, in Williams et
al., Leukemia 19:1432-1438, 2005, the disclosure of which is
incorporated herein by reference in its entirety. For example,
using mutagenesis methods known in the art, recombinant phage
libraries can be produced that encode antibodies, antibody
fragments, such as scFv fragments, Fab fragments, diabodies,
triabodies, and .sup.10Fn3 domains, among others, or ligands that
contain randomized amino acid cassettes (e.g., in one or more, or
all, of the CDRs or equivalent regions thereof or an antibody or
antibody fragment). The framework regions, hinge, Fc domain, and
other regions of the antibodies or antibody fragments may be
designed such that they are non-immunogenic in humans, for
instance, by virtue of having human germline antibody sequences or
sequences that exhibit only minor variations relative to human
germline antibodies.
[0436] Using phage display techniques described herein or known in
the art, phage libraries containing randomized antibodies, or
antibody fragments, covalently bound to the phage particles can be
incubated with a cell surface target antigen (e.g., CD117) antigen,
for instance, by first incubating the phage library with blocking
agents (such as, for instance, milk protein, bovine serum albumin,
and/or IgG so as to remove phage encoding antibodies, or fragments
thereof, that exhibit non-specific protein binding and phage that
encode antibodies or fragments thereof that bind Fc domains, and
then incubating the phage library with a population of
hematopoietic stem cells. The phage library can be incubated with
the target cells, such as cancer cells, autoimmune cells, or
hematopoietic stem cells for a time sufficient to allow cell
surface antigen specific antibodies, or antigen-binding fragments
thereof, (e.g., CD117-specific antibodies, or antigen-binding
fragments thereof) to bind cell-surface antigen (e.g., sell-surface
CD117) antigen and to subsequently be internalized by the cancer
cells, autoimmune cells, or hematopoietic stem cells (e.g., from 30
minutes to 6 hours at 4.degree. C., such as 1 hour at 4.degree.
C.). Phage containing antibodies, or fragments thereof, that do not
exhibit sufficient affinity for one or more of these antigens so as
to permit binding to, and internalization by, cancer cells,
autoimmune cells, or hematopoietic stem cells can subsequently be
removed by washing the cells, for instance, with cold (4.degree.
C.) 0.1 M glycine buffer at pH 2.8. Phage bound to antibodies, or
fragments thereof, that have been internalized by the cancer cells,
autoimmune cells, or hematopoietic stem cells can be identified,
for instance, by lysing the cells and recovering internalized phage
from the cell culture medium. The phage can then be amplified in
bacterial cells, for example, by incubating bacterial cells with
recovered phage in 2.times.YT medium using methods known in the
art. Phage recovered from this medium can then be characterized,
for instance, by determining the nucleic acid sequence of the
gene(s) encoding the antibodies, or fragments thereof, inserted
within the phage genome. The encoded antibodies, or fragments
thereof, can subsequently be prepared de novo by chemical synthesis
(for instance, of antibody fragments, such as scFv fragments) or by
recombinant expression (for instance, of full-length
antibodies).
[0437] An exemplary method for in vitro evolution of a cell surface
antigen antibody (e.g., anti-CD117) antibodies for use with the
compositions and methods described herein is phage display. Phage
display libraries can be created by making a designed series of
mutations or variations within a coding sequence for the CDRs of an
antibody or the analogous regions of an antibody-like scaffold
(e.g., the BC, CD, and DE loops of .sup.10Fn3 domains). The
template antibody-encoding sequence into which these mutations are
introduced may be, for example, a naive human germline sequence.
These mutations can be performed using standard mutagenesis
techniques known in the art. Each mutant sequence thus encodes an
antibody corresponding to the template save for one or more amino
acid variations. Retroviral and phage display vectors can be
engineered using standard vector construction techniques known in
the art. P3 phage display vectors along with compatible protein
expression vectors can be used to generate phage display vectors
for antibody diversification.
[0438] The mutated DNA provides sequence diversity, and each
transformant phage displays one variant of the initial template
amino acid sequence encoded by the DNA, leading to a phage
population (library) displaying a vast number of different but
structurally related amino acid sequences. Due to the well-defined
structure of antibody hypervariable regions, the amino acid
variations introduced in a phage display screen are expected to
alter the binding properties of the binding peptide or domain
without significantly altering its overall molecular structure.
[0439] In a typical screen, a phage library may be contacted with
and allowed to bind one of the foregoing antigens or an epitope
thereof. To facilitate separation of binders and non-binders, it is
convenient to immobilize the target on a solid support. Phage
bearing a cell surface-binding moiety can form a complex with the
target on the solid support, whereas non-binding phage remain in
solution and can be washed away with excess buffer. Bound phage can
then liberated from the target by changing the buffer to an extreme
pH (pH 2 or pH 10), changing the ionic strength of the buffer,
adding denaturants, or other known means.
[0440] The recovered phage can then be amplified through infection
of bacterial cells, and the screening process can be repeated with
the new pool that is now depleted in non-binding antibodies and
enriched for antibodies that bind a target antigen (e.g., CD117).
The recovery of even a few binding phage is sufficient to amplify
the phage for a subsequent iteration of screening. After a few
rounds of selection, the gene sequences encoding the antibodies or
antigen-binding fragments thereof derived from selected phage
clones in the binding pool are determined by conventional methods,
thus revealing the peptide sequence that imparts binding affinity
of the phage to the target. During the panning process, the
sequence diversity of the population diminishes with each round of
selection until desirable peptide-binding antibodies remain. The
sequences may converge on a small number of related antibodies or
antigen-binding fragments thereof. An increase in the number of
phage recovered at each round of selection is an indication that
convergence of the library has occurred in a screen.
[0441] Another method for identifying antibodies includes using
humanizing non-human antibodies that bind a cell surface target
antigen (e.g., CD117), for instance, according to the following
procedure. Consensus human antibody heavy chain and light chain
sequences are known in the art (see e.g., the "VBASE" human
germline sequence database; Kabat et al. Sequences of Proteins of
Immunological Interest, Fifth Edition, U.S. Department of Health
and Human Services, NIH Publication No. 91-3242, 1991; Tomlinson et
al., J. Mol. Biol. 227:776-798, 1992; and Cox et al. Eur. J.
Immunol. 24:827-836, 1994, the disclosures of each of which are
incorporated herein by reference as they pertain to consensus human
antibody heavy chain and light chain sequences. Using established
procedures, one of skill in the art can identify the variable
domain framework residues and CDRs of a consensus antibody sequence
(e.g., by sequence alignment). One can substitute one or more CDRs
of the heavy chain and/or light chain variable domains of consensus
human antibody with one or more corresponding CDRs of a non-human
antibody that binds a cell surface antigen (e.g., CD117) as
described herein in order to produce a humanized antibody. This CDR
exchange can be performed using gene editing techniques described
herein or known in the art.
[0442] To produce humanized antibodies, one can recombinantly
express a polynucleotide encoding the above consensus sequence in
which one or more variable region CDRs have been replaced with one
or more variable region CDR sequences of a non-human antibody that
binds a cell surface target antigen (e.g., CD117). As the affinity
of the antibody for the hematopoietic stem cell antigen is
determined primarily by the CDR sequences, the resulting humanized
antibody is expected to exhibit an affinity for the hematopoietic
stem cell antigen that is about the same as that of the non-human
antibody from which the humanized antibody was derived. Methods of
determining the affinity of an antibody for a target antigen
include, for instance, ELISA-based techniques described herein and
known in the art, as well as surface plasmon resonance,
fluorescence anisotropy, and isothermal titration calorimetry,
among others.
[0443] The internalizing capacity of an antibody, or fragment
thereof, can be assessed, for instance, using radionuclide
internalization assays known in the art. For example, antibodies,
or fragments thereof, identified using in vitro display techniques
described herein or known in the art can be functionalized by
incorporation of a radioactive isotope, such as .sup.18F,
.sup.75Br, .sup.77Br, .sup.122I, .sup.123I, .sup.124I, .sup.125I,
.sup.129I, .sup.131I, .sup.211At, .sup.67Ga, .sup.111In, .sup.99Tc,
.sup.169Yb, .sup.186Re, .sup.64Cu, .sup.67Cu, .sup.177Lu,
.sup.77As, .sup.72As, .sup.86Y, .sup.90Y, .sup.89Zr, .sup.212Bi,
.sup.213Bi, or .sup.225Ac. For instance, radioactive halogens, such
as .sup.18F, .sup.75Br, .sup.77Br, .sup.122I, .sup.123I, .sup.124I,
.sup.125I, .sup.129I, .sup.131I, .sup.211At, can be incorporated
into antibodies, or fragments thereof, using beads, such as
polystyrene beads, containing electrophilic halogen reagents (e.g.,
Iodination Beads, Thermo Fisher Scientific, Inc., Cambridge,
Mass.). Radiolabeled antibodies, or fragments thereof, can be
incubated with cancer cells, autoimmune cells, or hematopoietic
stem cells for a time sufficient to permit internalization (e.g.,
from 30 minutes to 6 hours at 4.degree. C., such as 1 hour at
4.degree. C.). The cells can then be washed to remove
non-internalized antibodies, or fragments thereof, (e.g., using
cold (4.degree. C.) 0.1 M glycine buffer at pH 2.8). Internalized
antibodies, or fragments thereof, can be identified by detecting
the emitted radiation (e.g., .gamma.-radiation) of the resulting
cancer cells, autoimmune cells, or hematopoietic stem cells in
comparison with the emitted radiation (e.g., .gamma.-radiation) of
the recovered wash buffer.
[0444] Antibodies may be produced using recombinant methods and
compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one
embodiment, isolated nucleic acid encoding an antibody described
herein is provided. Such nucleic acid may encode an amino acid
sequence comprising the VL and/or an amino acid sequence comprising
the VH of the antibody (e.g., the light and/or heavy chains of the
antibody). In a further embodiment, one or more vectors (e.g.,
expression vectors) comprising such nucleic acid are provided. In a
further embodiment, a host cell comprising such nucleic acid is
provided. In one such embodiment, a host cell comprises (e.g., has
been transformed with): (1) a vector comprising a nucleic acid that
encodes an amino acid sequence comprising the VL of the antibody
and an amino acid sequence comprising the VH of the antibody, or
(2) a first vector comprising a nucleic acid that encodes an amino
acid sequence comprising the VL of the antibody and a second vector
comprising a nucleic acid that encodes an amino acid sequence
comprising the VH of the antibody. In one embodiment, the host cell
is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid
cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of
making an anti-CLL-1 antibody is provided, wherein the method
comprises culturing a host cell comprising a nucleic acid encoding
the antibody, as provided above, under conditions suitable for
expression of the antibody, and optionally recovering the antibody
from the host cell (or host cell culture medium).
[0445] For recombinant production of an antibody, nucleic acid
encoding an antibody, e.g., as described above, is isolated and
inserted into one or more vectors for further cloning and/or
expression in a host cell. Such nucleic acid may be readily
isolated and sequenced using conventional procedures (e.g., by
using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of the
antibody).
[0446] Suitable host cells for cloning or expression of
antibody-encoding vectors include prokaryotic or eukaryotic cells
described herein. For example, antibodies may be produced in
bacteria, in particular when glycosylation and Fc effector function
are not needed. For expression of antibody fragments and
polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237,
5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular
Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.,
2003), pp. 245-254, describing expression of antibody fragments in
E. coli.) After expression, the antibody may be isolated from the
bacterial cell paste in a soluble fraction and can be further
purified.
[0447] Vertebrate cells may also be used as hosts. For example,
mammalian cell lines that are adapted to grow in suspension may be
useful. Other examples of useful mammalian host cell lines are
monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic
kidney line (293 or 293 cells as described, e.g., in Graham et al.,
J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse
sertoli cells (TM4 cells as described, e.g., in Mather, Biol.
Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African
green monkey kidney cells (VERO-76); human cervical carcinoma cells
(HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL
3A); human lung cells (W138); human liver cells (Hep G2); mouse
mammary tumor (MMT 060562); TRI cells, as described, e.g., in
Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5
cells; and FS4 cells. Other useful mammalian host cell lines
include Chinese hamster ovary (CHO) cells, including DHFR- CHO
cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980));
and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of
certain mammalian host cell lines suitable for antibody production,
see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248
(B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268
(2003).
Pharmaceutical Compositions
[0448] ADCs described herein can be administered to a patient
(e.g., a human patient suffering from an immune disease or cancer)
in a variety of dosage forms. For instance, ADCs described herein
can be administered to a patient suffering from an immune disease
or cancer in the form of an aqueous solution, such as an aqueous
solution containing one or more pharmaceutically acceptable
excipients. Suitable pharmaceutically acceptable excipients for use
with the compositions and methods described herein include
viscosity-modifying agents. The aqueous solution may be sterilized
using techniques known in the art.
[0449] Pharmaceutical formulations comprising ADCs as described
herein are prepared by mixing such ADC with one or more optional
pharmaceutically acceptable carriers (Remington's Pharmaceutical
Sciences 16th edition, Osol, A. Ed. (1980)), in the form of
lyophilized formulations or aqueous solutions. Pharmaceutically
acceptable carriers are generally nontoxic to recipients at the
dosages and concentrations employed, and include, but are not
limited to: buffers such as phosphate, citrate, and other organic
acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride; benzethonium
chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol;
3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g. Zn-protein complexes); and/or
non-ionic surfactants such as polyethylene glycol (PEG).
Methods of Use
[0450] ADCs described herein may be administered by a variety of
routes, such as orally, transdermally, subcutaneously,
intranasally, intravenously, intramuscularly, intraocularly, or
parenterally. The most suitable route for administration in any
given case will depend on the particular antibody, or
antigen-binding fragment, administered, the patient, pharmaceutical
formulation methods, administration methods (e.g., administration
time and administration route), the patient's age, body weight,
sex, severity of the diseases being treated, the patient's diet,
and the patient's excretion rate.
[0451] The effective dose of an ADC, antibody, or antigen-binding
fragment thereof, described herein can range, for example from
about 0.001 to about 100 mg/kg of body weight per single (e.g.,
bolus) administration, multiple administrations, or continuous
administration, or to achieve an optimal serum concentration (e.g.,
a serum concentration of 0.0001-5000 .mu.g/mL) of the antibody,
antigen-binding fragment thereof. The dose may be administered one
or more times (e.g., 2-10 times) per day, week, or month to a
subject (e.g., a human) suffering from cancer, an autoimmune
disease, or undergoing conditioning therapy in preparation for
receipt of a hematopoietic stem cell transplant. In the case of a
conditioning procedure prior to hematopoietic stem cell
transplantation, the ADC, antibody, or antigen-binding fragment
thereof, can be administered to the patient at a time that
optimally promotes engraftment of the exogenous hematopoietic stem
cells, for instance, from 1 hour to 1 week (e.g., about 1 hour,
about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6
hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours,
about 11 hours, about 12 hours, about 13 hours, about 14 hours,
about 15 hours, about 16 hours, about 17 hours, about 18 hours,
about 19 hours, about 20 hours, about 21 hours, about 22 hours,
about 23 hours, about 24 hours, about 2 days, about 3 days, about 4
days, about 5 days, about 6 days, or about 7 days) or more prior to
administration of the exogenous hematopoietic stem cell
transplant.
EXAMPLES
[0452] The following examples are put forth so as to provide those
of ordinary skill in the art with a description of how the
compositions and methods described herein may be used, made, and
evaluated, and are intended to be purely exemplary of the invention
and are not intended to limit the scope of what the inventors
regard as their invention.
Example 1: Comparative Study of Amatoxins
[0453] Three different amanitins were tested in parallel to
determine their kinetics and tolerability as toxins. FIG. 1
provides the structures of three amanitin/linker conjugates. FIG.
1A provides an amanitin/linker conjugate represented by Formula
(IV) (also referred to as "Conjugate A" or "ADC A"), where the
amanitin has a cleavable linker (BMP-Val-Ala-PAB) linker on AA1
(Asn). The amanitin in Formula (IV) is based on amatoxin having
thiotryptophan moiety. FIG. 1B provides an amanitin/linker
conjugate represented by Formula (VI) (also referred to as
"Conjugate B" or "ADC B", where the amanitin is conjugated to a
non-cleavable linker on indole 6' oxygen. The amanitin described in
Formula (VI) is based on amatoxin having 6-hydroxy-tryptophan
sulfoxide moiety. FIG. 1C provides an amanitin/linker conjugate
described herein in Formula (IIa) (also referred to as "Conjugate
C" or "ADC C", including a non-cleavable linker on indole 6'
oxygen, where the amanitin is based on amatoxin having
6-hydroxy-thiotryptophan moiety.
[0454] Conjugates A, B and C were tested in parallel for their
potency on CD117 expressing cells with or without a pre-incubation
in human serum. ADC A, B, and C were either pre-incubated in cell
culture media without human serum or 50% human serum at 37 C for 48
hours. The titrated ADC was then added to Kasumi-1 cells and
incubated for 3 days at 37 C and cell killing was determined using
CellTiter-Go. As described in FIG. 2, in the absence of serum
incubation, cleavable Conjugate A and non-cleavable Conjugate C
reached similar efficacy by day 3, with non-cleavable conjugate B
demonstrating reduced maximum killing at higher concentrations.
Each ADC conjugate demonstrated picomolar IC50 killing. When ADC
was pre-incubated for 48 hours in the presence of human serum,
potency was significantly decreased for non-cleavable conjugate B
but was maintained for cleavable conjugate A and non-cleavable
conjugate C. Thus, cleavable and non-cleavable conjugates A and C
were serum stable while non-cleavable conjugate B was inactivated
in the presence of human serum as measured by in vitro
cytotoxicity.
[0455] To determine differences in the kinetics of ADC-mediated
cytotoxicity, Kasumi-1 cells were incubated with titrations of
cleavable conjugate A or non-cleavable conjugate C for 3-7 days at
37 C and cell viability was measured on day 3, 4, 5, 6, and 7 by
CellTiter-Glo. As shown in FIG. 3, significant differences were
observed in maximum cell killing at high concentrations for
cleavable and non-cleavable ADC. When cells were incubated for a
total of 6 days at 37 C with ADC, both cleavable conjugate A and
non-cleavable conjugate C were able to achieve nearly complete cell
killing at high concentrations. Killing of greater than 80% of
Kasumi-1 cells in culture with 160 pM non-cleavable conjugate C
could only be achieved after incubation of Kasumi-1 cells for 5
days or longer, while a similar threshold was achieved for
cleavable conjugate A after 3 days or longer incubation.
[0456] In sum, the enzyme cleavable amanitin of FIG. 1A (Conjugate
A) and the non-cleavable amanitin (conjugate C in FIG. 1C) showed
long term stability in serum, while amanitin/linker B showed
instability and inactivation in serum. Non-cleavable conjugate C
demonstrated extended kinetics of cytotoxicity as measured in an in
vitro assay compared to a similar cleavable amanitin conjugate
(conjugate A).
Example 2: Anti-CD117 ADC Demonstrates Potent Killing of AML Cells
and Human CD34+ Cells In Vitro, Selectively Depletes Human CD34+
Cells in Humanized Mice, and Demonstrates Anti-AML Activity in
Xenograft Models
[0457] An anti-CD117 antibody (Ab85 having Fc modifications L234A,
L235A, D265C, and H435A) was conjugated to Conjugate C forming
anti-CD117 ADC C. Anti-CD117 ADC C was tested both in vitro and in
vivo for its ability to target and kill cells expressing CD117 and
human HSCs.
[0458] Two in vitro assays were performed using anti-CD117 ADC C.
The first tested the ability of the ADC to kill Kasumi-1 cells (an
AML cell line), which express human CD117. As described in FIG. 4A,
Anti-CD117 ADC C (referred to as "Anti-CD117-AM" in FIG. 4A) was
titrated and incubated with Kasumi-1 cells for 6 days at 37 C and
viability was assessed by CellTiter-Glo. The control was a
non-specific isotype matched ADC C. Non-cleavable conjugate C
demonstrated potent killing of Kasumi-1 cells with an IC50 of 6.4
pM. In FIG. 4B, a similar cytotoxicity assay using Human CD34+ bone
marrow cells collected was performed. Human CD34+ bone marrow cells
were incubated with non-cleavable conjugate C or a corresponding
isotype control ADC for 6 days. Cell killing was determined by flow
cytometry. The non-cleavable conjugate C demonstrated potent
killing of primary human CD34+ CD90+ cells with an IC50 of 5.1
pM.
[0459] An in vivo assay was also performed to test the ability of
anti-CD117 ADC C to selectively deplete human CD34+ cells. A single
dose of 0.1, 0.3, or 1.0 mg/kg of the anti-CD117 ADC C was
administered to humanized NSG mice. Controls consisted of a 1 mg/kg
dose of the unconjugated antibody that comprised part of
non-cleavable conjugate C and vehicle (PBS) treatment. At Day 21,
the number of human CD34+ cells were determined by flow cytometry
analysis of bone marrow collected from the femur of treated
humanized NSG mice. As described in FIG. 5, anti-CD117 ADC C was
able to potently deplete human CD34+ cells, achieving greater than
95% depletion compared to PBS for both 0.3 and 1 mg/kg doses. The
unconjugated antibody demonstrated no depletion as compared to
vehicle control.
[0460] To assess in vivo anti-tumor activity of ADCs, humanized NSG
mice were implanted with Kasumi-1 cells and then treated with
vehicle, 30 mg/kg QD.times.5 cytarabine (ARA-C), cleavable
conjugate A (1 mg/kg 1.times., 1 mg/kg QOD.times.2) or 10 mg/kg
isotype conjugated to cleavable amanitin (FIG. 1A). In addition,
Kasumi-1 implanted mice were treated with non-cleavable conjugate C
(1 mg/kg 1.times., 3 mg/kg 1.times., 10 mg/kg 1.times.) or 10 mg/kg
isotype conjugated to non-cleavable amanitin (FIG. 1C).
Kaplan-Meier curves demonstrating survival of animals treated as
indicated is depicted in FIG. 6. Kasumi-1 implanted mice treated
with cleavable conjugate A demonstrate median survival above 50% at
day 130 for groups treated with either 1 mg/kg or 1 mg/kg
QOD.times.2 in comparison to isotype, ARA-C, or vehicle treated
animals. Mice treated with either 3 mg/kg or 10 mg/kg non-cleavable
conjugate C demonstrate full survival at day 130 in comparison to
isotype, ARA-C, 1 mg/kg non-cleavable conjugate C, or vehicle
treated animals.
[0461] In summary, non-cleavable conjugate C demonstrates potent in
vitro cell killing of Kasumi-1 cells, an AML cell line, and primary
human CD34+ CD90+ bone marrow cells. Conjugate C is capable of
depleting more than 95% of human CD34+ cells from the bone marrow
of humanized NSG mice. Both cleavable and non-cleavable conjugates
demonstrated potent anti-tumor activity in vivo.
Example 3: Efficacy and Tolerability of ADC C in Non-Human Primates
(NHPs)
[0462] To determine the efficacy of non-cleavable conjugate C in
non-human primates, male cynomologus monkeys were treated with a
single dose of non-cleavable conjugate C at 0.5, 1.0, and 2.0
mg/kg. The 0.5 and 1.0 mg/kg doses were with Ab85 with the
following Fc modifications: D265C H435A (EU numbering) conjugated
to non-cleavable amanitin C (FIG. 1C). The 2.0 mg/kg dose comprised
Ab85 with the following Fc modifications: L234A L235A D265C H435A
(EU numbering) conjugated to non-cleavable amanitin C (FIG. 1C).
Bone marrow aspirates were collected from treated animals on day 7
and efficacy was assessed by quantitation of CD34+ CD90+ CD45RA-
populations by flow cytometry. Significant depletion was observed
at 0.5 and 1.0 mg/kg doses (FIG. 7). Peripheral blood samples were
collected throughout the course of the 28 day study. Reticulocyte
counts of animals treated at 0.5, 1.0, and 2.0 mg/kg decreased
significantly beginning on day 2 with reticulocyte rebound
occurring in a dose-dependent manner (FIG. 7). This is expected
on-target pharmacology as reticulocytes are short-lived and
progenitor populations in this hematopoietic lineage strongly
express CD117. Neutrophil depletion was observed beginning on day
18 for all treatment groups (FIG. 7). This is also expected
on-target pharmacology, as neutrophils are dependent on
hematopoietic stem cell differentiation for regeneration.
[0463] In addition to efficacy, tolerability of ADCs containing
either anti-CD117 ADC A or anti-CD117 ADC C were tested in NHPs. As
described in FIG. 8, treatment of cynomologus monkeys with a 0.3
mg/kg dose of cleavable conjugate A conjugated to antibody CK6 (Fc
modifications D265C and H435A) resulted in mild transient and
reversible elevation of aspartate aminotransferase (AST) levels,
with no elevation above normal range for alanine aminotransferase
(ALT), lactate dehydrogenase (LDH), or total bilirubin (TBIL) over
the course of the study. Treatment of animals with a 0.6 mg/kg dose
of conjugate A resulted in more significant elevation of AST, ALT,
LDH, and TBIL.
[0464] In cynomolgus monkeys treated with 0.5 and 1.0 mg/kg
non-cleavable conjugate C, Ab85 with the following Fc
modifications: D265C H435A (EU numbering) conjugated to
non-cleavable amanitin C (FIG. 1C), demonstrated mild transient and
reversible elevation in AST with no elevation above normal range
for ALT, LDH, and TBIL throughout the course of the study. In
animals treated with 2.0 mg/kg non-cleavable conjugate C, Ab85 with
the following Fc modifications: L234A L235A D265C H435A (EU
numbering) conjugated to non-cleavable amanitin C (FIG. 1C), more
significant elevation was observed for AST and ALT. Results are
described in FIG. 8.
[0465] Pharmacokinetic characteristics were also studied in
anti-CD117 ADC A vs. C. As described in FIG. 9, well tolerated
doses of ADC conjugate C achieved saturating explosures in NHPs
compared to ADC Conjugate A. Pharmacokinetic data was also analyzed
for ADC conjugate C with various Fc mutations. For both anti-CD117
ADC A and anti-CD117 ADC C, ex vivo cytotoxicity assays revealed
that for boths ADCs there was a loss of efficacy at plasma
concentrations below 100 ng/ml (data not shown).
[0466] In sum, anti-CD117 ADC C demonstrated efficacy at doses as
low as 0.5 mg/kg and was tolerated at a single dose of 2.0 mg/kg in
cynomologus monkeys while the cleavable conjugate A was efficacious
at a dose as low as 0.3 mg/kg but not tolerated at a single dose of
0.6 mg/kg supporting the finding that non-cleavable amanitin (FIG.
1C) is better tolerated.
Example 4: Primary Human T-Cell Killing with Anti-CD2 ADC C and
Anti-CD5 ADC C
[0467] A study was performed to determine if anti-CD2 and anti-CD5
D265C H435A antibodies used in an ADC C (as described above and in
FIG. 1) was as efficacious as Conjugate A for killing primary T
cells. Thus, an in vitro cell killing assay was used. The protocol
of the study is provided below:
TABLE-US-00011 General Protocol T cell killing assay: 384 well
format Coat plate with 0.5 mg/mL anti-CD3 incubate in 37 C. for 2
hours in TC treated low flange 384 well plate Wash plate Thaw
primary T cells with AIM-V media Plate 2500 cells per well + 20 ng
recombinant human IL-2 Titrate antibodies and add to cells in
duplicate for 30 min on ice Culture for in 37.degree. C. for 5 days
On day 5, stain cells for CD3, Live/Dead marker for 30 min, using
Viaflo aspirate volume and add PBS Run cells on Celesta Readout:
viability, CD2 and CD5 expression by flow
[0468] Anti-CD2 ADCs A and C included anti-CD2 antibody RPA with FC
modifications D265C/H435A. Naked RPA was used as a control.
Anti-CD5 ADCs A and C included anti-CD5 antibody 5D7 with Fc
modifications D265/H435A. Naked 5D7 was used as a control. As
described in FIG. 10, Conjugate C demonstrated T cell depletion
comparable to Conjugate A. Effiicacy results are also provide in
the table below.
TABLE-US-00012 IC50 % Label DAR (pM) Efficacy Ab85 D265C/H435A ADC
A 1.9 -- 0.9 CD2 RPA naked -- -- 0.0 CD2 RPA2.10 D265C/H435A ADC A
2.1 54.0 85.7 CD2 RPA2.10 D265C/H435A ADC C 2.1 86.9 78.7 CD5 5D7
naked -- -- 0.0 CD5 5D7 D265C/H435A ADC A 2 22.1 89.4 CD5 5D7
D265C/H435A Ab ADC C 2.0 50.8 84.9
[0469] FIG. 11 provides results showing that CD2 is saturated by
day 5, whereas some cells still express CD5.
[0470] The results above and in FIGS. 10 and 11 show that both
anti-CD2 and anti-CD5 ADCs C (D265C H435A) were as efficacious as
Conjugate A on primary human T-cells in vitro.
Example 5: Efficacy of Anti-CD45 ADC C
[0471] In addition to CD2, CD5, and CD117, Conjugate C was tested
in comparison to Conjugate A in the context of anti-CD45
antibodies. A chimeric anti-CD45 antibody 3D6 was used in the below
experiments (murine 3D6 variable regions and a human IgG1 framework
with Fc modifications D265C and H435A).
[0472] An in vitro cell killing assay was performed comparing
anti-CD45 ADC A and anti-CD45 ADC C. As described in FIG. 12A, both
ADCs A and C were able to kill human bone marrow CD34+ cells, as
well as PBMC. An isotype negative control was also tested. As
described in the Table presented in FIG. 12A, both anti-CD45 ADCs A
and C were effective at killing CD34+ bone marrow and PBMC cells.
This assay was repeated with anti-CD45 ADC A and B, As described in
FIG. 12B, anti-CD45 ADC A showed a higher efficiency for killing
CD34+ bone marrow cells vs. anti-CD45 ADC B. Both molecules were
effective in a similar manner at killing human and cyno PBMCs.
[0473] A second in vitro cell killing assay was also performed
using anti-CD45 ADCs A and C looking at the ability of each ADC to
kill cells expressing either SKNO-1 or REH. The results are
provided in FIG. 13 (left panel are the number of live SKNO-1 cells
following exposure to anti-CD45 ADC A or C; right panel are the
number of live REH cells following exposure to anti-CD45 ADC A or
C). The efficiency of each molecule in these assays is described in
the table in FIG. 13.
[0474] Anti-CD45 ADCs A and C were further tested for the ability
of each ADC to deplete CD45+ cells in vivo. Both ADC A (cleavable)
and ADC C (non-cleavable) were able to deplete CD45+ cells
efficiently in a humanized NSG mouse model. The results of the
study are provided in FIG. 14. As described in FIG. 14, both ADCs
were able to deplete peripheral CD45+ cells as well as bone marrow
(BM) CD34+ cells. The maximum total dose in the mice for anti-CD45
ADC A was 3 mg/kg, whereas a much higher dose of ADC C was
tolerated for anti-CD45 ADC C at more than 51 mg/kg. Thus, efficacy
was observed for both anti-CD45 ADCs, but the ADC C was tolerated
by the mice at higher doses.
[0475] Anti-CD45 ADCs A and C were also tested for their ability to
deplete peripheral lymphocytes, bone marrow (BM) HSCs and
lymphocytes in humanized NSG mice. Anti-CD45 ADCs A and C were each
delivered at a dose of 1 mg/kg to the mice. The results from these
studies are described in FIG. 15 and show that anti-CD45 ADCs A and
C had comparable depletion of peripheral lymphocytes, HSCs, and BM
lymphocytes at day 7 post injection at 1 mg/kg. Anti-CD45 ADC A
showed mild, transient reversible liver enzyme elevation at 1
mg/kg, while little to no liver enzyme elevation was observed with
anti-CD45 ADC C with the same 1 mg/kg dose.
Example 6: Anti-CD137 ADC A and C Characterization
[0476] Anti-CD137 ADC A and ADC C were tested for their ability to
kill T cells, as well as for serum stability. Anti-CD137 antibody
BBK2 was used in this example. An in vitro T cell killing assay was
performed, where the results shown in FIG. 16 demonstrated both
anti-CD137 ADC A and C were able to kill activated T cells in
comparison to the isotype ADC A and C control. In addition, cell
line serum stability was tested for both anti-CD137 ADC A and C
over 48 hours, as described in FIG. 17.
Example 7: Synthesis of S-desoxy-5'-hydroxy-amaninamide
[0477] The ADCs of formula (IIa) as disclosed herein were prepared
from the corresponding linker-amatoxin conjugates according to
standard methods known to one of skill in the art. The penultimate
amatoxin-linker conjugate to the ADCs of formula (IIa) (compound
14; Scheme 3) may be prepared from amatoxin derivative 11 following
the general procedure for O-alkylation of the related amatoxin
(.alpha.-amanitin) disclosed in U.S. Patent Application Publication
No. 2018/0043033, the disclosure of which is incorporated by
reference herein in its entirety. Amatoxin derivative 11 may be
prepared according to the procedures disclosed in International
Patent Application Publication No. WO2019/030173, the disclosure of
which is incorporated by reference herein in its entirety. Compound
7 (Scheme 1) may be prepared according to the methods reported in
International Patent Application Publication No. WO2014/009025, the
disclosure of which is incorporated herein in its entirety.
TABLE-US-00013 SEQUENCE TABLE Sequence Identifier Description
Sequence SEQ ID NO: 1 CK6 CDR-H1 SYWIG SEQ ID NO: 2 CK6 CDR-H2
IIYPGDSDTRYSPSFQG SEQ ID NO: 3 CK6 CDR-H3 HGRGYNGYEGAFDI SEQ ID NO:
4 CK6 CDR-L1 RASQGISSALA SEQ ID NO: 5 CK6 CDR-L2 DASSLES SEQ ID NO:
6 CK6 CDR-L3 CQQFNSYPLT SEQ ID NO: 7 Consensus human
EVQLVESGGGLVQPGGSLRLSCAASGFTFSD Ab YAMSWVRQAPGKGLEWVAVISENGSDTYYA
Heavy chain variable DSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV domain
YYCARDRGGAVSYFDVWGQGTLVTVSS SEQ ID NO: 8 Consensus human
DIQMTQSPSSLSASVGDRVTITCRASQDVSSY Ab LAWYQQKPGKAPKLLIYAASSLESGVPSRFS
Light chain variable GSGSGTDFTLTISSLQPEDFATYYCQQYNSLP domain
YTFGQGTKVEIKRT SEQ ID NO: 9 Ab67 Heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSD variable region (e.g.,
ADMDWVRQAPGKGLEWVGRTRNKAGSYTTE as found in HC-67)
YAASVKGRFTISRDDSKNSLYLQMNSLKTEDT (CDRs in bold)
AVYYCAREPKYWIDFDLWGRGTLVTVSS SEQ ID NO: 10 Ab67 Light chain
DIQMTQSPSSLSASVGDRVTITCRASQSISSYL variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-67)
GSGTDFILTISSLOPEDFATYYCQQSYIAPYT (CDRs in bold) FGGGTKVEIK SEQ ID
NO: 11 Ab67 CDR-H1 FTFSDADMD SEQ ID NO: 12 Ab67 CDR-H2
RTRNKAGSYTTEYAASVKG SEQ ID NO: 13 Ab67 CDR-H3 AREPKYWIDFDL SEQ ID
NO: 14 Ab67 CDR-L1 RASQSISSYLN SEQ ID NO: 15 Ab67 CDR-L2 AASSLQS
SEQ ID NO: 16 Ab67 CDR-L3 QQSYIAPYT SEQ ID NO: 17 Ab67 Heavy chain
GAGGTGCAGCTGGTGGAGTCTGGGGGAGG variable region
CTTGGTCCAGCCTGGAGGGTCCCTGAGACT (nucl)
CTCCTGTGCAGCCTCTGGATTCACCTTCAGT GACGCCGACATGGACTGGGTCCGCCAGGC
TCCAGGGAAGGGGCTGGAGTGGGTTGGCC GTACTAGAAACAAAGCAGGAAGTTACACCAC
AGAATACGCCGCGTCTGTGAAAGGCAGATT CACCATCTCAAGAGATGATTCAAAGAACTCA
CTGTATCTGCAAATGAACAGCCTGAAAACCG AGGACACGGCGGTGTACTACTGCGCCAGAG
AGCCTAAATACTGGATCGACTTCGACCTATG GGGGAGAGGTACCTTGGTCACCGTCTCCTC A
SEQ ID NO: 18 Ab67 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC
variable region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAGC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAAGC TACATCGCCCCTTACACTTTTGGCGGAGGG
ACCAAGGTTGAGATCAAA SEQ ID NO: 19 Ab55 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFRI variable region (e.g.,
YAISWVRQAPGQGLEWMGGIIPDFGVANYAQ as found in HC-55)
KFQGRVTITADESTSTAYMELSSLRSEDTAVY (CDRs in bold)
YCARGGLDTDEFDLWGRGTLVTVSS SEQ ID NO: 20 Ab55 Light chain
DIQMTQSPSSLSASVGDRVTITCRASQSINSYL variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-55)
SGSGTDFTLTISSLQPEDFATYYCQQGVSDITF (CDRs in bold) GGGTKVEIK SEQ ID
NO: 21 Ab55 CDR-H1 GTFRIYAIS SEQ ID NO: 22 Ab55 CDR-H2
GIIPDFGVANYAQKFQG SEQ ID NO: 23 Ab55 CDR-H3 ARGGLDTDEFDL SEQ ID NO:
24 Ab55 CDR-L1 RASQSINSYLN SEQ ID NO: 25 Ab55 CDR-L2 AASSLQS SEQ ID
NO: 26 Ab55 CDR-L3 QQGVSDIT SEQ ID NO: 27 Ab55 Heavy chain
CAGGTGCAGCTGGTGCAGTCTGGGGCTGA variable region
GGTGAAGAAGCCTGGGTCCTCGGTGAAGGT (nucl)
CTCCTGCAAGGCTTCTGGAGGCACCTTCCG AATCTATGCTATCAGCTGGGTGCGACAGGC
CCCTGGACAAGGGCTTGAGTGGATGGGAG GGATCATCCCTGACTTCGGTGTAGCAAACTA
CGCACAGAAGTTCCAGGGCAGAGTCACGAT TACCGCGGACGAATCCACGAGCACAGCCTA
CATGGAGCTGAGCAGCCTGAGATCTGAGGA CACGGCGGTGTACTACTGCGCCAGAGGTGG
ATTGGACACAGACGAGTTCGACCTATGGGG GAGAGGTACCTTGGTCACCGTCTCCTCA SEQ ID
NO: 28 Ab55 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC variable
region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAAC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAGGA GTCAGTGACATCACTTTTGGCGGAGGGACC
AAGGTTGAGATCAAA SEQ ID NO: 29 Ab54 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSS variable region (e.g.,
YAISWVRQAPGQGLEWMGGIIPIFGTANYAQK as found in HC-54)
FQGRVTITADESTSTAYMELSSLRSEDTAVYY hIgG1 backbone
CARGGLDTDEFDLWGRGTLVTVSS (CDRs in bold) SEQ ID NO: 30 Ab54 Light
chain DIQMTQSPSSLSASVGDRVTITCRASQSINSYL variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-54)
GSGTDFTLTISSLQPEDFATYYCQQGVSDITF (CDRs in bold) GGGTKVEIK SEQ ID
NO: 31 Ab54 CDR-H1 GTFSSYAIS SEQ ID NO: 32 Ab54 CDR-H2
GIIPIFGTANYAQKFQG SEQ ID NO: 33 Ab54 CDR-H3 ARGGLDTDEFDL SEQ ID NO:
34 Ab54 CDR-L1 RASQSINSYLN SEQ ID NO: 35 Ab54 CDR-L2 AASSLQS SEQ ID
NO: 36 Ab54 CDR-L3 QQGVSDIT SEQ ID NO: 37 Ab54 Heavy chain
CAGGTGCAGCTGGTGCAGTCTGGGGCTGA variable region
GGTGAAGAAGCCTGGGTCCTCGGTGAAGGT (nucl)
CTCCTGCAAGGCTTCTGGAGGCACCTTCAG CAGCTATGCTATCAGCTGGGTGCGACAGGC
CCCTGGACAAGGGCTTGAGTGGATGGGAG GGATCATCCCTATCTTTGGTACAGCAAACTA
CGCACAGAAGTTCCAGGGCAGAGTCACGAT TACCGCGGACGAATCCACGAGCACAGCCTA
CATGGAGCTGAGCAGCCTGAGATCTGAGGA CACGGCGGTGTACTACTGCGCCAGAGGTGG
ATTGGACACAGACGAGTTCGACCTATGGGG GAGAGGTACCTTGGTCACCGTCTCCTCA SEQ ID
NO: 38 Ab54 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC variable
region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAAC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAGGA GTCAGTGACATCACTTTTGGCGGAGGGACC
AAGGTTGAGATCAAA SEQ ID NO: 39 Ab56 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSL variable region
YAISWVRQAPGQGLEWMGGIIPAFGTANYAQ (e.g., as found in
KFQGRVTITADESTSTAYMELSSLRSEDTAVY HC-56) YCARGGLDTDEFDLWGRGTLVTVSS
(CDRs in bold) SEQ ID NO: 40 Ab56 Light chain
DIQMTQSPSSLSASVGDRVTITCRASQSINSYL variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-56)
GSGTDFTLTISSLQPEDFATYYCQQGVSDITF (CDRs in bold) GGGTKVEIK SEQ ID
NO: 41 Ab56 CDR-H1 GTFSLYAIS SEQ ID NO: 42 Ab56 CDR-H2
GIIPAFGTANYAQKFQG SEQ ID NO: 43 Ab56 CDR-H3 ARGGLDTDEFDL SEQ ID NO:
44 Ab56 CDR-L1 RASQSINSYLN SEQ ID NO: 45 Ab56 CDR-L2 AASSLQS SEQ ID
NO: 46 Ab56 CDR-L3 QQGVSDIT SEQ ID NO: 47 Ab56 Heavy chain
CAGGTGCAGCTGGTGCAGTCTGGGGCTGA variable region
GGTGAAGAAGCCTGGGTCCTCGGTGAAGGT (nucl)
CTCCTGCAAGGCTTCTGGAGGCACCTTCAG CCTCTATGCTATCTCCTGGGTGCGACAGGC
CCCTGGACAAGGGCTTGAGTGGATGGGAG GGATCATCCCTGCCTTCGGTACCGCAAACT
ACGCACAGAAGTTCCAGGGCAGAGTCACGA TTACCGCGGACGAATCCACGAGCACAGCCT
ACATGGAGCTGAGCAGCCTGAGATCTGAGG ACACGGCGGTGTACTACTGCGCCAGAGGTG
GATTGGACACAGACGAGTTCGACCTATGGG GGAGAGGTACCTTGGTCACCGTCTCCTCA SEQ ID
NO: 48 Ab56 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC variable
region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAAC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAGGA GTCAGTGACATCACTTTTGGCGGAGGGACC
AAGGTTGAGATCAAA SEQ ID NO: 49 Ab57 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSL variable region (e.g.,
YAISWVRQAPGQGLEWMGGIIPHFGLANYAQ as found in HC-57)
KFQGRVTITADESTSTAYMELSSLRSEDTAVY hIgG1 backbone
YCARGGLDTDEFDLWGRGTLVTVSS (CDRs in bold) SEQ ID NO: 50 Ab57 Light
chain DIQMTQSPSSLSASVGDRVTITCRASQSINSYL variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-57)
SGSGTDFTLTISSLQPEDFATYYCQQGVSDITF hKappa backbone GGGTKVEIK (CDRs
in bold) SEQ ID NO: 51 Ab57 CDR-H1 GTFSLYAIS SEQ ID NO: 52 Ab57
CDR-H2 GIIPHFGLANYAQKFQG SEQ ID NO: 53 Ab57 CDR-H3 ARGGLDTDEFDL SEQ
ID NO: 54 Ab57 CDR-L1 RASQSINSYLN SEQ ID NO: 55 Ab57 CDR-L2 AASSLQS
SEQ ID NO: 56 Ab57 CDR-L3 QQGVSDIT SEQ ID NO: 57 Ab57 Heavy chain
CAGGTGCAGCTGGTGCAGTCTGGGGCTGA variable region
GGTGAAGAAGCCTGGGTCCTCGGTGAAGGT (nucl)
CTCCTGCAAGGCTTCTGGAGGCACCTTCTC CCTCTATGCTATCAGCTGGGTGCGACAGGC
CCCTGGACAAGGGCTTGAGTGGATGGGAG GGATCATCCCTCACTTCGGTCTCGCAAACTA
CGCACAGAAGTTCCAGGGCAGAGTCACGAT TACCGCGGACGAATCCACGAGCACAGCCTA
CATGGAGCTGAGCAGCCTGAGATCTGAGGA CACGGCGGTGTACTACTGCGCCAGAGGTGG
ATTGGACACAGACGAGTTCGACCTATGGGG GAGAGGTACCTTGGTCACCGTCTCCTCA SEQ ID
NO: 58 Ab57 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC variable
region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAAC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAGGA GTCAGTGACATCACTTTTGGCGGAGGGACC
AAGGTTGAGATCAAA SEQ ID NO: 59 Ab5. 8 Heavy chain
EVQLLESGGGLVQPGGSLRLSCAASGFTFSN variable region (e.g.,
YAMSWVRQAPGKGLEWVSAISGSGGSTYYA as found in HC-58)
DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV (CDRs in bold)
YYCAKGPPTYHTNYYYMDVWGKGTTVTVSS SEQ ID NO: 60 Ab58 Light chain
DIQMTQSPSSVSASVGDRVTITCRASQGISSW variable region (e.g.,
LAWYQQKPGKAPKLLIYAASSLQSGVPSRFS as found in LC-58)
GSGSGTDFTLTISSLQPEDFATYYCQQTNSFP (CDRs in bold) YTFGGGTKVEIK SEQ ID
NO: 61 Ab58 CDR-H1 FTFSNYAMS SEQ ID NO: 62 Ab58 CDR-H2
AISGSGGSTYYADSVKG SEQ ID NO: 63 Ab58 CDR-H3 AKGPPTYHTNYYYMDV SEQ ID
NO: 64 Ab58 CDR-L1 RASQGISSWLA SEQ ID NO: 65 Ab58 CDR-L2 AASSLQS
SEQ ID NO: 66 Ab58 CDR-L3 QQTNSFPYT SEQ ID NO: 67 Ab58 Heavy chain
GAGGTGCAGCTGTTGGAGTCTGGGGGAGG variable region
CTTGGTACAGCCTGGGGGGTCCCTGAGACT (nucl)
CTCCTGTGCAGCCTCTGGATTCACCTTTAGC AATTATGCCATGAGCTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTCTCAGC TATTAGTGGTAGTGGTGGTAGCACATACTAC
GCAGACTCCGTGAAGGGCCGGTTCACCATC TCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCGGTGTACTACTGCGCCAAGGGCCCTC
CTACATACCACACAAACTACTACTACATGGA CGTATGGGGCAAGGGTACAACTGTCACCGT
CTCCTCA SEQ ID NO: 68 Ab58 Light chain
GACATCCAGATGACCCAGTCTCCATCTTCCG variable region
TGTCTGCATCTGTAGGAGACAGAGTCACCAT (nucl)
CACTTGTCGGGCGAGTCAGGGTATTAGCAG CTGGTTAGCCTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATGCTGCA TCCAGTTTGCAAAGTGGGGTCCCATCAAGG
TTCAGCGGCAGTGGATCTGGGACAGATTTC ACTCTCACCATCAGCAGCCTGCAGCCTGAA
GATTTTGCAACTTATTACTGTCAGCAAACAA ATAGTTTCCCTTACACTTTTGGCGGAGGGAC
CAAGGTTGAGATCAAA SEQ ID NO: 69 Ab61 Heavy chain
EVQLLESGGGLVQPGGSLRLSCAASGFTFSS variable region (e.g.,
YVMIWVRQAPGKGLEWVSSISGDSVTTYVAD as found in HC-61)
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY hIgG1 backbone
YCAKGPPTYHTNYYYMDVWGKGTIVIVSS (CDRs in bold) SEQ ID NO: 70 Ab61
Light chain DIQMTQSPSSVSASVGDRVTITCRASQGISSW variable region (e.g.,
LAWYQQKPGKAPKLLIYAASSLQSGVPSRFS as found in LC-61)
GSGSGTDFTLTISSLQPEDFATYYCQQTNSFP (CDRs in bold) YTFGGGTKVEIK SEQ ID
NO: 71 Ab61 CDR-H1 FTFSSYVMI SEQ ID NO: 72 Ab61 CDR-H2
SISGDSVTTYYADSVKG SEQ ID NO: 73 Ab61 CDR-H3 AKGPPTYHTNYYYMDV SEQ ID
NO: 74 Ab61 CDR-L1 RASQGISSWLA SEQ ID NO: 75 Ab61 CDR-L2 AASSLQS
SEQ ID NO: 76 Ab61 CDR-L3 QQTNSFPYT SEQ ID NO: 77 Ab61 Heavy chain
GAGGTGCAGCTGTTGGAGTCTGGGGGAGG variable region
CTTGGTACAGCCTGGGGGGTCCCTGAGACT (nucl)
CTCCTGTGCAGCCTCTGGATTCACCTTTAGC AGCTATGTCATGATCTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTCTCAAG CATTAGTGGTGACAGCGTAACAACATACTAC
GCAGACTCCGTGAAGGGCCGGTTCACCATC TCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCGGTGTACTACTGCGCCAAGGGCCCTC
CTACATACCACACAAACTACTACTACATGGA CGTATGGGGCAAGGGTACAACTGTCACCGT
CTCCTCA SEQ ID NO: 78 Ab61 Light chain
GACATCCAGATGACCCAGTCTCCATCTTCCG variable region
TGTCTGCATCTGTAGGAGACAGAGTCACCAT (nucl)
CACTTGTCGGGCGAGTCAGGGTATTAGCAG CTGGTTAGCCTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATGCTGCA TCCAGTTTGCAAAGTGGGGTCCCATCAAGG
TTCAGCGGCAGTGGATCTGGGACAGATTTC ACTCTCACCATCAGCAGCCTGCAGCCTGAA
GATTTTGCAACTTATTACTGTCAGCAAACAA ATAGTTTCCCTTACACTTTTGGCGGAGGGAC
CAAGGTTGAGATCAAA SEQ ID NO: 79 Ab66 Heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSD variable region (e.g.,
HYMDWVRQAPGKGLEWVGRTRNKASSYTTE as found in HC-66)
YAASVKGRFTISRDDSKNSLYLQMNSLKTEDT (CDRs in bold)
AVYYCAREPKYWIDFDLWGRGTLVTVSS SEQ ID NO: 80 Ab66 Light chain
DIQMTQSPSSLSASVGDRVTITCRASQSISSYL variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-66)
SGSGTDFTLTISSLQPEDFATYYCQQSYIAPYT hKappa backbone FGGGTKVEIK (CDRs
in bold) SEQ ID NO: 81 Ab66 CDR-H1 FTFSDHYMD SEQ ID NO: 82 Ab66
CDR-H2 RTRNKASSYTTEYAASVKG SEQ ID NO: 83 Ab66 CDR-H3 AREPKYWIDFDL
SEQ ID NO: 84 Ab66 CDR-L1 RASQSISSYLN SEQ ID NO: 85 Ab66 CDR-L2
AASSLQS SEQ ID NO: 86 Ab66 CDR-L3 QQSYIAPYT SEQ ID NO: 87 Ab66
Heavy chain GAGGTGCAGCTGGTGGAGTCTGGGGGAGG variable region
CTTGGTCCAGCCTGGAGGGTCCCTGAGACT (nucl)
CTCCTGTGCAGCCTCTGGATTCACCTTCAGT GACCACTACATGGACTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTTGGCCG TACTAGAAACAAAGCTAGTAGTTACACCACA
GAATACGCCGCGTCTGTGAAAGGCAGATTC ACCATCTCAAGAGATGATTCAAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAAAACCGA GGACACGGCGGTGTACTACTGCGCCAGAGA
GCCTAAATACTGGATCGACTTCGACCTATGG GGGAGAGGTACCTTGGTCACCGTCTCCTCA SEQ
ID NO: 88 Ab66 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC variable
region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAGC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAAGC TACATCGCCCCTTACACTTTTGGCGGAGGG
ACCAAGGTTGAGATCAAA SEQ ID NO: 89 Ab68 Heavy chain
EVQLVESGGGLVQPGRSLRLSCTASGFTFSD variable region (e.g.,
HDMNWVRQAPGKGLEWVGRTRNAAGSYTTE as found in HC-68)
YAASVKGRFTISRDDSKNSLYLQMNSLKTEDT (CDRs in bold)
AVYYCAREPKYWIDFDLWGRGTLVTVSS SEQ ID NO: 90 Ab68 Light chain
DIQMTQSPSSLSASVGDRVTITCRASQSISSYL variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-68)
GSGTDFILTISSLQPEDFATYYCQQSYIAPYT (CDRs in bold) FGGGTKVEIK SEQ ID
NO: 91 Ab68 CDR-H1 FTFSDHDMN SEQ ID NO: 92 Ab68 CDR-H2
RTRNAAGSYTTEYAASVKG SEQ ID NO: 93 Ab68 CDR-H3 AREPKYWIDFDL SEQ ID
NO: 94 Ab68 CDR-L1 RASQSISSYLN SEQ ID NO: 95 Ab68 CDR-L2 AASSLQS
SEQ ID NO: 96 Ab68 CDR-L3 QQSYIAPYT SEQ ID NO: 97 Ab68 Heavy chain
GAGGTGCAGCTGGTGGAGTCTGGGGGAGG variable region
CTTGGTACAGCCAGGGCGGTCCCTGAGACT (nucl)
CTCCTGTACAGCTTCTGGATTCACCTTCAGT GACCACGACATGAACTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTTGGCCG TACTAGAAACGCCGCTGGAAGTTACACCAC
AGAATACGCCGCGTCTGTGAAAGGCAGATT CACCATCTCAAGAGATGATTCAAAGAACTCA
CTGTATCTGCAAATGAACAGCCTGAAAACCG AGGACACGGCGGTGTACTACTGCGCCAGAG
AGCCTAAATACTGGATCGACTTCGACCTATG GGGGAGAGGTACCTTGGTCACCGTCTCCTC A
SEQ ID NO: 98 Ab68 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC
variable region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAGC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAAGC TACATCGCCCCTTACACTTTTGGCGGAGGG
ACCAAGGTTGAGATCAAA SEQ ID NO: 99 Ab69 Heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFVD variable region (e.g.,
HDMDWVRQAPGKGLEWVGRTRNKLGSYTTE as found in HC-69)
YAASVKGRFTISRDDSKNSLYLQMNSLKTEDT (CDRs in bold)
AVYYCAREPKYWIDFDLWGRGTLVTVSS SEQ ID NO: Ab69 Light chain
DIQMTQSPSSLSASVGDRVTITCRASQSISSYL 100 variable region (e.g.,
NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG as found in LC-69)
SGSGTDFTLTISSLQPEDFATYYCQQSYIAPYT (CDRs in bold) FGGGTKVEIK SEQ ID
NO: Ab69 CDR-H1 FTFVDHDMD 101 SEQ ID NO: Ab69 CDR-H2
RTRNKLGSYTTEYAASVKG 102 SEQ ID NO: Ab69 CDR-H3 AREPKYWIDFDL 103 SEQ
ID NO: Ab69 CDR-L1 RASQSISSYLN 104 SEQ ID NO: Ab69 CDR-L2 AASSLQS
105 SEQ ID NO: Ab69 CDR-L3 QQSYIAPYT 106 SEQ ID NO: Ab69 Heavy
chain GAGGTGCAGCTGGTGGAGTCTGGGGGAGG 107 variable region
CTTGGTCCAGCCTGGAGGGTCCCTGAGACT (nucl)
CTCCTGTGCAGCCTCTGGATTCACCTTCGTA GACCACGACATGGACTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTTGGCCG TACTAGAAACAAACTAGGAAGTTACACCACA
GAATACGCCGCGTCTGTGAAAGGCAGATTC ACCATCTCAAGAGATGATTCAAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAAAACCGA GGACACGGCGGTGTACTACTGCGCCAGAGA
GCCTAAATACTGGATCGACTTCGACCTATGG GGGAGAGGTACCTTGGTCACCGTCTCCTCA
SEQ ID NO: Ab69 Light chain GACATCCAGATGACCCAGTCTCCATCCTCC 108
variable region CTGTCTGCATCTGTAGGAGACAGAGTCACC (nucl)
ATCACTTGCCGGGCAAGTCAGAGCATTAGC AGCTATTTAAATTGGTATCAGCAGAAACCAG
GGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCCCATCAA
GGTTCAGTGGCAGTGGATCTGGGACAGATT TCACTCTCACCATCAGCAGTCTGCAACCTGA
AGATTTTGCAACTTACTACTGTCAGCAAAGC TACATCGCCCCTTACACTTTTGGCGGAGGG
ACCAAGGTTGAGATCAAA SEQ ID NO: Ab67 Light chain
DIQMTQSPSSLSASVGDRVTITCRASQSIS 109 LC constant region
SYLNWYQQKPGKAPKLLIYAASSLQSGVP underlined
SRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYIAPYTFGGGTKVEIKRTVAAPSVFIF
PPSDEQLKSGTASVVCLLNNFYPREAKVQ WKVDNALQSGNSQESVTEQDSKDSTYSL
SSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC SEQ ID NO: Ab67 Heavy
chain EVQLVESGGGLVQPGGSLRLSCAASGFT 110 HC constant region
FSDADMDWVRQAPGKGLEWVGRTRNKA underlined
GSYTTEYAASVKGRFTISRDDSKNSLYLQ MNSLKTEDTAVYYCAREPKYWIDFDLWG
RGTLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISK
AKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:
Ab67 Heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFT 111 (D265C)*
FSDADMDWVRQAPGKGLEWVGRTRNKA HC constant region
GSYTTEYAASVKGRFTISRDDSKNSLYLQ underlined
MNSLKTEDTAVYYCAREPKYWIDFDLWG RGTLVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVCVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: Ab67 Heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFT 112 (L234A/L235A/
FSDADMDWVRQAPGKGLEWVGRTRNKA D265C)* GSYTTEYAASVKGRFTISRDDSKNSLYLQ
HC constant region MNSLKTEDTAVYYCAREPKYWIDFDLWG underlined
RGTLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPEAAGGPSVFLFPPKPKDTL MISRTPEVTCVVVCVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:
Ab67 Heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFT 113 (D265C/H435A)*
FSDADMDWVRQAPGKGLEWVGRTRNKA HC constant region
GSYTTEYAASVKGRFTISRDDSKNSLYLQ underlined
MNSLKTEDTAVYYCAREPKYWIDFDLWG RGTLVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVCVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNAYTQKSLSLSPGK SEQ ID NO: Ab67 Heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFT 114 (L234A/L235A/
FSDADMDWVRQAPGKGLEWVGRTRNKA D265C/H435A)*
GSYTTEYAASVKGRFTISRDDSKNSLYLQ HC constant region
MNSLKTEDTAVYYCAREPKYWIDFDLWG underlined
RGTLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPEAAGGPSVFLFPPKPKDTL MISRTPEVTCVVVCVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNAYTQKSLSLSPGK SEQ ID NO:
Ab55 Light chain DIQMTQSPSSLSASVGDRVTITCRASQSINSYL 115 LC constant
region NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG underlined
SGSGTDFTLTISSLQPEDFATYYCQQGVSDITF GGGTKVEIKRTVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKAD
YEKHKVYACEVTHQGLSSPVTKSFNRGE C SEQ ID NO: Ab55 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFRI 116 HC constant region
YAISWVRQAPGQGLEWMGGIIPDFGVANYAQ underlined
KFQGRVTITADESTSTAYMELSSLRSEDTAVY YCARGGLDTDEFDLWGRGTLVTVSSASTKG
PSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLP
PSRDELTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK SEQ ID NO: Ab55 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFRI 117 (D265C)*
YAISWVRQAPGQGLEWMGGIIPDFGVANYAQ HC constant region
KFQGRVTITADESTSTAYMELSSLRSEDTAVY underlined
YCARGGLDTDEFDLWGRGTLVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVCV
SHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCK
VSNKALPAPIEKTISKAKGQPREPQVYTLP PSRDELTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFSCSVMHEALHNHYT
QKSLSLSPGK SEQ ID NO: Ab55 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFRI 118 (L234A/L235A /
YAISWVRQAPGQGLEWMGGIIPDFGVANYAQ D265C)*
KFQGRVTITADESTSTAYMELSSLRSEDTAVY HC constant region
YCARGGLDTDEFDLWGRGTLVTVSSASTKG underlined
PSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVC VSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK SEQ ID NO: Ab55 Heavy
chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFRI 119 (D265C/H435A)*
YAISWVRQAPGQGLEWMGGIIPDFGVANYAQ HC constant region
KFQGRVTITADESTSTAYMELSSLRSEDTAVY underlined
YCARGGLDTDEFDLWGRGTLVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVCV
SHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCK
VSNKALPAPIEKTISKAKGQPREPQVYTLP PSRDELTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFSCSVMHEALHNAYT
QKSLSLSPGK SEQ ID NO: Ab55 Heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFRI 120 (L234A/L235A/
YAISWVRQAPGQGLEWMGGIIPDFGVANYAQ D265C/H435A)*
KFQGRVTITADESTSTAYMELSSLRSEDTAVY HC constant region
YCARGGLDTDEFDLWGRGTLVTVSSASTKG underlined
PSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVC VSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNAY TQKSLSLSPGK SEQ ID NO: Light chain
constant RTVAAPSVFIFPPSDEQLKSGTASVVCLL 121 region of LC-54,
NNFYPREAKVQWKVDNALQSGNSQESVT LC-55, LC-56, LC-
EQDSKDSTYSLSSTLTLSKADYEKHKVYA 57, LC-58, LC-61,
CEVTHQGLSSPVTKSFNRGEC LC-66, LC-67, LC- 68, LC-69 SEQ ID NO: Heavy
chain ASTKGPSVFPLAPSSKSTSGGTAALGCLV 122 constant region of
KDYFPEPVTVSWNSGALTSGVHTFPAVL WT QSSGLYSLSSVVTVPSSSLGTQTYICNVN
HKPSNTKVDKKVEPKSCDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEA
LHNHYTQKSLSLSPGK SEQ ID NO: Heavy chain
ASTKGPSVFPLAPSSKSTSGGTAALGCLV 123 constant region
KDYFPEPVTVSWNSGALTSGVHTFPAVL (D265C)* QSSGLYSLSSVVTVPSSSLGTQTYICNVN
HKPSNTKVDKKVEPKSCDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTC
VVVCVSHEDPEVKFNWYVDGVEVHNAKT KPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEA
LHNHYTQKSLSLSPGK SEQ ID NO: Heavy chain
ASTKGPSVFPLAPSSKSTSGGTAALGCLV 124 constant region
KDYFPEPVTVSWNSGALTSGVHTFPAVL (L234A/L235A/
QSSGLYSLSSVVTVPSSSLGTQTYICNVN D265C)* HKPSNTKVDKKVEPKSCDKTHTCPPCPA
PEAAGGPSVFLFPPKPKDTLMISRTPEVT CVVVCVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGS
FFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK SEQ ID NO: Heavy
chain ASTKGPSVFPLAPSSKSTSGGTAALGCLV 125 constant region
KDYFPEPVTVSWNSGALTSGVHTFPAVL (H435A/D265C)*
QSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTHTCPPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEVTC
VVVCVSHEDPEVKFNWYVDGVEVHNAKT KPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEA
LHNAYTQKSLSLSPGK SEQ ID NO: Heavy chain
ASTKGPSVFPLAPSSKSTSGGTAALGCLV 126 constant region
KDYFPEPVTVSWNSGALTSGVHTFPAVL (L234A/L235A/
QSSGLYSLSSVVTVPSSSLGTQTYICNVN H435A/D265C)*
HKPSNTKVDKKVEPKSCDKTHTCPPCPA PEAAGGPSVFLFPPKPKDTLMISRTPEVT
CVVVCVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEA
LHNAYTQKSLSLSPGK SEQ ID NO: Consensus GTF(S/R)(S/I/L)YAIS 127
sequence of variable heavy chain CDR1 (Abs 54-57) SEQ ID NO:
Consensus GIIP(I/D/A/H)FG(T/V/L)ANYAQKFQG 128 sequence of variable
heavy chain CDR2 (Abs 54-57) SEQ ID NO: Variable heavy chain
ARGGLDTDEFDL 129 CDR3 (Abs 54-57) SEQ ID NO: Variable light chain
RASQSINSYLN 130 CDR1 (Abs 54-57) SEQ ID NO: Variable light chain
AASSLQS 131 CDR2 (Abs 54-57) SEQ ID NO: Variable light chain
QQGVSDIT 132 CDR3 (Abs 54-57) SEQ ID NO: Consensus
FTFS(N/S)Y(A/V)M(S/I) 133 sequence of variable heavy chain CDR1
(Abs 58, 61) SEQ ID NO: Consensus (A/S)ISG(S/D)(G/S)(G/V)(S/T) 134
sequence of variable TYYADSVKG heavy chain CDR2 (Abs 58, 61) SEQ ID
NO: Variable heavy chain AKGPPTYHTNYYYMDV 135 CDR3 (Abs 58, 61) SEQ
ID NO: Variable light chain RASQGISSWLA 136 CDR1 (Abs 58, 61) SEQ
ID NO: Variable light chain AASSLQS 137 CDR2 (Abs 58, 61) SEQ ID
NO: Variable light chain QQTNSFPYT 138 CDR3 (Abs 58, 61) SEQ ID NO:
Consensus FTF(S/V)D(H/A)(Y/D)M(D/N) 139 sequence of variable heavy
chain CDR1 (Abs 66-69) SEQ ID NO: Consensus
RTRN(K/A)(A/L)(S/G)SYTTEYAASVKG 140 sequence of variable heavy
chain CDR2 (Abs 66-69) SEQ ID NO: Variable heavy chain AREPKYWIDFDL
141 CDR3 (Abs 66-69) SEQ ID NO: Variable light chain RASQSISSYLN
142 CDR1 (Abs 66-69) SEQ ID NO: Variable light chain AASSLQS 143
CDR2 (Abs 66-69) SEQ ID NO: Variable light chain QQSYIAPYT 144 CDR3
(Abs 66-69) SEQ ID NO: Human CD117 MRGARGAWDFLCVLLLLLRVQTGSSQPS 145
(mast/stem cell VSPGEPSPPSIHPGKSDLIVRVGDEIRLLC growth factor
TDPGFVKWTFEILDETNENKQNEWITEKA receptor Kit isoform
EATNTGKYTCTNKHGLSNSIYVFVRDPAK 1 precursor)
LFLVDRSLYGKEDNDTLVRCPLTDPEVTN Protein NCBI
YSLKGCQGKPLPKDLRFIPDPKAGIMIKSV Reference
KRAYHRLCLHCSVDQEGKSVLSEKFILKV Sequence:
RPAFKAVPVVSVSKASYLLREGEEFTVTC NP_000213.1
TIKDVSSSVYSTWKRENSQTKLQEKYNS WHHGDFNYERQATLTISSARVNDSGVFM
CYANNIFGSANVITTLEVVDKGFINIFPMI NTTVFVNDGENVDLIVEYEAFPKPEHQQ
WIYMNRTFTDKWEDYPKSENESNIRYVSE LHLTRLKGTEGGTYTFLVSNSDVNAAIAF
NVYVNTKPEILTYDRLVNGMLQCVAAGFP EPTIDWYFCPGTEQRCSASVLPVDVQTLN
SSGPPFGKLVVQSSIDSSAFKHNGTVECK AYNDVGKTSAYFNFAFKGNNKEQIHPHTL
FTPLLIGFVIVAGMMCIIVMILTYKYLQKPM YEVQWKVVEEINGNNYVYIDPTQLPYDHK
WEFPRNRLSFGKTLGAGAFGKVVEATAY GLIKSDAAMTVAVKMLKPSAHLTEREALM
SELKVLSYLGNHMNIVNLLGACTIGGPTLV ITEYCCYGDLLNFLRRKRDSFICSKQEDH
AEAALYKNLLHSKESSCSDSTNEYMDMK PGVSYVVPTKADKRRSVRIGSYIERDVTP
AIMEDDELALDLEDLLSFSYQVAKGMAFL ASKNCIHRDLAARNILLTHGRITKICDFGLA
RDIKNDSNYVVKGNARLPVKWMAPESIFN CVYTFESDVWSYGIFLWELFSLGSSPYPG
MPVDSKFYKMIKEGFRMLSPEHAPAEMY DIMKTCWDADPLKRPTFKQIVQLIEKQISE
STNHIYSNLANCSPNRQKPVVDHSVRINS VGSTASSSQPLLVHDDV SEQ ID NO: Human
CD117 MRGARGAWDFLCVLLLLLRVQTGSSQPS 146 (mast/stem cell
VSPGEPSPPSIHPGKSDLIVRVGDEIRLLC growth factor
TDPGFVKWTFEILDETNENKQNEWITEKA receptor Kit isoform
EATNTGKYTCTNKHGLSNSIYVFVRDPAK 2 precursor)
LFLVDRSLYGKEDNDTLVRCPLTDPEVTN Protein NCBI
YSLKGCQGKPLPKDLRFIPDPKAGIMIKSV Reference
KRAYHRLCLHCSVDQEGKSVLSEKFILKV Sequence:
RPAFKAVPVVSVSKASYLLREGEEFTVTC NP_001087241.1
TIKDVSSSVYSTWKRENSQTKLQEKYNS WHHGDFNYERQATLTISSARVNDSGVFM
CYANNTFGSANVITTLEVVDKGFINIFPMI NTTVFVNDGENVDLIVEYEAFPKPEHQQ
WIYMNRTFTDKWEDYPKSENESNIRYVSE LHLTRLKGTEGGTYTFLVSNSDVNAAIAF
NVYVNTKPEILTYDRLVNGMLQCVAAGFP EPTIDWYFCPGTEQRCSASVLPVDVQTLN
SSGPPFGKLVVQSSIDSSAFKHNGTVECK AYNDVGKTSAYFNFAFKEQIHPHTLFTPLL
IGFVIVAGMMCIIVMILTYKYLQKPMYEVQ WKVVEEINGNNYVYIDPTQLPYDHKWEFP
RNRLSFGKTLGAGAFGKVVEATAYGLIKS DAAMTVAVKMLKPSAHLTEREALMSELKV
LSYLGNHMNIVNLLGACTIGGPTLVITEYC CYGDLLNFLRRKRDSFICSKQEDHAEAAL
YKNLLHSKESSCSDSTNEYMDMKPGVSY VVPTKADKRRSVRIGSYIERDVTPAIMEDD
ELALDLEDLLSFSYQVAKGMAFLASKNCI HRDLAARNILLTHGRITKICDFGLARDIKN
DSNYVVKGNARLPVKWMAPESIFNCVYT FESDVWSYGIFLWELFSLGSSPYPGMPV
DSKFYKMIKEGFRMLSPEHAPAEMYDIMK TCWDADPLKRPTFKQIVQLIEKQISESTNH
IYSNLANCSPNRQKPVVDHSVRINSVGST ASSSQPLLVHDDV SEQ ID NO: Heavy chain
variable QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-1
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIQLTQSPSSLSASVGDRVTITCRASQGVSSAL 148 region of LC-1
AWYQQKPGKAPKLLIYDASSLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-2
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGIRTDL 149 region of LC-2
GWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNSYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-3
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIRMTQSPSSLSASVGDRVTITCRASQGIRNDL 150 region of LC-3
AWYQQKPGKTPKLLIYDASSLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-4
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIQMTQSPSSLSASVGDRVTITCRASQGIRND 151 region of LC-4
LGWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNSYPL
TFGGGTKVDIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-5
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
NIQMTQSPSSLSASVGDRVTITCRASQAISDYL 152 region of LC-5
AWFQQKPGKAPKLLIYDASNLETGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQLNSYPLTF
GGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-6
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIRMTQSPSSLSASVGDRVIIACRASQGIGGAL 153 region of LC-6
AWYQQKPGNAPKVLVYDASTLESGVPSRFSG GGSGTDFTLTISSLQPEDFATYYCQQFNSYPL
TFGGGTKLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-7
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIAMTQSPPSLSAFVGDRVTITCRASQGIISSL 154 region of LC-7
AWYQQKPGKAPKLLIYDASSLESGVPSRFSGS GSGTDFTLTIRSLQPEDFATYYCQQFNSYPLT
FGGGTKLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-8
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGISSAL 155 region of LC-8
AWYQQKAGKAPKVLISDASSLESGVPSRFSG SGSGTDFTLSISSLQPEDFATYYCQQFNGYPL
TFGGGTKVDIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-9
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS amino acid
FQGQVTISAGKSISTAYLQWSSLKASDTAMYY sequence
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIRMTQSPSSLSASVGDRVTITCQASQGIRND 156 region of LC-9
LGWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTFTISSLQPEDIATYYCQQFNSYPLT
FGGGTKLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-10
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS
SEQ ID NO: Light chain variable NIQMTQSPSSLSTSVGDRVTITCRASQGIGTSL
157 region of LC-10 AWYQQKPGKPPKLLIYDASSLESGVPSRLSGS
GSGTDFTLTISSLQPEDFATYYCQQSNSYPITF GQGTRLEIK SEQ ID NO: Heavy chain
variable QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-11
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIQLTQSPSSLSASVGDRVTITCRASQSIGDYL 158 region of LC-11
TWYQQKPGKAPKVLIYGASSLQSGVPPRFSG SGSGTDFTLTVSSLQPEDFATYYCQQLNSYPL
TFGGGTKLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-12
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVRST 159 region of LC-12
LAWYQQKPGKAPKLLIYDASILESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNGYPL
TFGQGTRLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-13
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIVMTQSPSSLSASVGDRVTITCRASQGIRNDL 160 region of LC-13
GWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNSYPL
TFGGGTKLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-14
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGISSFL 161 region of LC-14
AWYQQKPGKAPKLLIYDASTLQSGVPSRFSG SASGTDFTLTISSLQPEDFATYYCQQLNGYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-15
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIQLTQSPSSLSASVGDRVTITCRASQGIGSAL 162 region of LC-15
AWYQQKPGIGPKLLIYDASTLESGVPARFSGS GSRTDFTLTITSLQPEDFATYYCQQFNGYPLT
FGGGTKLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-16
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
AIQLTQSPSSLSASVGDRVTITCRASQGITSAL 163 region of LC-16
AWYQEKPGKAPNLLIYDASSLESGVPSRFSGS GYGTDFTLTISSLQPEDFATYYCQQLNSYPLTF
GGGTKVDIK SEQ ID NO: Heavy chain variable
QIQLVQSGPELRKPGESVKISCKASGYTFTDY 164 region of HC-17
AMYWVKQAPGKGLKWMGWINTYTGKPTYAD DFKGRFVFSLEASANTANLQISNLKNEDTATYF
CARARGLVDDYVMDAWGQGTSVTVSS SEQ ID NO: Light chain variable
SYELIQPPSASVTLGNTVSLTCVGDELSKRYA 165 region of LC-17
QWYQQKPDKTIVSVIYKDSERPSGISDRFSGS SSGTTATLTIHGTLAEDEADYYCLSTYSDDNLP
VFGGGTKLTVL SEQ ID NO: Heavy chain variable
EVQLQQYGAELGKPGTSVRLSCKVSGYNIRN 166 region of HC-18
TYIHWVNQRPGEGLEWIGRIDPTNGNTISAEK FKTKATLTADTSSHTAYLQFSQLKSDDTAIYFC
ALNYEGYADYWGQGVMVTGSS SEQ ID NO: Light chain variable
DIQMTQSPSFLSASVGDRVTINCKASQNINKYL 167 region of LC-18
NWYQQKVGEAPKRLIFKTNSLQTGIPSRFSGS GSGTDYTLTISSLQTEDVATYFCFQYNIGYTFG
AGTKVELK SEQ ID NO: Heavy chain variable
EVQLQESGPGLVKPSQSLSLTCSVTGYSISSN 168 region of HC-19
YRWNWIRKFPGNKVEWMGYINSAGSTNYNPS LKSRISMTRDTSKNQFFLQVNSVTTEDTATYY
CARSLRGYITDYSGFFDYWGQGVMVTVSS SEQ ID NO: Light chain variable
DIRMTQSPASLSASLGETVNIECLASEDIFSDL 169 region of LC-19
AWYQQKPGKSPQLLIYNANSLQNGVPSRFSG SGSGTRYSLKINSLQSEDVATYFCQQYKNYPL
TFGSGTKLEIK SEQ ID NO: Heavy chain variable
EVQLQQYGAELGKPGTSVRLSCKLSGYKIRNT 170 region of HC-20
YIHWVNQRPGKGLEWIGRIDPANGNTIYAEKF KSKVTLTADTSSNTAYMQLSQLKSDDTALYFC
AMNYEGYEDYWGQGVMVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSFLSASVGDSVTINCKASQNINKYL 171 region of LC-20
NWYQQKLGEAPKRLIHKTDSLQTGIPSRFSGS GSGTDYTLTISSLQPEDVATYFCFQYKSGFMF
GAGTKLELK SEQ ID NO: Heavy chain variable
QIQLVQSGPELKKPGESVKISCKASGYTFTDY 172 region of HC-21
AVYWVIQAPGKGLKWMGWINTYTGKPTYADD FKGRFVFSLETSASTANLQISNLKNEDTATYFC
ARGAGMTKDYVMDAWGRGVLVTVS SEQ ID NO: Light chain variable
SYELIQPPSASVTLGNTVSLTCVGDELSKRYA 173 region of LC-21
QWYQQKPDKTIVSVIYKDSERPSDISDRFSGS SSGTTATLTIHGTLAEDEADYYCLSTYSDDNLP
VFGGGTKLTVL SEQ ID NO: Heavy chain variable
QVQLKESGPGLVQPSQTLSLICTVSGFSLTSY 174 region of HC-22
LVHWVRQPPGKTLEWVGLMWNDGDTSYNSA LKSRLSISRDTSKSQVFLKMHSLQAEDTATYY
CARESNLGFTYWGHGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPASLSASLEEIVTITCKASQGIDDDLS 175 region of LC-22
WYQQKPGKSPQLLIYDVTRLADGVPSRFSGS RSGTQYSLKISRPQVADSGIYYCLQSYSTPYT
FGAGTKLELK SEQ ID NO: Heavy chain variable
EVQLQQYGAELGKPGTSVRLSCKVSGYNIRN 176 region of HC-23
TYIHWVHQRPGEGLEWIGRIDPTNGNTISAEK FKSKATLTADTSSNTAYMQFSQLKSDDTAIYF
CAMNYEGYADYWGQGVMVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSFLSASVGDRLTINCKASQNINKYL 177 region of LC-23
NWYQQKLGEAPKRLIFKTNSLQTGIPSRFSGS GSGTDYTLTISSLQPEDVATYFCFQYNIGFTFG
AGTKLELK SEQ ID NO: Heavy chain variable
EVQLVESGGGLVQSGRSLKLSCAASGFTVSD 178 region of HC-24
YYMAWVRQAPTKGLEWVATINYDGSTTYHRD SVKGRFTISRDNAKSTLYLQMDSLRSEDTATY
YCARHGDYGYHYGAYYFDYWGQGVMVTVSS SEQ ID NO: Light chain variable
DIVLTQSPALAVSLGQRATISCRASQTVSLSGY 179 region of LC-24
NLIHWYQQRTGQQPKLLIYRASNLAPGIPARF SGSGSGTDFTLTISPVQSDDIATYYCQQSRES
WTFGGGTNLEMK SEQ ID NO: Heavy chain variable
QIQLVQSGPELKKPGESVKISCKASGYTFTDY 180 region of HC-25
AIHWVKQAPGQGLRWMAWINTETGKPTYADD FKGRFVFSLEASASTAHLQISNLKNEDTATFFC
AGGSHWFAYWGQGTLVTVSS SEQ ID NO: Light chain variable
SYELIQPPSASVTLENTVSITCSGDELSNKYAH 181 region of LC-25
WYQQKPDKTILEVIYNDSERPSGISDRFSGSS SGTTAILTIRDAQAEDEADYYCLSTFSDDDLPIF
GGGTKLTVL SEQ ID NO: Heavy chain variable
QIQLVQSGPELKKPGESVKISCKASGYTFTDY 172 region of HC-26
AVYWVIQAPGKGLKWMGWINTYTGKPTYADD FKGRFVFSLETSASTANLQISNLKNEDTATYFC
ARGAGMTKDYVMDAWGRGVLVTVS SEQ ID NO: Light chain variable
SYELIQPPSTSVTLGNTVSLTCVGNELPKRYAY 182 region of LC-26
WFQQKPDQSIVRLIYDDDRRPSGISDRFSGSS SGTTATLTIRDAQAEDEAYYYCHSTYTDDKVPI
FGGGTKLTVL SEQ ID NO: Heavy chain variable
EVQLVESGGGLVQPGRSMKLSCKASGFTFSN 183 region of HC-27
YDMAWVRQAPTRGLEWVASISYDGITAYYRD SVKGRFTISRENAKSTLYLQLVSLRSEDTATYY
CTTEGGYVYSGPHYFDYWGQGVMVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSMSVSLGDTVTITCRASQDVGIF 184 region of LC-27
VNWFQQKPGRSPRRMIYRATNLADGVPSRFS GSRSGSDYSLTISSLESEDVADYHCLQYDEFP
RTFGGGTKLELK SEQ ID NO: Heavy chain variable
EVQLQQYGAELGKPGTSVRLSCKVSGYKIRNT 185 region of HC-28
YIHWVNQRPGKGLEWIGRIDPANGNTIYAEKF KSKVTLTADTSSNTAYMQLSQLKSDDTALYFC
AMNYEGYEDYWGQGVMVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSFLSASVGDSVTINCKASQNINKYL 186 region of LC-28
NWYQQKLGEAPKRLIHKTNSLQPGFPSRFSG SGSGTDYTLTISSLQPEDVAAYFCFQYNSGFT
FGAGTKLELK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFTD 187 region of HC-29
YYIHWVRQAPGQGLEWMGWMNPHSGDTGY AQKFQGRVTMTRDTSTSTVYMELSSLRSEDT
AVYYCARHGRGYNGYEGAFDIWGQGTLVTVS SAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIGNE 188 region of LC-29
LGWYQQKPGKAPKLLIYAASNLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQYDNLP
LTFGQGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFTG 189 region of HC-30
YYLHWVRQAPGQGLEWMGWINPNSGDTNYA QNFQGRVTMTRDTSTSTVYMELSSLRSEDTA
VYYCARHGRGYNGYEGAFDIWGQGTLVTVSS AS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 190 region of LC-30
LGWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFTG 191 region of HC-31
YYLHWVRQAPGQGLEWMGWINPNSGGTNYA QKFQGRVTMTRDTSTSTVYMELSSLRSEDTA
VYYCARHGRGYEGYEGAFDIWGQGTLVTVSS AS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 192 region of LC-31
LGWYQQKPGKAPKLLIYDASELETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPIT
FGQGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFTS 193 region of HC-32
YYIHWVRQAPGQGLEWMGWLNPSGGGTSYA QKFQGRVTMTRDTSTSTVYMELSSLRSEDTA
VYYCARHGRGYDGYEGAFDIWGQGTLVTVSS AS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 194 region of LC-32
LGWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFST 195 region of HC-33
YYMHWVRQAPGQGLEWMGIINPSGGSTSYA QKFQGRVTMTRDTSTSTVYMKLSSLRSEDTA
VYYCARHGRGYEGYEGAFDIWGQGTLVTVSS AS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRDD 196 region of LC-33
LGWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQANGFPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFTG 197 region of HC-34
YYIHWVRQAPGQGLEWMGIINPSGGNTNYAQ NFQGRVTMTRDTSTSTVYMELSSLRSEDTAV
YYCARHGRGYNAYEGAFDIWGQGTLVTVSSA S SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 198 region of LC-34
LGWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQVNGYPL
TFGGGTKVEIK
SEQ ID NO: Heavy chain variable QVQLVQSGAEVKKPGASVKVSCKASGGTFSS 199
region of HC-35 YAISWVRQAPGQGLEWMGVINPTVGGANYAQ
KFQGRVTMTRDTSTSTVYMELSSLRSEDTAV YYCARHGRGYNEYEGAFDIWGQGTLVTVSSA S
SEQ ID NO: Light chain variable DIQMTQSPSSLSASVGDRVTITCQASQDISDYL
200 region of LC-35 NWYQQKPGKAPKLLIYDASNLETGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQQGNSFPL TFGGGTKLEIK SEQ ID NO: Heavy chain
variable QVQLVQSGAEVKKLGASVKVSCKASGYTFSS 201 region of HC-36
YYMHWVRQAPGQGLEWMGVINPNGAGTNFA QKFQGRVTMTRDTSTSTVYMELSSLRSEDTA
VYYCARHGRGYEGYEGAFDIWGQGTLVTVSS AS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 190 region of LC-36
LGWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFTT 202 region of HC-37
YYMHWVRQAPGQGLEWMGWINPTGGGTNY AQNFQGRVTMTRDTSTSTVYMELSSLRSEDT
AVYYCARHGRGYEGYEGAFDIWGQGTLVTVS SAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 203 region of LC-37
VSWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDATYYCQQLSGYPIT
FGQGTKLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYTFTS 204 region of HC-38
YYIHWVRQAPGQGLEWMGMINPSGGSTNYA QKFQGRVTMTRDTSTSTVYMELSSLRSEDTA
VYYCARHGRGYNDYEGAFDIWGQGTLVTVSS AS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQSISDW 205 region of LC-38
LAWYQQKPGKAPKLLIYEASNLEGGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQANSFPY
TFGQGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAEVKKPGASVKVSCKASGYIFSAY 206 region of HC-39
YIHWVRQAPGQGLEWMGIINPSGGSTRYAQK FQGRVTMTRDTSTSTVYMELSSLRSEDTAVY
YCARHGRGYGGYEGAFDIWDQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIGDY 207 region of LC-39
VAWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPIT
FGQGTRLEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYRFTSY 208 region of HC-40
WIGWVRQMPGKGLEWMGIIYPDDSDTRYSPS FQGQVTISVDKSNSTAYLQWSSLKASDTAMY
YCARHGRGYNGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGISSYL 209 region of LC-40
AWYQQKPGKAPKLLIYDASNLETGVPSRFSGS GSGTYFTLTISSLQPEDFATYYCQQGASFPITF
GQGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGSSFPNS 210 region of HC-41
WIAWVRQMPGKGLEWMGIIYPSDSDTRYSPS FQGQVTISADKSISTAYLQWSSLEASDTAMYY
CARHGRGYNGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRNY 211 region of LC-41
LAWYQQKPGKAPKLLIYDASSLQSGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNSYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYSFDSY 212 region of HC-42
WIGWVRQMPGKGLEWMGIMYPGDSDTRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMY
YCARHGRGYNAYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQSINNW 213 region of LC-42
LAWYQQKPGKAPKLLIYDAFILQSGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCLQLNSYPLT
FGPGTKVDIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYSFTN 214 region of HC-43
WIAWVRQMPGKGLEWMGIIYPGDSETRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYYGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGISDN 215 region of LC-43
LNWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQAISFPLT
FGQGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYNFTSY 216 region of HC-44
WIGWVRQMPGKGLEWMGVIYPDDSETRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMY
YCARHGRGYNGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASRDIRDDL 217 region of LC-44
GWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQANSFPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYTFNTY 218 region of HC-45
IGWVRQMPGKGLEWMGIIYPGDSGTRYSPSF QGQVTISADKAISTAYLQWSSLKASDTAMYYC
ARHSRGYNGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGISNYL 219 region of LC-45
AWYQQKPGKAPKLLIYDASNLETGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQANSFPVT
FGQGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYNFTTY 220 region of HC-46
WIGWVRQMPGKGLEWMGIIHPADSDTRYNPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRVSQGISSYL 221 region of LC-46
AWYQQKPGKAPKLLIYDASNLETGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQANSFPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYRFSNY 222 region of HC-47
WIAWVRQMPGKGLEWMGIIYPDNSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYDGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRSD 223 region of LC-47
LAWYQQKPGKAPKLLIYGASSLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQANSFP
LSFGQGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYRFASY 224 region of HC-48
WIGWVRQMPGKGLEWMGITYPGDSETRYNP SQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYGGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 225 region of LC-48
LGWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQANSFPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSY 226 region of HC-49
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTLVTVSSAS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQSISNW 227 region of LC-49
LAWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQTNSFPL
TFGQGTRLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-74
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVISAL 228 region of LC-74
AWYQQKPGKAPKLLIYDASSLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-75
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGIRSAL 229 region of LC-75
AWYQQKPGKAPKLLIYDASSLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-76
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVGSA 230 region of LC-76
LAWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNSYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-77
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVISAL 231 region of LC-77
AWYQQKPGKAPKLLIYDASILESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-78
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGIRSAL 232 region of LC-78
AWYQQKPGKAPKLLIYDASILESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-79
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVGSA 233 region of LC-79
LAWYQQKPGKAPKLLIYDASILESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNSYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-80
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGISSAL 234 region of LC-80
AWYQQKPGKAPKLLIYDASILESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-81
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVISAL 235 region of LC-81
AWYQQKPGKAPKLLIYDASTLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-82
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGIRSAL 236 region of LC-82
AWYQQKPGKAPKLLIYDASTLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT
FGGGTKVEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-83
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVGSA
237 region of LC-83 LAWYQQKPGKAPKLLIYDASTLESGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQQFNSYPL TFGGGTKVEIK SEQ ID NO: Heavy chain
variable QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-84
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQLTQSPSSLSASVGDRVTITCRASQGVGSA 237 region of LC-84
LAWYQQKPGKAPKLLIYDASTLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNSYPL
TFGGGTKVEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYRFTTS 238 region of HC-245
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGLGYNGYEGAFDIWGQGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIGSA 239 region of LC-245
LAWYQQKPGKAPKLLIYDASTLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNGYPL
TFGQGTRLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-246
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIGSA 239 region of LC-246
LAWYQQKPGKAPKLLIYDASTLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQFNGYPL
TFGQGTRLEIK SEQ ID NO: Heavy chain variable
QVQLVQSGAAVKKPGESLKISCKGSGYRFTTY 147 region of HC-247
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISAGKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASRGISDYL 240 region of LC-247
AWYQQKPGKAPKLLIYDASNLETGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQANSFPITF
GQGTRLEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYRFTTS 238 region of HC-248
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGLGYNGYEGAFDIWGQGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIGSA 241 region of LC-248
LAWYQQKPGKAPKLLIYDASTLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPL
TFGQGTRLEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYRFTTS 238 region of HC-249
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGLGYNGYEGAFDIWGQGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIGSA 242 region of LC-249
LAWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPL
TFGQGTRLEIK SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 243 region of Ab 85
WIGWVRQMPGKGLEWMAIINPRDSDTRYRPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYEGYEGAFDIWGQGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRSSQGIRSD 244 region of Ab 85
LGWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQANGFPL
TFGGGTKVEIK SEQ ID NO: Ab85 CDR-H1 NYWIG 245 SEQ ID NO: Ab85 CDR-H2
IINPRDSDTRYRPSFQG 246 SEQ ID NO: Ab85 CDR-H3 HGRGYEGYEGAFDI 247 SEQ
ID NO: Ab85 CDR-L1 RSSQGIRSDLG 248 SEQ ID NO: Ab85 CDR-L2 DASNLET
249 Ab249 CDR-L2 SEQ ID NO: Ab85 CDR-L3 QQANGFPLT 250 SEQ ID NO:
Heavy chain variable EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 251 region of
Ab 86 WIGWVRQMPGKGLEWMGIIYPGDSDIRYSPS
LQGQVTISVDTSTSTAYLQWNSLKPSDTAMYY CARHGRGYNGYEGAFDIWGQGTLVTVSS SEQ
ID NO: Light chain variable DIQMTQSPSSLSASVGDRVTITCRASQGIGDS 252
region of Ab 86 LAWYQQKPGKAPKLLIYDASNLETGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQQLNGYPIT FGQGTKVEIK SEQ ID NO: Ab86 CDR-H1
NYWIG 245 SEQ ID NO: Ab86 CDR-H2 IIYPGDSDIRYSPSLQG 253 SEQ ID NO: 3
Ab86 CDR-H3 HGRGYNGYEGAFDI SEQ ID NO: Ab86 CDR-L1 RASQGIGDSLA 254
SEQ ID NO: Ab86 CDR-L2 DASNLET 249 SEQ ID NO: Ab86 CDR-L3 QQLNGYPIT
255 SEQ ID NO: Heavy chain variable
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 243 region of Ab 87
WIGWVRQMPGKGLEWMAIINPRDSDTRYRPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYEGYEGAFDIWGQGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 256 region of Ab 87
LGWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPIT
FGQGTKVEIK SEQ ID NO: Ab87 CDR-H1 NYWIG 245 SEQ ID NO: Ab87 CDR-H2
IINPRDSDTRYRPSFQG 246 SEQ ID NO: Ab87 CDR-H3 HGRGYEGYEGAFDI 247 SEQ
ID NO: Ab87 CDR-L1 RASQGIRNDLG 257 SEQ ID NO: 5 Ab87 CDR-L2 DASSLES
SEQ ID NO: Ab87 CDR-L3 QQLNGYPIT 255 SEQ ID NO: Heavy chain
variable EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 258 region of Ab 88
WIGWVRQMPGKGLEWMGIIYPGDSLTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIRND 256 region of Ab 88
LGWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPIT
FGQGTKVEIK SEQ ID NO: Ab88 CDR-H1 NYWIG 245 SEQ ID NO: Ab88 CDR-H2
IIYPGDSLTRYSPSFQG 259 SEQ ID NO: 3 Ab88 CDR-H3 HGRGYNGYEGAFDI SEQ
ID NO: Ab88 CDR-L1 RASQGIRNDLG 257 SEQ ID NO: 5 Ab88 CDR-L2 DASSLES
SEQ ID NO: Ab88 CDR-L3 QQLNGYPIT 255 SEQ ID NO: Heavy chain
variable EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 260 region of Ab89
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYY
CARHGRGYNGYEGAFDIWGQGTLVTVSS SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQGIGDS 252 region of Ab89
LAWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQLNGYPIT
FGQGTKVEIK SEQ ID NO: Ab89 CDR-H1 NYWIG 245 SEQ ID NO: 2 Ab89
CDR-H2 IIYPGDSDTRYSPSFQG SEQ ID NO: 3 Ab89 CDR-H3 HGRGYNGYEGAFDI
SEQ ID NO: Ab89 CDR-L1 RASQGIGDSLA 254 SEQ ID NO: Ab89 CDR-L2
DASNLET 249 SEQ ID NO: Ab89 CDR-L3 QQLNGYPIT 255 SEQ ID NO: Heavy
chain variable QVQLVQSGAAVKKPGESLKISCKGSGYRFTSY 261 region amino
acid WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS sequence of CK6
FQGQVTISAGKSISTAYLQWSSLKASDTAMYY CARHGRGYNGYEGAFDIWGQGTMVTVSS SEQ
ID NO: Light chain variable AIQLTQSPSSLSASVGDRVTITCRASQGISSAL 262
region amino acid AWYQQKPGKAPKLLIYDASSLESGVPSRFSGS sequence of CK6
GSGTDFTLTISSLQPEDFATYYCQQFNSYPLT FGGGTKVEIK SEQ ID NO: Ab77 CDR-H1
TYWIG 263 SEQ ID NO: 2 Ab77 CDR-H2 IIYPGDSDTRYSPSFQG SEQ ID NO: 3
Ab77 CDR-H3 HGRGYNGYEGAFDI SEQ ID NO: Ab77 CDR-L1 RASQGVISALA 264
SEQ ID NO: Ab77 CDR-L2 DASILES 265 SEQ ID NO: Ab77 CDR-L3 QQFNSYPLT
266 SEQ ID NO: Ab79 CDR-H1 TYWIG 263 SEQ ID NO: 2 Ab79 CDR-H2
IIYPGDSDTRYSPSFQG SEQ ID NO: 3 Ab79 CDR-H3 HGRGYNGYEGAFDI SEQ ID
NO: Ab79 CDR-L1 RASQGVGSALA 267 SEQ ID NO: Ab79 CDR-L2 DASILES 265
SEQ ID NO: Ab79 CDR-L3 QQFNSYPLT 266 SEQ ID NO: Ab81 CDR-H1 TYWIG
263 SEQ ID NO: 2 Ab81 CDR-H2 IIYPGDSDTRYSPSFQG SEQ ID NO: 3 Ab81
CDR-H3 HGRGYNGYEGAFDI SEQ ID NO: Ab81 CDR-L1 RASQGVISALA 264 SEQ ID
NO: Ab81 CDR-L2 DASTLES
268 SEQ ID NO: Ab81 CDR-L3 QQFNSYPLT 266 SEQ ID NO: Heavy chain
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 269 constant region
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLY (Wild type (WT))
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD KKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
HNHYTQKSLSLSPGK SEQ ID NO: Heavy chain
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 270 constant region with
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLY L234A, L235A
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD (LALA) mutations
KKVEPKSCDKTHTCPPCPAPEAAGGPSVFLF (mutations in bold)*
PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
HNHYTQKSLSLSPGK SEQ ID NO: Heavy chain constant
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 271 region with D265C
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLY mutation
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD (mutation in bold)*
KKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP PKPKDTLMISRTPEVTCVVVCVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Heavy
chain constant ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 272 region with
H435A FPEPVTVSWNSGALTSGVHTFPAVLQSSGLY mutation
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD (mutation in bold)*
KKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNAYTQKSLSLSPGK SEQ ID NO: Heavy
chain ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 273 constant region:
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLY modified Fc region
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD with L234A, L235A,
KKVEPKSCDKTHTCPPCPAPEAAGGPSVFLF D265C mutations
PPKPKDTLMISRTPEVTCVVVCVSHEDPEVKF (mutations in bold)*
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISK
AKGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Heavy
chain ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 274 constant region:
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLY modified Fc region
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD with L234A, L235A,
KKVEPKSCDKTHTCPPCPAPEAAGGPSVFLF D265C, H435A
PPKPKDTLMISRTPEVTCVVVCVSHEDPEVKF mutations (mutations
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVL in bold)*
TVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
HNAYTQKSLSLSPGK SEQ ID NO: Ab85 full length
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 275 heavy chain
WIGWVRQMPGKGLEWMAIINPRDSDTRYRPS sequence; constant
FQGQVTISADKSISTAYLQWSSLKASDTAMYY region underlined
CARHGRGYEGYEGAFDIWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK SEQ ID NO: Ab85 full
length EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 276 heavy chain
WIGWVRQMPGKGLEWMAIINPRDSDTRYRPS sequence; constant
FQGQVTISADKSISTAYLQWSSLKASDTAMYY region underlined;
CARHGRGYEGYEGAFDIWGQGTLVTVSSAST modified Fc region
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE with L234A, L235A
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS mutations (mutations
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE in bold)*
PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK SEQ ID NO: Ab85 full
length EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 277 heavy chain
WIGWVRQMPGKGLEWMAIINPRDSDTRYRPS sequence: constant
FQGQVTISADKSISTAYLQWSSLKASDTAMYY region underlined;
CARHGRGYEGYEGAFDIWGQGTLVTVSSAST modified Fc region
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE with L234A, L235A,
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS D2650 mutations
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE (mutations in bold)*
PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKP KDTLMISRTPEVTCVVVCVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK SEQ ID NO: Ab85 full
length EVQLVQSGAEVKKPGESLKISCKGSGYSFTNY 278 heavy chain
WIGWVRQMPGKGLEWMAIINPRDSDTRYRPS sequence (LALA-
FQGQVTISADKSISTAYLQWSSLKASDTAMYY D265C-H435A
CARHGRGYEGYEGAFDIWGQGTLVTVSSAST mutant); constant
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE region underlined
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKP KDTLMISRTPEVTCVVVCVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNAYT QKSLSLSPGK SEQ ID NO: Ab249 full
length EVQLVQSGAEVKKPGESLKISCKGSGYRFTTS 279 heavy chain
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS sequence; constant
FQGQVTISADKSISTAYLQWSSLKASDTAMYY region underlined
CARHGLGYNGYEGAFDIWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK SEQ ID NO: Ab249 full
length EVQLVQSGAEVKKPGESLKISCKGSGYRFTTS 280 heavy chain
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS sequence; constant
FQGQVTISADKSISTAYLQWSSLKASDTAMYY region underlined
CARHGLGYNGYEGAFDIWGQGTLVTVSSAST (LALA mutations)*
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSRDELTKNQVSLTCLVKGFYP
SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
QKSLSLSPGK SEQ ID NO: Ab249 full length
EVQLVQSGAEVKKPGESLKISCKGSGYRFTTS 281 heavy chain
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS sequence; constant
FQGQVTISADKSISTAYLQWSSLKASDTAMYY region underlined
CARHGLGYNGYEGAFDIWGQGTLVTVSSAST (LALA-D265C
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE mutations)*
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKP KDTLMISRTPEVTCVVVCVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK SEQ ID NO: Ab249 full
length EVQLVQSGAEVKKPGESLKISCKGSGYRFTTS 282 heavy chain
WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS sequence; constant
FQGQVTISADKSISTAYLQWSSLKASDTAMYY region underlined;
CARHGLGYNGYEGAFDIWGQGTLVTVSSAST (LALA-D265C-
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE H435A mutations)*
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKP KDTLMISRTPEVTCVVVCVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNAYT QKSLSLSPGK SEQ ID NO: Light chain
constant RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY 283 region
PREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLS
SPVTKSFNRGEC SEQ ID NO: Ab85 full length light
DIQMTQSPSSLSASVGDRVTITCRSSQGIRSD 284 chain; constant
LGWYQQKPGKAPKLLIYDASNLETGVPSRFSG region underlined
SGSGTDFTLTISSLQPEDFATYYCQQANGFPL TFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: Ab249 light chain;
DIQMTQSPSSLSASVGDRVTITCRASQGIGSA 285 constant region
LAWYQQKPGKAPKLLIYDASNLETGVPSRFSG underlined
SGSGTDFTLTISSLQPEDFATYYCQQLNGYPL TFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: Ab249 HC-CDR1 TSWIG 286 SEQ ID
NO: Ab249 HC-CDR3 HGLGYNGYEGAFDI 287 SEQ ID NO: Ab249 LC-CDR1
RASQGIGSALA 288 SEQ ID NO: Ab249 LC-CDR3 CQQLNGYPLT 289 SEQ ID NO:
ch-BBK2 Heavy Chain QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWI 290
(Variable region NWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKA italicized)
TLTVDKSSNTVYMQLNSPTSEDSAVYYCTRNGVE
GYPHYYAMEYWGQGTSVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD
IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
GK SEQ ID NO: ch-BBK2 Light Chain
DIQMTQTTSALSASLGDRVTIGCRASQDLSNHLYW 291 (Variable region
YQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTD italicized)
YSLTIRNLEQEDVATYFCQQGYTLPYTFGGGTKLEI
KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC SEQ ID NO: ch-BBK2 VH CDR1
SYWIN 292 SEQ ID NO: ch-BBK2 VH CDR2 NIYPSDSYTNYNQKFKD 293 SEQ ID
NO: ch-BBK2 VH CDR3 NGVEGYPHYYAMEY 294 SEQ ID NO: ch-BBK2 VL CDR1
RASQDLSNHLY 295 SEQ ID NO: ch-BBK2 VL CDR2 YTSRLHS 296 SEQ ID NO:
ch-BBK2 VL CDR3 QQGYTLPYT 297 SEQ ID NO: ch-BBK2 Light Chain
QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWI 298 Variable Region
NWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKA
TLTVDKSSNTVYMQLNSPTSEDSAVYYCTRNGVE GYPHYYAMEYWGQGTSVTVSS SEQ ID NO:
ch-BBK2 Heavy Chain DIQMTQTTSALSASLGDRVTIGCRASQDLSNHLYW 299
Variable Region YQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTD
YSLTIRNLEQEDVATYFCQQGYTLPYTFGGGTKLEI K. SEQ ID NO: Anti CD2 Ab1
CDR- EYYMY 300 H1 SEQ ID NO: Ab1 CDR-H2 RIDPEDGSIDYVEKFKK 301 SEQ
ID NO: Ab1 CDR-H3 GKFNYRFAY 302 SEQ ID NO: Ab1 CDR-L1
RSSQSLLHSSGNTYLN 303 SEQ ID NO: Ab1 CDR-L2 LVSKLES 304 SEQ ID NO:
Ab1 CDR-L3 MQFTHYPYT 305 SEQ ID NO: Ab1 Heavy chain
QVQLVQSGAEVKKPGASVKVSCKASGYTFTE 306 variable region
YYMYWVRQAPGQGLELMGRIDPEDGSIDYVE KFKKKVTLTADTSSSTAYMELSSLTSDDTAVY
YCARGKFNYRFAYWGQGTLVTVSS SEQ ID NO: Ab1 Light chain
DVVMTQSPPSLLVTLGQPASISCRSSQSLLHS 307 variable region
SGNTYLNWLLQRPGQSPQPLIYLVSKLESGVP DRFSGSGSGTDFTLKISGVEAEDVGVYYCMQ
FTHYPYTFGQGTKLEIK SEQ ID NO: Ab1a Heavy chain
QVQLVQSGAEVQRPGASVKVSCKASGYIFTE 308 variable region
YYMYWVRQAPGQGLELVGRIDPEDGSIDYVE KFKKKVTLTADTSSSTAYMELSSLTSDDTAVY
YCARGKFNYRFAYWGQGTLVTVSS SEQ ID NO: Ab1a Light chain
DVVMTQSPPSLLVTLGQPASISCRSSQSLLHS 309 variable region
SGNTYLNWLLQRPGQSPQPLIYLVSKLESGVP DRFSGSGSGTDFTLKISGVEAEDVGVYYCMQ
FTHYPYTFGQGTKLEIK SEQ ID NO: Consensus human
EVQLVESGGGLVQPGGSLRLSCAASGFTFSD 310 Ab
YAMSWVRQAPGKGLEWVAVISENGSDTYYA Heavy chain variable
DSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV domain YYCARDRGGAVSYFDVWGQGTLVTVSS
SEQ ID NO: Consensus human DIQMTQSPSSLSASVGDRVTITCRASQDVSSY 311 Ab
LAWYQQKPGKAPKLLIYAASSLESGVPSRFS Light chain variable
GSGSGTDFTLTISSLQPEDFATYYCQQYNSLP domain YTFGQGTKVEIKRT SEQ ID NO:
Human CD2 MSFPCKFVASFLLIFNVSSKGAVSKEITNALET 312 sequence
WGALGQDINLDIPSFQMSDDIDDIKWEKTSDK KKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLK
TDDQDIYKVSIYDTKGKNVLEKIFDLKIQERVSK PKISWTCINTTLTCEVMNGTDPELNLYQDGKH
LKLSQRVITHKWTTSLSAKFKCTAGNKVSKES SVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALL
VFYITKRKKQRSRRNDEELETRAHRVATEERG RKPHQIPASTPQNPATSQHPPPPPGHRSQAP
SHRPPPPGHRVQHQPQKRPPAPSGTQVHQQ KGPPLPRPRVQPKPPHGAAENSLSPSSN SEQ ID
NO: RPA-2.10 CDR-H1 GFTFSSY 313 SEQ ID NO: Anti-CD2 RPA-2.10 SGGGF
314 CDR-H2 SEQ ID NO: RPA-2.10 CDR-H3 SSYGEIMDY 315 Variant 1 SEQ
ID NO: RPA-2.10 CDR-H3 SSYGELMDY 316 Variant 2 SEQ ID NO: RPA-2.10
CDR-L1 RASQRIGTSIH 317 SEQ ID NO: RPA-2.10 CDR-L2 YASESIS 318 SEQ
ID NO: RPA-2.10 CDR-L3 QQSHGWPFTF 319 SEQ ID NO: RPA-2.10 Heavy
EVKLVESGGGLVKPGGSLKLSCAASGFTFSSY 320 chain variable
DMSWVRQTPEKRLEWVASISGGGFLYYLDSV region
KGRFTISRDNARNILYLHMTSLRSEDTAMYYC Variant 1 ARSSYGEIMDYWGQGTSVTVSS
SEQ ID NO: RPA-2.10 Heavy EVKLVESGGGLVKPGGSLKLSCAASGFTFSSY 321
chain variable DMSWVRQTPEKRLEWVASISGGGFLYYLDSV region
KGRFTISRDNARNILYLHMTSLRSEDTAMYYC Variant 2 ARSSYGELMDYWGQGTSVTVSS
SEQ ID NO: RPA-2.10 Light chain DILLTQSPAILSVSPGERVSFSCRASQRIGTSIH
322 variable region WYQQRTTGSPRLLIKYASESISGIPSRFSGSG
SGTDFTLSINSVESEDVADYYCQQSHGWPFT FGGGTKLEIE SEQ ID NO: RPA-2.10
Heavy AKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGY 323 chain constant region
FPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVPSSTVVPSETVICNVAHPASSTKVDK
KIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVL TITLTPKVTCVVVDISKDDPEVQFSWFVDDVEV
HTAQTQPREEQFNSTFRSVSELPIMHQDWLN GKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQ
VYTIPPPKEQMAKDKVSLTCMITDFFPEDITVE WQWNGQPAENYKNTQPIMDTDGSYFVYSKL
NVQKSNWEAGNTFTCSVLHEGLHNHHTEKSL SHSPGK SEQ ID NO: RPA-2.10 Light
chain RADAAPTVSIFPPSSEQLTSGGASVVCFLNNF 324 constant region
YPKDINVKWKIDGSERQNGVLNSWTDQDSKD STYSMSSTLTLTKDEYERHNSYTCEATHKTST
SPIVKSFNRNEC SEQ ID NO: Anti-CD5 antibody
DIQMTQSPSSMSASLGDRVTITCRASQDINSY 325 Light chain variable
LSWFQQKPGKSPKTLIYRANRLVDGVPSRFS region
GSGSGTDYTLTISSLQYEDFGIYYCQQYDESP WTFGGGTKLEIK SEQ ID NO: Heavy
chain variable QIQLVQSGPGLKKPGGSVRISCAASGYTFTNY 326 region
GMNWVKQAPGKGLRWMGWINTHTGEPTYAD DFKGRFTFSLDTSKSTAYLQINSLRAEDTATYF
CTRRGYDWYFDVWGQGTTVTVSS SEQ ID NO: CDR-H1 GYTFTNY 327 SEQ ID NO:
CDR-H2 NTHTGE 328 SEQ ID NO: CDR-H3 RGYDWYFDV 329 SEQ ID NO: CDR-L1
RASQDINSYLS 330 SEQ ID NO: CDR-L2 RANRLVD 331 SEQ ID NO: CDR-L3
QQYDESPWT 332 SEQ ID NO: Light chain variable
DIQMTQSPSSLSASVGDRVTITCRASQDINSYL 333 region
SWFQQKPGKAPKTLIYRANRLESGVPSRFSG SGSGTDYTLTISSLQYEDFGIYYCQQYDESPW
TFGGGTKLEIK SEQ ID NO: Heavy chain variable
EIQLVQSGGGLVKPGGSVRISCAASGYTFTNY 334 region
GMNWVRQAPGKGLEWMGWINTHYGEPTYAD SFKGTRTFSLDDSKNTAYLQINSLRAEDTAVYF
CTRRGYDWYFDVWGQGGTTVTVSS SEQ ID NO: CDR-H1 GYTFTNY 335 SEQ ID NO:
CDR-H2 NTHYGE 336 SEQ ID NO: CDR-H3 RRGYDWYFDV 337 SEQ ID NO:
CDR-L1 RASQDINSYLS 338 SEQ ID NO: CDR-L2 RANRLES 339 SEQ ID NO:
CDR-L3 QQYDESPWT 340 SEQ ID NO: CDR-H1 GYSITSGYY 341 SEQ ID NO:
CDR-H2 ISYSGFT 342 SEQ ID NO: CDR-H3 AGDRTGSWFAY 343 SEQ ID NO:
CDR-L1 QDISNY 344 SEQ ID NO: CDR-L2 ATS 345 SEQ ID NO: CDR-L3
LQYASYPFT 346 SEQ ID NO: CDR-H1 GYIFTNYG 347 SEQ ID NO: CDR-H2
INTYNGEP 348 SEQ ID NO: CDR-H3 ARGDYYGYEDY 349 SEQ ID NO: CDR-L1
QGISNY 350 SEQ ID NO: CDR-L2 YTS 351 SEQ ID NO: CDR-L3 QQYSKLPWT
352 SEQ ID NO: 5D7 CDR-H1 FSLSTSGMG 353 SEQ ID NO: 5D7 CDR-H2 WWDDD
354 SEQ ID NO: 5D7 CDR-H3 RRATGTGFDY 355
SEQ ID NO: 5D7 CDR-L1 QDVGTA 356 SEQ ID NO: 5D7 CDR-L2 WTSTRHT 357
SEQ ID NO: 5D7 CDR-L3 YNSYNT 358 SEQ ID NO: Humanized 5D7
QVTLKESGPVLVKPTETLTLTCTFSGFSLSTSG 359 Heavy chain variable
MGVGWIRQAPGKGLEWVAHIWWDDDVYYNP region (CDRs in
SLKSRLTITKDASKDQVSLKLSSVTAADTAVYY bold) CVRRRATGTGFDYWGQGTLVTVSS
SEQ ID NO: Humanized 5D7 Light NIVMTQSPSSLSASVGDRVTITCQASQDVGTA 360
chain variable region VAWYQQKPDQSPKLLIYWTSTRHTGVPDRFT (CDRs in
bold) GSGSGTDFTLTISSLQPEDIATYFCHQYNSYNT FGSGTKLEIK SEQ ID NO:
Consensus human EVQLVESGGGLVQPGGSLRLSCAASGFTFSD 361 Heavy chain
variable YAMSWVRQAPGKGLEWVAVISENGSDTYYA domain (CDRs in
DSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV bold) YYCARDRGGAVSYFDVWGQGTLVTVSS
SEQ ID NO: Consensus human DIQMTQSPSSLSASVGDRVTITCRASQDVSSY 362
Light chain variable LAWYQQKPGKAPKLLIYAASSLESGVPSRFS domain (CDRs
in GSGSGTDFTLTISSLQPEDFATYYCQQYNSLP bold) YTFGQGTKVEIKRT SEQ ID NO:
Human CD5 amino MVCSQSWGRS SKQWEDPSQA 363 acid sequence SKVCQRLNCG
VPLSLGPFLV TYTPQSSIIC YGQLGSFSNCSHSRNDMCHS LGLTCLEPQK TTPPTTRPPP
TTTPEPTAPP RLQLVAQSGG QHCAGVVEFYSGSLGGTISY EAQDKTQDLE NFLCNNLQCG
SFLKHLPETE AGRAQDPGEP REHQPLPIQWKIQNSSCTSL EHCFRKIKPQ KSGRVLALLC
SGFQPKVQSR LVGGSSICEG TVEVRQGAQWAALCDSSSAR SSLRWEEVCR EQQCGSVNSY
RVLDAGDPTS RGLFCPHQKL SQCHELWERNSYCKKVFVTC QDPNPAGLAA GTVASIILAL
VLLVVLLVVC GPLAYKKLVK KFRQKKQRQWIGPTGMNQNM SFHRNHTATV RSHAENPTAS
HVDNEYSQPP RNSHLSAYPA LEGALHRSSMQPDNSSDSDY DLHGAQRL
Other Embodiments
[0478] All publications, patents, and patent applications mentioned
in this specification are incorporated herein by reference to the
same extent as if each independent publication or patent
application was specifically and individually indicated to be
incorporated by reference.
[0479] While the invention has been described in connection with
specific embodiments thereof, it will be understood that it is
capable of further modifications and this application is intended
to cover any variations, uses, or adaptations of the invention
following, in general, the principles of the invention and
including such departures from the invention that come within known
or customary practice within the art to which the invention
pertains and may be applied to the essential features hereinbefore
set forth, and follows in the scope of the claims.
[0480] Other embodiments are within the claims.
Sequence CWU 1
1
44215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 1Ser Tyr Trp Ile Gly1 5217PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 2Ile
Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln1 5 10
15Gly314PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 3His Gly Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe
Asp Ile1 5 10411PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 4Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu
Ala1 5 1057PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 5Asp Ala Ser Ser Leu Glu Ser1 5610PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 6Cys
Gln Gln Phe Asn Ser Tyr Pro Leu Thr1 5 107120PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
7Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5
10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ala Val Ile Ser Glu Asn Gly Ser Asp Thr Tyr Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys
Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Arg Gly Gly Ala Val Ser
Tyr Phe Asp Val Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser
Ser 115 1208109PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 8Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Asp Val Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu
Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe
Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Leu Pro Tyr 85 90 95Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 100
1059121PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 9Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Asp Ala 20 25 30Asp Met Asp Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Ala Gly
Ser Tyr Thr Thr Glu Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asp Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met
Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg
Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly
Thr Leu Val Thr Val Ser Ser 115 12010107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
10Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ser Tyr Ile Ala Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105119PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 11Phe Thr Phe Ser Asp Ala Asp Met Asp1
51219PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 12Arg Thr Arg Asn Lys Ala Gly Ser Tyr Thr Thr Glu
Tyr Ala Ala Ser1 5 10 15Val Lys Gly1312PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 13Ala
Arg Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu1 5 101411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 14Arg
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5 10157PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 15Ala
Ala Ser Ser Leu Gln Ser1 5169PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 16Gln Gln Ser Tyr Ile Ala Pro
Tyr Thr1 517363DNAArtificial SequenceDescription of Artificial
Sequence Synthetic polynucleotide 17gaggtgcagc tggtggagtc
tgggggaggc ttggtccagc ctggagggtc cctgagactc 60tcctgtgcag cctctggatt
caccttcagt gacgccgaca tggactgggt ccgccaggct 120ccagggaagg
ggctggagtg ggttggccgt actagaaaca aagcaggaag ttacaccaca
180gaatacgccg cgtctgtgaa aggcagattc accatctcaa gagatgattc
aaagaactca 240ctgtatctgc aaatgaacag cctgaaaacc gaggacacgg
cggtgtacta ctgcgccaga 300gagcctaaat actggatcga cttcgaccta
tgggggagag gtaccttggt caccgtctcc 360tca 36318321DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
18gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcagcaa
agctacatcg ccccttacac ttttggcgga 300gggaccaagg ttgagatcaa a
32119119PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 19Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Gly Thr Phe Arg Ile Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Asp Phe Gly
Val Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr
Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser
Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly
Leu Asp Thr Asp Glu Phe Asp Leu Trp Gly Arg Gly 100 105 110Thr Leu
Val Thr Val Ser Ser 11520106PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 20Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile
Thr Cys Arg Ala Ser Gln Ser Ile Asn Ser Tyr 20 25 30Leu Asn Trp Tyr
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala
Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Val Ser Asp Ile Thr
85 90 95Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105219PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 21Gly Thr Phe Arg Ile Tyr Ala Ile Ser1
52217PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 22Gly Ile Ile Pro Asp Phe Gly Val Ala Asn Tyr Ala
Gln Lys Phe Gln1 5 10 15Gly2312PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 23Ala Arg Gly Gly Leu Asp Thr
Asp Glu Phe Asp Leu1 5 102411PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 24Arg Ala Ser Gln Ser Ile Asn
Ser Tyr Leu Asn1 5 10257PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 25Ala Ala Ser Ser Leu Gln
Ser1 5268PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 26Gln Gln Gly Val Ser Asp Ile Thr1
527357DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 27caggtgcagc tggtgcagtc tggggctgag
gtgaagaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggagg caccttccga
atctatgcta tcagctgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatgggaggg atcatccctg acttcggtgt agcaaactac 180gcacagaagt
tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac
240atggagctga gcagcctgag atctgaggac acggcggtgt actactgcgc
cagaggtgga 300ttggacacag acgagttcga cctatggggg agaggtacct
tggtcaccgt ctcctca 35728318DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 28gacatccaga
tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
gggcaagtca gagcattaac agctatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcagcaa
ggagtcagtg acatcacttt tggcggaggg 300accaaggttg agatcaaa
31829119PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 29Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Ile Phe Gly
Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr
Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser
Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly
Leu Asp Thr Asp Glu Phe Asp Leu Trp Gly Arg Gly 100 105 110Thr Leu
Val Thr Val Ser Ser 11530106PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 30Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile
Thr Cys Arg Ala Ser Gln Ser Ile Asn Ser Tyr 20 25 30Leu Asn Trp Tyr
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala
Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Val Ser Asp Ile Thr
85 90 95Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105319PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 31Gly Thr Phe Ser Ser Tyr Ala Ile Ser1
53217PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 32Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala
Gln Lys Phe Gln1 5 10 15Gly3312PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 33Ala Arg Gly Gly Leu Asp Thr
Asp Glu Phe Asp Leu1 5 103411PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 34Arg Ala Ser Gln Ser Ile Asn
Ser Tyr Leu Asn1 5 10357PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 35Ala Ala Ser Ser Leu Gln
Ser1 5368PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 36Gln Gln Gly Val Ser Asp Ile Thr1
537357DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 37caggtgcagc tggtgcagtc tggggctgag
gtgaagaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggagg caccttcagc
agctatgcta tcagctgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatgggaggg atcatcccta tctttggtac agcaaactac 180gcacagaagt
tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac
240atggagctga gcagcctgag atctgaggac acggcggtgt actactgcgc
cagaggtgga 300ttggacacag acgagttcga cctatggggg agaggtacct
tggtcaccgt ctcctca 35738318DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 38gacatccaga
tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
gggcaagtca gagcattaac agctatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcagcaa
ggagtcagtg acatcacttt tggcggaggg 300accaaggttg agatcaaa
31839119PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 39Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Gly Thr Phe Ser Leu Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Ala Phe Gly
Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr
Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser
Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly
Leu Asp Thr Asp Glu Phe Asp Leu Trp Gly Arg Gly 100 105 110Thr Leu
Val Thr Val Ser Ser 11540106PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 40Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile
Thr Cys Arg Ala Ser Gln Ser Ile Asn Ser Tyr 20 25 30Leu Asn Trp Tyr
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala
Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Val Ser Asp Ile Thr
85 90 95Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105419PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 41Gly Thr Phe Ser Leu Tyr Ala Ile Ser1
54217PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 42Gly Ile Ile Pro Ala Phe Gly Thr Ala Asn Tyr Ala
Gln Lys Phe Gln1 5 10 15Gly4312PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 43Ala Arg Gly Gly Leu Asp Thr
Asp Glu Phe Asp Leu1 5 104411PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 44Arg Ala Ser Gln Ser Ile Asn
Ser Tyr Leu Asn1 5 10457PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 45Ala Ala Ser Ser Leu Gln
Ser1 5468PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 46Gln Gln Gly Val Ser Asp Ile Thr1
547357DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 47caggtgcagc tggtgcagtc tggggctgag
gtgaagaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggagg caccttcagc
ctctatgcta tctcctgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatgggaggg atcatccctg ccttcggtac cgcaaactac 180gcacagaagt
tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac
240atggagctga gcagcctgag atctgaggac acggcggtgt actactgcgc
cagaggtgga 300ttggacacag acgagttcga cctatggggg agaggtacct
tggtcaccgt ctcctca 35748318DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 48gacatccaga
tgacccagtc tccatcctcc
ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca gagcattaac
agctatttaa attggtatca gcagaaacca 120gggaaagccc ctaagctcct
gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180aggttcagtg
gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct
240gaagattttg caacttacta ctgtcagcaa ggagtcagtg acatcacttt
tggcggaggg 300accaaggttg agatcaaa 31849119PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
49Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Leu
Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Gly Ile Ile Pro His Phe Gly Leu Ala Asn Tyr Ala
Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr
Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Leu Asp Thr Asp Glu
Phe Asp Leu Trp Gly Arg Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11550106PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 50Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
Gln Ser Ile Asn Ser Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr
Tyr Tyr Cys Gln Gln Gly Val Ser Asp Ile Thr 85 90 95Phe Gly Gly Gly
Thr Lys Val Glu Ile Lys 100 105519PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 51Gly Thr Phe Ser Leu Tyr
Ala Ile Ser1 55217PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 52Gly Ile Ile Pro His Phe Gly Leu Ala
Asn Tyr Ala Gln Lys Phe Gln1 5 10 15Gly5312PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 53Ala
Arg Gly Gly Leu Asp Thr Asp Glu Phe Asp Leu1 5 105411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 54Arg
Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asn1 5 10557PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 55Ala
Ala Ser Ser Leu Gln Ser1 5568PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 56Gln Gln Gly Val Ser Asp Ile
Thr1 557357DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 57caggtgcagc tggtgcagtc tggggctgag
gtgaagaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggagg caccttctcc
ctctatgcta tcagctgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatgggaggg atcatccctc acttcggtct cgcaaactac 180gcacagaagt
tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac
240atggagctga gcagcctgag atctgaggac acggcggtgt actactgcgc
cagaggtgga 300ttggacacag acgagttcga cctatggggg agaggtacct
tggtcaccgt ctcctca 35758318DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 58gacatccaga
tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
gggcaagtca gagcattaac agctatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcagcaa
ggagtcagtg acatcacttt tggcggaggg 300accaaggttg agatcaaa
31859123PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 59Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Asn Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Ser Gly Ser Gly Gly
Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Gly Pro
Pro Thr Tyr His Thr Asn Tyr Tyr Tyr Met Asp Val 100 105 110Trp Gly
Lys Gly Thr Thr Val Thr Val Ser Ser 115 12060107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
60Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Thr Asn Ser Phe Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105619PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 61Phe Thr Phe Ser Asn Tyr Ala Met Ser1
56217PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 62Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala
Asp Ser Val Lys1 5 10 15Gly6316PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 63Ala Lys Gly Pro Pro Thr Tyr
His Thr Asn Tyr Tyr Tyr Met Asp Val1 5 10 156411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 64Arg
Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala1 5 10657PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 65Ala
Ala Ser Ser Leu Gln Ser1 5669PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 66Gln Gln Thr Asn Ser Phe Pro
Tyr Thr1 567369DNAArtificial SequenceDescription of Artificial
Sequence Synthetic polynucleotide 67gaggtgcagc tgttggagtc
tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
cacctttagc aattatgcca tgagctgggt ccgccaggct 120ccagggaagg
ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac
180gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa
cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggcggtgt
actactgcgc caagggccct 300cctacatacc acacaaacta ctactacatg
gacgtatggg gcaagggtac aactgtcacc 360gtctcctca 36968321DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
68gacatccaga tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc
60atcacttgtc gggcgagtca gggtattagc agctggttag cctggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagat ttcactctca
ccatcagcag cctgcagcct 240gaagattttg caacttatta ctgtcagcaa
acaaatagtt tcccttacac ttttggcgga 300gggaccaagg ttgagatcaa a
32169123PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 69Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Ser Tyr 20 25 30Val Met Ile Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Asp Ser Val
Thr Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Gly Pro
Pro Thr Tyr His Thr Asn Tyr Tyr Tyr Met Asp Val 100 105 110Trp Gly
Lys Gly Thr Thr Val Thr Val Ser Ser 115 12070107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
70Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Thr Asn Ser Phe Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105719PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 71Phe Thr Phe Ser Ser Tyr Val Met Ile1
57217PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 72Ser Ile Ser Gly Asp Ser Val Thr Thr Tyr Tyr Ala
Asp Ser Val Lys1 5 10 15Gly7316PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 73Ala Lys Gly Pro Pro Thr Tyr
His Thr Asn Tyr Tyr Tyr Met Asp Val1 5 10 157411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 74Arg
Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala1 5 10757PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 75Ala
Ala Ser Ser Leu Gln Ser1 5769PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 76Gln Gln Thr Asn Ser Phe Pro
Tyr Thr1 577369DNAArtificial SequenceDescription of Artificial
Sequence Synthetic polynucleotide 77gaggtgcagc tgttggagtc
tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
cacctttagc agctatgtca tgatctgggt ccgccaggct 120ccagggaagg
ggctggagtg ggtctcaagc attagtggtg acagcgtaac aacatactac
180gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa
cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggcggtgt
actactgcgc caagggccct 300cctacatacc acacaaacta ctactacatg
gacgtatggg gcaagggtac aactgtcacc 360gtctcctca 36978321DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
78gacatccaga tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc
60atcacttgtc gggcgagtca gggtattagc agctggttag cctggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagat ttcactctca
ccatcagcag cctgcagcct 240gaagattttg caacttatta ctgtcagcaa
acaaatagtt tcccttacac ttttggcgga 300gggaccaagg ttgagatcaa a
32179121PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 79Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Asp His 20 25 30Tyr Met Asp Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Ala Ser
Ser Tyr Thr Thr Glu Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asp Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met
Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg
Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly
Thr Leu Val Thr Val Ser Ser 115 12080107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
80Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ser Tyr Ile Ala Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105819PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 81Phe Thr Phe Ser Asp His Tyr Met Asp1
58219PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 82Arg Thr Arg Asn Lys Ala Ser Ser Tyr Thr Thr Glu
Tyr Ala Ala Ser1 5 10 15Val Lys Gly8312PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 83Ala
Arg Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu1 5 108411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 84Arg
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5 10857PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 85Ala
Ala Ser Ser Leu Gln Ser1 5869PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 86Gln Gln Ser Tyr Ile Ala Pro
Tyr Thr1 587363DNAArtificial SequenceDescription of Artificial
Sequence Synthetic polynucleotide 87gaggtgcagc tggtggagtc
tgggggaggc ttggtccagc ctggagggtc cctgagactc 60tcctgtgcag cctctggatt
caccttcagt gaccactaca tggactgggt ccgccaggct 120ccagggaagg
ggctggagtg ggttggccgt actagaaaca aagctagtag ttacaccaca
180gaatacgccg cgtctgtgaa aggcagattc accatctcaa gagatgattc
aaagaactca 240ctgtatctgc aaatgaacag cctgaaaacc gaggacacgg
cggtgtacta ctgcgccaga 300gagcctaaat actggatcga cttcgaccta
tgggggagag gtaccttggt caccgtctcc 360tca 36388321DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
88gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcagcaa
agctacatcg ccccttacac ttttggcgga 300gggaccaagg ttgagatcaa a
32189121PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 89Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly
Phe Thr Phe Ser Asp His 20 25 30Asp Met Asn Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Gly Arg Thr Arg Asn Ala Ala Gly
Ser Tyr Thr Thr Glu Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asp Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met
Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg
Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly
Thr Leu Val Thr Val Ser Ser 115 12090107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
90Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ser Tyr Ile Ala Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100
105919PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 91Phe Thr Phe Ser Asp His Asp Met Asn1
59219PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 92Arg Thr Arg Asn Ala Ala Gly Ser Tyr Thr Thr Glu
Tyr Ala Ala Ser1 5 10 15Val Lys Gly9312PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 93Ala
Arg Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu1 5 109411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 94Arg
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5 10957PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 95Ala
Ala Ser Ser Leu Gln Ser1 5969PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 96Gln Gln Ser Tyr Ile Ala Pro
Tyr Thr1 597363DNAArtificial SequenceDescription of Artificial
Sequence Synthetic polynucleotide 97gaggtgcagc tggtggagtc
tgggggaggc ttggtacagc cagggcggtc cctgagactc 60tcctgtacag cttctggatt
caccttcagt gaccacgaca tgaactgggt ccgccaggct 120ccagggaagg
ggctggagtg ggttggccgt actagaaacg ccgctggaag ttacaccaca
180gaatacgccg cgtctgtgaa aggcagattc accatctcaa gagatgattc
aaagaactca 240ctgtatctgc aaatgaacag cctgaaaacc gaggacacgg
cggtgtacta ctgcgccaga 300gagcctaaat actggatcga cttcgaccta
tgggggagag gtaccttggt caccgtctcc 360tca 36398321DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
98gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcagcaa
agctacatcg ccccttacac ttttggcgga 300gggaccaagg ttgagatcaa a
32199121PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 99Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Val Asp His 20 25 30Asp Met Asp Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Leu Gly
Ser Tyr Thr Thr Glu Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asp Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met
Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg
Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly
Thr Leu Val Thr Val Ser Ser 115 120100107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
100Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ser Tyr Ile Ala Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 1051019PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 101Phe Thr Phe Val Asp His Asp Met Asp1
510219PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 102Arg Thr Arg Asn Lys Leu Gly Ser Tyr Thr Thr
Glu Tyr Ala Ala Ser1 5 10 15Val Lys Gly10312PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 103Ala
Arg Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu1 5 1010411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 104Arg
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5 101057PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 105Ala
Ala Ser Ser Leu Gln Ser1 51069PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 106Gln Gln Ser Tyr Ile Ala
Pro Tyr Thr1 5107363DNAArtificial SequenceDescription of Artificial
Sequence Synthetic polynucleotide 107gaggtgcagc tggtggagtc
tgggggaggc ttggtccagc ctggagggtc cctgagactc 60tcctgtgcag cctctggatt
caccttcgta gaccacgaca tggactgggt ccgccaggct 120ccagggaagg
ggctggagtg ggttggccgt actagaaaca aactaggaag ttacaccaca
180gaatacgccg cgtctgtgaa aggcagattc accatctcaa gagatgattc
aaagaactca 240ctgtatctgc aaatgaacag cctgaaaacc gaggacacgg
cggtgtacta ctgcgccaga 300gagcctaaat actggatcga cttcgaccta
tgggggagag gtaccttggt caccgtctcc 360tca 363108321DNAArtificial
SequenceDescription of Artificial Sequence Synthetic polynucleotide
108gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga
cagagtcacc 60atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca
gcagaaacca 120gggaaagccc ctaagctcct gatctatgct gcatccagtt
tgcaaagtgg ggtcccatca 180aggttcagtg gcagtggatc tgggacagat
ttcactctca ccatcagcag tctgcaacct 240gaagattttg caacttacta
ctgtcagcaa agctacatcg ccccttacac ttttggcgga 300gggaccaagg
ttgagatcaa a 321109214PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 109Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30Leu Asn Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala
Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ile Ala Pro Tyr
85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala
Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser Val Thr Glu Gln
Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175Ser Thr Leu Thr
Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190Ala Cys
Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200
205Phe Asn Arg Gly Glu Cys 210110451PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
110Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Ala 20 25 30Asp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Ala Gly Ser Tyr Thr Thr Glu
Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp
Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr
Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg Glu Pro Lys Tyr Trp
Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly Thr Leu Val Thr Val
Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125Val Phe Pro Leu Ala
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val145 150 155
160Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
Thr Val 180 185 190Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn Val Asn His 195 200 205Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
Val Glu Pro Lys Ser Cys 210 215 220Asp Lys Thr His Thr Cys Pro Pro
Cys Pro Ala Pro Glu Leu Leu Gly225 230 235 240Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280
285His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
Asn Gly305 310 315 320Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro Ala Pro Ile 325 330 335Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val 340 345 350Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro385 390 395
400Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val Met 420 425 430His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu Ser 435 440 445Pro Gly Lys 450111451PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
111Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Ala 20 25 30Asp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Ala Gly Ser Tyr Thr Thr Glu
Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp
Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr
Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg Glu Pro Lys Tyr Trp
Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly Thr Leu Val Thr Val
Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125Val Phe Pro Leu Ala
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val145 150 155
160Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
Thr Val 180 185 190Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn Val Asn His 195 200 205Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
Val Glu Pro Lys Ser Cys 210 215 220Asp Lys Thr His Thr Cys Pro Pro
Cys Pro Ala Pro Glu Leu Leu Gly225 230 235 240Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Cys Val Ser His 260 265 270Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280
285His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
Asn Gly305 310 315 320Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro Ala Pro Ile 325 330 335Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val 340 345 350Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro385 390 395
400Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val Met 420 425 430His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu Ser 435 440 445Pro Gly Lys 450112451PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
112Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Ala 20 25 30Asp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Ala Gly Ser Tyr Thr Thr Glu
Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp
Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr
Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg Glu Pro Lys Tyr Trp
Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly Thr Leu Val Thr Val
Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125Val Phe Pro Leu Ala
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val145 150 155
160Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
Thr Val 180 185 190Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn Val Asn His 195 200 205Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
Val Glu Pro Lys Ser Cys 210 215 220Asp Lys Thr His Thr Cys Pro Pro
Cys Pro Ala Pro Glu Ala Ala Gly225 230 235 240Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Cys Val Ser His 260 265 270Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280
285His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
Asn Gly305 310 315 320Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro Ala Pro Ile 325 330 335Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val 340 345 350Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro385 390 395
400Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val Met 420 425 430His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu Ser 435 440 445Pro Gly Lys 450113451PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
113Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Ala 20 25 30Asp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Ala Gly Ser Tyr Thr Thr Glu
Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp
Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr
Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg Glu Pro Lys Tyr Trp
Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly Thr Leu Val Thr Val
Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125Val Phe Pro Leu Ala
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val145 150 155
160Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
Thr Val 180 185 190Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn Val Asn His 195 200 205Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
Val Glu Pro Lys Ser Cys 210 215 220Asp Lys Thr His Thr Cys Pro Pro
Cys Pro Ala Pro Glu Leu Leu Gly225 230 235 240Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Cys Val Ser His 260 265 270Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280
285His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
Asn Gly305 310 315 320Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro Ala Pro Ile 325 330 335Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val 340 345 350Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro385 390 395
400Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val Met 420 425 430His Glu Ala Leu His Asn Ala Tyr Thr Gln Lys Ser
Leu Ser Leu Ser 435 440 445Pro Gly Lys 450114451PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
114Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Ala 20 25 30Asp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Gly Arg Thr Arg Asn Lys Ala Gly Ser Tyr Thr Thr Glu
Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp
Ser Lys Asn Ser65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr
Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg Glu Pro Lys Tyr Trp
Ile Asp Phe Asp Leu Trp Gly 100 105 110Arg Gly Thr Leu Val Thr Val
Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125Val Phe Pro Leu Ala
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val145 150 155
160Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
Thr Val 180 185 190Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn Val Asn His 195 200 205Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
Val Glu Pro Lys Ser Cys 210 215 220Asp Lys Thr His Thr Cys Pro Pro
Cys Pro Ala Pro Glu Ala Ala Gly225 230 235 240Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Cys Val Ser His 260 265 270Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280
285His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
Asn Gly305 310 315 320Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro Ala Pro Ile 325 330 335Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val 340 345 350Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro385 390 395
400Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val Met 420 425 430His Glu Ala Leu His Asn Ala Tyr Thr Gln Lys Ser
Leu Ser Leu Ser 435 440 445Pro Gly Lys 450115213PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
115Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Ser
Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Gly Val Ser Asp Ile Thr 85 90 95Phe Gly Gly Gly Thr Lys Val Glu Ile
Lys Arg Thr Val Ala Ala Pro 100 105 110Ser Val Phe Ile Phe Pro Pro
Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125Ala Ser Val Val Cys
Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140Val Gln Trp
Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu145 150 155
160Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
Tyr Ala 180 185 190Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
Thr Lys Ser Phe 195 200 205Asn Arg Gly Glu Cys
210116449PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 116Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Gly Thr Phe Arg Ile Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala
Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Asp Phe
Gly Val Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile
Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly
Gly Leu Asp Thr Asp Glu Phe Asp Leu Trp Gly Arg Gly 100 105 110Thr
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120
125Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp145 150 155 160Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
Phe Pro Ala Val Leu 165 170 175Gln Ser Ser Gly Leu Tyr Ser Leu Ser
Ser Val Val Thr Val Pro Ser 180 185 190Ser Ser Leu Gly Thr Gln Thr
Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205Ser Asn Thr Lys Val
Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220Thr His Thr
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro225 230 235
240Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp 260 265 270Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn 275 280 285Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val 290 295 300Val Ser Val Leu Thr Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu305 310 315 320Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350Leu
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 355 360
365Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu385 390 395 400Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys 405 410 415Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys Ser Val Met His Glu 420 425 430Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440
445Lys117449PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 117Gln Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Gly Thr Phe Arg Ile Tyr 20 25 30Ala Ile Ser Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro
Asp Phe Gly Val Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val
Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg Gly Gly Leu Asp Thr Asp Glu Phe Asp Leu Trp Gly Arg Gly 100 105
110Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
Ala Leu 130 135 140Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
Thr Val Ser Trp145 150 155 160Asn Ser Gly Ala Leu Thr Ser Gly Val
His Thr Phe Pro Ala Val Leu 165 170 175Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205Ser Asn Thr
Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro225 230
235 240Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser 245 250 255Arg Thr Pro Glu Val Thr Cys Val Val Val Cys Val Ser
His Glu Asp 260 265 270Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn 275 280 285Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg Val 290 295 300Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu305 310 315 320Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345
350Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu 370 375 380Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu385 390 395 400Asp Ser Asp Gly Ser Phe Phe Leu Tyr
Ser Lys Leu Thr Val Asp Lys 405 410 415Ser Arg Trp Gln Gln Gly Asn
Val Phe Ser Cys Ser Val Met His Glu 420 425 430Ala Leu His Asn His
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440
445Lys118449PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 118Gln Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Gly Thr Phe Arg Ile Tyr 20 25 30Ala Ile Ser Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro
Asp Phe Gly Val Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val
Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg Gly Gly Leu Asp Thr Asp Glu Phe Asp Leu Trp Gly Arg Gly 100 105
110Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
Ala Leu 130 135 140Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
Thr Val Ser Trp145 150 155 160Asn Ser Gly Ala Leu Thr Ser Gly Val
His Thr Phe Pro Ala Val Leu 165 170 175Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205Ser Asn Thr
Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro225 230
235 240Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser 245 250 255Arg Thr Pro Glu Val Thr Cys Val Val Val Cys Val Ser
His Glu Asp 260 265 270Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn 275 280 285Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg Val 290 295 300Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu305 310 315 320Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345
350Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu 370 375 380Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu385 390 395 400Asp Ser Asp Gly Ser Phe Phe Leu Tyr
Ser Lys Leu Thr Val Asp Lys
405 410 415Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
His Glu 420 425 430Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
Leu Ser Pro Gly 435 440 445Lys119449PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
119Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Ile
Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Gly Ile Ile Pro Asp Phe Gly Val Ala Asn Tyr Ala
Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr
Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Leu Asp Thr Asp Glu
Phe Asp Leu Trp Gly Arg Gly 100 105 110Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155
160Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro Ser 180 185 190Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
Asn His Lys Pro 195 200 205Ser Asn Thr Lys Val Asp Lys Lys Val Glu
Pro Lys Ser Cys Asp Lys 210 215 220Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu Leu Leu Gly Gly Pro225 230 235 240Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255Arg Thr Pro
Glu Val Thr Cys Val Val Val Cys Val Ser His Glu Asp 260 265 270Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280
285Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
Lys Glu305 310 315 320Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys 325 330 335Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg Glu Pro Gln Val Tyr Thr 340 345 350Leu Pro Pro Ser Arg Asp Glu
Leu Thr Lys Asn Gln Val Ser Leu Thr 355 360 365Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu385 390 395
400Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
His Glu 420 425 430Ala Leu His Asn Ala Tyr Thr Gln Lys Ser Leu Ser
Leu Ser Pro Gly 435 440 445Lys120449PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
120Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Ile
Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Gly Ile Ile Pro Asp Phe Gly Val Ala Asn Tyr Ala
Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr
Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Leu Asp Thr Asp Glu
Phe Asp Leu Trp Gly Arg Gly 100 105 110Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155
160Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro Ser 180 185 190Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
Asn His Lys Pro 195 200 205Ser Asn Thr Lys Val Asp Lys Lys Val Glu
Pro Lys Ser Cys Asp Lys 210 215 220Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu Ala Ala Gly Gly Pro225 230 235 240Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255Arg Thr Pro
Glu Val Thr Cys Val Val Val Cys Val Ser His Glu Asp 260 265 270Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280
285Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
Lys Glu305 310 315 320Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys 325 330 335Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg Glu Pro Gln Val Tyr Thr 340 345 350Leu Pro Pro Ser Arg Asp Glu
Leu Thr Lys Asn Gln Val Ser Leu Thr 355 360 365Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu385 390 395
400Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
His Glu 420 425 430Ala Leu His Asn Ala Tyr Thr Gln Lys Ser Leu Ser
Leu Ser Pro Gly 435 440 445Lys121107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
121Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu1
5 10 15Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
Phe 20 25 30Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln 35 40 45Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
Lys Asp Ser 50 55 60Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu65 70 75 80Lys His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser 85 90 95Pro Val Thr Lys Ser Phe Asn Arg Gly
Glu Cys 100 105122330PRTHomo sapiens 122Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr
Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90
95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys 130 135 140Val Val Val Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215
220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
Glu225 230 235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr305 310 315 320Gln
Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330123330PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
123Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1
5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val Val Val
Cys Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155
160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Arg Asp Glu225 230 235 240Leu Thr Lys Asn Gln
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280
285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
Tyr Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
330124330PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 124Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110Pro
Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120
125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140Val Val Val Cys Val Ser His Glu Asp Pro Glu Val Lys Phe
Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230 235
240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His Asn His Tyr Thr305 310 315 320Gln Lys Ser Leu Ser
Leu Ser Pro Gly Lys 325 330125330PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 125Ala Ser Thr Lys Gly
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75
80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys 130 135 140Val Val Val Cys Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190His Gln
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200
205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
Asp Glu225 230 235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser
Cys Ser Val Met His Glu Ala Leu His Asn Ala Tyr Thr305 310 315
320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
330126330PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 126Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu
Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val
Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110Pro Ala
Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120
125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140Val Val Val Cys Val Ser His Glu Asp Pro Glu Val Lys Phe
Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230 235
240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His Asn Ala Tyr Thr305 310 315 320Gln Lys Ser Leu Ser
Leu Ser Pro Gly Lys 325 3301279PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptideMOD_RES(4)..(4)Ser or
ArgMOD_RES(5)..(5)Ser, Ile or Leu 127Gly Thr Phe Xaa Xaa Tyr Ala
Ile Ser1 512817PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptideMOD_RES(5)..(5)Ile, Asp, Ala or
HisMOD_RES(8)..(8)Thr, Val or Leu 128Gly Ile Ile Pro Xaa Phe Gly
Xaa Ala Asn Tyr Ala Gln Lys Phe Gln1 5 10 15Gly12912PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 129Ala
Arg Gly Gly Leu Asp Thr Asp Glu Phe Asp Leu1 5 1013011PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 130Arg
Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asn1 5 101317PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 131Ala
Ala Ser Ser Leu Gln Ser1 51328PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 132Gln Gln Gly Val Ser Asp
Ile Thr1 51339PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptideMOD_RES(5)..(5)Asn or
SerMOD_RES(7)..(7)Ala or ValMOD_RES(9)..(9)Ser or Ile 133Phe Thr
Phe Ser Xaa Tyr Xaa Met Xaa1 513417PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
peptideMOD_RES(1)..(1)Ala or SerMOD_RES(5)..(5)Ser or
AspMOD_RES(6)..(6)Gly or SerMOD_RES(7)..(7)Gly or
ValMOD_RES(8)..(8)Ser or Thr 134Xaa Ile Ser Gly Xaa Xaa Xaa Xaa Thr
Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly13516PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 135Ala
Lys Gly Pro Pro Thr Tyr His Thr Asn Tyr Tyr Tyr Met Asp Val1 5 10
1513611PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 136Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala1 5
101377PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 137Ala Ala Ser Ser Leu Gln Ser1
51389PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 138Gln Gln Thr Asn Ser Phe Pro Tyr Thr1
51399PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptideMOD_RES(4)..(4)Ser or ValMOD_RES(6)..(6)His or
AlaMOD_RES(7)..(7)Tyr or AspMOD_RES(9)..(9)Asp or Asn 139Phe Thr
Phe Xaa Asp Xaa Xaa Met Xaa1 514019PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
peptideMOD_RES(5)..(5)Lys or AlaMOD_RES(6)..(6)Ala or
LeuMOD_RES(7)..(7)Ser or Gly 140Arg Thr Arg Asn Xaa Xaa Xaa Ser Tyr
Thr Thr Glu Tyr Ala Ala Ser1 5 10 15Val Lys Gly14112PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 141Ala
Arg Glu Pro Lys Tyr Trp Ile Asp Phe Asp Leu1 5 1014211PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 142Arg
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5 101437PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 143Ala
Ala Ser Ser Leu Gln Ser1 51449PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 144Gln Gln Ser Tyr Ile Ala
Pro Tyr Thr1 5145976PRTHomo sapiens 145Met Arg Gly Ala Arg Gly Ala
Trp Asp Phe Leu Cys Val Leu Leu Leu1 5 10 15Leu Leu Arg Val Gln Thr
Gly Ser Ser Gln Pro Ser Val Ser Pro Gly 20 25 30Glu Pro Ser Pro Pro
Ser Ile His Pro Gly Lys Ser Asp Leu Ile Val 35 40 45Arg Val Gly Asp
Glu Ile Arg Leu Leu Cys Thr Asp Pro Gly Phe Val 50 55 60Lys Trp Thr
Phe Glu Ile Leu Asp Glu Thr Asn Glu Asn Lys Gln Asn65 70 75 80Glu
Trp Ile Thr Glu Lys Ala Glu Ala Thr Asn Thr Gly Lys Tyr Thr 85 90
95Cys Thr Asn Lys His Gly Leu Ser Asn Ser Ile Tyr Val Phe Val Arg
100 105 110Asp Pro Ala Lys Leu Phe Leu Val Asp Arg Ser Leu Tyr Gly
Lys Glu 115 120 125Asp Asn Asp Thr Leu Val Arg Cys Pro Leu Thr Asp
Pro Glu Val Thr 130 135 140Asn Tyr Ser Leu Lys Gly Cys Gln Gly Lys
Pro Leu Pro Lys Asp Leu145 150 155 160Arg Phe Ile Pro Asp Pro Lys
Ala Gly Ile Met Ile Lys Ser Val Lys 165 170 175Arg Ala Tyr His Arg
Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly 180 185 190Lys Ser Val
Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe 195 200 205Lys
Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg 210 215
220Glu Gly Glu Glu Phe Thr Val Thr Cys Thr Ile Lys Asp Val Ser
Ser225 230 235 240Ser Val Tyr Ser Thr Trp Lys Arg Glu Asn Ser Gln
Thr Lys Leu Gln 245 250 255Glu Lys Tyr Asn Ser Trp His His Gly Asp
Phe Asn Tyr Glu Arg Gln 260 265 270Ala Thr Leu Thr Ile Ser Ser Ala
Arg Val Asn Asp Ser Gly Val Phe 275 280 285Met Cys Tyr Ala Asn Asn
Thr Phe Gly Ser Ala Asn Val Thr Thr Thr 290 295 300Leu Glu Val Val
Asp Lys Gly Phe Ile Asn Ile Phe Pro Met Ile Asn305 310 315 320Thr
Thr Val Phe Val Asn Asp Gly Glu Asn Val Asp Leu Ile Val Glu 325 330
335Tyr Glu Ala Phe Pro Lys Pro Glu His Gln Gln Trp Ile Tyr Met Asn
340 345 350Arg Thr Phe Thr Asp Lys Trp Glu Asp Tyr Pro Lys Ser Glu
Asn Glu 355 360 365Ser Asn Ile Arg Tyr Val Ser Glu Leu His Leu Thr
Arg Leu Lys Gly 370 375 380Thr Glu Gly Gly Thr Tyr Thr Phe Leu Val
Ser Asn Ser Asp Val Asn385 390 395 400Ala Ala Ile Ala Phe Asn Val
Tyr Val Asn Thr Lys Pro Glu Ile Leu 405 410 415Thr Tyr Asp Arg Leu
Val Asn Gly Met Leu Gln Cys Val Ala Ala Gly 420 425 430Phe Pro Glu
Pro Thr Ile Asp Trp Tyr Phe Cys Pro Gly Thr Glu Gln 435 440 445Arg
Cys Ser Ala Ser Val Leu Pro Val Asp Val Gln Thr Leu Asn Ser 450 455
460Ser Gly Pro Pro Phe Gly Lys Leu Val Val Gln Ser Ser Ile Asp
Ser465 470 475 480Ser Ala Phe Lys His Asn Gly Thr Val Glu Cys Lys
Ala Tyr Asn Asp 485 490 495Val Gly Lys Thr Ser Ala Tyr Phe Asn Phe
Ala Phe Lys Gly Asn Asn 500 505 510Lys Glu Gln Ile His Pro His Thr
Leu Phe Thr Pro Leu Leu Ile Gly 515 520 525Phe Val Ile Val Ala Gly
Met Met Cys Ile Ile Val Met Ile Leu Thr 530 535 540Tyr Lys Tyr Leu
Gln Lys Pro Met Tyr Glu Val Gln Trp Lys Val Val545 550 555 560Glu
Glu Ile Asn Gly Asn Asn Tyr Val Tyr Ile Asp Pro Thr Gln Leu 565 570
575Pro Tyr Asp His Lys Trp Glu Phe Pro Arg Asn Arg Leu Ser Phe Gly
580 585 590Lys Thr Leu Gly Ala Gly Ala Phe Gly Lys Val Val Glu Ala
Thr Ala 595 600 605Tyr Gly Leu Ile Lys Ser Asp Ala Ala Met Thr Val
Ala Val Lys Met 610 615 620Leu Lys Pro Ser Ala His Leu Thr Glu Arg
Glu Ala Leu Met Ser Glu625 630 635 640Leu Lys Val Leu Ser Tyr Leu
Gly Asn His Met Asn Ile Val Asn Leu 645 650 655Leu Gly Ala Cys Thr
Ile Gly Gly Pro Thr Leu Val Ile Thr Glu Tyr 660 665 670Cys Cys Tyr
Gly Asp Leu Leu Asn Phe Leu Arg Arg Lys Arg Asp Ser 675 680 685Phe
Ile Cys Ser Lys Gln Glu Asp His Ala Glu Ala Ala Leu Tyr Lys 690 695
700Asn Leu Leu His Ser Lys Glu Ser Ser Cys Ser Asp Ser Thr Asn
Glu705 710 715 720Tyr Met Asp Met Lys Pro Gly Val Ser Tyr Val Val
Pro Thr Lys Ala 725 730 735Asp Lys Arg Arg Ser Val Arg Ile Gly Ser
Tyr Ile Glu Arg Asp Val 740 745 750Thr Pro Ala Ile Met Glu Asp Asp
Glu Leu Ala Leu Asp Leu Glu Asp 755 760 765Leu Leu Ser Phe Ser Tyr
Gln Val Ala Lys Gly Met Ala Phe Leu Ala 770 775 780Ser Lys Asn Cys
Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu785 790 795 800Thr
His Gly Arg Ile Thr Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp 805 810
815Ile Lys Asn Asp Ser Asn Tyr Val Val Lys Gly Asn Ala Arg Leu Pro
820 825 830Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asn Cys Val Tyr
Thr Phe 835 840 845Glu Ser Asp Val Trp Ser Tyr Gly Ile Phe Leu Trp
Glu Leu Phe Ser 850 855 860Leu Gly Ser Ser Pro Tyr Pro Gly Met Pro
Val Asp Ser Lys Phe Tyr865 870 875 880Lys Met Ile Lys Glu Gly Phe
Arg Met Leu Ser Pro Glu His Ala Pro 885 890 895Ala Glu Met Tyr Asp
Ile Met Lys Thr Cys Trp Asp Ala Asp Pro Leu 900 905 910Lys Arg Pro
Thr Phe Lys Gln Ile Val Gln Leu Ile Glu Lys Gln Ile 915 920 925Ser
Glu Ser Thr Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro 930 935
940Asn Arg Gln Lys Pro Val Val Asp His Ser Val Arg Ile Asn Ser
Val945 950 955 960Gly Ser Thr Ala Ser Ser Ser Gln Pro Leu Leu Val
His Asp Asp Val 965 970 975146972PRTHomo sapiens 146Met Arg Gly Ala
Arg Gly Ala Trp Asp Phe Leu Cys Val Leu Leu Leu1 5 10 15Leu Leu Arg
Val Gln Thr Gly Ser Ser Gln Pro Ser Val Ser Pro Gly 20 25 30Glu Pro
Ser Pro Pro Ser Ile His Pro Gly Lys Ser Asp Leu Ile Val 35 40 45Arg
Val Gly Asp Glu Ile Arg Leu Leu Cys Thr Asp Pro Gly Phe Val 50 55
60Lys Trp Thr Phe Glu Ile Leu Asp Glu Thr Asn Glu Asn Lys Gln Asn65
70 75 80Glu Trp Ile Thr Glu Lys Ala Glu Ala Thr Asn Thr Gly Lys Tyr
Thr 85 90 95Cys Thr Asn Lys His Gly Leu Ser Asn Ser Ile Tyr Val Phe
Val Arg 100 105 110Asp Pro Ala Lys Leu Phe Leu Val Asp Arg Ser Leu
Tyr Gly Lys Glu 115 120 125Asp Asn Asp Thr Leu Val Arg Cys Pro Leu
Thr Asp Pro Glu Val Thr 130 135 140Asn Tyr Ser Leu Lys Gly Cys Gln
Gly Lys Pro Leu Pro Lys Asp Leu145 150 155 160Arg Phe Ile Pro Asp
Pro Lys Ala Gly Ile Met Ile Lys Ser Val Lys 165 170 175Arg Ala Tyr
His Arg Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly 180 185 190Lys
Ser Val Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe 195 200
205Lys Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg
210 215 220Glu Gly Glu Glu Phe Thr Val Thr Cys Thr Ile Lys Asp Val
Ser Ser225 230 235 240Ser Val Tyr Ser Thr Trp Lys Arg Glu Asn Ser
Gln Thr Lys Leu Gln 245 250 255Glu Lys Tyr Asn Ser Trp His His Gly
Asp Phe Asn Tyr Glu Arg Gln 260 265 270Ala Thr Leu Thr Ile Ser Ser
Ala Arg Val Asn Asp Ser Gly Val Phe 275 280 285Met Cys Tyr Ala Asn
Asn Thr Phe Gly Ser Ala Asn Val Thr Thr Thr 290 295 300Leu Glu Val
Val Asp Lys Gly Phe Ile Asn Ile Phe Pro Met Ile Asn305 310 315
320Thr Thr Val Phe Val Asn Asp Gly Glu Asn Val Asp Leu Ile Val Glu
325 330 335Tyr Glu Ala Phe Pro Lys Pro Glu His Gln Gln Trp Ile Tyr
Met Asn 340 345 350Arg Thr Phe Thr Asp Lys Trp Glu Asp Tyr Pro Lys
Ser Glu Asn Glu 355 360 365Ser Asn Ile Arg Tyr Val Ser Glu Leu His
Leu Thr Arg Leu Lys Gly 370 375 380Thr Glu Gly Gly Thr Tyr Thr Phe
Leu Val Ser Asn Ser Asp Val Asn385 390 395 400Ala Ala Ile Ala Phe
Asn Val Tyr Val Asn Thr Lys Pro Glu Ile Leu 405 410 415Thr Tyr Asp
Arg Leu Val Asn Gly Met Leu Gln Cys Val Ala Ala Gly 420 425 430Phe
Pro Glu Pro Thr Ile Asp Trp Tyr Phe Cys Pro Gly Thr Glu Gln 435 440
445Arg Cys Ser Ala Ser Val Leu Pro Val Asp Val Gln Thr Leu Asn Ser
450 455 460Ser Gly Pro Pro Phe Gly Lys Leu Val Val Gln Ser Ser Ile
Asp Ser465 470 475 480Ser Ala Phe Lys His Asn Gly Thr Val Glu Cys
Lys Ala Tyr Asn Asp 485 490 495Val Gly Lys Thr Ser Ala Tyr Phe Asn
Phe Ala Phe Lys Glu Gln Ile 500 505 510His Pro His Thr Leu Phe Thr
Pro Leu Leu Ile Gly Phe Val Ile Val 515 520 525Ala Gly Met Met Cys
Ile Ile Val Met Ile Leu Thr Tyr Lys Tyr Leu 530 535 540Gln Lys Pro
Met Tyr Glu Val Gln Trp Lys Val Val Glu Glu Ile Asn545 550 555
560Gly Asn Asn Tyr Val Tyr Ile Asp Pro Thr Gln Leu Pro Tyr Asp His
565 570 575Lys Trp Glu Phe Pro Arg Asn Arg Leu Ser Phe Gly Lys Thr
Leu Gly 580 585 590Ala Gly Ala Phe Gly Lys Val Val Glu Ala Thr Ala
Tyr Gly Leu Ile 595 600 605Lys Ser Asp Ala Ala Met Thr Val Ala Val
Lys Met Leu Lys Pro Ser 610 615 620Ala His Leu Thr Glu Arg Glu Ala
Leu Met Ser Glu Leu Lys Val Leu625 630 635 640Ser Tyr Leu Gly Asn
His Met Asn Ile Val Asn Leu Leu Gly Ala Cys 645 650 655Thr Ile Gly
Gly Pro Thr Leu Val Ile Thr Glu Tyr Cys Cys Tyr Gly 660 665 670Asp
Leu Leu Asn Phe Leu Arg Arg Lys Arg Asp Ser Phe Ile Cys Ser 675
680 685Lys Gln Glu Asp His Ala Glu Ala Ala Leu Tyr Lys Asn Leu Leu
His 690 695 700Ser Lys Glu Ser Ser Cys Ser Asp Ser Thr Asn Glu Tyr
Met Asp Met705 710 715 720Lys Pro Gly Val Ser Tyr Val Val Pro Thr
Lys Ala Asp Lys Arg Arg 725 730 735Ser Val Arg Ile Gly Ser Tyr Ile
Glu Arg Asp Val Thr Pro Ala Ile 740 745 750Met Glu Asp Asp Glu Leu
Ala Leu Asp Leu Glu Asp Leu Leu Ser Phe 755 760 765Ser Tyr Gln Val
Ala Lys Gly Met Ala Phe Leu Ala Ser Lys Asn Cys 770 775 780Ile His
Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu Thr His Gly Arg785 790 795
800Ile Thr Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Lys Asn Asp
805 810 815Ser Asn Tyr Val Val Lys Gly Asn Ala Arg Leu Pro Val Lys
Trp Met 820 825 830Ala Pro Glu Ser Ile Phe Asn Cys Val Tyr Thr Phe
Glu Ser Asp Val 835 840 845Trp Ser Tyr Gly Ile Phe Leu Trp Glu Leu
Phe Ser Leu Gly Ser Ser 850 855 860Pro Tyr Pro Gly Met Pro Val Asp
Ser Lys Phe Tyr Lys Met Ile Lys865 870 875 880Glu Gly Phe Arg Met
Leu Ser Pro Glu His Ala Pro Ala Glu Met Tyr 885 890 895Asp Ile Met
Lys Thr Cys Trp Asp Ala Asp Pro Leu Lys Arg Pro Thr 900 905 910Phe
Lys Gln Ile Val Gln Leu Ile Glu Lys Gln Ile Ser Glu Ser Thr 915 920
925Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro Asn Arg Gln Lys
930 935 940Pro Val Val Asp His Ser Val Arg Ile Asn Ser Val Gly Ser
Thr Ala945 950 955 960Ser Ser Ser Gln Pro Leu Leu Val His Asp Asp
Val 965 970147123PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 147Gln Val Gln Leu Val Gln Ser Gly
Ala Ala Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys
Gly Ser Gly Tyr Arg Phe Thr Thr Tyr 20 25 30Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Tyr Pro
Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln Gly Gln Val
Thr Ile Ser Ala Gly Lys Ser Ile Ser Thr Ala Tyr65 70 75 80Leu Gln
Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala
Arg His Gly Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp Ile 100 105
110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115
120148107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 148Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Val Ser Ser Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 105149107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
149Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Thr
Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105150107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 150Ala Ile Arg Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Thr Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105151107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 151Ala Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Asp Ile Lys 100 105152107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
152Asn Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Ser Asp
Tyr 20 25 30Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105153107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 153Ala Ile Arg Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Ile
Ile Ala Cys Arg Ala Ser Gln Gly Ile Gly Gly Ala 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Val Leu Val 35 40 45Tyr Asp
Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Gly
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100
105154107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 154Asp Ile Ala Met Thr Gln Ser Pro Pro Ser
Leu Ser Ala Phe Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ile Ser Ser 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Arg Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Lys 100 105155107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
155Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Ala Gly Lys Ala Pro Lys Val
Leu Ile 35 40 45Ser Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Phe Asn Gly Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Asp
Ile Lys 100 105156107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 156Ala Ile Arg Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Gln Ala Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100
105157107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 157Asn Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Thr Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Gly Thr Ser 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Pro Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Leu Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ser Asn Ser Tyr Pro Ile 85 90 95Thr Phe Gly
Gln Gly Thr Arg Leu Glu Ile Lys 100 105158107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
158Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Asp
Tyr 20 25 30Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val
Leu Ile 35 40 45Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Pro Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Val Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys 100 105159107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 159Asp Ile Gln Leu Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Val Arg Ser Thr 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Ile Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Gly Tyr Pro Leu
85 90 95Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100
105160107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 160Asp Ile Val Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Lys 100 105161107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
161Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
Phe 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Ala Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Gly Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105162107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 162Ala Ile Gln Leu Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Ser Ala 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Ile Gly Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Thr Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly 50 55 60Ser
Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Gly Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100
105163107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 163Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Thr Ser Ala 20 25 30Leu Ala Trp Tyr Gln Glu Lys Pro
Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Tyr Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Asp Ile Lys 100 105164121PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
164Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Arg Lys Pro Gly Glu1
5 10 15Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Tyr 20 25 30Ala Met Tyr Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys
Trp Met 35 40 45Gly Trp Ile Asn Thr Tyr Thr Gly Lys Pro Thr Tyr Ala
Asp Asp Phe 50 55 60Lys Gly Arg Phe Val Phe Ser Leu Glu Ala Ser Ala
Asn Thr Ala Asn65 70 75 80Leu Gln Ile Ser Asn Leu Lys Asn Glu Asp
Thr Ala Thr Tyr Phe Cys 85 90 95Ala Arg Ala Arg Gly Leu Val Asp Asp
Tyr Val Met Asp Ala Trp Gly 100 105 110Gln Gly Thr Ser Val Thr Val
Ser Ser 115 120165108PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 165Ser Tyr Glu Leu Ile
Gln Pro Pro Ser Ala Ser Val Thr Leu Gly Asn1
5 10 15Thr Val Ser Leu Thr Cys Val Gly Asp Glu Leu Ser Lys Arg Tyr
Ala 20 25 30Gln Trp Tyr Gln Gln Lys Pro Asp Lys Thr Ile Val Ser Val
Ile Tyr 35 40 45Lys Asp Ser Glu Arg Pro Ser Gly Ile Ser Asp Arg Phe
Ser Gly Ser 50 55 60Ser Ser Gly Thr Thr Ala Thr Leu Thr Ile His Gly
Thr Leu Ala Glu65 70 75 80Asp Glu Ala Asp Tyr Tyr Cys Leu Ser Thr
Tyr Ser Asp Asp Asn Leu 85 90 95Pro Val Phe Gly Gly Gly Thr Lys Leu
Thr Val Leu 100 105166117PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 166Glu Val Gln Leu Gln
Gln Tyr Gly Ala Glu Leu Gly Lys Pro Gly Thr1 5 10 15Ser Val Arg Leu
Ser Cys Lys Val Ser Gly Tyr Asn Ile Arg Asn Thr 20 25 30Tyr Ile His
Trp Val Asn Gln Arg Pro Gly Glu Gly Leu Glu Trp Ile 35 40 45Gly Arg
Ile Asp Pro Thr Asn Gly Asn Thr Ile Ser Ala Glu Lys Phe 50 55 60Lys
Thr Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser His Thr Ala Tyr65 70 75
80Leu Gln Phe Ser Gln Leu Lys Ser Asp Asp Thr Ala Ile Tyr Phe Cys
85 90 95Ala Leu Asn Tyr Glu Gly Tyr Ala Asp Tyr Trp Gly Gln Gly Val
Met 100 105 110Val Thr Gly Ser Ser 115167106PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
167Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys
Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Val Gly Glu Ala Pro Lys Arg
Leu Ile 35 40 45Phe Lys Thr Asn Ser Leu Gln Thr Gly Ile Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser
Ser Leu Gln Thr65 70 75 80Glu Asp Val Ala Thr Tyr Phe Cys Phe Gln
Tyr Asn Ile Gly Tyr Thr 85 90 95Phe Gly Ala Gly Thr Lys Val Glu Leu
Lys 100 105168124PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 168Glu Val Gln Leu Gln Glu Ser Gly
Pro Gly Leu Val Lys Pro Ser Gln1 5 10 15Ser Leu Ser Leu Thr Cys Ser
Val Thr Gly Tyr Ser Ile Ser Ser Asn 20 25 30Tyr Arg Trp Asn Trp Ile
Arg Lys Phe Pro Gly Asn Lys Val Glu Trp 35 40 45Met Gly Tyr Ile Asn
Ser Ala Gly Ser Thr Asn Tyr Asn Pro Ser Leu 50 55 60Lys Ser Arg Ile
Ser Met Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe65 70 75 80Leu Gln
Val Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95Ala
Arg Ser Leu Arg Gly Tyr Ile Thr Asp Tyr Ser Gly Phe Phe Asp 100 105
110Tyr Trp Gly Gln Gly Val Met Val Thr Val Ser Ser 115
120169107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 169Asp Ile Arg Met Thr Gln Ser Pro Ala Ser
Leu Ser Ala Ser Leu Gly1 5 10 15Glu Thr Val Asn Ile Glu Cys Leu Ala
Ser Glu Asp Ile Phe Ser Asp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45Tyr Asn Ala Asn Ser Leu Gln
Asn Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Arg
Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser65 70 75 80Glu Asp Val Ala
Thr Tyr Phe Cys Gln Gln Tyr Lys Asn Tyr Pro Leu 85 90 95Thr Phe Gly
Ser Gly Thr Lys Leu Glu Ile Lys 100 105170117PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
170Glu Val Gln Leu Gln Gln Tyr Gly Ala Glu Leu Gly Lys Pro Gly Thr1
5 10 15Ser Val Arg Leu Ser Cys Lys Leu Ser Gly Tyr Lys Ile Arg Asn
Thr 20 25 30Tyr Ile His Trp Val Asn Gln Arg Pro Gly Lys Gly Leu Glu
Trp Ile 35 40 45Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Ile Tyr Ala
Glu Lys Phe 50 55 60Lys Ser Lys Val Thr Leu Thr Ala Asp Thr Ser Ser
Asn Thr Ala Tyr65 70 75 80Met Gln Leu Ser Gln Leu Lys Ser Asp Asp
Thr Ala Leu Tyr Phe Cys 85 90 95Ala Met Asn Tyr Glu Gly Tyr Glu Asp
Tyr Trp Gly Gln Gly Val Met 100 105 110Val Thr Val Ser Ser
115171106PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 171Asp Ile Gln Met Thr Gln Ser Pro Ser Phe
Leu Ser Ala Ser Val Gly1 5 10 15Asp Ser Val Thr Ile Asn Cys Lys Ala
Ser Gln Asn Ile Asn Lys Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Leu
Gly Glu Ala Pro Lys Arg Leu Ile 35 40 45His Lys Thr Asp Ser Leu Gln
Thr Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Val Ala
Thr Tyr Phe Cys Phe Gln Tyr Lys Ser Gly Phe Met 85 90 95Phe Gly Ala
Gly Thr Lys Leu Glu Leu Lys 100 105172120PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
172Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu1
5 10 15Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Tyr 20 25 30Ala Val Tyr Trp Val Ile Gln Ala Pro Gly Lys Gly Leu Lys
Trp Met 35 40 45Gly Trp Ile Asn Thr Tyr Thr Gly Lys Pro Thr Tyr Ala
Asp Asp Phe 50 55 60Lys Gly Arg Phe Val Phe Ser Leu Glu Thr Ser Ala
Ser Thr Ala Asn65 70 75 80Leu Gln Ile Ser Asn Leu Lys Asn Glu Asp
Thr Ala Thr Tyr Phe Cys 85 90 95Ala Arg Gly Ala Gly Met Thr Lys Asp
Tyr Val Met Asp Ala Trp Gly 100 105 110Arg Gly Val Leu Val Thr Val
Ser 115 120173108PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 173Ser Tyr Glu Leu Ile Gln Pro Pro
Ser Ala Ser Val Thr Leu Gly Asn1 5 10 15Thr Val Ser Leu Thr Cys Val
Gly Asp Glu Leu Ser Lys Arg Tyr Ala 20 25 30Gln Trp Tyr Gln Gln Lys
Pro Asp Lys Thr Ile Val Ser Val Ile Tyr 35 40 45Lys Asp Ser Glu Arg
Pro Ser Asp Ile Ser Asp Arg Phe Ser Gly Ser 50 55 60Ser Ser Gly Thr
Thr Ala Thr Leu Thr Ile His Gly Thr Leu Ala Glu65 70 75 80Asp Glu
Ala Asp Tyr Tyr Cys Leu Ser Thr Tyr Ser Asp Asp Asn Leu 85 90 95Pro
Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100
105174116PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 174Gln Val Gln Leu Lys Glu Ser Gly Pro Gly
Leu Val Gln Pro Ser Gln1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser
Gly Phe Ser Leu Thr Ser Tyr 20 25 30Leu Val His Trp Val Arg Gln Pro
Pro Gly Lys Thr Leu Glu Trp Val 35 40 45Gly Leu Met Trp Asn Asp Gly
Asp Thr Ser Tyr Asn Ser Ala Leu Lys 50 55 60Ser Arg Leu Ser Ile Ser
Arg Asp Thr Ser Lys Ser Gln Val Phe Leu65 70 75 80Lys Met His Ser
Leu Gln Ala Glu Asp Thr Ala Thr Tyr Tyr Cys Ala 85 90 95Arg Glu Ser
Asn Leu Gly Phe Thr Tyr Trp Gly His Gly Thr Leu Val 100 105 110Thr
Val Ser Ser 115175107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 175Asp Ile Gln Met Thr
Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Glu1 5 10 15Glu Ile Val Thr
Ile Thr Cys Lys Ala Ser Gln Gly Ile Asp Asp Asp 20 25 30Leu Ser Trp
Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45Tyr Asp
Val Thr Arg Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Arg Ser Gly Thr Gln Tyr Ser Leu Lys Ile Ser Arg Pro Gln Val65 70 75
80Ala Asp Ser Gly Ile Tyr Tyr Cys Leu Gln Ser Tyr Ser Thr Pro Tyr
85 90 95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100
105176117PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 176Glu Val Gln Leu Gln Gln Tyr Gly Ala Glu
Leu Gly Lys Pro Gly Thr1 5 10 15Ser Val Arg Leu Ser Cys Lys Val Ser
Gly Tyr Asn Ile Arg Asn Thr 20 25 30Tyr Ile His Trp Val His Gln Arg
Pro Gly Glu Gly Leu Glu Trp Ile 35 40 45Gly Arg Ile Asp Pro Thr Asn
Gly Asn Thr Ile Ser Ala Glu Lys Phe 50 55 60Lys Ser Lys Ala Thr Leu
Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr65 70 75 80Met Gln Phe Ser
Gln Leu Lys Ser Asp Asp Thr Ala Ile Tyr Phe Cys 85 90 95Ala Met Asn
Tyr Glu Gly Tyr Ala Asp Tyr Trp Gly Gln Gly Val Met 100 105 110Val
Thr Val Ser Ser 115177106PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 177Asp Ile Gln Met Thr
Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Leu Thr
Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys Tyr 20 25 30Leu Asn Trp
Tyr Gln Gln Lys Leu Gly Glu Ala Pro Lys Arg Leu Ile 35 40 45Phe Lys
Thr Asn Ser Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Val Ala Thr Tyr Phe Cys Phe Gln Tyr Asn Ile Gly Phe Thr
85 90 95Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100
105178124PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 178Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ser Gly Arg1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser
Gly Phe Thr Val Ser Asp Tyr 20 25 30Tyr Met Ala Trp Val Arg Gln Ala
Pro Thr Lys Gly Leu Glu Trp Val 35 40 45Ala Thr Ile Asn Tyr Asp Gly
Ser Thr Thr Tyr His Arg Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr65 70 75 80Leu Gln Met Asp
Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95Ala Arg His
Gly Asp Tyr Gly Tyr His Tyr Gly Ala Tyr Tyr Phe Asp 100 105 110Tyr
Trp Gly Gln Gly Val Met Val Thr Val Ser Ser 115
120179109PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 179Asp Ile Val Leu Thr Gln Ser Pro Ala Leu
Ala Val Ser Leu Gly Gln1 5 10 15Arg Ala Thr Ile Ser Cys Arg Ala Ser
Gln Thr Val Ser Leu Ser Gly 20 25 30Tyr Asn Leu Ile His Trp Tyr Gln
Gln Arg Thr Gly Gln Gln Pro Lys 35 40 45Leu Leu Ile Tyr Arg Ala Ser
Asn Leu Ala Pro Gly Ile Pro Ala Arg 50 55 60Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Pro65 70 75 80Val Gln Ser Asp
Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Arg Glu 85 90 95Ser Trp Thr
Phe Gly Gly Gly Thr Asn Leu Glu Met Lys 100 105180116PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
180Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu1
5 10 15Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Tyr 20 25 30Ala Ile His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Arg
Trp Met 35 40 45Ala Trp Ile Asn Thr Glu Thr Gly Lys Pro Thr Tyr Ala
Asp Asp Phe 50 55 60Lys Gly Arg Phe Val Phe Ser Leu Glu Ala Ser Ala
Ser Thr Ala His65 70 75 80Leu Gln Ile Ser Asn Leu Lys Asn Glu Asp
Thr Ala Thr Phe Phe Cys 85 90 95Ala Gly Gly Ser His Trp Phe Ala Tyr
Trp Gly Gln Gly Thr Leu Val 100 105 110Thr Val Ser Ser
115181108PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 181Ser Tyr Glu Leu Ile Gln Pro Pro Ser Ala
Ser Val Thr Leu Glu Asn1 5 10 15Thr Val Ser Ile Thr Cys Ser Gly Asp
Glu Leu Ser Asn Lys Tyr Ala 20 25 30His Trp Tyr Gln Gln Lys Pro Asp
Lys Thr Ile Leu Glu Val Ile Tyr 35 40 45Asn Asp Ser Glu Arg Pro Ser
Gly Ile Ser Asp Arg Phe Ser Gly Ser 50 55 60Ser Ser Gly Thr Thr Ala
Ile Leu Thr Ile Arg Asp Ala Gln Ala Glu65 70 75 80Asp Glu Ala Asp
Tyr Tyr Cys Leu Ser Thr Phe Ser Asp Asp Asp Leu 85 90 95Pro Ile Phe
Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105182108PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
182Ser Tyr Glu Leu Ile Gln Pro Pro Ser Thr Ser Val Thr Leu Gly Asn1
5 10 15Thr Val Ser Leu Thr Cys Val Gly Asn Glu Leu Pro Lys Arg Tyr
Ala 20 25 30Tyr Trp Phe Gln Gln Lys Pro Asp Gln Ser Ile Val Arg Leu
Ile Tyr 35 40 45Asp Asp Asp Arg Arg Pro Ser Gly Ile Ser Asp Arg Phe
Ser Gly Ser 50 55 60Ser Ser Gly Thr Thr Ala Thr Leu Thr Ile Arg Asp
Ala Gln Ala Glu65 70 75 80Asp Glu Ala Tyr Tyr Tyr Cys His Ser Thr
Tyr Thr Asp Asp Lys Val 85 90 95Pro Ile Phe Gly Gly Gly Thr Lys Leu
Thr Val Leu 100 105183123PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 183Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1 5 10 15Ser Met Lys Leu
Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30Asp Met Ala
Trp Val Arg Gln Ala Pro Thr Arg Gly Leu Glu Trp Val 35 40 45Ala Ser
Ile Ser Tyr Asp Gly Ile Thr Ala Tyr Tyr Arg Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Ser Thr Leu Tyr65 70 75
80Leu Gln Leu Val Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95Thr Thr Glu Gly Gly Tyr Val Tyr Ser Gly Pro His Tyr Phe Asp
Tyr 100 105 110Trp Gly Gln Gly Val Met Val Thr Val Ser Ser 115
120184107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 184Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Met Ser Val Ser Leu Gly1 5 10 15Asp Thr Val Thr Ile Thr Cys Arg Ala
Ser Gln Asp Val Gly Ile Phe 20 25 30Val Asn Trp Phe Gln Gln Lys Pro
Gly Arg Ser Pro Arg Arg Met Ile 35 40 45Tyr Arg Ala Thr Asn Leu Ala
Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Arg Ser Gly Ser Asp
Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser65 70 75 80Glu Asp Val Ala
Asp Tyr His Cys Leu Gln Tyr Asp Glu Phe Pro Arg 85 90 95Thr Phe Gly
Gly Gly Thr Lys Leu Glu Leu Lys 100 105185117PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptide
185Glu Val Gln Leu Gln Gln Tyr Gly Ala Glu Leu Gly Lys Pro Gly Thr1
5 10 15Ser Val Arg Leu Ser Cys Lys Val Ser Gly Tyr Lys Ile Arg Asn
Thr 20 25 30Tyr Ile His Trp Val Asn Gln Arg Pro Gly Lys Gly Leu Glu
Trp Ile 35 40 45Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Ile Tyr Ala
Glu Lys Phe 50 55 60Lys Ser Lys Val Thr Leu Thr Ala Asp Thr Ser Ser
Asn Thr Ala Tyr65 70 75 80Met Gln Leu Ser Gln Leu Lys Ser Asp Asp
Thr Ala Leu Tyr Phe Cys 85 90 95Ala Met Asn Tyr Glu Gly Tyr Glu Asp
Tyr Trp Gly Gln Gly Val Met 100 105 110Val Thr Val Ser Ser
115186106PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 186Asp Ile Gln Met Thr Gln Ser Pro Ser Phe
Leu Ser Ala Ser Val Gly1 5 10 15Asp Ser Val Thr Ile Asn Cys Lys Ala
Ser Gln Asn Ile Asn Lys Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Leu
Gly Glu Ala Pro Lys Arg Leu Ile 35 40 45His Lys Thr Asn Ser Leu Gln
Pro Gly Phe Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Val Ala
Ala Tyr Phe Cys Phe Gln Tyr Asn Ser Gly Phe Thr 85 90 95Phe Gly Ala
Gly Thr Lys Leu Glu Leu Lys 100 105187125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
187Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Tyr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Trp Met Asn Pro His Ser Gly Asp Thr Gly Tyr Ala
Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr
Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125188107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
188Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Asn
Glu 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Tyr Asp Asn Leu Pro Leu 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105189125PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 189Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30Tyr Leu His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp
Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Asn Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125190107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 190Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser
Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Gly Tyr Pro Leu 85 90 95Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105191125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
191Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly
Tyr 20 25 30Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala
Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr
Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Glu Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125192107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
192Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn
Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Glu Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Gly Tyr Pro Ile 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105193125PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 193Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Tyr Ile His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp
Leu Asn Pro Ser Gly Gly Gly Thr Ser Tyr Ala Gln Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Asp Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125194107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 194Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Gly Tyr Pro Leu 85 90 95Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105195125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
195Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr
Tyr 20 25 30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala
Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr
Ser Thr Val Tyr65 70 75 80Met Lys Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Glu Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125196107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
196Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp
Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala Asn Gly Phe Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105197125PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 197Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30Tyr Ile His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Asn Pro Ser Gly Gly Asn Thr Asn Tyr Ala Gln Asn Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Asn Ala Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125198107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 198Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Val Asn Gly Tyr Pro Leu 85 90 95Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105199125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
199Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser
Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Val Ile Asn Pro Thr Val Gly Gly Ala Asn Tyr Ala
Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr
Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Glu
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125200107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
200Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asp
Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Gly Asn Ser Phe Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys 100 105201125PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 201Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Leu Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30Tyr Met His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Val
Ile Asn Pro Asn Gly Ala Gly Thr Asn Phe Ala Gln Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125202125PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 202Gln Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30Tyr Met His Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Asn Pro
Thr Gly Gly Gly Thr Asn Tyr Ala Gln Asn Phe 50 55 60Gln Gly Arg Val
Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg His Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala Phe Asp Ile 100 105
110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 115 120
125203107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 203Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Arg Asn Asp 20 25 30Val Ser Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Leu Ser Gly Tyr Pro Ile 85 90 95Thr Phe Gly
Gln Gly Thr Lys Leu Glu Ile Lys 100 105204125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
204Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
Tyr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Met 35 40 45Gly Met Ile Asn Pro Ser Gly Gly Ser Thr Asn Tyr
Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser
Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn
Asp Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu
Val Thr Val Ser Ser Ala Ser 115 120 125205107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
205Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asp
Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Glu Ala Ser Asn Leu Glu Gly Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala Asn Ser Phe Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105206125PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 206Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ser Ala Tyr 20 25 30Tyr Ile His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Asn Pro Ser Gly Gly Ser Thr Arg Tyr Ala Gln Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Gly Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Asp Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125207107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 207Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Gly Asp Tyr 20 25 30Val Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Gly Tyr Pro Ile 85 90 95Thr
Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105208125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
208Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1
5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser
Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
Trp Met 35 40 45Gly Ile Ile Tyr Pro Asp Asp Ser Asp Thr Arg Tyr Ser
Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Asn
Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp
Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125209107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
209Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Tyr Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Gly Ala Ser Phe Pro Ile 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105210125PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 210Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Ser Ser Phe Pro Asn Ser 20 25 30Trp Ile Ala
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Tyr Pro Ser Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Glu Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125211107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 211Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Arg Asn Tyr 20 25 30Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Leu 85 90 95Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105212125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
212Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1
5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Asp Ser
Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
Trp Met 35 40 45Gly Ile Met Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser
Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile
Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp
Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Ala
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125213107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
213Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Asn
Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Phe Ile Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln
Leu Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Pro Gly Thr Lys Val Asp
Ile Lys 100 105214124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 214Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Trp 20 25 30Ile Ala Trp
Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly 35 40 45Ile Ile
Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln 50 55 60Gly
Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu65 70 75
80Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95Arg His Gly Arg Gly Tyr Tyr Gly Tyr Glu Gly Ala Phe Asp Ile
Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 115
120215107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 215Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Asp Asn 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala Ile Ser Phe Pro Leu 85 90 95Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 105216125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
216Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1
5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Asn Phe Thr Ser
Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
Trp Met 35 40 45Gly Val Ile Tyr Pro Asp Asp Ser Glu Thr Arg Tyr Ser
Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile
Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp
Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125217107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
217Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Asp Ile Arg Asp
Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala Asn Ser Phe Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105218124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 218Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Thr Phe Asn Thr Tyr 20 25 30Ile Gly Trp
Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly 35 40 45Ile Ile
Tyr Pro Gly Asp Ser Gly Thr Arg Tyr Ser Pro Ser Phe Gln 50 55 60Gly
Gln Val Thr Ile Ser Ala Asp Lys Ala Ile Ser Thr Ala Tyr Leu65 70 75
80Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95Arg His Ser Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp Ile
Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 115
120219107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 219Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Asn Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Val 85 90 95Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 105220125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
220Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1
5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Asn Phe Thr Thr
Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
Trp Met 35 40 45Gly Ile Ile His Pro Ala Asp Ser Asp Thr Arg Tyr Asn
Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile
Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp
Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125221107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
221Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Val Ser Gln Gly Ile Ser Ser
Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala Asn Ser Phe Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105222125PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 222Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Arg Phe Ser Asn Tyr 20 25 30Trp Ile Ala
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Tyr Pro Asp Asn Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Asp Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125223107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 223Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Arg Ser Asp 20 25 30Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Gly Ala Ser Ser
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70
75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro
Leu 85 90 95Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
105224124PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 224Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser
Gly Tyr Arg Phe Ala Ser Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met
Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile Thr Tyr Pro Gly Asp
Ser Glu Thr Arg Tyr Asn Pro Ser Gln 50 55 60Gly Gln Val Thr Ile Ser
Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu65 70 75 80Gln Trp Ser Ser
Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95Arg His Gly
Arg Gly Tyr Gly Gly Tyr Glu Gly Ala Phe Asp Ile Trp 100 105 110Gly
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 115
120225107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 225Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 105226125PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
226Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1
5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser
Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
Trp Met 35 40 45Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser
Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile
Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp
Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125227107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
227Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn
Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Thr Asn Ser Phe Pro Leu 85 90 95Thr Phe Gly Gln Gly Thr Arg Leu Glu
Ile Lys 100 105228107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 228Asp Ile Gln Leu Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Val Ile Ser Ala 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105229107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 229Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Arg Ser Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 105230107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
230Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Val Gly Ser
Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105231107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 231Asp Ile Gln Leu Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Val Ile Ser Ala 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Ile Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105232107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 232Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Arg Ser Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ile Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 105233107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
233Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Val Gly Ser
Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Ile Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105234107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 234Asp Ile Gln Leu Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Ile Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105235107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 235Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Val Ile Ser Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Thr Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 105236107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
236Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Ser
Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105237107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 237Asp Ile Gln Leu Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Val Gly Ser Ala 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105238123PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 238Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser
Gly Tyr Arg Phe Thr Thr Ser 20 25 30Trp Ile Gly Trp Val Arg Gln Met
Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Tyr Pro Gly Asp
Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile
Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser
Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His
Gly Leu Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120239107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
239Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Ser
Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Phe Asn Gly Tyr Pro Leu 85 90 95Thr Phe Gly Gln Gly Thr Arg Leu Glu
Ile Lys 100 105240107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 240Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Arg Gly Ile Ser Asp Tyr 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Ile
85 90 95Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100
105241107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 241Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Gly Ser Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Thr Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Leu Asn Gly Tyr Pro Leu 85 90 95Thr Phe Gly
Gln Gly Thr Arg Leu Glu Ile Lys 100 105242107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
242Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Ser
Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Gly Tyr Pro Leu 85 90 95Thr Phe Gly Gln Gly Thr Arg Leu Glu
Ile Lys 100 105243123PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 243Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30Trp Ile Gly
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Ala Ile
Ile Asn Pro Arg Asp Ser Asp Thr Arg Tyr Arg Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
120244107PRTArtificial SequenceDescription of Artificial
Sequence
Synthetic polypeptide 244Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ser
Ser Gln Gly Ile Arg Ser Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala Asn Gly Phe Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 1052455PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 245Asn
Tyr Trp Ile Gly1 524617PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 246Ile Ile Asn Pro Arg Asp
Ser Asp Thr Arg Tyr Arg Pro Ser Phe Gln1 5 10
15Gly24714PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 247His Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala
Phe Asp Ile1 5 1024811PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 248Arg Ser Ser Gln Gly Ile
Arg Ser Asp Leu Gly1 5 102497PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 249Asp Ala Ser Asn Leu Glu
Thr1 52509PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 250Gln Gln Ala Asn Gly Phe Pro Leu Thr1
5251123PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 251Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser
Gly Tyr Ser Phe Thr Asn Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met
Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Tyr Pro Gly Asp
Ser Asp Ile Arg Tyr Ser Pro Ser Leu 50 55 60Gln Gly Gln Val Thr Ile
Ser Val Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Asn
Ser Leu Lys Pro Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His
Gly Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120252107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
252Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Asp
Ser 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Gly Tyr Pro Ile 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 10525317PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 253Ile Ile Tyr Pro Gly Asp Ser Asp Ile
Arg Tyr Ser Pro Ser Leu Gln1 5 10 15Gly25411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 254Arg
Ala Ser Gln Gly Ile Gly Asp Ser Leu Ala1 5 102559PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 255Gln
Gln Leu Asn Gly Tyr Pro Ile Thr1 5256107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
256Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn
Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Gly Tyr Pro Ile 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 10525711PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 257Arg Ala Ser Gln Gly Ile Arg Asn Asp
Leu Gly1 5 10258123PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 258Glu Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys
Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Tyr Pro
Gly Asp Ser Leu Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln Gly Gln Val
Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75 80Leu Gln
Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala
Arg His Gly Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp Ile 100 105
110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
12025917PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 259Ile Ile Tyr Pro Gly Asp Ser Leu Thr Arg Tyr
Ser Pro Ser Phe Gln1 5 10 15Gly260123PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
260Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1
5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn
Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
Trp Met 35 40 45Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser
Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile
Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp
Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly
Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser 115 120261123PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 261Gln Val Gln Leu Val
Gln Ser Gly Ala Ala Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr 20 25 30Trp Ile Gly
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Gly Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Arg Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115
120262107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 262Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Ser Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 1052635PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 263Thr
Tyr Trp Ile Gly1 526411PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 264Arg Ala Ser Gln Gly Val
Ile Ser Ala Leu Ala1 5 102657PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 265Asp Ala Ser Ile Leu Glu
Ser1 52669PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 266Gln Gln Phe Asn Ser Tyr Pro Leu Thr1
526711PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 267Arg Ala Ser Gln Gly Val Gly Ser Ala Leu Ala1 5
102687PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 268Asp Ala Ser Thr Leu Glu Ser1 5269330PRTHomo
sapiens 269Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser
Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys
Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150
155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu 165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230 235 240Leu Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265
270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly
Lys 325 330270330PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 270Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105
110Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys 130 135 140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys Ala Leu
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230
235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met
His Glu Ala Leu His Asn His Tyr Thr305 310 315 320Gln Lys Ser Leu
Ser Leu Ser Pro Gly Lys 325 330271330PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
271Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1
5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val Val Val
Cys Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155
160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Arg Asp Glu225 230 235 240Leu Thr Lys Asn Gln
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280
285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
Tyr Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
330272330PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 272Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr
Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro
Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val Val Val Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170
175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu225 230 235 240Leu Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295
300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Ala Tyr
Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
330273330PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 273Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110Pro
Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120
125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140Val Val Val Cys Val Ser His Glu Asp Pro Glu Val Lys Phe
Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230 235
240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His Asn His Tyr Thr305 310 315 320Gln Lys Ser Leu Ser
Leu Ser Pro Gly Lys 325 330274330PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 274Ala Ser Thr Lys Gly
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75
80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
Cys 100 105 110Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys 130 135 140Val Val Val Cys Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190His Gln
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200
205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
Asp Glu225 230 235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser
Cys Ser Val Met His Glu Ala Leu His Asn Ala Tyr Thr305 310 315
320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
330275453PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 275Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser
Gly Tyr Ser Phe Thr Asn Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met
Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Ala Ile Ile Asn Pro Arg Asp
Ser Asp Thr Arg Tyr Arg Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile
Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser
Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His
Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120
125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
Pro Val145 150 155 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
Gly Val His Thr Phe 165 170 175Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220Ser Cys Asp
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225 230 235
240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Asp Val 260 265 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val 275 280 285Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu305 310 315 320Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 355 360
365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
Thr Thr385 390 395 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser 420 425 430Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445Leu Ser Pro Gly Lys
450276453PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 276Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser
Gly Tyr Ser Phe Thr Asn Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met
Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Ala Ile Ile Asn Pro Arg Asp
Ser Asp Thr Arg Tyr Arg Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile
Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser
Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His
Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120
125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
Pro Val145 150 155 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
Gly Val His Thr Phe 165 170 175Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220Ser Cys Asp
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala225 230 235
240Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Asp Val 260 265 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val 275 280 285Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu305 310 315 320Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 355 360
365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
Thr Thr385 390 395 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser 420 425 430Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445Leu Ser Pro Gly Lys
450277453PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 277Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser
Gly Tyr Ser Phe Thr Asn Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met
Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Ala Ile Ile Asn Pro Arg Asp
Ser Asp Thr Arg Tyr Arg Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile
Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser
Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His
Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala Phe Asp Ile 100 105 110Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120
125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
Pro Val145 150 155 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
Gly Val His Thr Phe 165 170 175Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220Ser Cys Asp
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala225 230 235
240Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Cys Val 260 265 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val 275 280 285Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu305 310 315 320Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 355 360
365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
Thr Thr385 390 395 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser 420 425 430Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445Leu Ser Pro Gly Lys
450278453PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 278Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Lys Gly Ser
Gly Tyr Ser Phe Thr Asn Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met
Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Ala Ile Ile Asn Pro Arg Asp
Ser Asp Thr Arg Tyr Arg Pro Ser Phe 50 55 60Gln Gly Gln Val Thr Ile
Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser
Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg His
Gly Arg Gly Tyr Glu Gly Tyr Glu Gly Ala Phe Asp Ile
100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
Lys Gly 115 120 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
Thr Ser Gly Gly 130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val145 150 155 160Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215
220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
Ala225 230 235 240Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
Pro Lys Asp Thr 245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val Val Val Cys Val 260 265 270Ser His Glu Asp Pro Glu Val Lys
Phe Asn Trp Tyr Val Asp Gly Val 275 280 285Glu Val His Asn Ala Lys
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg Val
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305 310 315 320Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330
335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
Asn Gln 355 360 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
Ser Asp Ile Ala 370 375 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
Asn Asn Tyr Lys Thr Thr385 390 395 400Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430Val Met His
Glu Ala Leu His Asn Ala Tyr Thr Gln Lys Ser Leu Ser 435 440 445Leu
Ser Pro Gly Lys 450279453PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 279Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Thr Ser 20 25 30Trp Ile Gly
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Leu Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
Thr Lys Gly 115 120 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
Ser Thr Ser Gly Gly 130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val145 150 155 160Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175Pro Ala Val Leu
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200
205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Leu225 230 235 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr 245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val 260 265 270Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305 310 315
320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro 340 345 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln 355 360 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala 370 375 380Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr385 390 395 400Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440
445Leu Ser Pro Gly Lys 450280453PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 280Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Thr Ser 20 25 30Trp Ile Gly
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Leu Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
Thr Lys Gly 115 120 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
Ser Thr Ser Gly Gly 130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val145 150 155 160Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175Pro Ala Val Leu
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200
205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Ala225 230 235 240Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr 245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val 260 265 270Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305 310 315
320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro 340 345 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln 355 360 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala 370 375 380Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr385 390 395 400Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440
445Leu Ser Pro Gly Lys 450281453PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 281Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Thr Ser 20 25 30Trp Ile Gly
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Leu Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
Thr Lys Gly 115 120 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
Ser Thr Ser Gly Gly 130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val145 150 155 160Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175Pro Ala Val Leu
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200
205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Ala225 230 235 240Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr 245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Cys Val 260 265 270Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305 310 315
320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro 340 345 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln 355 360 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala 370 375 380Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr385 390 395 400Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440
445Leu Ser Pro Gly Lys 450282453PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 282Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile
Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Thr Ser 20 25 30Trp Ile Gly
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile
Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65 70 75
80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95Ala Arg His Gly Leu Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp
Ile 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
Thr Lys Gly 115 120 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
Ser Thr Ser Gly Gly 130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val145 150 155 160Thr Val Ser Trp Asn Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175Pro Ala Val Leu
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200
205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Ala225 230 235 240Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr 245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Cys Val 260 265 270Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305 310 315
320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro 340 345 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln 355 360 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala 370 375 380Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr385 390 395 400Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430Val
Met His Glu Ala Leu His Asn Ala Tyr Thr Gln Lys Ser Leu Ser 435 440
445Leu Ser Pro Gly Lys 450283107PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 283Arg Thr Val Ala Ala
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu1 5 10 15Gln Leu Lys Ser
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30Tyr Pro Arg
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45Ser Gly
Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60Thr
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu65 70 75
80Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100
105284214PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 284Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ser
Ser Gln Gly Ile Arg Ser Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala Asn Gly Phe Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120
125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140Lys Val Gln Trp Lys
Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser
Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170
175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys 210285214PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
285Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Ser
Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Leu Asn Gly Tyr Pro Leu 85 90 95Thr Phe Gly Gln Gly Thr Arg Leu Glu
Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155
160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys
2102865PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 286Thr Ser Trp Ile Gly1 528714PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 287His
Gly Leu Gly Tyr Asn Gly Tyr Glu Gly Ala Phe Asp Ile1 5
1028811PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 288Arg Ala Ser Gln Gly Ile Gly Ser Ala Leu Ala1 5
1028910PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 289Cys Gln Gln Leu Asn Gly Tyr Pro Leu Thr1 5
10290453PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 290Gln Val Gln Leu Gln Gln Pro Gly Ala Glu
Leu Val Arg Pro Gly Ala1 5 10 15Ser Val Lys Leu Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Trp Ile Asn Trp Val Lys Gln Arg
Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Asn Ile Tyr Pro Ser Asp
Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60Lys Asp Lys Ala Thr Leu
Thr Val Asp Lys Ser Ser Asn Thr Val Tyr65 70 75 80Met Gln Leu Asn
Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95Thr Arg Asn
Gly Val Glu Gly Tyr Pro His Tyr Tyr Ala Met Glu Tyr 100 105 110Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120
125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
Pro Val145 150 155 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
Gly Val His Thr Phe 165 170 175Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val 180 185 190Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220Ser Cys Asp
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225 230 235
240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Asp Val 260 265 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val 275 280 285Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser 290 295 300Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu305 310 315 320Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 355 360
365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
Thr Thr385 390 395 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu 405 410 415Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser 420 425 430Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445Leu Ser Pro Gly Lys
450291214PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 291Asp Ile Gln Met Thr Gln Thr Thr Ser Ala
Leu Ser Ala Ser Leu Gly1 5 10 15Asp Arg Val Thr Ile Gly Cys Arg Ala
Ser Gln Asp Leu Ser Asn His 20 25 30Leu Tyr Trp Tyr Gln Gln Lys Pro
Asp Gly Thr Val Lys Leu Leu Ile 35 40 45Tyr Tyr Thr Ser Arg Leu His
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Tyr Ser Leu Thr Ile Arg Asn Leu Glu Gln65 70 75 80Glu Asp Val Ala
Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Tyr 85 90 95Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120
125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
Ser Gln145 150 155 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
Thr Tyr Ser Leu Ser 165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp
Tyr Glu Lys His Lys Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln
Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu
Cys 2102925PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 292Ser Tyr Trp Ile Asn1 529317PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 293Asn
Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys1 5 10
15Asp29414PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 294Asn Gly Val Glu Gly Tyr Pro His Tyr Tyr Ala
Met Glu Tyr1 5 1029511PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 295Arg Ala Ser Gln Asp Leu
Ser Asn His Leu Tyr1 5 102967PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 296Tyr Thr Ser Arg Leu His
Ser1 52979PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 297Gln Gln Gly Tyr Thr Leu Pro Tyr Thr1
5298123PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 298Gln Val Gln Leu Gln Gln Pro Gly Ala Glu
Leu Val Arg Pro Gly Ala1 5 10 15Ser Val Lys Leu Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Trp Ile Asn Trp Val Lys Gln Arg
Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Asn Ile Tyr Pro Ser Asp
Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60Lys Asp Lys Ala Thr Leu
Thr Val Asp Lys Ser Ser Asn Thr Val Tyr65 70 75 80Met Gln Leu Asn
Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95Thr Arg Asn
Gly Val Glu Gly Tyr Pro His Tyr Tyr Ala Met Glu Tyr 100 105 110Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120299107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
299Asp Ile Gln Met Thr Gln Thr Thr Ser Ala Leu Ser Ala Ser Leu Gly1
5 10 15Asp Arg Val Thr Ile Gly Cys Arg Ala Ser Gln Asp Leu Ser Asn
His 20 25 30Leu Tyr Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu
Leu Ile 35 40 45Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Arg
Asn Leu Glu Gln65 70 75 80Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln
Gly Tyr Thr Leu Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys 100 1053005PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 300Glu Tyr Tyr Met Tyr1
530117PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 301Arg Ile Asp Pro Glu Asp Gly Ser Ile Asp Tyr
Val Glu Lys Phe Lys1 5 10 15Lys3029PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 302Gly
Lys Phe Asn Tyr Arg Phe Ala Tyr1 530316PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 303Arg
Ser Ser Gln Ser Leu Leu His Ser Ser Gly Asn Thr Tyr Leu Asn1 5 10
153047PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 304Leu Val Ser Lys Leu Glu Ser1
53059PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 305Met Gln Phe Thr His Tyr Pro Tyr Thr1
5306118PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 306Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Glu Tyr 20 25 30Tyr Met Tyr Trp Val Arg Gln Ala
Pro Gly Gln Gly Leu Glu Leu Met 35 40 45Gly Arg Ile Asp Pro Glu Asp
Gly Ser Ile Asp Tyr Val Glu Lys Phe 50 55 60Lys Lys Lys Val Thr Leu
Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser
Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly
Lys Phe Asn Tyr Arg Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110Leu
Val Thr Val Ser Ser 115307112PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 307Asp Val Val Met Thr
Gln Ser Pro Pro Ser Leu Leu Val Thr Leu Gly1 5 10 15Gln Pro Ala Ser
Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30Ser Gly Asn
Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45Pro Gln
Pro Leu Ile Tyr Leu Val Ser Lys Leu Glu Ser Gly Val Pro 50 55 60Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75
80Ser Gly Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Phe
85 90 95Thr His Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110308118PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 308Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Gln Arg Pro Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Glu Tyr 20 25 30Tyr Met Tyr
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Leu Val 35 40 45Gly Arg
Ile Asp Pro Glu Asp Gly Ser Ile Asp Tyr Val Glu Lys Phe 50 55 60Lys
Lys Lys Val Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Gly Lys Phe Asn Tyr Arg Phe Ala Tyr Trp Gly Gln Gly
Thr 100 105 110Leu Val Thr Val Ser Ser 115309112PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
309Asp Val Val Met Thr Gln Ser Pro Pro Ser Leu Leu Val Thr Leu Gly1
5 10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His
Ser 20 25 30Ser Gly Asn Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly
Gln Ser 35 40 45Pro Gln Pro Leu Ile Tyr Leu Val Ser Lys Leu Glu Ser
Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
Thr Leu Lys Ile65 70 75 80Ser Gly Val Glu Ala Glu Asp Val Gly Val
Tyr Tyr Cys Met Gln Phe 85 90 95Thr His Tyr Pro Tyr Thr Phe Gly Gln
Gly Thr Lys Leu Glu Ile Lys 100 105 110310120PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
310Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ala Val Ile Ser Glu Asn Gly Ser Asp Thr Tyr Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys
Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Arg Gly Gly Ala Val Ser
Tyr Phe Asp Val Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser
Ser 115 120311109PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 311Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Val Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala Ser Ser
Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Leu Pro Tyr 85 90 95Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 100
105312351PRTHomo sapiens 312Met Ser Phe Pro Cys Lys Phe Val Ala Ser
Phe Leu Leu Ile Phe Asn1 5 10 15Val Ser Ser Lys Gly Ala Val Ser Lys
Glu Ile Thr Asn Ala Leu Glu 20 25 30Thr Trp Gly Ala Leu Gly Gln Asp
Ile Asn Leu Asp Ile Pro Ser Phe 35 40 45Gln Met Ser Asp Asp Ile Asp
Asp Ile Lys Trp Glu Lys Thr Ser Asp 50 55 60Lys Lys Lys Ile Ala Gln
Phe Arg Lys Glu Lys Glu Thr Phe Lys Glu65 70 75 80Lys Asp Thr Tyr
Lys Leu Phe Lys Asn Gly Thr Leu Lys Ile Lys His 85 90 95Leu Lys Thr
Asp Asp Gln Asp Ile Tyr Lys Val Ser Ile Tyr Asp Thr 100 105 110Lys
Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu Lys Ile Gln Glu 115
120 125Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile Asn Thr Thr
Leu 130 135 140Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu Asn
Leu Tyr Gln145 150 155 160Asp Gly Lys His Leu Lys Leu Ser Gln Arg
Val Ile Thr His Lys Trp 165 170 175Thr Thr Ser Leu Ser Ala Lys Phe
Lys Cys Thr Ala Gly Asn Lys Val 180 185 190Ser Lys Glu Ser Ser Val
Glu Pro Val Ser Cys Pro Glu Lys Gly Leu 195 200 205Asp Ile Tyr Leu
Ile Ile Gly Ile Cys Gly Gly Gly Ser Leu Leu Met 210 215 220Val Phe
Val Ala Leu Leu Val Phe Tyr Ile Thr Lys Arg Lys Lys Gln225 230 235
240Arg Ser Arg Arg Asn Asp Glu Glu Leu Glu Thr Arg Ala His Arg Val
245 250 255Ala Thr Glu Glu Arg Gly Arg Lys Pro His Gln Ile Pro Ala
Ser Thr 260 265 270Pro Gln Asn Pro Ala Thr Ser Gln His Pro Pro Pro
Pro Pro Gly His 275 280 285Arg Ser Gln Ala Pro Ser His Arg Pro Pro
Pro Pro Gly His Arg Val 290 295 300Gln His Gln Pro Gln Lys Arg Pro
Pro Ala Pro Ser Gly Thr Gln Val305 310 315 320His Gln Gln Lys Gly
Pro Pro Leu Pro Arg Pro Arg Val Gln Pro Lys 325 330 335Pro Pro His
Gly Ala Ala Glu Asn Ser Leu Ser Pro Ser Ser Asn 340 345
3503137PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 313Gly Phe Thr Phe Ser Ser Tyr1
53145PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 314Ser Gly Gly Gly Phe1 53159PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 315Ser
Ser Tyr Gly Glu Ile Met Asp Tyr1 53169PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 316Ser
Ser Tyr Gly Glu Leu Met Asp Tyr1 531711PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 317Arg
Ala Ser Gln Arg Ile Gly Thr Ser Ile His1 5 103187PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 318Tyr
Ala Ser Glu Ser Ile Ser1 531910PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 319Gln Gln Ser His Gly Trp
Pro Phe Thr Phe1 5 10320117PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 320Glu Val Lys Leu Val
Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1 5 10 15Ser Leu Lys Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Asp Met Ser
Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 35 40 45Ala Ser
Ile Ser Gly Gly Gly Phe Leu Tyr Tyr Leu Asp Ser Val Lys 50 55 60Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ile Leu Tyr Leu65 70 75
80His Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95Arg Ser Ser Tyr Gly Glu Ile Met Asp Tyr Trp Gly Gln Gly Thr
Ser 100 105 110Val Thr Val Ser Ser 115321117PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
321Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1
5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30Asp Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
Trp Val 35 40 45Ala Ser Ile Ser Gly Gly Gly Phe Leu Tyr Tyr Leu Asp
Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn
Ile Leu Tyr Leu65 70 75 80His Met Thr Ser Leu Arg Ser Glu Asp Thr
Ala Met Tyr Tyr Cys Ala 85 90 95Arg Ser Ser Tyr Gly Glu Leu Met Asp
Tyr Trp Gly Gln Gly Thr Ser 100 105 110Val Thr Val Ser Ser
115322107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 322Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile
Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Val Ser Phe Ser Cys Arg Ala
Ser Gln Arg Ile Gly Thr Ser 20 25 30Ile His Trp Tyr Gln Gln Arg Thr
Thr Gly Ser Pro Arg Leu Leu Ile 35 40 45Lys Tyr Ala Ser Glu Ser Ile
Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65 70 75 80Glu Asp Val Ala
Asp Tyr Tyr Cys Gln Gln Ser His Gly Trp Pro Phe 85 90 95Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Glu 100 105323324PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
323Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala1
5 10 15Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly
Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu
Ser Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu
Tyr Thr Leu 50 55 60Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro
Ser Glu Thr Val65 70 75 80Thr Cys Asn Val Ala His Pro Ala Ser Ser
Thr Lys Val Asp Lys Lys 85 90 95Ile Val Pro Arg Asp Cys Gly Cys Lys
Pro Cys Ile Cys Thr Val Pro 100 105 110Glu Val Ser Ser Val Phe Ile
Phe Pro Pro Lys Pro Lys Asp Val Leu 115 120 125Thr Ile Thr Leu Thr
Pro Lys Val Thr Cys Val Val Val Asp Ile Ser 130 135 140Lys Asp Asp
Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu145 150 155
160Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr
165 170 175Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp
Leu Asn 180 185 190Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala
Phe Pro Ala Pro 195 200 205Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly
Arg Pro Lys Ala Pro Gln 210 215 220Val Tyr Thr Ile Pro Pro Pro Lys
Glu Gln Met Ala Lys Asp Lys Val225 230 235 240Ser Leu Thr Cys Met
Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val 245 250 255Glu Trp Gln
Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln 260 265 270Pro
Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn 275 280
285Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val
290 295 300Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu
Ser His305 310 315 320Ser Pro Gly Lys324107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
324Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu1
5 10 15Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn
Phe 20 25 30Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser
Glu Arg 35 40 45Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser
Lys Asp Ser 50 55 60Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys
Asp Glu Tyr Glu65 70 75 80Arg His Asn Ser Tyr Thr Cys Glu Ala Thr
His Lys Thr Ser Thr Ser 85 90 95Pro Ile Val Lys Ser Phe Asn Arg Asn
Glu Cys 100 105325107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 325Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Met Ser Ala Ser Leu Gly1 5 10 15Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30Leu Ser Trp
Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45Tyr Arg
Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Tyr65 70 75
80Glu Asp Phe Gly Ile Tyr Tyr Cys Gln Gln Tyr Asp Glu Ser Pro Trp
85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100
105326118PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 326Gln Ile Gln Leu Val Gln Ser Gly Pro Gly
Leu Lys Lys Pro Gly Gly1 5 10 15Ser Val Arg Ile Ser Cys Ala Ala Ser
Gly Tyr Thr Phe Thr Asn Tyr 20 25 30Gly Met Asn Trp Val Lys Gln Ala
Pro Gly Lys Gly Leu Arg Trp Met 35 40 45Gly Trp Ile Asn Thr His Thr
Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60Lys Gly Arg Phe Thr Phe
Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr65 70 75 80Leu Gln Ile Asn
Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95Thr Arg Arg
Gly Tyr Asp Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr 100 105 110Thr
Val Thr Val Ser Ser 1153277PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 327Gly Tyr Thr Phe Thr Asn
Tyr1 53286PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 328Asn Thr His Thr Gly Glu1 53299PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 329Arg
Gly Tyr Asp Trp Tyr Phe Asp Val1 533011PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 330Arg
Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser1 5 103317PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 331Arg
Ala Asn Arg Leu Val Asp1 53329PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 332Gln Gln Tyr Asp Glu Ser
Pro Trp Thr1 5333107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 333Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30Leu Ser Trp Phe Gln Gln
Lys Pro Gly Lys Ala Pro Lys Thr Leu Ile 35 40 45Tyr Arg Ala Asn Arg
Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Tyr65 70 75 80Glu Asp
Phe Gly Ile Tyr Tyr Cys Gln Gln Tyr Asp Glu Ser Pro Trp 85 90 95Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105334119PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
334Glu Ile Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1
5 10 15Ser Val Arg Ile Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn
Tyr 20 25 30Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Met 35 40 45Gly Trp Ile Asn Thr His Tyr Gly Glu Pro Thr Tyr Ala
Asp Ser Phe 50 55 60Lys Gly Thr Arg Thr Phe Ser Leu Asp Asp Ser Lys
Asn Thr Ala Tyr65 70 75 80Leu Gln Ile Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Phe Cys 85 90 95Thr Arg Arg Gly Tyr Asp Trp Tyr Phe
Asp Val Trp Gly Gln Gly Gly 100 105 110Thr Thr Val Thr Val Ser Ser
1153357PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 335Gly Tyr Thr Phe Thr Asn Tyr1
53366PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 336Asn Thr His Tyr Gly Glu1 533710PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 337Arg
Arg Gly Tyr Asp Trp Tyr Phe Asp Val1 5 1033811PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 338Arg
Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser1 5 103397PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 339Arg
Ala Asn Arg Leu Glu Ser1 53409PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 340Gln Gln Tyr Asp Glu Ser
Pro Trp Thr1 53419PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 341Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr1
53427PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 342Ile Ser Tyr Ser Gly Phe Thr1
534311PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 343Ala Gly Asp Arg Thr Gly Ser Trp Phe Ala Tyr1 5
103446PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 344Gln Asp Ile Ser Asn Tyr1 53453PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 345Ala
Thr Ser13469PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 346Leu Gln Tyr Ala Ser Tyr Pro Phe Thr1
53478PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 347Gly Tyr Ile Phe Thr Asn Tyr Gly1
53488PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 348Ile Asn Thr Tyr Asn Gly Glu Pro1
534911PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 349Ala Arg Gly Asp Tyr Tyr Gly Tyr Glu Asp Tyr1 5
103506PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 350Gln Gly Ile Ser Asn Tyr1 53513PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 351Tyr
Thr Ser13529PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 352Gln Gln Tyr Ser Lys Leu Pro Trp Thr1
53539PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 353Phe Ser Leu Ser Thr Ser Gly Met Gly1
53545PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 354Trp Trp Asp Asp Asp1 535510PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 355Arg
Arg Ala Thr Gly Thr Gly Phe Asp Tyr1 5 103566PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 356Gln
Asp Val Gly Thr Ala1 53577PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 357Trp Thr Ser Thr Arg His
Thr1 53586PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 358Tyr Asn Ser Tyr Asn Thr1 5359120PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
359Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu1
5 10 15Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr
Ser 20 25 30Gly Met Gly Val Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly
Leu Glu 35 40 45Trp Val Ala His Ile Trp Trp Asp Asp Asp Val Tyr Tyr
Asn Pro Ser 50 55 60Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Ala Ser
Lys Asp Gln Val65 70 75 80Ser Leu Lys Leu Ser Ser Val Thr Ala Ala
Asp Thr Ala Val Tyr Tyr 85 90 95Cys Val Arg Arg Arg Ala Thr Gly Thr
Gly Phe Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser
Ser 115 120360106PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 360Asn Ile Val Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Gln Ala Ser Gln Asp Val Gly Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln
Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile 35 40 45Tyr Trp Thr Ser Thr
Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55
60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Ile Ala Thr Tyr Phe Cys His Gln Tyr Asn Ser Tyr Asn
Thr 85 90 95Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100
105361120PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 361Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Asp Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Val Ile Ser Glu Asn Gly
Ser Asp Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp
Arg Gly Gly Ala Val Ser Tyr Phe Asp Val Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115 120362109PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
362Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Ser
Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Tyr Asn Ser Leu Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys Arg Thr 100 105363438PRTHomo sapiens 363Met Val Cys Ser Gln
Ser Trp Gly Arg Ser Ser Lys Gln Trp Glu Asp1 5 10 15Pro Ser Gln Ala
Ser Lys Val Cys Gln Arg Leu Asn Cys Gly Val Pro 20 25 30Leu Ser Leu
Gly Pro Phe Leu Val Thr Tyr Thr Pro Gln Ser Ser Ile 35 40 45Ile Cys
Tyr Gly Gln Leu Gly Ser Phe Ser Asn Cys Ser His Ser Arg 50 55 60Asn
Asp Met Cys His Ser Leu Gly Leu Thr Cys Leu Glu Pro Gln Lys65 70 75
80Thr Thr Pro Pro Thr Thr Arg Pro Pro Pro Thr Thr Thr Pro Glu Pro
85 90 95Thr Ala Pro Pro Arg Leu Gln Leu Val Ala Gln Ser Gly Gly Gln
His 100 105 110Cys Ala Gly Val Val Glu Phe Tyr Ser Gly Ser Leu Gly
Gly Thr Ile 115 120 125Ser Tyr Glu Ala Gln Asp Lys Thr Gln Asp Leu
Glu Asn Phe Leu Cys 130 135 140Asn Asn Leu Gln Cys Gly Ser Phe Leu
Lys His Leu Pro Glu Thr Glu145 150 155 160Ala Gly Arg Ala Gln Asp
Pro Gly Glu Pro Arg Glu His Gln Pro Leu 165 170 175Pro Ile Gln Trp
Lys Ile Gln Asn Ser Ser Cys Thr Ser Leu Glu His 180 185 190Cys Phe
Arg Lys Ile Lys Pro Gln Lys Ser Gly Arg Val Leu Ala Leu 195 200
205Leu Cys Ser Gly Phe Gln Pro Lys Val Gln Ser Arg Leu Val Gly Gly
210 215 220Ser Ser Ile Cys Glu Gly Thr Val Glu Val Arg Gln Gly Ala
Gln Trp225 230 235 240Ala Ala Leu Cys Asp Ser Ser Ser Ala Arg Ser
Ser Leu Arg Trp Glu 245 250 255Glu Val Cys Arg Glu Gln Gln Cys Gly
Ser Val Asn Ser Tyr Arg Val 260 265 270Leu Asp Ala Gly Asp Pro Thr
Ser Arg Gly Leu Phe Cys Pro His Gln 275 280 285Lys Leu Ser Gln Cys
His Glu Leu Trp Glu Arg Asn Ser Tyr Cys Lys 290 295 300Lys Val Phe
Val Thr Cys Gln Asp Pro Asn Pro Ala Gly Leu Ala Ala305 310 315
320Gly Thr Val Ala Ser Ile Ile Leu Ala Leu Val Leu Leu Val Val Leu
325 330 335Leu Val Val Cys Gly Pro Leu Ala Tyr Lys Lys Leu Val Lys
Lys Phe 340 345 350Arg Gln Lys Lys Gln Arg Gln Trp Ile Gly Pro Thr
Gly Met Asn Gln 355 360 365Asn Met Ser Phe His Arg Asn His Thr Ala
Thr Val Arg Ser His Ala 370 375 380Glu Asn Pro Thr Ala Ser His Val
Asp Asn Glu Tyr Ser Gln Pro Pro385 390 395 400Arg Asn Ser His Leu
Ser Ala Tyr Pro Ala Leu Glu Gly Ala Leu His 405 410 415Arg Ser Ser
Met Gln Pro Asp Asn Ser Ser Asp Ser Asp Tyr Asp Leu 420 425 430His
Gly Ala Gln Arg Leu 43536415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 364Glu Pro Lys Ser Ser Asp
Lys Thr His Thr Ser Pro Pro Ser Pro1 5 10 153658PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
peptideMOD_RES(7)..(7)Asn or Asp 365Ile Trp Gly Ile Gly Cys Xaa
Pro1 536610PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 366Ser Gly Tyr Ser Phe Thr Gly Tyr Thr Met1 5
1036710PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 367Ser Gly Tyr Ser Phe Thr Asp Tyr Thr Met1 5
1036810PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 368Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met1 5
1036910PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 369Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met1 5
1037010PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 370Ser Gly Tyr Ser Phe Thr Ala Tyr Asn Ile1 5
1037110PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 371Ser Gly Tyr Ser Phe Thr Ala Tyr Ser Met1 5
1037210PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 372Ser Gly Tyr Thr Phe Thr Asn Phe Ala Ile1 5
1037310PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 373Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met1 5
1037410PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 374Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Met1 5
1037510PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 375Ser Gly Phe Ser Leu Thr Asn Tyr Asp Val1 5
1037610PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 376Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met1 5
1037710PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 377Ser Gly Tyr Ile Phe Ala Asn Tyr Gly Met1 5
1037810PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 378Ser Gly Tyr Asn Phe Thr Asn Tyr Gly Met1 5
1037910PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 379Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met1 5
1038010PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 380Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile1 5
1038110PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 381Ser Gly Asn Thr Phe Thr Asn Phe Tyr Leu1 5
1038210PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 382Ser Glu Phe Thr Phe Ser Asn Tyr Ala Met1 5
1038310PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 383Ser Gly Tyr Thr Phe Thr Ser Tyr Arg Met1 5
1038410PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 384Ser Gly Tyr Met Phe Thr Asn His Gly Met1 5
1038510PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 385Ser Gly Tyr Met Phe Thr Asn Tyr Gly Met1 5
1038610PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 386Ser Gly Tyr Ile Phe Thr Asn Tyr Gly Met1 5
1038710PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 387Ser Gly Phe Asn Ile Lys Asp Tyr Tyr Ile1 5
1038810PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 388Ser Gly Tyr Thr Phe Ile Asn Tyr Gly Met1 5
1038910PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 389Ser Gly Tyr Thr Phe Thr Asp Tyr Phe Ile1 5
1039010PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 390Ser Gly Tyr Ile Phe Thr Gly Tyr Asn Ile1 5
1039110PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 391Leu Ile Asn Pro Tyr Asn Gly Gly Thr Thr1 5
1039210PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 392Leu Ile Asn Pro Tyr Asn Gly Gly Thr Met1 5
103939PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 393Ser Ile Ser Ser Gly Gly Asn Thr Phe1
53949PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 394Ser Ile Ser Ser Gly Gly Ser Thr Tyr1
539510PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 395Ser Ile Asp Pro Tyr Tyr Gly Asp Thr Lys1 5
1039610PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 396Leu Ile Ser Ser Asn Ser Gly Asp Val Ser1 5
1039710PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 397Leu Ile Ser Thr Ser Ser Gly Asp Val Ser1 5
1039810PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 398Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys1 5
1039910PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 399Met Ile His Pro Ser Asp Ser Glu Thr Arg1 5
104009PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 400Val Ile Trp Ser Gly Gly Asn Thr Asp1
540110PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 401Ala Ile Asn Ser Asn Gly Asp Ile Thr Tyr1 5
1040210PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 402Leu Ile Asn Pro Tyr Asn Gly Gly Thr Arg1 5
1040310PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 403Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr1 5
1040410PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 404Trp Ile Tyr Pro Gly Gly Gly Asn Thr Arg1 5
1040510PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 405Cys Ile Tyr Pro Gly Asn Val Lys Thr Lys1 5
1040610PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 406Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr1 5
1040710PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 407Arg Ile Asp Pro Tyr Asp Ser Gly Thr His1 5
1040810PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 408Trp Ile Asp Pro Glu Asn Gly Arg Thr Glu1 5
1040910PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 409Glu Ile Tyr Pro Gly Ser Ser Asn Thr Tyr1 5
1041010PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 410Ala Val Tyr Pro Gly Asn Gly Asp Thr Ser1 5
1041115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 411Cys Ala Arg Asp Tyr Tyr Gly Ser Ser Pro Asp
Phe Asp Tyr Trp1 5 10 1541215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 412Cys Ala Arg Asp Asn Tyr
Gly Ser Ser Pro Asp Phe Asp Tyr Trp1 5 10 1541315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 413Cys
Ala Arg Asp Asn Tyr Gly Ser Ser Pro Tyr Phe Asp Tyr Trp1 5 10
1541416PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 414Cys Val Arg Tyr Tyr Tyr Gly Val Thr Tyr Trp
Tyr Phe Asp Val Trp1 5 10 1541516PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 415Cys Val Arg Tyr Tyr Tyr
Gly Ile Arg Tyr Trp Tyr Phe Asp Val Trp1 5 10 1541616PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 416Cys
Ala Arg Arg Met Ile Thr Met Gly Asp Trp Tyr Phe Asp Val Trp1 5 10
1541716PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 417Cys Ala Arg Arg Met Ile Thr Thr Gly Asp Trp
Tyr Phe Asp Val Trp1 5 10 1541814PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 418Cys Ala Arg His Tyr Gly
Ala His Asn Tyr Phe Asp Tyr Trp1 5 1041914PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 419Cys
Ala Arg His Tyr Gly Ala Asn Asn Tyr Phe Asp Tyr Trp1 5
1042016PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 420Cys Ala Arg Glu Glu Asn Tyr Tyr Gly Thr Tyr
Tyr Phe Asp Tyr Trp1 5 10 1542114PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 421Cys Ala Arg Trp Gly Asp
His Asp Asp Ala Met Asp Phe Trp1 5 1042217PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 422Cys
Ala Arg Asn His Gly Asp Gly Tyr Phe Asn Trp Tyr Phe Asp Val1 5 10
15Trp42317PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 423Cys Ala Arg Asn His Gly Asp Gly Tyr Tyr Asn
Trp Tyr Phe Asp Val1 5 10 15Trp42411PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 424Cys
Ala Arg Gly Thr Ala Trp Phe Thr Tyr Trp1 5 1042514PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 425Cys
Ala Arg Asp Gly Asp Asp Gly Trp Asp Ile Asp Val Trp1 5
1042613PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 426Cys Ala Arg Arg Gly Thr Tyr Trp His Phe Asp
Val Trp1 5 1042713PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 427Cys Ala Arg Arg Gly Ser Tyr Trp His
Phe Asp Val Trp1 5 1042812PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 428Cys Ala Arg Arg Ser Thr
Leu Val Phe Asp Tyr Trp1 5 1042912PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 429Cys Ala Arg Asn Gly Tyr
Trp Tyr Phe Asp Val Trp1 5 1043016PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 430Cys Ala Lys Glu Gly Asp
Tyr Asp Gly Thr Ala Tyr Phe Asp Tyr Trp1 5 10 1543112PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 431Cys
Ala Arg Arg Arg Asp Gly Asn Phe Asp Tyr Trp1 5 1043210PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 432Cys
Val Arg His Gly Tyr Phe Asp Val Trp1 5 104339PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 433Cys
Ala Phe Tyr Asp Gly Ala Tyr Trp1 54349PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 434Cys
Ala Ser Tyr Asp Pro Asp Tyr Trp1 543514PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 435Cys
Ala Arg Asp Thr Thr Ala Thr Tyr Tyr Phe Asp Tyr Trp1 5
1043612PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 436Cys Ala Arg Arg Val Ala Thr Tyr Phe
Asp Val Trp1 5 1043712PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 437Cys Thr Arg Arg Ser His
Ile Thr Leu Asp Tyr Trp1 5 1043812PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 438Cys Ala Arg Arg Arg Thr
Thr Ala Phe Asp Tyr Trp1 5 1043915PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 439Cys Asn Asn Gly Asn Tyr
Val Arg His Tyr Tyr Phe Asp Tyr Trp1 5 10 1544012PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 440Cys
Thr Arg Arg Arg Glu Ile Thr Phe Asp Tyr Trp1 5 1044112PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 441Cys
Ala Arg Ser Gly Ile Ser Pro Phe Thr Tyr Trp1 5 1044211PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 442Cys
Ala Lys Tyr Asp Arg Phe Phe Ala Ser Trp1 5 10
* * * * *